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Abstract 
Chronic myeloid leukaemia (CML) is a clonal myeloproliferative disorder that is associated 
with a reciprocal translocation between the long arms of chromosomes 22 and 9, giving rise 
to the Philadelphia (Ph) chromosome and the subsequent formation of the BCR-ABL fusion 
gene, encoding the constitutively active oncogenic tyrosine kinase, BCR-ABL.  Advances 
in targeted therapies in chronic phase (CP) CML, notably the use of tyrosine kinase 
inhibitors (TKI), have led to a ten-fold reduction in disease progression to an accelerated or 
blast phase (BP).  However, if left untreated, or in patients where resistance to TKIs exists 
or develops, the disease eventually progresses.  BP can be myeloid, lymphoid or of an 
undifferentiated immunophenotype and, despite chemotherapeutic agents, will often end 
with a terminal outcome.  
 
Progression to BP disease is thought to arise for three reasons: patient non-compliance, TKI 
resistance, which may be BCR-ABL dependent or independent, and disease persistence.  
Disease persistence suggests that a small population of cells survive despite TKI therapy, 
gain or have self-renewal properties, and reside in select haemopoietic bone marrow niches.  
These cells, termed leukaemic stem cells (LSCs), are not fully dependent on BCR-ABL, 
relying on deregulation of stem cell intrinsic pathways for their survival.   
 
Within this thesis, we have explored the role of the self-renewal pathway, Notch, in the 
maintenance and progression of stem and progenitor populations within primary CML 
samples.  We firstly identified, through focussed gene expression analysis, a deregulation of 
Notch pathway components within CP-CML samples.  The Notch receptor, NOTCH2, was 
upregulated within this population.  This was confirmed at protein level.  The pathway was, 
however, deemed not to be activated through in vitro experimental assessment of 
proliferation, apoptosis, and cell cycle analysis in CP primary samples treated with the 
gamma-secretase inhibitor, DAPT.  In view of the abundant expression of the receptor, we 
hypothesised that the pathway could be reactivated through exogenous stimulation upon 
ligand binding.  An OP9 co-culture system, as well as plate-bound recombinant ligand, were 
utilised to allow for the overexpression of the Notch ligands, Delta-like 1 and Jagged1.  We 
have demonstrated that Notch signalling can be reactivated within CP-CML samples, and 
that cellular function upon reactivation is dependent on cell maturity, i.e. immature Lin-
CD34+CD38- and mature Lin-CD34+CD38+ cells.  The short-term effects of Notch activation 
through Jagged1 in CD34+ CP-CML cells led to early erythroid differentiation that is 
blocked in an immature state.  This was determined through cell surface identification of 
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erythroid markers.  There was an increase in expression of both CD71 and GlyA with the 
addition of stromal co-culture.  As CD33 expression was maintained, it suggested that 
although the samples had initiated differentiation, they could not progress beyond an 
immature phenotype.  To corroborate the possible involvement of Notch activation through 
Jagged1 interaction in early differentiation, gene expression was investigated in primary 
CD34+ CP-CML patient samples.  There was a statistically significant increase in expression 
of key genes involved in early erythroid differentiation, namely, p38 and PU.1, which have 
notable involvement in development of (pro)erythroblasts.  Further to this, within the Lin-
CD34+CD38- population, short-term activation of Notch through Jagged1 led to a significant 
reduction in colony formation with long-term colony initiating cell assays.  This suggests 
that pulsed Notch activation may exhaust stem cell activity within the CP-CML phenotype 
and represent a possible targeted approach towards the CML LSC.   
 
These findings did not translate on disease progression to a myeloid BP phenotype.  Notch 
could not be reactivated despite the presence of the Notch receptor, NOTCH2. To investigate 
this further, we sorted CP (n=12), myeloid BP (n=11), and lymphoid BP (n=5) into stem and 
progenitor populations, before undertaking quantitative PCR of 90 self-renewal gene 
components of Wnt/β-catenin, Notch, Hedgehog, and BMP signalling pathways. The self-
renewal pathways were highly deregulated between CP and BP, and suggested a two-phase 
disease process (i.e. CP and AP/BP), rather than triphasic (i.e. CP, AP and BP).  There was 
statistically significant upregulation in Wnt/β-catenin components in myeloid BP compared 
to CP, particularly TCF7.  We hypothesised that Wnt upregulation was preventing Notch 
activation in myeloid BP-CML.  Further to this, transcriptional expression of self-renewal 
and cell survival pathways was compared between the Ph positive (+) acute leukaemias, 
namely, myeloid BP, lymphoid BP and Ph+ acute lymphoblastic leukaemia (ALL) (n=5).  
There was limited change in gene expression profiles of the self-renewal pathway 
components between myeloid and lymphoid BP disease, but gene expression could segregate 
Ph+ ALL from lymphoid BP upon gene clustering.  This suggests that self-renewal gene 
components may offer diagnostic implications in the diagnosis of lymphoid BP and Ph+ 
ALL.  
 
We next sought to provide further functional data as to the immunophenotypic marker of the 
CML LSC within CP disease.  Our group has previously identified that CD93 is highly 
upregulated in CP-CML LSCs.  Furthermore, using flow cytometry, we demonstrated 
significant upregulation of CD93 protein expression on lin-CD34+CD38-CD45RA-CD90+ 
CML LSCs from peripheral blood and bone marrow of CP-CML patients (n= 17) compared 
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to normal HSC from healthy peripheral blood stem cell donors (n=7) and bone marrow 
donors (n=4).  FISH confirmed that 100% of lin-CD34+CD38-CD45RA-CD90+CD93+ CML 
cells were BCR-ABL+ in all samples assessed.  This thesis has further highlighted the LSC 
capability of a CD93+-selected population through functional in vitro and in vivo analysis.  
We have demonstrated that CD93+ CML-LSCs have increased colony-forming capability 
within long-term colony initiating cell assays.  Furthermore, in xenograft transplantation 
experiments (n = 5), after 16 weeks, CD34+CD93+ CML LSC engrafted lethally irradiated 
NOD/SCID/IL-2Rg-/- (NSG) mice with BCR-ABL positive cells, whereas CD34+CD93- 
cells from the same patient samples failed to engraft to significant levels.  FISH confirmed 
that engrafted human cells were BCR-ABL positive.  We further highlighted the immature 
LSC phenotype of CD93-selected cells through bulk and single cell gene expression analysis 
of 90 cell survival and self-renewal pathway components.  
 
Overall the work presented in this thesis has furthered our understanding of the role of self-
renewal within CML maintenance and progression, as well as further implicating the use of 
the cell surface marker, CD93, in the identification of the CML-LSC.  This data will help 
guide novel therapeutic approaches towards the CML LSC in future experimental work, as 
well as guide further development in the transcriptional differences and potential targets in 
the Ph+ acute leukaemias. 
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1. Introduction 
1.1. Haemopoiesis 
1.1.1. Hierarchical haemopoiesis 
The generation of mature and differentiated blood cells from a haemopoietic stem cell (HSC) 
is one of the best-characterised hierarchical systems.  It relies on an intricate balance between 
self-renewal and differentiation, highlighting key features that have been critical to our 
understanding of how stem cells are maintained, differentiate, and are altered during 
haematological disease (Bhatia et al, 1997a; Bhatia et al, 1997b; Doulatov et al, 2010; Kiel 
et al, 2005; Majeti et al, 2007; Notta et al, 2011; Notta et al, 2016; Spangrude et al, 1988; 
Till & McCulloch, 1961). 
 
In general, self-renewing cell types with extended life spans are rare and remain at the 
theoretical peak of the hierarchy (figure 1-1).  These include long-term HSCs, as well as 
short-term HSCs, and intermediates with less durable self-renewal potential, termed 
multipotent progenitors (MPPs).  They are defined by the capacity to perpetually self-renew, 
whilst contributing to a pool of differentiating cells.  Oligoclonal progenitors (i.e. common 
myeloid progenitors (CMP) and common lymphoid progenitors (CLP)) appear in increased 
numbers below the self-renewing cell types.  They have a shorter life-span and it is from 
these the common lineages for myelopoiesis (Akashi et al, 2000) and lymphopoiesis (Kondo 
et al, 1997) are isolated.  Oligopotent CMPs undergo further constraint into megakaryocyte-
erythroid progenitors (MEPs) that make platelets and erythrocytes, and granulocyte-
monocyte progenitors (GMPs) that make granulocytes and monocytes.  
 
Much of this understanding was developed within murine models using in vivo repopulating 
assays to assess sustained self-renewal and multipotent differentiation capacity.  
Subsequently, xenotransplantation models and robust in vitro colony assays, including long-
term culture initiating cell assays (LTC-IC), have translated these findings into a humanised 
model (Copland et al, 2008; Doulatov et al, 2010; Galy et al, 1995; Laurenti et al, 2013; 
Manz et al, 2002; Sutherland et al, 1990).  
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Although, this hierarchical idea was first postulated in 1909 (Konstantinov, 2000; 
Maximow, 1909), the continual advancement of scientific technique has led to an increased 
understanding of haemopoiesis, and its re-development.  Although the standard model is 
used extensively as an operational paradigm, experimental data have challenged it.  For 
example, the identification of a population of cells that have lymphoid developmental 
capacities, but can also give rise to granulocytes and macrophages, but not to 
megakaryocytes or erythrocytes, has been identified in both murine and human studies 
(Adolfsson et al, 2005; Ceredig et al, 2006; Doulatov et al, 2010; Reynaud et al, 2003). This 
population of cells, termed lymphoid-primed multipotent progenitors (LMPP), are not 
consistent with the established concept of dichotomous lineage segregation and remain 
contentious.  However, their identification questions the mechanism through which MPPs 
lose lineage specific potential. 
 
Furthermore, uncertainty remains concerning the myelo-erythro-megakaryocytic arm of the 
hierarchy, in part due to the fact that clonogenic in vitro assays do not read out all colony 
types at the same time making it difficult to account for all cells within a phenotypically pure 
Figure 1-1 Simplified hierarchical model of haemopoiesis 
Schematic diagram of a hierarchical model of haemopoiesis.  HSCs reside at the peak of the hierarchy 
and have maximal self-renewal potential.  They give rise to the MPP population.  From MPPs, lineage 
committed progenitors are derived and from them more differentiated intermediate progenitors (not 
shown) before terminally differentiated cells are generated.  
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population.  Paired daughter analysis of mouse HSC cell divisions have demonstrated that 
MEPs can be derived from HSCs directly without progressing through conventional MPPs 
and CMPs (Yamamoto et al, 2013).  Transcriptional studies of highly purified or single-cell 
murine HSCs have established that molecular programmes corresponding to myeloid-
erythroid-megakaryocyte fates can directly emerge in multipotent cells, arguing that cellular 
differentiation is not a gradual process and that myeloid differentiation can occur without 
progressing through the CMP stage (Guo et al, 2013; Månsson et al, 2007; Pronk et al, 2007; 
Yamamoto et al, 2013).  Most recently, Notta et al mapped the lineage potential of nearly 
3000 single cells from 33 different cell populations of stem and progenitor cells to obtain a 
two-tier hierarchy for development in early and late haemopoiesis (Notta et al, 2016).  
Regardless, although these data challenge the standard model, a clear consensus has yet to 
be made on a revised model of haemopoiesis and for the purpose of this thesis, the former 
hierarchical model will be used.  
 
1.1.2. Phenotypic characterisation of human HSCs 
As already described, murine models remain an indispensable approach for studying 
haemopoiesis, with loss or gain of gene function models allowing precise determination of 
the cellular components essential in its maintenance and deregulation.  Human studies, 
however, remain imperative in our understanding of the haemopoietic hierarchy in view of 
the complex interactions within the bone marrow (BM) and peripheral blood (PB), as well 
as the differences that are noted between murine and human models.  For example, 
tumourigenesis or epigenetic vulnerability in species that vary in size, ecology, age to 
reproductive maturity, and lifespan will lead to differing cellular responses (Hahn & 
Weinberg, 2002).  
 
The phenotypic characterisation of human HSCs has been fundamental in the pursuit to 
understand normal and abnormal haemopoiesis.  CD34, a surface glycoprotein, was initially 
discovered to be expressed on primitive haemopoietic tissues, but absent on mature 
differentiated cells, representing only 1-4% of BM haemopoietic cells (Civin et al, 1984).  
This population has been shown to be multipotent, highly enriched for colony forming cell 
(CFC) activity in assays in vitro and having the capacity for long-term haemopoietic 
reconstitution in murine xenograft models and clinical HSC transplantation studies (Hogan 
et al, 2002; Kang et al, 2008; Krause et al, 2013a; Lu et al, 1993; Sutherland et al, 1989; 
Sutherland et al, 1990; Vogel et al, 2000).  Its physiological function is poorly understood, 
but roles in adhesion and differentiation have been described (Belay et al, 2017; Domogala 
et al, 2017; Ohnishi et al, 2013; Salati et al, 2008).  However, it has been demonstrated that 
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CD34-deficient mice retain normal PB counts and a response to haemopoietic stress (Cheng 
et al, 1996).  This may be, in part, due to the observation that CD34 positive (CD34+) cells 
appear to be a heterogeneous population, with some evidence to suggest that CD34 negative 
(CD34-) cells may be more primitive (Anjos-Afonso et al, 2013; Bhatia et al, 1998; Bonnet 
& Dick, 1997; Matsuoka et al, 2015; Zanjani et al, 1998).  Within human studies, Zajani et 
al demonstrated in vivo engraftment potential of some Lin-CD34- BM cells in foetal sheep 
in primary and secondary recipients, and Bhatia et al showed engraftment of human cord 
blood Lin-CD34- cells in NOD/SCID mice (Bhatia et al, 1998; Zanjani et al, 1998).  Within 
the latter, CD34+ cells were noted from the Lin-CD34- transplanted animals, suggesting 
CD34- to be more primitive.  These studies suggest that Lin-CD34- possess in vivo 
repopulating activity, rather than clonogenic and LTC-IC activity.  Because these findings 
have been shown within in vivo models, it may suggest that cell-to-cell interaction within 
the BM microenvironment can influence self-renewal and repopulating potential, and this 
will be explored later in this chapter.   
 
In view that the specificity of CD34 within an HSC population has yet to be fully determined, 
other surface markers in combination have been used to identify an HSC population.  These 
include CD38, CD90, CD49f and CD45RA.  Between 90 and 99% of CD34+ cells express 
CD38; these cells have been shown not to possess self-renewal potential.  Subsequently, it 
is the Lin-CD34+CD38- cells which are enriched in LTC-IC and have engraftment potential 
(Bhatia et al, 1997a; Hao et al, 1995; Huang & Terstappen, 1994a).  In combination with 
CD34, CD90 demarcates a population of immature cells, with expression reducing in the 
presence of markers of maturing lineage commitment (Baum et al, 1992; Chen et al, 1995; 
Murray et al, 1995; Negrin et al, 2000).  Further studies have introduced CD45RA as a 
marker of more differentiated cells (Bhatia et al, 1997b; Conneally et al, 1997; Craig et al, 
1994; Lansdorp et al, 1990; Majeti et al, 2007; Schiavone et al, 1995).  Similarly, CD49f 
expression has been described with enriched long-term HSC activity (van Galen et al, 2014; 
Yu et al, 2012), although its precision is variable between samples and, therefore, it is not 
typically used to define an HSC population in refined sorting strategies of human samples.  
Therefore, a current phenotype for human HSCs can be identified as Lin-CD34+CD38-
CD90+CD45RA- (figure 1-2). 
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1.1.3. The maintenance of HSCs through quiescence and self-renewal 
A refined cell sorting strategy to isolate highly purified stem and progenitor cell populations 
has led to an increased understanding of their functional and molecular properties, 
particularly within an HSC population.  In order for an HSC population to be maintained, 
HSC loss through apoptosis, senescence or commitment to differentiation must be balanced 
with self-renewal capability (Goodell et al, 1996; Orford & Scadden, 2008; Passegué et al, 
2005).  HSCs are mainly quiescent (i.e. residing in G0 phase of the cell cycle).  However, as 
they differentiate, a progressive reduction in the percentage of G0 cells is noted with a 
corresponding increase in the proliferation rate of each progenitor population (Catlin et al, 
2011; Nygren et al, 2006).  Although quiescence in itself does not define a stem cell, it is a 
major regulator of HSC function, with the ability to promote higher engraftment potential in 
HSC 
MPP 
CMP 
MEP GMP 
Platelets Erythrocytes Granulocytes Monocytes 
Lin- 
High CD34+ 
CD38- 
CD90+ 
CD45RA- 
Lin- 
High CD34+ 
CD38- 
CD90- 
CD45RA- 
Lin+/- 
High CD34+ 
CD38+/- 
CD90- 
CD45RA+ 
Lin+ 
High CD34- 
Cell specific markers 
Figure 1-2 Phenotypic characterisation of the haemopoietic hierarchy 
Schematic diagram depicting a phenotypic characterisation classification for an adult human haemopoietic 
hierarchy.  For the purpose of this thesis, HSCs can be phenotypically classified as Lin-CD34+CD38-
CD90+CD45RA-, with MPP population classified as Lin-CD34+CD38-CD90-CD45RA-, and mature 
populations classified by cell specific surface makers.  Each population used within experimental design is 
described within both the methods and results chapters, with appropriate sorting strategies defined. 
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in vivo models, and its loss resulting in an imbalance of progenitor cells leading to HSC 
depletion (Cheshier et al, 1999; Mahmud et al, 2001; Orford & Scadden, 2008; Vanegas & 
Vernot, 2017; Wang et al, 2015).  At a molecular level, cell cycle regulators play an integral 
role.  As expected within a non-proliferative state, there are higher levels of the negative cell 
cycle regulators and lower levels of genes involved in DNA replication, for example 
CyclinA2 and CyclinB1 are downregulated owing to their role in cell cycle progression and 
proliferation (Forsberg et al, 2010; Kalaszczynska et al, 2009).  Genes integral in 
transcriptional regulation, such as Foxo3 and Ezh1 are conversely upregulated within an 
HSC population (Miyamoto et al, 2007; Mochizuki-Kashio et al, 2011).  In keeping with 
this, expression of positive cell cycle regulators, such as CyclinD1, has been shown to 
increase during differentiation (Passegué et al, 2005).  
 
Although quiescence is a major regulator of HSCs, it is the cell’s capacity for self-renewal 
that defines it.  This function is critical to sustaining a hierarchical cell population.  Self-
renewal can be achieved through symmetric and asymmetric cell division, but the regulation 
of this has yet to be fully elucidated (Caussinus & Hirth, 2007; Daynac & Petritsch, 2017; 
Morrison & Kimble, 2006; Wu et al, 2007).  Recent evidence suggests that ligand-dependent 
signalling pathways’, such as Notch, Hedgehog (Hh), and Wnt/β-catenin, play a pivotal role 
(Campbell et al, 2008; Duncan et al, 2005; Staal et al, 2016; Weli et al, 2010).  These 
pathways are often controlled through cell-to-cell interaction in the BM microenvironment, 
where the HSCs reside.  Further to this, external signals from epigenetic modification and 
hypoxia, as well as intrinsic factors of the HSCs are deemed important (Belle et al, 2016; 
Bourdieu et al, 2017; Hasemann et al, 2014; Kramer & Challen, 2017; Vukovic et al, 2016).  
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1.2. Intrinsic and extrinsic regulation of HSC function 
1.2.1. The bone marrow microenvironment 
Haemopoietic stem and progenitor cells (HSPC) reside within the BM, which harbours 
distinct areas (or ‘niches’) that allow for the exogenous regulation of HSPC behaviour.  
Schofield first postulated this in 1978 (Schofield, 1978); however, it has only been in recent 
years with the advances in imaging techniques and selective genetic manipulation of specific 
cell populations that detailed insights of the BM anatomy and physiology have been 
generated (Kim et al, 2017; Le et al, 2017; Malide et al, 2014; Pang et al, 2015; Wang et al, 
2017).  
 
The BM microenvironment (figure 1-3) is composed of extracellular matrix proteins, 
including collagen, fibronectin, laminin and hyaluronic acid, as well as cellular elements, 
including haemopoietic and non-haemopoietic cells.  Non-haemopoietic cells include 
mesenchymal stem and progenitor cells (MSPC), osteoprogenitors, osteocytes, endothelial 
cells, adipocytes, sympathetic nerve fibres, and non-myelinating Schwann cells (Smith & 
Calvi, 2013).  These cells make up two distinct, yet controversial, niche types, namely the 
vascular and osteoblastic niches (Calvi et al, 2003; Kiel et al, 2005; Leatherman, 2013; 
Nilsson, 2001; Zhang et al, 2003).  The exact roles that each niche contribute in the 
maintenance of haemopoietic cells, and indeed HSCs, remains contentious, with it being 
suggested that the more primitive cells mainly reside in one niche (i.e. the osteoblastic niche) 
and then migrate on their development (Ding & Morrison, 2013; Ehninger & Trumpp, 2011).  
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Figure1-3 Simplified representation of the bone marrow microenvironment 
Schematic representation of the BM microenvironment.  The BM consists of two niche-types, 
namely the osteoblastic and vascular niche.  Within both niches is a collection of cells that lead 
to the secretion of chemokines, cytokines, and ligand interaction that governs HSC maintenance, 
expansion and self-renewal.   
   
The niche cells bi-directionally communicate with haemopoietic cells via a number of 
different mechanisms.  One such mechanism is through secreted factors, such as stem cell 
factor (SCF), transforming growth factor beta 1 (TGF-β1), and platelet factor 4 (PF4 also 
called CXCL4), and chemokines, such as stromal cell-derived factor 1 (CXCL12) (Camacho 
et al, 2017; Schroeder et al, 2016).  Furthermore, sympathetic nerve fibres can modulate 
HSPC function via the secretion of noradrenaline, as well as oxygen tension within the niche 
(Yamazaki et al, 2011).  Beside these mechanisms, cell-bound molecules such as adhesion 
molecules and ligands play an important role in HSPC maintenance and development, 
leading to both self-renewal and differentiation properties.  
 
MSPC have a clear functional role within normal and deregulated haemopoiesis 
(Friedenstein et al, 1968).  It has been shown that the simultaneous injection of donor MSCs 
with HSCs accelerates the recovery of haemopoiesis after lethal total body irradiation (Noort 
et al, 2002; Zhang et al, 2004).  Similarly marrow stromal cells can maintain haemopoiesis 
in vitro for periods longer than 6 months (Dexter et al, 1977).   
 
Self-renewal 
Endothelial cell 
HSC 
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Schwann cell 
Osteoclast 
Osteoblast 
MSC 
Adipocytes 
Macrophages 
Vascular  
Sinusoid 
Extracellular 
 matrix 
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Further to this, it is known that HSPC fate can be influenced by different tissue environments 
(Trentin, 1971), and indeed deregulated states can influence the environment in which they 
reside.  This highlights the role for bi-directional communication as being integral in the 
maintenance and development of HSCs in haematological disease.  For example, the first 
evidence for niche-driven deregulation of haemopoiesis was demonstrated in mice with 
deletions in the retinoblastoma gene, the retinoic acid receptor gamma, or the Notch ligand 
endocytosis regulator, Mib1 (Kim et al, 2008; Walkley et al, 2007).  Deletions in these genes 
led to a myeloproliferative disease phenotype and highlighted that deletions in non-
haemopoietic cells could contribute to hematological disease initiation.  Furthermore, 
alterations in evolutionary conserved self-renewal pathways have been shown to predispose 
to leukaemia induction.  For example, constitutively active β-catenin in osteoblasts has been 
demonstrated to induce an acute myeloid leukaemic (AML) phenotype (Kode et al, 2014).  
Furthermore, within this paper was the observation that Jagged1 was increased in 
osteoblasts, which, in turn increased Notch signalling in HSC progenitors.  It was 
subsequently suggested within this paper that Notch activation led to the development of 
genomic instability and chromosomal deregulation leading to the development of AML.    
 
Further to this, many examples have been presented to demonstrate that leukaemic HSPCs 
can also remodel the BM microenvironment.  For example, within chronic phase (CP) 
chronic myeloid leukaemia (CML), it has been shown that CML cells secrete granulocyte 
colony stimulating factor (GCSF) that results in decreased expression of CXCL12 and 
impairment of HSPC function (Zhang et al, 2012).  Moreover, CML cells can stimulate the 
expansion of osteoblasts by a number of mechanisms, including cell-to-cell contact between 
leukaemic cells and mesenchymal stem cells (MSCs) (Schepers et al, 2013).  This data 
suggests that remodeling of the BM microenvironment by leukaemia cells or other disease 
processes may reduce its ability to support normal haemopoiesis.   
 
Taken together, these data demonstrate the importance of, not only HSC to the BM 
microenvironment, but also how deregulated cells can influence their surroundings, and vice 
versa.    
 
1.2.2. Intrinsic regulation of HSC function 
As has previously been determined, haemopoiesis and HSC activity relies on an intricate 
balance of self-renewal and differentiation.  This is achieved through both intrinsic and 
extrinsic mechanisms that act as regulating controls.  As has been described above, extrinsic 
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regulation is imperative in this process; however, it is known that external regulatory signals 
must integrate with intrinsic mechanisms to have their effect.  
 
There are many intrinsic factors that have been shown to be implicated in the regulation of 
self-renewal and differentiation.  For example, in brief, translocation Ets leukaemia (Tel) 
has been demonstrated to be required for HSC self-renewal, with its inactivation leading to 
the depletion of HSCs in the BM (Hock et al, 2004).  Furthermore, overexpression of the 
transcription factor, HoxB4 has been shown to increase the self-renewal potential of HSCs 
in both in vitro and in vivo models (Hong et al, 2014; Magnusson et al, 2007; Oshima et al, 
2011; Sharma et al, 2006; Yu et al, 2014).  Growth factor independence 1 (Gfi1) has been 
identified as a positive regulator of HSC self-renewal that functions to restrain HSC 
proliferation through upregulation of the cell cycle inhibitor, p21, since its expression is 
decreased in Gfi1 null HSCs (Zeng et al, 2004).  As has previously been described, cell cycle 
regulators are imperative within this process.  In keeping with this is the balance of cell 
survival pathways, such as Janus kinase/signal transducers and activators of transcription 
(JAK-STAT) (amongst others), with Stat3 and Stat5 being shown to be positive regulators 
of HSC self-renewal (Kato et al, 2005; Schuringa et al, 2004a; Schuringa et al, 2004b).  This 
list is not exhaustive but highlights the importance of intrinsic regulation within the process 
of HSC function.  
 
1.2.3. Haemopoiesis and developmental signalling pathways 
Data has been presented above that highlights the critical role for extrinsic and intrinsic 
signals in the maintenance and function of HSCs.  Within this discussion has been the 
importance of cell-to-cell interaction between HSCs and the BM microenvironment where 
they reside.  Included in these are the ligand-dependent evolutionary conserved self-renewal 
pathways, Notch, Wnt/β-catenin, bone morphogenic protein (BMP), and Hh.  All have been 
implicated in the regulation of HSC self-renewal and stem cell expansion (Campbell et al, 
2008; Delaney et al, 2010; Delaney et al, 2005; Duncan et al, 2005; Staal et al, 2016; Weli 
et al, 2010). 
 
1.2.3.1. The Notch signalling pathway 
The Notch signalling pathway has a recognised role in the maintenance and expansion of 
HSCs.  It is an evolutionary conserved signalling pathway that was first discovered in 1917 
by Thomas Hunt Morgan in Drosophila melanogaster with observations of a notched 
phenotype in the wings of flies with the Notch gene mutation (Morgan, 1917).  Notch 
 11 
signalling has been shown to be involved in a variety of cell-fate decisions that influence the 
development and function of many organs, including stem cell maintenance, cell 
proliferation, haemopoiesis and apoptosis (Capaccione & Pine, 2013; Chiba, 2006; Cowart 
et al, 2012; Ohishi et al, 2003; Schwanbeck & Just, 2011; Yugawa et al, 2013).   
 
It is a ligand-dependent signalling pathway that activates as a result of cell-to-cell interaction 
between the Notch receptor on the target cell and the ligand on the adjacent cell (figure 1-
4).  Mammals express four transmembrane Notch receptors (Notch 1-4) and five 
transmembrane ligands (Delta-like (DLL) 1, DLL3, DLL4, Jagged (JAG) 1, and JAG2).  The 
ligands differ in their extracellular domains and functional capability dependent on cell 
contact.  For example, Delta family ligands can mediate Notch activation in trans and Notch 
inhibition in cis (Espinoza et al, 2013).  The relative affinity of Notch receptors for Notch 
ligands is controlled by receptor glycosylation mediated by the addition of fucose-N-
acetylglucosamine (fucose-GIcNAc) moieties (Stanley, 2007).  Three intracellular 
proteolytic cleavages occur to alter downstream gene expression. 
    
Firstly, Notch precursor proteins, processed in the trans-Golgi apparatus, are cleaved by a 
furin-like convertase to produce the mature Notch receptor, consisting of Notch extracellular 
and Notch transmembrane subunits.  Mature receptors are then taken to the plasma 
membrane, with subsequent membrane-associated ligand engagement.  Upon ligand-
receptor interaction, extracellular Notch is dissociated from the intracellular subunit.  This 
triggers cleavage by a disintegrin and metalloproteinase (ADAM) protease (either ADAM 
10 or 17).  This cleavage allows release of a short extracellular peptide that is then 
immediately cleaved by the gamma secretase complex (GSC), liberating intracellular Notch 
to translocate to the nucleus and initiate Notch signalling by binding to the CBF-1-
Suppressor of Hairless/lag1 (CSL), a constitutive transcriptional repressor, displacing co-
repressors and recruiting co-activators, such as Mastermind-like (MAML) proteins.  The 
Notch-CSL-MAML complex, in turn, recruits transcriptional regulators forming the Notch 
transcriptional complex.  It is this that activates Notch downstream target genes, including 
HES1 (Ohishi et al, 2003).  Notch signalling, particularly in the haemopoietic system is 
complicated by the number of Notch receptors and ligands expressed by both haemopoietic 
and stromal cells within the microenvironment, as well as the interaction between Notch and 
other key self-renewal signalling pathways, namely, Hh and Wnt/β-catenin (Campbell et al, 
2008; Duncan et al, 2005).  
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Aside from ligands, Notch signalling is positively regulated by Musashi-1 (Msi-1), an RNA-
binding protein belonging to a conserved family of neural RNA-binding proteins. Msi-1 
binds and represses the translation of Numb.  Numb is a membrane associated negative 
regulator of Notch that prevents the intracellular domain of the Notch receptor migrating to 
the nucleus (Imai et al, 2001; Pasto et al, 2014).  Furthermore, other negative regulators exist 
in this complex system.  Phosphorylation of the intracellular domain by CDK8 promotes 
FBXW7-modified ubiquitination and degradation of the intracellular Notch receptor, which 
subsequently terminates Notch signalling (Hannon et al, 2012; King et al, 2013; Takeishi et 
al, 2013).  To add another level of complexity, the addition of one of the fringe N-
acetylglucosamine (GIcNAc)-transferases (lunatic, manic, or radical) leads to the ‘fringe 
effect’ whereby the addition of GIcNAc to the O-fucose sugar can either inhibit Notch 
signalling when interacting with the JAG ligand, or initiate Notch signalling when 
interacting with the DLL ligand (LaVoie & Selkoe, 2003; Thomas & van Meyel, 2007). 
 
There is a documented role for Notch signalling in haemopoiesis, with differing roles in 
HSCs and differentiated cells described.  For example, forced activation of Notch1 in 
haemopoietic cells has been shown to increase HSC self-renewal capacity (Kunisato et al, 
2003).  However, in differentiated cells, Notch1 activation favours lymphoid lineage 
Figure1-4 Simplified representation of the Notch signalling pathway 
At the plasma membrane, Notch extracellular domain binds to the relevant ligand to facilitate ADAM 
protease activity and GSC cleavage. Intracellular Notch is dissociated and translocated to the nucleus, 
and forms a transcriptional activation complex with CSL (blue circle) and MAML (orange hexagon), which 
recruit co-activators that activate Notch target genes.  Phosphorylation of the intracellular Notch promotes 
FBXW7-mediated ubiquitination and degradation of intracellular Notch, terminating Notch signalling.  
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commitment (Stier et al, 2002), particularly within early T-lineage development.  
Furthermore, in vivo exposure of mouse or human haemopoietic progenitors to Notch 
ligands has been shown to enhance cytokine-mediated expansion and, thus has led to clinical 
trials assessing the role of Notch within haemopoietic recovery after cord blood 
transplantation (Dahlberg et al, 2011; Delaney et al, 2010; Delaney et al, 2005; Varnum-
Finney et al, 2003).   
 
Within HSC regulation, the role of Notch signalling remains controversial.  Several in vivo 
studies have demonstrated preserved HSC function despite genetic strategies to block 
transcriptional activation of all Notch receptors (Maillard et al, 2008).  However, 
inactivation of Notch2 has also been shown to delay reconstitution (Varnum-Finney et al, 
2011). Further to this, there is a noted role of cell-to-cell interaction between osteoblasts that 
express Jagged1, and HSCs, maintaining a self-renewal HSC state (Benveniste et al, 2014; 
Poulos et al, 2013).  In keeping with this, pan inhibition of activated Notch blocks both T 
cell development and HSC maintenance and expansion, demonstrating the role of Notch 
within the HSC-BM environment.  However, there have been published reports that suggest 
the contrary – that inhibition of Notch1 or Jagged1 has no effect on HSC self-renewal 
capacity (Mancini et al, 2005).   
 
The role of Notch is complex with divergent reports both from in vitro and in vivo 
experiments.  The reasons for this are numerous.  Firstly, the pathway can generate numerous 
ligand-receptor interactions, each with differing functional relevance, with expression on the 
tissue of interest being integral in its assessment.  For example, in murine B cell 
development, DLL1 functions as the main ligand for Notch2 whereas in T cell development 
DLL4 interacts with Notch1 (Kang et al, 2014; Meng et al, 2016; Ting et al, 2017).   
Furthermore, differing experimental design can lead to variation in Notch signal intensity 
(Delaney et al, 2010; Gama-Norton et al, 2015; Varnum-Finney et al, 2003); for example, it 
has never been formally shown if signal intensity varies in vitro or in vivo.  There will also 
be varying signalling intensity between plate-bound ‘isolated’ ligands versus stromal 
support from in vivo experiments, which will have a much wider array of ligands and self-
renewal pathway interactions.  A further explanation could come from non-canonical Notch 
signalling, whereby downstream signalling molecules can be activated through bypassing 
the co-complex formation with MAML.  For example, DLL1 ligands have been suggested 
to activate IL-6 mediated signalling in CD34+ cells, but not in purified HSCs.  This not only 
suggests a potential for non-canonical activation, but also highlights the differing roles one 
may see in immature and mature populations (Csaszar et al, 2014).  There remains much to 
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be gained through the understanding of this pathway and its interactions in normal and 
malignant HSCs. 
 
1.2.3.2. The Wnt/β-catenin signalling pathway 
The Wnt/β-catenin signalling pathway (figure 1-5) has been shown to be integral in 
haemopoiesis and malignant haematology (Galán-Díez et al, 2016; Richter et al, 2017; Staal 
et al, 2016).  In the absence of Wnt/β-catenin signalling, free cytoplasmic β-catenin is 
degraded by a multiprotein complex, including glycogen synthase kinase 3β (GSK3β), 
casein kinase 1 (CK1) alpha, and scaffold proteins (including adenomatous polypopsis coli 
(APC) and axin).  Phosphorylation is initiated by CK1 alpha, which primes β-catenin for 
GSK3β-dependent phosphorylation of Ser33, Ser37 and Thr41 residues. Receptor-ligand 
interaction allows for the stabilisation of β-catenin via the recruitment of axin and inhibition 
of GSK3β (Li et al, 2012a).  This allows β-catenin to accumulate within the cytoplasm and 
translocate to the nucleus where it interacts with members of the T-cell factor/lymphoid 
enhancer factor (TCF/LEF) subfamily of transcription factors to induce expression of Wnt 
downstream target genes (Willert & Nusse, 1998).   
 
It has been demonstrated that many cellular proteins can directly and indirectly interact with 
β-catenin and other components of the Wnt/β-catenin pathway.  Further to this, the intensity 
of the signal can have a concentration-dependent effect on cell fate (Luis et al, 2011).  It is 
well established that there is a role for Wnt/β-catenin signalling in embryonic haemopoiesis 
(Austin et al, 1997; Cheng et al, 2008; Corrigan et al, 2009; Tran et al, 2010), however, its 
role in adult haemopoiesis is yet to be fully determined.  In the adult BM microenvironment, 
the ligands, Wnt2b, Wnt5a, and Wnt10b are expressed (Van Den Berg et al, 1998), with 
evidence to suggest a role in lineage commitment.  Wnt5a is expressed by mature B cells, 
while Wnt10b is produced by myeloid cells, erythrocytes and immature B cells (Congdon et 
al, 2008; Liang et al, 2003).  Further to this, Wnt10b has been shown to be upregulated 
within BM regeneration (Congdon et al, 2008).   
 
In vitro experiments and gain- or loss-of-function in vivo studies have yielded differing 
results as to the role of Wnt/β-catenin signalling in HSC function (Kirstetter et al, 2006; Luis 
et al, 2009; Reya et al, 2003).  For example, constitutively active β-catenin in vivo in a Bcl2-
transgenic model increases HSC proliferation, and repopulation capacity upon 
transplantation into lethally irradiated mice (Reya et al, 2003).  However, conditional 
overexpression of a stabilised form of β-catenin led to a block in multi-lineage 
differentiation, transient HSC expansion, and long-term HSC exhaustion (Kirstetter et al, 
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2006; Scheller et al, 2006).  Additionally, HSCs from Wnt3a knockout murine foetal liver 
reconstituted haemopoiesis in primary transplant, but had severely impaired secondary 
transplant capacity, suggesting impaired self-renewal potential (Luis et al, 2009).  In some 
respects these results mirror the inconsistencies found in the similar experiments 
interrogating self-renewal pathways, including Notch (described above) and Hh signalling, 
as described below (Gao et al, 2009; Hofmann et al, 2009b; Merchant et al, 2010). 
 
 
 
 
 
 
 
 
 
 
 
Figure1-5 Simplified representation of the Wnt/β-catenin signalling pathway 
In the absence of Wnt signalling, free cytoplasmic β-catenin is degraded by a multiprotein complex.  
Receptor-ligand interaction allows for the stabilisation of β-catenin via the recruitment of axin and inhibition 
of GSK3β.  This allows β-catenin to accumulate within the cytoplasm and translocate to the nucleus where 
it interacts with members of the T-cell factor/lymphoid enhancer factor (TCF/LEF) subfamily of transcription 
factors to induce expression of Wnt downstream target genes.   
 
1.2.3.3. The Hedgehog signalling pathway 
The Hh signalling pathway (figure 1-6) is an evolutionarily conserved signalling pathway 
that was first discovered during the study of embryonic patterning in Drosophila (Nusslein-
Volhard, 1980).  It is critical for both embryonic development and adult tissue homeostasis, 
including chromatin formation (Zhan et al, 2011), cell cycle regulation (Kenney, 2000; Roy 
& Ingham, 2002) and stem cell self-renewal (Memmi et al, 2015).  In the adult, its functions 
are cell and tissue dependent, with its activation being implicated in the maintenance of 
cancer stem cells (CSC) in both solid (Ischenko et al, 2008; Samadani & Akhavan-Niaki, 
2015) and haematological malignancies (Irvine et al, 2016; Long et al, 2011; Zhao et al, 
2009).  Activation of the canonical Hh pathway appears to be linked to primary immotile 
cilia, with documented reports of primary cilia within haemopoietic tissue (Irvine et al, 2016; 
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Singh et al, 2016a).  The canonical pathway is ligand-dependent, relying upon receptor-
ligand interaction between one of the three possible ligand isoforms – Sonic (SHH), Desert 
(DHH), and Indian (IHH) – to the Hh receptors, Patched1 (PTCH1) and Patched2 (PTCH2).  
In the absence of ligand support, PTCH1 is located within the primary cilia, emphasising the 
importance of cilia within the canonical route.  Ligand-PTCH1 interaction causes the 
internalisation of PTCH and the subsequent activation of Smoothened (SMO).  Activated 
SMO then moves into the cilium allowing for the accumulation of the active forms of GLI2 
and GLI3 in the nucleus.  This potentiates the activity of other positive regulators, including 
serine threonine kinase 36 (STK36), resulting in activation of key downstream targets 
(Ischenko et al, 2008).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1-6 Simplified representation of the Hh signalling pathway 
Upon receptor-ligand interaction, PTCH1 is internalised and there is subsequent activation of SMO.  
Activated SMO moves into the cilium allowing for the accumulation of the active forms of GLI2 and GLI3 
in the nucleus.  This potentiates the activity of other positive regulators, including STK36, resulting in 
activation of key downstream targets. 
 
The role of Hh signalling in haemopoiesis is complex and has been shown to be dependent 
on developmental stage, cell lineage, and extrinsic factors, for example, under regenerative 
stress (Bhardwaj et al, 2001; Trowbridge et al, 2006a).  Evidence suggests that Hh plays a 
vital role in early haemopoietic development (Cridland et al, 2009).  However, its role within 
adult haemopoiesis is controversial, with some reports suggesting a dispensable role within 
normal haemopoiesis (Gao et al, 2009; Hofmann et al, 2009b; Trowbridge et al, 2006a).  For 
example, knockout of SMO in in vivo models has been shown not to adversely affect steady-
state normal haemopoiesis (Gao et al, 2009; Hofmann et al, 2009b).  Furthermore, SMO 
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inhibition within early phase clinical trials has shown little or no haemopoietic toxicity 
(Cohen, 2012; Feldmann et al, 2007). 
 
1.2.3.4. The BMP signalling pathway 
Like the self-renewal signalling pathways described above, there is a complex role noted 
within BMP signalling and haemopoiesis.  The BMPs belong to the transforming growth 
factor beta (TGF-β) superfamily and have been shown to be involved in diverse cellular 
functions, including cell proliferation, differentiation, apoptosis, and stem cell self-renewal, 
in both embryonic and adult phenotypes (Herpin & Cunningham, 2007; Miyazono et al, 
2005). The BMP pathway functions through receptor-mediated intracellular signalling 
(figure 1-7) (Toofan et al, 2014).  Two types of receptors have been identified; namely type 
I receptors (Alk2, Alk3, and Alk6) and the type II receptors (Bmpr2a and Bmpr2b) 
(Kirmizitas et al, 2017).  Different combinations of type II receptors with any of the type I 
receptors confers specificity and cellular consequence.  Within the canonical system, upon 
ligand binding with BMP2 or 4, type I receptors become phosphorylated, leading to the 
heterodimerisation with the type II receptor. This, in turn, phosphorylates the corresponding 
Smad proteins and drives the formation of the Smad-Smad complex (Blank & Karlsson, 
2011). This complex translocates to the nucleus where it regulates transcription of the 
downstream target genes (Derynck & Zhang, 2003). 
 
Canonical BMP signalling has been shown to be important in both early embryonic and adult 
haemopoiesis (Crisan et al, 2015).  BMP4 maintains the reconstitutive ability of HSCs in 
vitro (Bhatia et al, 1999).  Furthermore, Smad5 has been shown to negatively regulate the 
proliferation and self-renewal of early yolk sac derived multipotent haemopoietic 
progenitors (Khurana et al, 2014; Liu et al, 2003) with inhibition of Smad-dependent BMP 
signalling enhancing homing and engraftment of BM HSCs (Monteiro et al, 2008). In vivo, 
in conditional Bmpr1a mutant mice, the pool size of HSCs is controlled by trabecular bone 
volume (Zhang, 2003).  Thereby suggesting that BMP signalling mediated by Bmpr1a 
controls HSC number through regulation of the niche.  This is consistent with previous 
findings using a transgenic mouse model in which parathyroid hormone receptor is 
expressed (Calvi et al, 2003). 
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Figure1-7 Simplified representation of the BMP signalling pathway 
Upon ligand binding, type I receptors become phosphorylated, which leads to the heterodimerization of 
these receptors with type II receptors. This in turn phosphorylates the corresponding R-Smads and drives 
the formation of R-Smad–co-Smad complex. The Smad–Smad complex then translocates to the nucleus 
where it forms a complex with transcription factors and cofactors to regulate the transcription of BMP target 
genes involved in the cell cycle, proliferation and self-renewal. 
 
1.2.4. Integration of signalling pathways 
The evolutionary-conserved self-renewal pathways’ described above have a clear, yet 
complex, role within haemopoiesis.  The complexity to understand their role in haemopoiesis 
lies in the fact that they do not act in isolation, relying on interactions between pathways to 
maintain a balance between self-renewal and differentiation.  This is particularly relevant 
within the BM microenvironment, where intracellular signalling proteins can impact on one 
or more of the pathways.  But while many of the phenotypic and functional properties have 
been determined, the regulation of how these pathways interact has not been fully elucidated 
(Reya, 2003).  The complexity of the interconnectivity between self-renewal pathways can 
be demonstrated on basic proteomic analysis of self-renewal pathway proteins in normal 
HSCs, as demonstrated in figure 1-8.  Although gene and protein interconnectivity can be 
hypothesised through bioinformatic analysis, ongoing experimental analysis of the 
functional output has allowed some of these interactions to be validated.   
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Figure1-8 Protein interconnectivity of self-renewal pathways in normal HSCs 
Protein interconnectivity analysis of self-renewal pathways in normal HSCs as determined by 
proteinstring.com. There is a clear interconnectivity between proteins of the self-renewal pathways 
depicted, namely, Notch, Wnt/β-catenin, Hh, and BMP.  
 
Many of these interactions are dependent on communication between the BM 
microenvironment and the cell of interest, as described above.  Also, hypoxia has been 
shown to promote an undifferentiated state in a Notch-dependent manner, likely owing to 
the activation of HIF-1α (Gustafsson et al, 2005).  Furthermore, downstream targets of Notch 
signalling are Hh and Wnt/β-catenin components, including Gli2, Gli3, and TCF4 (Li et al, 
2012b).  Further to this, Wnt/β-catenin signalling influences Notch1 expression, with 
manipulation of the pathway by overexpression of β-catenin promoting significant 
expansion of murine HSCs in vitro (Reya, 2003).  However, its role, as stated above in vivo 
has been questioned since β-catenin has been conditionally expressed or deleted without 
having an effect on haemopoiesis (Cobas et al, 2004; Kirstetter et al, 2006).  Again, this 
suggests a complex role in an in vivo setting and influence through the BM 
microenvironment.  As described previously, axin and GSK3β mediate the phosphorylation 
and degradation of β-catenin in a basal state.  Inhibitors of GSK3β gene have been shown to 
promote human and mouse HSC maintenance (Sato et al, 2004) and haemopoietic 
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repopulation in transplanted mice (Trowbridge et al, 2006b) by modulating gene targets of 
Wnt/β-catenin, Notch and Hh pathways.  Furthermore, Wnt/β-catenin signalling influences 
the stability of GLI1 allowing for its accumulation (Nakamura et al, 2013; Noubissi et al, 
2009).   
 
As well as direct interactions between pathways, it has been shown that protein concentration 
influences cellular function.  For example, BMP4 has differential effects on human HSCs 
depending on concentration, maintaining but not expanding human HSCs in vitro (Bhatia et 
al, 1999).  Cross talk between hypoxia, HIF-1α, and TGF-β/Smad signalling has, in fact, 
been demonstrated in relation to CXCL12 induction and subsequent HSC induced homing 
towards this chemokine (Tabatabai et al, 2006).  Furthermore, Wnt/β-catenin signalling and 
BMP cooperate to influence HOX activity.   
 
This data demonstrates the complexities of interactions between self-renewal pathways at a 
basal HSC level, but it is the alterations and interconnectivity within haematological 
malignancy that may warrant further investigation when considering potential therapeutic 
targets, particularly within a stem cell driven disease phenotype, such as CML.  
 
1.2.5. Cancer stem cells in haematological malignancy 
CSC offer the concept that a small population of cells sharing characteristics of 
differentiation, self-renewal and homeostatic control, allow for the maintenance and 
dissemination of disease (Alison et al, 2011; Reya et al, 2001).  Within haematological 
disease, these are referred to as leukaemic stem cells (LSCs).  LSCs are mostly quiescent, in 
G0-phase and out of the cell cycle, and home to the BM microenvironment, in which they 
are protected from apoptosis and conventional treatments (Busfield et al, 2014; Crews & 
Jamieson, 2012; Zhang et al, 2013).  Within a variety of haematological malignancies, 
including AML (Bonnet & Dick, 1997), CML (Graham et al, 2007; Zhang et al, 2013), and 
multiple myeloma (Yaccoby et al, 1998), the existence of LSCs has been identified.  In vivo 
and in vitro experimental models have demonstrated that LSCs share many features with 
HSCs (Bhatia et al, 1997c), including self-renewal and engraftment potential, but have also 
offered critical differences in functional properties (Jordan et al, 2006), which allows for a 
therapeutic index of intervention, that would permit targeting of LSCs, whilst maintaining 
normal haemopoiesis.  For the purpose of this thesis, only AML and CML LSCs will be 
discussed in detail.    
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1.2.5.1. The identification and origin of LSCs 
AML LSCs were one of the first CSC populations to be characterised within haematological 
and solid malignancy (Bonnet & Dick, 1997; Lapidot et al, 1994).  The complexity in 
morphological, genetic, and epigenetic heterogeneity within AML makes identifying an 
appropriate therapeutic target challenging, but may allow for LSC characterisation if the 
AML LSCs have distinct features according to their subtype.  However, the 
immunophenotypic identification of the AML LSC remains a persistent area of debate (Blair 
et al, 1997; Blair et al, 1998; Bonnet & Dick, 1997; Jordan et al, 2000).  Historically, LSCs 
(both in AML and CML) have been characterised within the CD34+CD38- population, where 
their presence has been shown to be capable of generating leukaemic primary, secondary 
and tertiary engraftment in non-obese diabetic severe combined immunodeficient (NOD-
SCID) mice (Bonnet & Dick, 1997; Lapidot et al, 1994).  However, recent studies have 
suggested that LSC activity can extend into the CD34+CD38+ population, with data 
indicating that leukaemia-initiating capacity could be present in a mature CD34- population 
(Sarry et al, 2011; Taussig et al, 2010).  This suggests that LSCs can either be derived from 
HSCs or from progenitor cells that acquire self-renewal properties.   
 
Additional markers of AML LSCs have been identified, including CD123 (Al-Mawali et al, 
2016; Ehninger et al, 2014), CD33 (Ehninger et al, 2014), CD45RA (Kersten et al, 2016), 
CD47 (Majeti et al, 2009), CD96 (Hosen et al, 2007), and CD93 (Iwasaki et al, 2015).  Some 
are currently being translated into the clinical setting for identification or targeting of the 
LSC, including monoclonal antibodies towards CD47 (NCT02678338) and CD123 
(NCT02848248), as well as anti-CD123-chimeric antigen receptor-T (CART) cells 
(NCT03114670; NCT02159495) (Luo et al, 2015; Mardiros et al, 2013).  However, safety 
concerns have been described.  For example, CD47 is expressed on the majority of normal 
tissues and may prevent the ability to achieve a therapeutic level of antibody (Jaiswal et al, 
2009; Oldenborg, 2013).  Further to this, CD123 has been demonstrated to be expressed on 
HSCs, and not on all LSCs, therefore inhibition of CD123 may have some consequences in 
normal haemopoiesis (Gill et al, 2014; Taussig et al, 2005).    
 
Probably the most well established of these approaches, is the use of gemtuzumab 
ozogamicin (GO), an anti-CD33 monoclonal antibody conjugated with calicheamicin, which 
remains under clinical evaluation.  There have been large randomised studies of the use of 
GO in newly diagnosed patients with AML (Burnett et al, 2011; Burnett et al, 2012; 
Castaigne et al, 2012; Petersdorf et al, 2013b).  Within the AML15 clinical trial (Burnett et 
al, 2011), a subgroup analysis revealed an improved overall survival at 5 years for patients 
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with favourable cytogenetics (79% versus 71%, p=0.001), but no benefit for patients with 
unfavourable cytogenetics.  Furthermore, 70% of all intermediate-risk patients had a 10% 
improvement in 5-year overall survival if given GO during induction, but this seemed 
dependent on white cell count, performance status, or secondary disease. Within AML16 
(Burnett et al, 2012), there was no difference in the initial response rate, and the treatment-
related mortality was similar, without any increase in toxicity with GO. However, at a 
median follow-up of 30 months, the relapse rate was significantly lower with GO (68% 
versus 76%, p=0.007), and the 3-year overall survival was significantly better (25% versus 
20%, p=0.05).   
 
The difficulties in identifying a universal marker of AML LSCs are, in part, due to the intra-
patient and inter-patient heterogeneity identified within AML LSC populations (Eppert et 
al, 2011; Taussig et al, 2010) and has been particularly noted within relapse, where AML 
LSC frequency and phenotypic diversity have been shown to be much greater compared to 
the initial diagnostic LSC (Mendler et al, 2015; van Rhenen et al, 2007).   
 
Regardless of these complexities, the importance of AML LSCs clinically is well 
established.  Most pertinently, within the identification of minimal residual disease (MRD) 
(i.e. submicroscopic disease identified using molecular and immunophenotypic techniques), 
which resembles that of the diagnostic disease population, allows response to therapy to be 
followed over time, and offers a prognostic indicator for adverse outcome (Feller et al, 2004; 
Ivey et al, 2016).  It seems reasonable that LSCs reside within this population, having only 
been minimally impacted by conventional chemotherapy that targets dividing cells, and 
therefore, it stands that treatments focussing on the elimination of LSCs will reduce MRD 
and ultimately improve disease outcomes.  Furthermore, it has been shown that AML 
patients with a greater number of LSCs or a more prevalent stem cell phenotype at diagnosis 
have inferior clinical outcomes compared to those who have fewer LSCs or a less prevalent 
stem cell phenotype (Eppert et al, 2011; van Rhenen et al, 2005). 
 
Although the most historic evidence of LSCs within haematological disease arise within 
AML, much insight into potential therapeutic strategies can be acquired from CML, where 
the CP disease represents a classic example of the stochastic CSC hypothesis model, without 
the molecular, epigenetic and genetic heterogeneity seen within AML.  Furthermore, it is 
known that as the disease progresses to the acute BP, committed progenitors gain self-
renewal function; again highlighting the potential for LSC to be derived from a more mature 
progenitor population (Jamieson et al, 2004; Kinstrie et al, 2016; Radich et al, 2006).  
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Therefore, understanding the LSC in CML may be clinically transferable to other stem cell-
driven diseases, including AML.  
 
In CML, low-level BCR-ABL positive LSCs, as defined within a CD34+CD38- population, 
have been identified in the BM of tyrosine kinase inhibitor (TKI)-treated CP-CML patients 
in deep molecular response (i.e. those that achieve a 4-log or greater reduction of quantitative 
BCR-ABL expression from standardised baseline over a prolonged period) (Bhatia et al, 
2003a; Chomel et al, 2011; Chomel et al, 2016; Chu et al, 2011).   These cells have been 
shown to be capable of growth in LTC-IC assays and have murine engraftment potential, 
demonstrating their self-renewal capability.  The demonstration that CML LSCs persist in 
the presence of a targeted therapy explains the phenomenon of disease persistence, and 
highlights that LSCs are BCR-ABL independent, relying on other pathways to sustain their 
survival (Corbin et al, 2011; Hamilton et al, 2012).  The concept of disease persistence 
through quiescent LSCs has been further highlighted in recent years by trials exploring the 
discontinuation of TKIs in CP-CML patients with sustained deep molecular response; these 
will be described in detail within a later section in this introduction (Mahon et al, 2010; 
Richter et al, 2016; Ross et al, 2013; Takahashi et al, 2012).  
 
A number of challenges remain within both the scientific and clinical communities in the 
eradication of LSCs, in both AML and CML.  Firstly, in the identification of an appropriate 
specific target, or pan-target, that will enable permanent eradication of the LSCs.  Secondly, 
when an appropriate target is identified that is clinically justifiable, the timings of 
intervention must be deduced, as well as the evaluation of disease persistence.  This will 
remain a huge clinical challenge, especially in view that therapies that are only effective 
against the stem cell compartment (which represents 1-2% of bulk) may be difficult to 
evaluate due to the persistence of bulk malignant cells and concordant chemotherapy-based 
treatment.   
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1.2.5.2. Self-renewal pathways in LSCs – a potential target 
As discussed, self-renewal is considered to be the integral property of the LSC, and its 
deregulation is known to affect the development, maintenance, and persistence of LSCs in 
both AML and CML.  To date, a number of aberrant signalling pathways have been proposed 
to contribute to the LSC phenotype (Liao et al, 2012; Martelli et al, 2010; Naughton et al, 
2009; Sengupta et al, 2007; Zhao et al, 2007).  These pathways, including Hh, Notch and 
Wnt/β-catenin, are known regulators of self-renewal, and are often differentially expressed 
following genetic events.  A number of deregulated proteins within these pathways may 
represent a broadly applicable therapeutic strategy, however, it is well known that these 
pathways rarely work in isolation, and rely on a web of activity leading to disease 
maintenance, persistence, and progression.  The complexities in interaction between these 
pathways in LSCs are well documented and will be discussed under each heading below 
(figure 1-9).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure1-9 Complex interactions between self-renewal pathways.   
The interconnectivity between self-renewal pathways is well documented within the LSC.  It is known that 
proteins within each of the pathways, namely Hh, Wnt/β-catenin, and Notch, can both antagonise and 
agonise the other pathways by cross talk leading to both up- and downregulation of downstream targets. 
 
 
 
To add to this complexity in AML is the genetic variation that is seen, as this can mediate 
the proliferative and anti-apoptotic signals.   Expression of specific oncogenes, such as 
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FLT3, RAS, and MLL, may create new dependencies on specific signalling pathways in 
LSCs, and activate signalling pathways in isolation or simultaneously (Somervaille et al, 
2009; Stirewalt et al, 2001).  Therefore, developing a therapeutic intervention that is 
efficacious in all activated pathways remains unachievable.  Our best option remains to 
understand the acquired vulnerability in the mechanisms of the signalling pathways, which 
may offer a therapeutic window to eradicate the LSCs and plan for clinical translation. 
 
1.2.5.3. Evolutionary conserved self-renewal pathways in LSCs 
1.2.5.3.1. Hedgehog signalling and the LSC 
The Hh signalling pathway has been shown to be inappropriately activated in a number of 
malignancies, including AML and CML, where it is intrinsically involved in the 
maintenance and expansion of the LSC compartment (Dierks et al, 2008; Long et al, 2011; 
Zhao et al, 2009).  Within haematological malignancy, activation of the pathway has been 
shown to be linked to primary immotile cilia (Campbell et al, 2016; Singh et al, 2016), where 
the receptor-ligand interaction causes the internalisation of PTCH1 and subsequent 
activation of SMO.  This enables SMO to move into the cilium allowing for the accumulation 
of the active forms and the activation of key downstream targets (Irvine & Copland, 2012).  
SMO is the critical mediator in the canonical pathway and, therefore, represents a key 
therapeutic target to prevent the pathway’s activation. SMO can be readily targeted with 
pharmacological agents, including cyclopamine, and clinical grade agents, such as LDE225 
(sonidegib) (Irvine et al, 2016) or PF-04449913 (glasdegib) (Irvine & Copland, 2012; 
Martinelli et al, 2015). 
 
However, the pathway’s complexity lies in its interactions and dependency with other key 
survival pathways.  It has been suggested that the survival of CML progenitor cells is 
maintained by both the auto-activation of Hh and β-catenin (Su et al, 2012).  Furthermore, 
Hh activation modulates NUMB-p53 responses, therefore, Hh suppression will subsequently 
alter p53 target genes; p53 is referred to as the guardian of the genome, therefore, careful 
evaluation of modulation of its function needs to be gained (Colaluca et al, 2008; Sheng et 
al, 2013).  p53 as a modulatory target in leukaemia is an area which is becoming of increasing 
interest; both in CML (Abraham et al, 2016) and AML (Latif et al, 2015). 
 
The importance of Hh signalling in CML is well established, with SMO inhibition leading 
to reduced self-renewal capacity of CML LSCs in both in vitro models with clinical grade 
SMO antagonists, and in vivo¸ where Smo-deficient mice have reduced leukaemogenesis in 
primary and secondary transplantation models (Dierks et al, 2008; Irvine et al, 2016; Zhao 
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et al, 2009).  Furthermore, combination of SMO antagonists with TKIs has been 
demonstrated to lead to a synergistic reduction of CP CML LSCs in patient samples in vitro 
and CP and BC CML xenograft transplantation models (Irvine et al, 2016; Sadarangani et 
al, 2015).  Our group has recently demonstrated that LDE225, a small molecule clinically 
investigated SMO inhibitor, used alone and in combination with the TKI, nilotinib, inhibited 
the Hh pathway in CD34+ CP-CML cells, reducing the number and self-renewal capacity of 
CML LSC in vitro (Irvine et al, 2016).  The combination had no effect on normal HSCs and 
when combined, these agents reduced CD34+ CP-CML cell engraftment in NSG mice.  
Furthermore, upon administration to EGFP+/SCLtTA/TRE-BCR-ABL mice, the 
combination enhanced survival with reduced leukaemia development in secondary 
transplant recipients.   
 
Importantly, deregulation of Hh may potentially contribute to disease progression, with 
differential Hh activity increasing as CML progresses to blast phase (BP) (Su et al, 2012), 
and increased gene expression of PTCH1 has been observed in BP samples (Sengupta et al, 
2007).  Therefore, early targeting of the pathway may be therapeutically viable to reduce 
disease progression. 
 
Whilst preclinical data appears promising to support the Hh pathway as a therapeutic target 
in CML, clinical trials utilising SMO antagonists as a therapeutic option have halted in early 
phases. Within solid tumors, these inhibitors have successfully been translated into clinical 
practice (Rudin et al, 2009; Von Hoff et al, 2009), however, within CML when combined 
with TKI, toxicity has been a major limitation (Ottmann et al, 2015; Shah et al, 2014).   
 
In AML, the role of Hh has not been fully elucidated, with limited data available on the 
implications of Hh deregulation on disease biology, perhaps due to the vast heterogeneity 
seen within the disease.  Activation of Hh, through SMO and GLI expression, has been 
described within primary AML samples, particularly acute promyelocytic leukaemia 
(APML) (Bai et al, 2008; Yang et al, 2013); no SMO mutations have been identified to 
account for this increase in activity (Campbell et al, 2016).   It is clear, however, that there 
is a prognostic significance in its expression, with increased GLI1 and GLI2 being associated 
with reduced overall survival and as a marker of prognosis, respectively (Wellbrock et al, 
2015).  
 
Studies suggest that HHIP, a membrane-associated or soluble glycoprotein that functions to 
bind Hh ligands, can suppress leukaemic cell proliferation (Kobune et al, 2012); 
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furthermore, within the same study, reduced stromal HHIP expression was shown to 
contribute towards the development of AML.   HHIP can be modulated through standard 
chemotherapy agents, where it has been demonstrated that 5-azacitadine-mediated 
amplification of stromal cell HHIP expression led to attenuated leukaemic cell proliferation 
potential. 
 
The biological significance of pathway modulation has yet to be fully understood, with 
varying results available.  Genetic inactivation of SMO in MLL-AF9-transformed LSCs does 
not affect AML development in primary recipient mice (Hofmann et al, 2009).  Conversely, 
SMO inhibition with cyclopamine has been shown to reduce proliferation in 
myelomonocytic cell lines (Campbell et al, 2016).  AML, as a disease, shows great 
heterogeneity and, therefore, focused evaluation through each of the classified disease 
entities needs to be undertaken, but it appears that there may be a therapeutic role for Hh 
inhibitors within a myelomonocytic phenotype.  It is more clear that pharmacologic 
inhibition of Hh signalling appears to enhance AML ‘gold-standard’ therapy by sensitising 
LSCs to chemotherapy within the BM microenvironment (Fukushima et al, 2016a), which 
may lead to clinical advances in the eradication of AML LSCs.  Currently, clinical trials are 
under way to investigate Hh inhibitors in AML, and early phase 1/2 results appear promising 
(Cortes et al, 2016a; Martinelli et al, 2015). Of note, a subsequent phase 2 clinical trial of 
LDE225 in AML, NCT01826214, recently closed due to lack of efficacy as a single agent; 
perhaps highlighting the limited activity of SMO inhibition on bulk disease.  
 
1.2.5.3.2. Wnt/β-catenin Signalling and the LSC 
The Wnt/β-catenin signalling pathway plays an essential role in the maintenance and 
differentiation of LSCs and the propagation of malignancies (Clevers, 2006; Jamieson et al, 
2004).  Its activation has been demonstrated in acute disease, namely AML LSCs and within 
myeloid BC CML (Ho et al, 2016; Jamieson et al, 2004).  Furthermore, it has been suggested 
that a deletion within β-catenin reduces the ability of mice to develop Bcr-Abl positive 
leukaemia, which is suggestive of a role in the pathogenesis of chronic disease (Zhao et al, 
2007).  Therefore, targeting Wnt/β-catenin is a viable option in eradication of the LSC and 
in the prevention of disease progression and dissemination.   
Within CML, loss of β-catenin in a murine model of CML impaired the development of the 
disease by inhibiting LSC self-renewal, and genetic and pharmacological inhibition of β-
catenin activity synergised with TKI to target the loss of CML LSCs (Heidel et al, 2012; 
Jamieson et al, 2004).  CBP/catenin antagonists have demonstrated efficacy in eliminating 
the CML and acute lymphoblastic leukaemia (ALL) LSC population in vitro and in vivo  
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(Gang et al, 2014; Zhao et al, 2016). A similar importance is seen within AML, where high 
expression of Ctnnb1 has been reported to correlate with poor prognosis (Ysebaert et al, 
2006).  Deletion of β-catenin within murine models has been shown to significantly reduce 
development and transplantation of AML driven by MLL-AF9 or HoxA9 (Wang et al, 2010; 
Yeung et al, 2010).  In turn, within murine models of MLL-rearrangement AML it has been 
shown that self-renewal of LSCs is mediated, in part, by Ctnnb1, suggesting that Ctnnb1 
may represent a therapeutic target within this subtype.  Genetic and pharmacological 
inhibition of Ctnnb1 leads to decreased leukaemia formation.  Interference with 
prostaglandin signalling has been shown to target the Wnt/β-catenin axis in HSCs (Goessling 
et al, 2009), and treatment with COX inhibitors, such as indomethacin, has been shown to 
lead to a decrease of LSCs in secondary recipients (Wang et al, 2010).  This is mediated 
through Ctnnb1, although translating this clinically would be a challenge in view of adverse 
risk of bleeding.  Inhibitors of canonical Wnt/β-catenin signalling are currently undergoing 
phase I clinical trials in AML (NCT01398462) (Cortes et al, 2014b).  
 
Again, the interactions with other survival pathways, complicates antagonising Wnt/β-
catenin.  For example, within CML, TKI exposure has been shown to upregulate CD27 
signalling, resulting in activation of Wnt target genes, which include Notch and c-Myc 
(Riether et al, 2015; Schurch et al, 2012).  Wnt/β-catenin-Notch interaction is well 
documented, particularly within the BM microenvironment, where mutations of Ctnnb1 
have been found in osteoblasts resulting in overexpression of Notch ligands and activation 
of the Notch pathway in HSCs (Kode et al, 2014). 
 
The non-canonical Wnt (i.e. β-catenin independent) signalling pathways are diverse and can 
be initiated by WNT interaction with Frizzled receptors, or RYK and ROR receptor tyrosine 
kinases, to regulate small GTPases, as well as calcium flux and kinase cascades (Ford et al, 
2013).  This area is not as well characterised in LSC maintenance as the canonical pathway 
(Shen et al, 2014). Non-canonical signalling has been shown to exert an antagonistic effect 
on canonical signalling, with Wnt5a promoting GSK3β independent degradation of β-
catenin and competing with Wnt3a for binding to the receptor complex (Anastas & Moon, 
2013).  A greater understanding of the non-canonical pathway may decipher an interesting 
therapeutic approach in β-catenin inhibition.  
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1.2.5.3.3. Notch signalling and the LSC 
Notch signalling is involved in a variety of cell-fate decisions that influence the development 
and function of many organs, including stem cell maintenance, cell proliferation, 
haemopoiesis and apoptosis (Bray, 2016; Chiba, 2006).  
 
Its role in malignancy has been shown to be cell and tissue-dependent, with the pathway 
playing both oncogenic and tumour suppressive roles depending on cell and cancer type 
(Capaccione & Pine, 2013; Pancewicz & Nicot, 2011; Schwanbeck & Just, 2011; Yugaw et 
al, 2013). In haemopoietic malignancies, accumulating evidence demonstrates its 
importance in growth, differentiation, and apoptosis (Chiang et al, 2013; Etet et al, 2012; 
Hannon et al, 2012; Kamdje et al, 2011; Pancewicz & Nicot, 2011; Schwanbeck & Just, 
2011), with its role in T-ALL, chronic lymphocytic leukaemia (CLL), and B cell leukaemias 
and lymphomas well documented (Ellisen et al, 1991; Etet et al, 2012; Hannon et al, 2012; 
Kamdje & Krampera, 2011). Improved understanding of the Notch signalling pathway in 
these malignancies suggests that the Notch pathway may be a prime drug target; however, 
the therapeutic role of Notch inhibition may be directly dictated by its toxicities and the 
influence of its inhibition on other cell lineages, including the myeloid lineage (Deangelo et 
al, 2006; Krop et al, 2012). 
 
Reports about the role which Notch plays in myeloid disease are conflicting, as Notch 
activation in myeloid precursors has been shown to promote self-renewal, induce and inhibit 
differentiation to monocytes, or induce apoptosis (Carlesso et al, 1999; Li et al, 1998; 
Sarmento et al, 2005; Schroeder et al, 2003).  Early observations suggested that Notch 
signalling may play a role in myeloid progression (Milner et al, 1996; Schroeder et al, 2003; 
Tan-Pertel et al, 2000), with its role best characterised within AML.  Importantly, it has been 
shown that exposing AML cells to plate-bound Notch ligands led to a full range of responses 
from proliferation to growth arrest that varied with patient sample, suggesting again the 
difficultly evaluating signalling pathways due to inter-patient heterogeneity (Tohda & Nara, 
2001).  More recently, observations have supported a tumour suppressive role for Notch 
signalling in immature LSC compartments of AML disease models (Chen et al, 2008; 
Kannan et al, 2013; Klinakis et al, 2011; Lobry et al, 2013; Tohda & Nara, 2001). 
Furthermore, in AML cell lines and primary patient blasts, downregulation of Notch1 
expression was associated with a decrease in PU.1-mediated differentiation capacity, 
indicating a pivotal role in maintenance of an immature state (Chen et al, 2008).  
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Within CML, the data is limited. In another myeloproliferative disorder, chronic 
myelomonocytic leukaemia, a tumour suppressor role for the Notch pathway was again 
described, supporting a loss-of-function hypothesis (Klinakis et al, 2011). Conversely, 
however, a recent paper has identified an antagonistic role between Notch and TKIs within 
primitive samples; although the mechanisms have not been fully elicited, this perhaps is 
representative of crosstalk between signalling pathways (Aljedai et al, 2015).  Recent data 
from our group has suggested the importance of Notch activation within LTC-IC assays, 
where activation of the CD34+38- population through Jagged1 led to a statistically 
significant reduction in colonies (Horne et al, 2016).  It remains to be seen if this pathway 
has a functional and, indeed, therapeutic role, within CML biology.  There are no clinical 
trials underway evaluating Notch modulation in myeloid disease. 
 
1.2.5.3.4. BMP signalling and the LSC 
BMP have been shown to be involved in diverse cellular functions, from apoptosis to self-
renewal, in embryonic and adult phenotypes.  Dysregulation within the BMP-TGF-β 
pathway is critical in LSC survival (Laperrousaz et al, 2013; Miyanari & Torres-Padilla, 
2012; Naka et al, 2010), particularly mediated by its downstream target genes in the Cdx-
Hox axis.   
 
Interaction between Wnt/β-catenin and BMP signalling regulates the Cdx family of 
homeobox transcription factors – the master regulators of Hox gene expression (Lengerke 
et al, 2008).  Cdx2 is aberrantly expressed in AML and promotes leukaemia propagation 
through deregulation of Hox genes (Scholl et al, 2007), with its overexpression demonstrated 
in 90% of AML patients and overexpression in vivo leading to increased engraftment in NSG 
murine models.   Aberrant expression of HOX genes has been linked to both AML and CML 
(Grier et al, 2005; Scholl et al, 2007), with overexpression of HoxB3 (Sauvageau et al, 1997), 
HoxB8 (Perkins et al, 1990), or HoxA10 (Sauvageau et al, 1997) leading to the generation 
of acute leukaemia in murine models, as well as being associated with expansion of the HSC 
compartment in in vitro and in vivo models (Antonchuk et al, 2002; Thorsteinsdottir et al, 
2002).  Although this represents an interesting target of both Wnt/β-catenin and BMP, no 
translational evidence is available for an antagonistic influence in LSC regression.  
 
Genomic studies within primary CD34+ CML samples suggest that components of the 
pathway, including target genes, are downregulated (Gerber et al, 2013; Radich et al, 2006; 
Toofan et al, 2014).  This raises the possibility that the pathway can be activated through 
extrinsic mechanisms, and emphasises the role of the BM microenvironment in the 
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protection of LSCs against TKI-mediated apoptosis.   It has been shown that type 1 receptors 
are present on LSCs in primary CML samples, with an associated downregulation of BMP 
ligands (Laperrousaz et al, 2013; Toofan et al, 2014). CML aspirate and trephine BM 
samples had significantly higher levels of BMP2 and BMP4 compared to normal donors.  
This suggests that there is the ability to upregulate the BMP pathway and that it is via 
extrinsic mechanisms within the diseased BM microenvironment/niche.  Laperrousaz et al 
(Laperrousaz et al, 2013) demonstrated that expression of BMP2 and BMP4 varied 
depending on niche cell type, with BMP2 and BMP4 being more highly expressed in 
polymorphonuclear cells and endothelial sinusoid cells, respectively.  In response to 
increased levels of soluble BMP2 and BMP4, they showed that CML LSCs maintained their 
primitive phenotypes and enhanced LTC-IC potential, indicating that the BMP pathway can 
suppress differentiation and potentiate LSC survival. 
 
1.2.6. Clinical implications of LSC and drug targets 
The above suggests that as LSCs retain dependency on self-renewal pathways, they could 
be selectively targeted if the complexities in their interactions are fully understood.  
Disappointingly, despite strong in vitro and in vivo preclinical data, drugs against these 
targets have yet to be implemented in the clinical setting as a standard of care.  This is, in 
part, due to trial design, as well as toxicities that are generated, particularly in areas with 
high cell turnover, such as within the gastrointestinal tract. 
 
The clinical need for alternative and more effective therapies in AML and CML are different.   
AML represents a disease where there has been little progress in therapeutic strategies, with 
improvement in survival likely secondary to better supportive measurements rather than 
improvements in standard chemotherapeutics.  The need for targeted and individualised 
treatments is a necessity in the disease for improved outcome and eventual cure.  However, 
the targeting of LSCs is likely only to be effective in a minority of patients and will vary, 
dependent on the sub-class of disease.  The difficulty remains in 1) identification of LSC in 
bulk samples with no established immunophenotype, and 2) understanding the differences 
in signalling pathways within an epigenetic, genetic, and morphologically heterogeneous 
disease. 
 
Within CML, there has been an overall improvement in survival of approximately ten-fold 
since the introduction of targeted therapy against BCR-ABL (Bower et al, 2016).  This has 
led to the majority of patients achieving close to normal life expectancy, when treated with 
TKIs.  The need for eradication of the LSC is necessary to enable complete eradication of 
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CML and subsequent cure, allowing patients to stop therapy, and to alleviate a financial 
burden within healthcare systems.  Like AML, a biomarker of the LSC needs to be identified 
and sensitive enough to identify CML LSCs at low level following treatment. Although 
many labs have performed extensive analysis to identify markers of a primitive cell 
population in the preclinical setting, including CD26 (Culen et al, 2016; Herrmann et al, 
2015; Warfvinge et al, 2017) and IL1-RAP (Järås et al, 2010; Landberg et al, 2016; 
Warfvinge et al, 2017; Ågerstam et al, 2016), none have been shown, as yet, to be robust 
enough at clinical translation.  CD26, however, is showing increasing promise in this area 
with recent data suggesting a correlation between CD26 expression and treatment response, 
as well as Lin-CD34+CD38-/lowCD45RA-cKIT-CD26+ population being identified as a 
potential therapeutic target at a single cell level (Culen et al, 2016; Warfvinge et al, 2017). 
Although identification of the CML LSC appears to be within reach, little is known about 
the biology of the LSC in those patients that are in deep molecular response, with much of 
our understanding and the previous data coming from a drug-naïve population.  Clinically, 
the therapeutic need will be in those that are on TKI therapy. 
 
The biological understanding of aberrant self-renewal pathways within the LSC and 
potential targets is well underway; however the preparation for translation into the clinical 
setting needs to be considered.  Firstly, as stated above, within each disease the 
immunophenotypic characterisation of the LSC needs to be established.  When this is 
verified and supported internationally, there are considerations that need to be addressed to 
translate targeted inhibition or activation clinically. 
 
Firstly, decisions regarding evaluation of response to self-renewal modulation.  Within an in 
vivo and in vitro setting, these responses are often generated by utilising immature 
populations of sorted cells or genetically manipulating murine models.  Within a clinical 
setting, the response of bulk disease cannot be used as a surrogate for the clinical effect on 
the LSC population as there are differential sensitivities between the bulk and LSC 
populations, nor can evaluation of survival be used as a surrogate in treatment evaluation.  
Clearly, established markers of the LSC (e.g. murine engraftment, LTC-IC assessment, re-
plating efficiency) may be used as a surrogate for response, or an MRD evaluation could be 
used to generate some understanding of the proportion of LSC at diagnosis and then 
following treatment.    
 
Secondly, comparing new, targeted approaches to standardised chemotherapy regimens 
needs to be carefully executed.  The use of GO in AML has directed understanding of the 
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evaluation of a targeted response compared to standard treatments (Petersdorf et al, 2013; 
Rowe & Lowenberg, 2013), with a realisation that often a targeted therapeutic approach 
within bulk samples will require a longer treatment period to achieve a clinical response.  
Can overall survival be used as an endpoint if standard chemotherapy eradicates bulk 
disease, whereas targeted approaches are acting as an adjunctive therapy that requires longer 
duration to see an effect? 
 
Thirdly, treatment timings of intervention will be essential in the understanding of disease 
biology.  The treatments could be started simultaneously to allow for the likely longer 
duration needed for the targeted therapy to achieve a response.  But this would cause 
difficulties in an appropriate primary clinical end-point and evaluation of the LSC response 
to therapy.  Alternatively, the treatments could be sequenced to allow for identification of 
those patients, particularly with CML, where targeted therapy (in addition to BCR-ABL 
TKI) is not needed, and in AML, in those that have MRD positivity despite chemotherapy.  
This would, however, open the potential for clonal evolution of the disease, which may 
render it more difficult to treat and skew results of an LSC-targeted approach.  With a 
concurrent approach, it is likely that drug toxicities may be a clinical issue, rendering the 
approach undeliverable as a standard-of-care.  
 
Therefore, not only is an in-depth understanding of aberrant signalling pathway biology 
within LSCs required for generation of appropriate and justifiable therapeutic targets in the 
eradication of LSCs, careful consideration in the isolation and identification of LSCs, 
endpoint response, and timing of therapy is needed to enable translation of the therapeutic 
targets into a clinical setting. 
 
1.2.7. Chronic myeloid leukaemia as a paradigm for a cancer stem cell 
malignancy 
As described above, increasing evidence suggests that many malignancies function through 
primitive cell populations that share properties with somatic stem cells, termed CSCs (LSCs 
for leukaemias).  Conventional chemotherapy is unable to eradicate these and, therefore, 
development of targeted therapies is a necessity to lead to cure.  CML represents an excellent 
disease model of LSCs, as it is a clonal disorder with its origin traceable to the very primitive 
multipotent stem cell (Fialkow et al, 1967; Fitzgerald et al, 1971; Yamamoto et al, 2013).   
Furthermore, CML is a well understood disease, with numerous well validated experimental 
models that can be manipulated, when compared to the heterogeneity seen within AML 
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(Clarke & Holyoake, 2017; Daley et al, 1990; Eaves et al, 1998; Gelebart et al, 2016; 
Holyoake & Vetrie, 2017; Milne, 2017; Sontakke et al, 2016; Van Etten, 2001). 
 
Much evidence has been provided to demonstrate a functional role of CML as a paradigm 
for a stem cell disease.  Clinically, it has been observed that packed red cell transfusions 
from cells derived from CML patients could lead to temporary homologous BM engraftment 
and Philadelphia positive (Ph+) progeny in the PB of severely neutropenic recipients’ (Levin 
et al, 1963).  The first experimental evidence came from in vivo transplantation and in vitro 
stem cell assays (Copland et al, 2008; Daley et al, 1990; Foley et al, 2013; Graham et al, 
2007a; Holyoake et al, 1999; Koschmieder et al, 2005).  Furthermore, unlike other 
oncogenes, Bcr-Abl expression in murine haemopoietic progenitors fails to confer self-
renewal capability and fails to induce leukaemia in vivo, confirming a stem cell origin of 
disease (Foley et al, 2013; Huntly et al, 2004). 
 
Although it is generally accepted that the cell of origin within CML is the HSC, its clonal 
origin is traceable to the multipotent stem cell, giving rise to both haemopoietic and 
endothelial cells (Fang et al, 2005; Fialkow et al, 1967; Gunsilius et al, 2000).  This 
highlights evidence presented in the previous section of the thesis of the importance of the 
BM microenvironment within the disease process, altering intra-cellular signalling and 
protein expression that may affect cross talk between the LSC and BM microenvironment.  
The interactions between LSCs and the BM remain an important area of research and may 
determine the best strategy for eradication of the LSC.  In many myeloid leukaemias’ there 
is enhanced osteoblastic proliferation and a marked increase in LSCs and progenitor 
expansion (Krause et al, 2013).  LSCs rely on the BM niche for their persistence and 
modulate it to enhance survival, and a number of key interactions with self-renewal 
pathways contribute to the chemo-resistance that is seen.  Deregulation of BMP has been 
shown in murine models where Bmpr1a/Alk3 conditional knockout mice have impaired 
BMP signalling, which leads to increased niche size and thereby enhanced numbers of HSCs 
(Zhang et al, 2003b).  Furthermore, a number of ligand-receptor mediated pathways regulate 
CML LSC, and in turn alter signalling pathways responsible for their maintenance, including 
the thrombopoietin receptor, MPL, which regulates JAK-STAT signalling (Zhang et al, 
2016).  MPL has been shown in high levels to lead to reduced TKI sensitivity in CML, 
although, in turn, a higher sensitivity to JAK inhibitors.  Expansion of the osteoblast layer 
of the CML BM microenvironment can contribute to creating a hostile environment for HSC, 
mediated through alterations in TGF-β, Notch and pro-inflammatory signalling (Bowers et 
al, 2015; Krause et al, 2013).  However, there are difficulties in utilising the BM 
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microenvironment therapeutically – how should the pathways within the marrow be 
targeted? Would peripheral injections suffice to produce a large enough concentration of 
blockade without leading to adverse effects?  Signalling pathways clearly play an important 
role in determining cell survival, proliferation and differentiation of the leukaemic clone.  
Therefore, it seems pertinent to understand the role of differing signals within a CML LSC 
population, to fully identify potential therapeutic targets.    
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1.3. Chronic myeloid leukaemia 
CML is an acquired myeloproliferative disorder that originates from a constitutively active 
oncogenic tyrosine kinase, BCR-ABL.  It was first identified in the mid-1800s, where 
descriptions of splenomegaly and leucocytosis were described by independent physicians’ 
(Bennett, 1845; Craigie, 1845; Kampen, 2012; Virchow, 1845).  Although Bennett initially 
described his case as an infective process, Virchow suspected a neoplastic disorder that he 
called ‘white blood cell disease’ or ‘leukaemia’.  Following this, the Philadelphia 
chromosome was identified, where the observation of an abnormally small G-group 
chromosome was made – this was the first link between chromosomal abnormalities and 
human cancer (Nowell, 1962; Nowell & Hungerford, 1960) and paved the way in the 
understanding that cancer could be of genetic consequence.  However, despite these initial 
discoveries, it was only in 1973 that Janet Rowley recognised that the Ph chromosome was 
the product of a reciprocal translocation between chromosome 9 and 22 (Rowley, 1973).  
The translocation partners were later identified as BCR and ABL, with the associated 
upregulation of tyrosine kinase activity leading to the cell’s proliferation and survival 
(Groffen et al, 1984; Heisterkamp et al, 1983; Melo et al, 1993; Shtivelman et al, 1985).      
 
CML accounts for 15-20% of all adult leukaemias', with an incidence of approximately 1 in 
100,000.  The median age of presentation is between 40 and 60 years.  The disease normally 
runs a triphasic course from an initial CP to an accelerated phase (AP), and then to the acute 
phase of the disease, termed BC or BP.  Without treatment, disease progression is inevitable.  
Duration of disease, before progression or death has been shown to be 4-6 years, 1 year, and 
3-6 months, if left untreated for CP, AP and BP, respectively, but this remains highly 
variable between patients (Jabbour & Kantarjian, 2014).  Expansion of the myeloid 
compartment in the BM characterises the CP of the disease and leads to a left shift of the 
myeloid lineage in the PB and resultant accumulation of mature neutrophils, often with the 
presence of basophilia and thrombocytosis.  Splenomegaly is often detected on clinical 
examination.  On progression to AP and BP, there is a block in differentiation and leukaemic 
blasts accumulate in the BM and PB, leading to a similar clinical presentation as seen in 
acute leukaemia, with severe BM failure (Sawyers, 1999), and a very poor prognosis.      
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1.3.1. Molecular biology and clinical pathogenesis of CML 
The Philadelphia chromosome is pathognomonic of CML (Nowell, 1962; Nowell & 
Hungerford, 1960; Rowley, 1973).  It consists of a shortened chromosome 22, resulting from 
a reciprocal translocation, t(9,22)(q34;q11), between the long arms of chromosome 9 and 22 
(figure 1-9) (Rowley, 1973).  The Philadelphia translocation adds a 3’ segment of the 
Abelson murine leukemia viral oncogene homolog (ABL) gene from chromosome 9q34 to 
the 5’ segment of the breakpoint cluster region protein (BCR) gene on chromosome 22q11.  
This creates a hybrid BCR-ABL that can be subsequently transcribed into mRNA which gives 
rise to the BCR-ABL protein.  More than 95% of patients with CML harbour this mutation, 
along with 15-30% of adults with ALL, and 2% of adults with de novo AML (Crews & 
Jamieson, 2012).   
 
The ABL gene encodes a 145kD non-receptor kinase and contains 3 SRC homology (SH) 
domains, SH1, SH2, and SH3 (Van Etten, 1999).  SH1 is the functionally active tyrosine 
kinase domain, with SH2 important in protein-protein interactions, and SH3 regulating 
tyrosine kinase activity through an inhibitory function.  The main function of the ABL 
protein is to integrate signals from intra- and extracellular sources to affect survival, 
proliferation and apoptosis (Brasher & Van Etten, 2000; Hantschel et al, 2012; Nagar et al, 
2003).  The BCR gene encodes a 160kD protein that acts as a serine threonine kinase via a 
domain at the N-terminus.  Further to this, it has a dimerisation domain, as well as central 
and C-terminal domains that allow interaction with signalling proteins (Hantschel & Superti-
Furga, 2004).  The phosphorylation of BCR itself can activate signalling pathways, including 
RAS, as well as JAK-STAT and PI3k-AKT, maintaining the cell’s proliferation and survival 
(Danial & Rothman, 2000).    
Figure1-10 The development of BCR-ABL through the translocation of chromosome 
9 and 22 
The reciprocal translocation between chromosome 9 and 22 results in the formation of the Philadelphia 
chromosome (shortened 22) and the BCR-ABL fusion transcript. 
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As discussed, the translocation of the 3’ portion of ABL to 5’ portion of BCR leads to the 
formation of a BCR-ABL transcript, which gives rise to the BCR-ABL protein.  Different 
breakpoints within the BCR sequence have been identified and, depending on where the 
break occurs, three chimeric BCR-ABL proteins of different molecular weight can be 
produced (p190, p210, and p230 BCR-ABL) (Melo, 1997).  Most CML patients harbour the 
p210 BCR-ABL protein, while the p190 BCR-ABL is mainly seen in patients with 
Philadelphia chromosome positive (Ph+) ALL, and rarely patients with CML.  p230 BCR-
ABL has been associated with a variant form of CML, termed chronic neutrophilic 
leukaemia, which tends to run an indolent course, although classical cases of CML in 
association with p230 BCR-ABL have been described (Arana-Trejo et al, 2002; Bertorelle 
et al, 2001; Elliott et al, 2005).  All three proteins have been shown to have in vitro 
transformation properties and in vivo leukaemogenic activity, although have different kinase 
affinity (Clark et al, 1988; Daley et al, 1990; Konopka et al, 1984; Li et al, 1999).  Via 
autophosphorylation and substrate phosphorylation, BCR-ABL can directly and indirectly 
activate the signalling pathways central to its transforming activity (Cai et al, 2017; Cutler 
et al, 2017; Horne et al, 2017).  Further to the activation of signalling pathways, various 
structural alterations of ABL and BCR can facilitate leukaemogenic activity.  For example, 
the N-terminal coiled-coil motif of BCR increases its tyrosine kinase activity and enables 
binding by ABL (Dorey et al, 2001; Hantschel, 2012; Hantschel & Superti-Furga, 2004; 
Schindler et al, 2000).  Structurally, these alterations allow for multiple protein-protein 
interactions and activation of downstream signalling pathways that confer a survival and 
proliferative advantage.  Furthermore, BCR interferes with the adjacent SH3 kinase 
regulatory domain, which in turn causes ABL to become constitutively active. 
 
There is a clear pathognomonic role for BCR-ABL in CML.  Furthermore, it also enables 
diagnostic certainty and an ability to monitor disease response to treatment via assessment 
of quantitative (q)BCR-ABL.    
 
1.3.2. Defining treatment response 
It has been well described that patient outcome correlates with speed and depth of treatment 
response (Druker et al, 2006; Hanfstein et al, 2012; Hochhaus et al, 2009; Hughes et al, 
2010).  The aim of treatment is to achieve haematological, cytogenetic and molecular 
response at critical time points from treatment initiation (table 1-1).  Molecular 
measurements utilise qRT-PCR to estimate the amount of BCR-ABL mRNA relative to an 
internal reference gene/housekeeping, most commonly ABL1 or GUSB. The results are 
 39 
expressed on an International Scale (IS) as a percentage, with 100% BCR-ABL IS 
corresponding to the International Randomized Study of Interferon and STI571 (IRIS) study 
(NCT00333840) standardized baseline and 0.1% BCR-ABL IS being defined as a major 
molecular response (MMR or MR3; 3 log reduction from the standardized baseline) (Hughes 
et al., 2006).  An International Scale has been developed to ensure molecular responses 
across laboratories are consistent (Branford et al, 2008).      
 
Response Criteria 
Complete haematological response (CHR) Normalisation of peripheral blood 
Resolution of splenomegaly 
Minimal cytogenetic response  >65-95% Ph+ metaphases in bone marrow 
Minor cytogenetic response  >35-65% Ph+ metaphases in bone marrow 
Partial cytogenetic response  1-35% Ph+ metaphases in bone marrow 
Major cytogenetic response (MCyR) 0-35% Ph+ metaphases in bone marrow 
Complete cytogenetic response (CCyR) 0% Ph+ metaphases in bone marrow 
Major molecular response (MMR) or 
MR3.0 
3 log reduction in BCR-ABL relative to control 
MR4.0 BCR-ABL <0.01% or undetectable disease in 
cDNA with 10,000–31,999 ABL1 transcripts 
or 24,000–76,999 GUSB transcripts 
MR4.5 BCR-ABL <0.0032% or undetectable disease 
in cDNA with 32,000–99,999 ABL1 
transcripts or 77,000–239,999 GUSB 
transcripts 
MR5 BCR-ABL<0.001% or undetectable disease in 
cDNA with greater than or equal to100,000 
ABL1 transcripts, or greater than or equal 
to240,000 GUSB transcripts 
 
Table 1-1 Definitions of treatment response in CML 
European Leukemia Net (ELN) criteria detailing definitions of response to TKI. BCR-ABL is the 
quantitative RT-PCR assessment of BCR-ABL1:ABL1 (or other housekeeping gene) in the 
International Scale. Ph+; Philadelphia chromosome positive (Baccarani et al, 2013; Cross et al, 
2015). 
 
 
Evidence and guidelines suggest that at 3 months, a BCR-ABL of greater than 10% should 
trigger an examination of compliance and, if indicated, TKI resistance.   Within the German 
CML IV study, amongst the patients that did not achieve a BCR-ABL of less than 10% at 3 
months, overall survival at 5 years was poorer (87% versus 97% for patients with a BCR-
ABL of less than 1%) (Hanfstein et al, 2012).  Furthermore, a BCR-ABL of greater than 
9.84% has been demonstrated to be the strongest predictor of inferior event free survival and 
overall survival (Marin et al, 2012). 
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Within Europe, these findings have been adopted and formalised into guidelines developed 
by the ELN (Baccarani et al, 2013) and the National Comprehensive Cancer Network 
(NCCN), recommending key treatment milestones which form the basis of CML monitoring, 
enabling an objective and internationally validated assessment of response to therapy, and 
early recognition of those being treated sub-optimally or failing therapy and would warrant 
a change in therapy or further investigation (table 1-2).    
 
Time Optimal  Warning Failure 
Baseline  High risk; 
CCA 
 
3 months BCR-ABL1 ≤ 10% 
+/- Ph+ ≤  35%  
BCR-ABL1 > 10% 
+/- Ph+ 36-95% 
No CHR, and/or 
Ph+ >95% 
6 months BCR-ABL1 <1% +/- 
Ph+ 0 
BCR-ABL1 >10% 
+/- Ph+ 1-35% 
BCR-ABL1 >10% and/or 
Ph+ >35% 
12 months BCR-ABL1 ≤ 0.1% BCR-ABL1 >0.1-1% BCR-ABL1 >1% and/or 
Ph+ >0 
Then, and 
at any time 
BCR-ABL1 ≤ 0.1% Confirmed clonal 
abnormalities, Ph- 
Loss of CHR 
Loss of CCyR 
Confirmed loss of MMR 
 
Table 1-2 Definition of minimum required response to TKI therapy 
ELN criteria detailing minimum required response to first-line TKI therapy from initiation 
(Baccarani et al, 2013). 
 
Molecular monitoring is the most sensitive approach in determining TKI-failure and disease 
progression, and enables salvage therapy to be commenced at loss of molecular rather than 
loss of cytogenetic or haematological response. (Branford et al, 2012; Hanfstein et al, 2012; 
Hughes et al, 2010; Milojkovic et al, 2012).  However, at present, cytogenetic response 
remains included in the guidelines, and BM examinations are still recommended in a 
diagnostic approach.  This is particularly important at baseline to assess for additional 
cytogenetic abnormalities.  Current guidelines suggest performing a BM examination at 
baseline, 3, 6, and 12 months to ensure CCyR has been achieved (Baccarani et al, 2013).  
There is evidence to support the association between event free survival and overall survival 
with cytogenetic response, as demonstrated within the 6 year follow-up for the IRIS trial, 
where the event free survival rate was 59%, 85%, and 91% for patients with no cytogenetic 
response, MCyR, or CCyR at 6 months, respectively (Hochhaus et al, 2009).   For second 
generation TKIs, these milestones occur earlier (Kantarjian et al, 2012; Larson et al, 2012).   
However, with advances and increased sensitivity in molecular monitoring, most centres, 
including our own, are moving away from this frequency of BM assessment.  An alternative 
method to determine cytogenetic response is with the use of Fluorescence In Situ 
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Hybridisation (FISH) on PB, and when combined with a BCR-ABL transcript level of ≤1% 
(IS) leads to reassurance that the disease is being adequately treated (Oehler, 2013).  
 
1.3.3. Treatment of CML 
The introduction of TKIs in the management of CML is one of the greatest advances in the 
treatment of leukaemia.  Since their introduction, there has been at least a 10-fold increase 
in survival rates compared to the pre-TKI era, where initial treatment was based on standard 
cytotoxic chemotherapy, such as busulphan and hydroxycarbamide.  Although these 
treatments allowed for a haematological response, no cytogenetic response could be 
achieved as the pathognomonic insult was not being targeted (Hehlmann et al, 1993).  
Furthermore, these treatments are associated with numerous side-effects, including 
myelosuppression.  Interferon alpha was introduced as a standard of care in the mid-80s, and 
demonstrated a significant improvement compared to preceding therapies, with a 15% higher 
5-year survival (Talpaz et al, 1986).   Cytogenetic response and overall survival were 
improved when combined with systemic chemotherapy, such as cytarabine (Beck et al, 
2001).  Within the 1980s, it also became clear that allogeneic stem cell transplantation could 
result in long-term disease-free survival and probably cure the disease for selected patients, 
though not without significant risk of morbidity and mortality (Clift et al, 1982; Fefer et al, 
1979; Goldman et al, 1982).   
 
With the discovery of BCR-ABL activation, came the hypothesis that targeting BCR-ABL 
could eliminate disease, and in 1996 preclinical data demonstrated that a modified 2-
phenylaminopyrimidine induced apoptosis of BCR-ABL positive human cells, including 
primary CML cells, with little toxicity on normal cells (Druker et al, 1996). This compound, 
now known as imatinib, specifically inhibited BCR-ABL tyrosine kinase activity by 
competitive inhibition at the ATP-binding site of the BCR-ABL protein.  This subsequently 
resulted in the inhibition of phosphorylated proteins from downstream signalling pathways. 
Although it effectively inhibits BCR-ABL, it blocks other kinases, including platelet-derived 
growth factor receptor and c-KIT (Giles et al, 2009).  Its clinical ability was demonstrated 
in the International Randomized Study of Interferon and STI571 (IRIS) study, where 
imatinib (STI571) was shown to induce significantly higher rates of haematological and 
cytogenetic responses, and subsequently overall survival compared to the interferon-alpha 
plus low-dose cytarabine; the gold-standard therapy prior to TKIs (O'Brien et al, 2003; 
O'Brien, 2008).  Initial assessment at 19 months, demonstrated a CCyR rate of 74% versus 
9% (p<0.001) and failure to progress at 12 months of 99% versus 93% (p<0.001) in the 
imatinib arm compared to interferon-alpha plus low-dose cytarabine, respectively.  
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Importantly this response was durable, with an 8-year follow-up demonstrating an event free 
survival rate of 91% and overall survival rate of 93% (Hochhaus et al, 2009; O'Brien, 2008).  
Now, off pharmaceutical patent (2016), imatinib is the current gold standard for first line 
therapy of CML in UK.  However, 8-year follow-up within the trial highlighted that only 
55% of patients enrolled remained on imatinib therapy, highlighting potential issues with 
tolerability and adverse events amongst this patient group.  Although dose escalation of 
imatinib can improve response rates in patients with a sub-optimal response, switching to 
second or third generation TKIs can be more effective (Cortes et al, 2010a; Cortes et al, 
2010b; Kantarjian et al, 2012; Larson et al, 2012).  Since the introduction of imatinib, second 
and third generation TKIs have been developed.  Current guidelines suggest that for first-
line therapy, dasatinib and nilotinib can be used as an alternative or for treatment of cases 
with TKI failure (Baccarani et al, 2013).   
 
Dasatinib is a second generation TKI that has been shown to be significantly more potent 
than imatinib in vitro.  Again, like imatinib, dasatinib has been shown to target other tyrosine 
kinases, including the Src family, which influences the increased incidence of TKI-related 
side-effects, such as pleural effusions (Aplenc et al, 2011; Hantschel et al, 2007; Kantarjian 
et al, 2012; Lindauer & Hochhaus, 2010; Shah et al, 2004) seen with dasatinib.  The 
DASISION trial (NCT00481247) compared dasatinib 100mg OD and imatinib 400mg OD 
in the setting of front-line treatment (Kantarjian et al, 2010).  At 12 months, the primary 
outcome of confirmed CCyR was 83% versus 72% (p=0.007) (Jabbour et al, 2014) in the 
dasatinib and imatinib arms, respectively.   Five year follow-up demonstrated that dasatinib 
achieved deeper responses at earlier time points, with a higher proportion of patients 
achieving MMR at 3 months in the dasatinib arm (84% versus 64%, p<0.0001) (Cortes et al, 
2016b).  Correlating with this was a decreased progression to BC.  Rates of grade 3 or 4 
haematologic adverse events were higher for dasatinib versus imatinib.  Drug related pleural 
effusion was more common with dasatinib (28%) than with imatinib (0.8%), but did not 
impair the achievement of cytogenetic and molecular response (Cortes et al, 2016b).   The 
UK STI571 Prospective International RandomIsed Trial 2 (SPIRIT2) phase 3 clinical trial 
(NCT01460693) confirmed these results, with 12 month MMR being achieved in 57.5% 
versus 46% in the dasatinib and imatinib arms, respectively (p<0.001).  Again treatment 
toxicity played a major role in dasatinib treatment, with pleural effusions occurring more 
frequently with dasatinib than imatinib (24.1% versus 1.2%) (Osborne et al, 2015).  In 
patients intolerant or resistant to imatinib, dasatinib has demonstrated durable response rates, 
with the START-C phase 2 study demonstrating a 2 year CCyR rate of 53%, with 90% of 
these being maintained at 24 months.  Furthermore, the START-R study demonstrated 
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significantly higher rates of CCyR comparing dasatinib 70mg twice daily with high dose 
imatinib at 2 years (i.e. 400mg twice daily)(44% versus 18%, p=0.0025) (Kantarjian et al, 
2009; Mauro et al, 2008; Milojkovic et al, 2012)  
 
Nilotinib, a structural analogue to imatinib, has increased affinity for BCR-ABL in vitro 
compared to imatinib (Weisberg et al, 2005).  Like dasatinib, nilotinib has been shown to 
induce a sustained haematological and cytogenetic response in more patients, when 
compared with imatinib.  The Evaluating Nilotinib Efficacy and Safety in Clinical Trials – 
Newly Diagnosed patients (ENESTnd) study (NCT00471497) presents the mainstay of this 
data.  This phase 3, randomised clinical trial compared two doses of nilotinib (300mg BD, 
and 400mg BD) to imatinib (400mg OD).  The use of nilotinib was associated with 
significantly higher MMR at 12 months compared to imatinib, with limited change between 
the two doses of nilotinib used (44% versus 43% versus 22% for nilotinib 300mg BD, 
nilotinib 400mg BD and imatinib 400mg OD, respectively; p<0.001) (Kantarjian et al, 
2011b; Saglio et al, 2010).  Five-year follow-up demonstrated the cumulative incidence of 
MMR to be 77% for both doses of nilotinib and 60% with imatinib (p<0.0001) (Kantarjian 
et al, 2011b; Saglio et al, 2010).  Although, event free survival was not statistically changed 
between trial arms, there was an advantage with reducing rates of disease progression in 
those with intermediate and high-risk disease receiving nilotinib, as estimated through the 
Sokal score.  This highlights the role for second generation TKIs in prevention of disease 
transformation.  As with dasatinib, adverse events and toxicity with nilotinib use is 
significant.  Within the ENESTnd study, the 6 year cumulative cardiovascular side effect 
event rate was significantly increased in the nilotinib arm, with a concentration effect of 
increasing doses (Hochhaus et al, 2016).  Other notable side-effects, included skin rash, 
headaches, and pancreatitis (rarely).  As well as first line therapy, like dasatinib, nilotinib 
has been shown to offer an alternative for a second-line approach (Kantarjian et al, 2011a).   
 
As well as the first and second generation TKIs, bosutinib and ponatinib are available for 
use in treatment failure, or, in the case of ponatinib, with the detection of a T315I mutation 
(Brümmendorf et al, 2015; Cortes et al, 2014a; Cortes et al, 2012; Cortes et al, 2013).  
Bosutinib, a dual Src/Abl TKI, demonstrates a more potent in vitro activity against Bcr-Abl 
than imatinib (Golas et al, 2003; Puttini et al, 2006; Rassi & Khoury, 2013).  Like other 
TKIs, bosutinib has activity against a wide range of tyrosine kinases, including c-KIT and 
platelet-derived growth factor receptor (Puttini et al, 2006).  The phase 3 clinical trial, 
Bosutinib Efficacy and Safety in newly diagnosed chronic myeloid leukemia (BELA) 
(NCT00574873), compared the efficacy and safety of bosutinib against imatinib (Cortes et 
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al, 2012).  Following a dose escalation to 500mg OD, the trial allowed the potential for 
further increase to 600mg OD for patients with inadequate molecular and cytogenetic 
response.  At 24 months, cumulative CCyR were similar in bosutinib (79%) and imatinib 
(80%) arms; however, cumulative MMR rates were significantly higher with bosutinib (59% 
versus 49%) (Brümmendorf et al, 2015).  Importantly, bosutinib appeared to retain activity 
across mutations that confer imatinib resistance (see section 1.3.4.2), with the exception of 
T315I and responses were independent of whether patients had resistance or intolerance to 
imatinib.  The most common side effects have been shown to include, diarrhoea, nausea, and 
vomiting (Gambacorti-Passerini et al, 2014; Nakaseko et al, 2015).  Diarrhoea is the most 
common side-effects noted clinically with bosutinib.  Within the BELA trial, it occurred in 
84% of patients, with 9% experiencing grade 3 symptoms.  It is generally self-limiting and 
patients should be warned of this prior to drug initiation and given prophylactic loperamide.  
 
Ponatinib is currently the only TKI active against the T315I mutation (O'Hare et al, 2009; 
Zhou et al, 2011), and therefore remains an important treatment modality in CML.   The 
Ponatinib Ph-positive ALL and CML Evaluation (PACE) trial (NCT01207440) evaluated 
approximately 500 patients that were considered resistant or intolerant of dasatinib and 
nilotinib or if they had CML with a T315I mutation (Cortes et al, 2013).  The trial used a 
dose of 45mg OD ponatinib and patients were stratified into both disease phase and 
mutational state.  Within our own clinical practice, this dose can be reduced to 30mg with 
good effect, and clinical trials assessing this lower dose are currently ongoing.  In the PACE 
trial, at 12 months, MCyR was achieved in 56% of the patient cohort, with 75% of patients 
harbouring the T315I mutation achieving MCyR.  Long-term follow-up confirmed a 
sustained response, with 83% of these patients remaining in MCyR at 3 years (Cortes et al, 
2014a) and 39% of patients achieving MMR or better.  Within this trial, patients responded 
more favourably if they had received fewer prior TKIs.  As with other TKIs, significant 
adverse events were noted.  Particularly, arterial occlusive events occurred in 28% of 
patients, with the most common treatment adverse events being abdominal pain, rash, 
headache, and constipation (Cortes et al, 2014a).  Severe hypertension occurred in 20% of 
the cohort taking ponatinib.  Vascular occlusion and cardiovascular events occurred more 
commonly with increasing age and prior cardiovascular co-morbidities.  Clearly, for our own 
clinical practice, cardiovascular side effects must be considered and in early 2014, a revised 
warning was issued regarding ponatinib and the risk of thrombotic events, vascular 
occlusions, and heart failure (Gainor & Chabner, 2015).  The indications for ponatinib use 
according to manufacturers prescribing information (www.iclusig.com) include the 
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treatment of adult patients with T315I-positive CML or Ph+ ALL, or in the treatment of 
adults with any stage of CML or Ph+ ALL for whom no other TKI therapy is indicated.  
 
With the information depicted above, figure 1-10 represents a schematic plan for TKI 
therapy within CP-CML according to ELN guidelines and current evidence. 
 
 
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-11 Schematic diagram of a treatment algorithm for TKI use in CML 
Schematic for TKI use in CP-CML, with 1st, 2nd and 3rd line therapy available.  TKI choice should be based 
on a individual-basis, with co-morbid conditions carefully evaluated.  For example, cardiovascular disease 
and diabetes should be considered prior to initiating nilotinib in view of significant adverse events.  This 
is based on current ELN guidelines 
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With such an array of TKIs available and a significant increase in survival compared to the 
pre-TKI era, the role of allogeneic transplant is more limited than in the pre-TKI era.  It 
remains an important treatment option however, with high-risk disease, and those with T315I 
positive advanced CML.  Outcomes following transplantation remain superior for patients 
in CP compared to advanced phase disease, with a 5-year survival of approximately 90% in 
those with CP compared to 10-20% with BP.  However, in view that TKI therapy is generally 
well tolerated and not associated with the significant morbidity and mortality seen with 
allogeneic transplantation, the question remains whether there is a role for transplantation in 
CP-CML at all.  Targeted therapy in CP-CML is clearly a great medical achievement and 
success.  However, despite a targeted therapeutic approach, a small number of patients will 
not respond, or sub-optimally respond, to TKI therapy.   
 
1.3.4. Why does treatment fail? 
It has been estimated that about 30% of patients’ fail to achieve an MMR at 2 years 
(Kantarjian & Cortes, 2011).  The reasons for this are three fold, relying on patient 
compliance to TKI, resistance to therapy, and disease persistence.   
 
1.3.4.1. Patient compliance  
Patient compliance remains integral to achieving adequate response.  Indeed, it has been 
estimated that non-compliance with TKI increases sub-optimal response by approximately 
3-fold (Noens et al, 2009).  The Adherence Assessment with Glivec: Indicators and 
Outcomes (ADAGIO) study allowed assessment of compliance in a cohort of 169 CML 
patients over a 90-day period.  Only 14.2% of the cohort was found to be completely 
compliant with TKI, while 71% took less than recommended, and 14.8% more than 
recommended.    Non-compliance was associated with sub-optimal response to TKI (Noens 
et al, 2009).   
 
The assessment of compliance remains a difficult area of clinical evaluation.  However, 
microelectronic monitoring has allowed observation of the number of times a bottle cap is 
removed, and serves as a marker of compliance within a population.  In a study by Marin et 
al, it was determined that treatment compliance is a critical factor in achieving and 
maintaining a  deep molecular response, with the probability of achieving MMR and 
complete molecular response (CMR) significantly better in those with compliance of greater 
than 90%.  Furthermore, compliance was the only independent predictor for achieving CMR 
(Marin et al, 2010).  Compliance of 85% or less and having never achieved MMR have been 
shown to be the only independent predictors of TKI failure (Ibrahim et al, 2011). 
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Non-compliance remains a complex clinical issue with a number of factors demonstrated to 
influence this.  Included in this are complex psychological issues, such as depression, 
disbelief of disease, as well as polypharmacy, longevity of taking the medication, and side-
effects, to name a few.  In view of its importance clinically, methods have, and are, being 
introduced to provide patients with increasing support (Bordonaro et al, 2014; Cornelison et 
al, 2012).  For example, within our own services at the West of Scotland Cancer Centre, 
increased support is being made available through the introduction of CML-specific nurse 
specialists that give ongoing psychological support, as well as phone-consultations and the 
development of support groups. This has allowed for increased home support, as well as 
peer-to-peer support in CML community groups, to enable better compliance.  It has been 
demonstrated that increased accessibility to pharmacists, behavioural specialists, and other 
healthcare professionals assists with the identification of an individual’s reasons behind non-
compliance and ultimately, development of individualised care plans to overcome it 
(Eliasson et al, 2011; Osterberg & Blaschke, 2005).   
 
1.3.4.2. Resistance to therapy 
Non-compliance can be managed within a multidisciplinary team if identified promptly.  
However, despite good compliance, a number of patients’ will respond sub-optimally or fail 
therapy.  This can be due, in part, to developing resistance to TKI therapy.  Inherent or 
acquired resistance to therapy has been demonstrated in in vitro cell line models and primary 
samples (Mahon et al, 2000).  There has been increasing interest in resistance to TKI therapy 
of late, but in depth discussion is beyond the scope of this thesis.  However, to aid 
understanding of the reasons for disease progression and the complex nature of its 
underlying mechanisms, this will be discussed in brief.  Resistance to therapy can occur via 
BCR-ABL-dependent or BCR-ABL-independent mechanisms.      
 
1.3.4.2.1. BCR-ABL-dependent mechanisms 
The most common mechanism of resistance to TKI is the development of point mutations 
or amplification of the BCR-ABL gene, which alters the kinase domain of BCR-ABL 
rendering the TKI ineffective.  These mutations can develop at any stage of disease, and can 
be utilised clinically to guide TKI choice.    
 
To date, more than 90 BCR-ABL point mutations have been identified, with a lesser number 
biologically characterised (Azevedo et al, 2017; Cavelier et al, 2015; Gibbons et al, 2014; 
Khorashad et al, 2013; Shah et al, 2002; Szankasi et al, 2016).  Four different clusters of 
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BCR-ABL kinase domain mutations have been described, and include those that affect the 
P-loop, the SH2 domain, the SH3 domain, and the activation loop (Branford et al, 2003; 
Schindler et al, 2000; Soverini et al, 2011).  The T315I mutation that results from the 
replacement of threonine by isoleucine at ABL amino acid position 315 is arguably the most 
therapeutically relevant mutation within CML, as ponatinib remains the only therapeutic 
option.  Although many mutations have been identified, their clinical significance varies, 
with not all mutations resulting in relapse or disease progression (Hughes et al, 2006; 
Jabbour et al, 2006; Nicolini et al, 2006).  Identification of specific mutations, including 
T315I, F317L/V/I/C, Y253H, F359V/C/I, V299L, and E255K, however remains imperative 
to TKI choice (table 1-3; figure 1-11). 
 
Mutation Action 
T315I Consider ponatinib 
T315A 
F317L/V/I/C 
Consider nilotinib or bosutinib (rather than 
dasatinib) 
Y253H 
F359V/C/I 
Consider dasatinib or bosutinib (rather than 
nilotinib 
V299L Consider nilotinib 
E255K/V Consider dasatinib 
Any other mutation Consider dasatinib, nilotinib, bosutinib, 
ponatinib 
Table 1-3 Point mutation and recommended action for TKI choice (Ai & Tiu, 2014) 
 
Furthermore, the type of mutation can be associated with phase of disease, with mutations 
at M244, M351, and G250 frequently detected in CP, and mutations at T315, E255, and 
Y253 being found in AP and BP (Branford et al, 2009; Soverini et al, 2006).  The ELN 
recommends screening for mutations in any patient with treatment failure or sub-optimal 
response, including rise in BCR-ABL transcript levels to allow for early detection of 
mutations and appropriate change in therapy.  
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Figure 1-11 Schematic of point mutations according to position 
Schematic of point mutations associated with clinically relevant TKI choice.  Asterisks are amino acid 
substitutions more associated with advanced disease stage.  
 
 
Further to this, additional mechanisms have been postulated to confer TKI resistance.  For 
example, within the BP cell line, K562, it has been demonstrated that there is an increase in 
expression of the P-glycoprotein efflux pump when passaged through increasing doses of 
imatinib (Mahon et al, 2000).  However, this same cell line also demonstrated a 6-fold 
amplification of the BCR-ABL gene, and no discrimination between the imatinib resistance 
versus the P-glycoprotein overexpression was made. 
 
1.3.4.2.2. BCR-ABL-independent mechanisms 
As well as BCR-ABL-dependent mechanisms, BCR-ABL-independent mechanisms of 
resistance have been described that rely on the alteration of cellular signalling, and cell cycle 
regulation within the downstream pathways that have been altered with activation of the 
protein and inhibition of multiple non-BCR-ABL kinases (Li & Li, 2007).  The BCR-ABL 
protein activates alternative signalling pathways, including SRC kinase, RAS, and JAK-
STAT signalling (Cortez et al, 1997; Gallipoli et al, 2014; Pendergast et al, 1993).  The 
aberrant activation of these pathways leads to the CML cell’s proliferation and enhanced 
survival.  
 
The activation of the SRC family kinases has been shown to promote both disease 
progression, as well as TKI-unresponsiveness.  BCR-ABL directly interacts with SRC 
family kinases resulting in both a conformational change in the ABL kinase domain through 
phosphorylation of SH2 and SH3, as well as activation of SRC family kinases, Hck, Lyn, 
and Fyn), leading to cell growth, differentiation and survival (Danhauser-Riedl et al, 1996; 
Hu et al, 2006; Meyn et al, 2006; Stanglmaier et al, 2003).  Additionally, while there have 
been no clinical examples of SRC-activating mutations in imatinib-resistant cell lines or 
primary CML specimens, cellular activation of this pathway through numerous other cross-
talk networks may still facilitate resistance (Donato et al, 2003; Ptasznik et al, 2004; Wu et 
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al, 2008).  RAS signalling has also shown to be activated through Grb2-mediated binding of 
the Y177 moiety in the BCR sequence (Cortez et al, 1997; Pendergast et al, 1993), however, 
the specific mitogen-activated protein kinases that Ras activates in CML are yet to be fully 
elucidated.  Furthermore, studies have demonstrated that Grb2 can recruit Gab-2 with 
subsequent activation of both PI3k and ERK pathways (Sattler et al, 2002).   The mechanism 
by which these signalling pathways are activated has been shown to be through the 
expression of plasma membrane transporter molecules, including the ABC family of 
transporters, ABCG2 and MDR-1.  It has been suggested that overexpression of these protein 
complexes might confer resistance through reducing intracellular imatinib concentration 
(Mahon et al, 2003).  However, a clear correlation between transporter molecule expression 
and patient response to imatinib has not been fully elucidated. 
 
Furthermore, clonal evolution occurs when CML cells acquire additional chromosomal 
abnormalities, or epigenetic modulation.  Cytogenetic aberrations have been described in an 
increasing percentage in BP compared to CP, with some, such as aberrations within 
chromosome 17 leading to changes within the TP53 gene, and subsequent poor outcome 
(Cortes et al, 2003; Lahaye et al, 2005; O'Dwyer et al, 2002; Wendel et al, 2006).  Epigenetic 
methylation and post-translation acetylation alter gene expression and subsequent protein 
function.  Within CML, the role of epigenetic modification at a biological and therapeutic 
level are becoming of increasing interest (Bixby & Talpaz, 2011; Lee et al, 2007; Scott et 
al, 2016).  
 
1.3.4.3. Disease persistence  
TKI resistance and activation of alternative signalling pathways has been shown to be 
involved in failure to respond to TKI therapy.  However, in addition to this is the 
phenomenon of disease persistence, which suggests that despite a targeted therapeutic 
approach, BCR-ABL-independent mechanisms are being exploited to sustain the survival of 
LSC (Bhatia et al, 2003b; Chomel et al, 2011; Deininger, 2012).  As described, these cells 
are resistant to therapy, meaning that on cessation of TKI treatment the disease is likely to 
return (Chu et al, 2011; Deininger, 2012; Graham et al, 2008; Hamilton et al, 2012; Ross et 
al, 2013).  The role of LSCs has been extensively described above, and highlights that further 
information and understanding is needed to identify the underlying mechanisms that confer 
survival to CML LSCs under TKI therapy.   
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1.3.4.4. Stopping trials 
Multiple clinical trials exploring the discontinuation of TKIs in CP patients with sustained 
molecular remission (Etienne et al, 2017; Mahon et al, 2014; Mahon, 2015; Mahon et al, 
2010; Mahon et al, 2016; Rea et al, 2012; Ross et al, 2010; Ross et al, 2013; Takahashi et al, 
2012) have been performed.  These trials have demonstrated that discontinuation of therapy 
can be selectively achieved, with most recent ‘Stop Imatinib’ (STIM) trial (NCT00478985) 
data stating the cumulative incidence of molecular relapse at 60 months was 61% (CI 52-
70%), with few cases of late relapse being observed (Mahon et al, 2014).  This suggests that 
if molecular relapse is to occur, it happens early.  Comparable results have been reported 
worldwide (Mahon et al, 2014; Mahon et al, 2010; Rea et al, 2012; Ross et al, 2010; Ross et 
al, 2013; Takahashi et al, 2012).  The European Stop Kinase Inhibitor (EURO-SKI) trial 
(NCT01596114) is the largest study to date, with recruitment of over 800 patients.  Most 
recent analysis demonstrated a molecular-recurrence free survival of 62% at 6 months, 56% 
at 12 months, and 52% at 24 months (Mahon et al, 2016).  The DAsatinib DIscontinuation 
(DADI) study (NCT01627132) analysed molecular-relapse free survival after stopping 
dasatinib as second-line therapy or beyond.  The probability of molecular-recurrence free 
survival was 49% at 6 months, and 48% at 12 months, with all molecular relapses occurring 
within 7 months of stopping therapy.  All patients with molecular relapse regained deep 
molecular response within 6 months  (Imagawa et al, 2015).  The UK equivalent trial 
currently in process (DESTINY – DeEscalation and Stopping Treatment of Imatinib, 
Nilotinib or sprYcel in chronic myeloid leukaemia: NCT01804985) and is analysing the role 
of dose reduction before complete suspension of TKI treatment.  Interim data suggested that 
decreasing TKI treatment to half the standard dose was associated with improvement in TKI 
adverse events, in patients with stable MR3 or more.  This suggested that many patients are 
being overtreated and that there is scope for TKI dose reduction prior to discontinuation to 
assess response (Clark et al, 2016).   
 
Although these results indicate the possibility for TKI discontinuation in a small subset of 
CML patients, they highlight an uncertainty surrounding the ‘trigger’ event(s) in molecular 
relapse, and question if sustained BCR-ABL expression, LSC persistence, 
microenvironmental factors or, indeed, multiple factors are the cause.  Within the TWISTER 
trial (Ross et al, 2013), LSCs could still be identified by functional assays in all undetectable 
(by quantitative-polymerase chain reactions (qPCR)) MRD samples derived from patients’ 
no longer on TKI treatment, suggesting that these cells, although present, were not yet 
driving a leukaemic process.  But then, it is known that in up to 30% of normal individuals, 
low level of BCR-ABL expression can be identified (Bose et al, 1998; Takahashi et al, 2012), 
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perhaps suggesting that BCR-ABL transcript level alone is not sufficient for CML 
maintenance.  It is unknown, however, what cell types these transcripts are originating from 
and if this is significant long-term.  Interestingly, a single copy of Bcr-Abl expressed from 
the endogenous BCR locus in a knock-in murine model is not sufficient to induce leukaemia 
(Foley et al, 2013).  Therefore, although it is clear that a certain level of BCR-ABL needs to 
be expressed at the stem cell level to cause CML, it is unclear if further molecular changes 
or aberrant signalling is needed to drive molecular relapse and disease progression.  
Furthermore, it is unknown if BCR-ABL is the initiating insult, or if host factors, such as 
epigenetic and genetic changes influence disease outcome and precede the acquisition of 
BCR-ABL.  Regardless, it is apparent, that further insight into why LSCs survive TKIs is 
vital in the quest for cure.    
 
1.3.5. Ph+ Acute leukaemia 
As has been previously described, CML runs a triphasic disease course.  If left untreated, 
the disease will inevitably progress to the more acute form of the disease, termed BC or BP.  
The median survival remains poor, with most treatments ineffective in this phase of disease.  
BP CML does not represent the only Ph+ acute leukaemia, with both Ph+ ALL and de novo 
Ph+ AML described within the literature.  Within this group of diseases, the treatment 
approaches differ, although survival advantage remains poor in all groups.  This section will 
describe each disease entity separately to aid understanding of their similarities and 
differences at a molecular level.  
 
1.3.5.1. Blast phase CML 
Despite a targeted therapeutic approach with TKIs in CML, a small number of patients will 
present in or progress to the acute phase of the disease, termed BC or BP.  BP is defined by 
the World Health Organisation (Arber et al, 2016) as the presence of at least one of  
 blasts comprising approximately 20% of PB white cells or nucleated BM cells,  
 extramedullary blast proliferation, or  
 large foci or clusters of blasts in the BM 
 
The ELN diagnostic criteria rests on at least 30% blasts in PB white cells or nucleated BM 
cells, or the demonstration of extramedullary blastic infiltrates (Baccarani et al, 2013).  
Regardless, if progression to BP is suspected, it needs to be acted on with immediate effect 
to aid outcome.  It can present as either myeloid or lymphoid in lineage, with approximately 
two-thirds of cases being found to be of a myeloid phenotype (Kinstrie et al, 2016).  
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Approximately 25% of patients present with a pre B-lymphoblastic phenotype, with 
occasional cases of T-cell transformation having been identified (Atallah et al, 2002; 
Rosenthal et al, 1977).  This suggests that within BP, LSCs may play an important role in 
view of the ability to differentiate to both lineages.  However, a high degree of heterogeneity 
has been recognised, with multiple immunophenotypically distinct populations identified 
(Kinstrie et al, 2016).  Furthermore, it has been shown that within BP disease, committed 
progenitors can acquire self-renewal properties (Jamieson et al. 2004).  As such, the LSC in 
BP-CML may reside in at least 3 subsets, namely Lin–CD34+CD38–, Lin–CD34+ cells 
remaining from CP, and the disease-driving Lin–CD34+CD38+ granulocyte-macrophage 
progenitors/common myeloid progenitors (GMPs/CMPs) (Jamieson et al, 2004). 
 
The incidence of progression to BP under TKI treatment ranges between 0.7 and 4.5% 
(Cortes et al, 2013; Hehlmann et al, 2011; Hughes et al, 2014).  As expected, there is a great 
reduction in incidence of progression on treatment compared to the pre-TKI era, where, 
within the German CML study group, it was shown that incidence of progression decreased 
from 1.5-3.7% (CML studies I-IIIA (Hehlmann et al, 1994a; Hehlmann et al, 2003; 
Hehlmann et al, 1994b)) to 0.3-2.2% (CML IV (Hehlmann et al, 2014)) per year.  The rate 
of progression falls sharply when MMR is obtained (Hehlmann et al, 2011; Hehlmann et al, 
2014).  Reported incidence of CML presentation in BP ranges from 0.9 to 6.7% (Hoffmann 
et al, 2015).  
 
Responses to TKIs in BP are transitory, and median survival following diagnosis of BP 
remains only 6.5 to 11 months in those treated with TKI alone (Hehlmann, 2012).  This is, 
in part, secondary to the development of additional mutations within the BCR-ABL kinase 
domain leading to TKI resistance.  As such, the mainstay of treatment remains TKI plus 
conventional aggressive chemotherapy, followed by allogeneic stem cell transplantation (if 
able) (Hehlmann et al, 2012).  Despite this approach, 5-year survival rates have been shown 
to be less than 20%, therefore, deciphering a therapeutic strategy remains of utmost 
importance for this patient group. 
 
The mechanisms responsible for progression to BP remain poorly understood, particularly 
when determining why patients progress to either lymphoid or myeloid lineage BP.  
Although, the risk of progression to BP on TKI therapy is greatly reduced if MMR is 
reached, there has been no correlation found between BCR-ABL expression and either 
progression or the development of secondary genetic changes.  It is thought that BCR-ABL 
expression provides a favourable environment for genetic instability and maintenance of 
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secondary DNA modifications (Bacher et al, 2005a; Bacher et al, 2005b; Bacher et al, 2005c; 
Radich, 2007).  Although this, in itself, does not explain why some of these mutations are 
lineage-specific.  However, common mutations have been identified within phenotypes, with 
20-30% and 38% generating mutations in TP53 and RUNX1, respectively, within a myeloid 
phenotype and almost 50% of lymphoid BP cases having a CDKN2A/B or IKZF1 mutation 
(Bacher et al, 2005c; Mullighan et al, 2008; Roche-Lestienne et al, 2008).  
 
As described, studies to identify the LSC population in BP disease are more limited when 
compared to the information available for CP.  Jamieson et al found that the HSC population 
(lin-CD34+CD38-CD90+CD45RA-) was not expanded in myeloid BP-CML and identified 
the GMP population as a potential source of LSCs in myeloid BP (Jamieson et al, 2004). 
However, this study did not assess the multipotent progenitor (MPP; lin-CD34+CD38-
CD90-CD45RA-)/LMPP-like subpopulations, nor did it assess in vivo LSC activity.  Further 
studies by the Jamieson group identified activation of β-catenin as the likely mechanism of 
enhanced self-renewal capacity in the myeloid BP GMP cells (Jamieson et al, 2004; Minami 
et al, 2008).  Less information is available regarding the LSC populations in lymphoid BP-
CML.  A case report of a patient with imatinib-resistant lymphoid BP-CML indicated that 
the imatinib-resistant sub-clone (E255K kinase domain mutation) likely originated in the B-
cell committed progenitor compartment, but no functional stem cell assays were performed 
(Kobayashi et al, 2011).  The LSC is, however, likely to be fundamental in view of the role 
it plays in disease development and persistence.  From the literature, it can be gleaned that 
in BP-CML, the LSC subsets are Lin–CD34+CD38– and Lin–CD34+ cells remaining from 
CP-CML and the disease-driving Lin–CD34+CD38+ GMP/CMPs.  Each of these has 
deregulated self-renewal.  However, understanding their role is made hugely complicated by 
the inter-connectivity seen between self-renewal pathways (Radich, 2007), and also the 
heterogeneity seen between cases (Kinstrie et al, 2016).  Various self-renewal pathways have 
been implicated in this, including Wnt-β-catenin, which is probably the most established 
(Abrahamsson et al, 2009; Radich et al, 2006; Sengupta et al, 2007; Zhao et al, 2007).  Other 
self-renewal pathways’, including Hh and BMP, have been linked to this process, but their 
exact role has yet to be fully elucidated (Jamieson et al, 2004; Radich et al, 2006; Su et al, 
2012).  Certainly, it may arise that the role for self-renewal pathways will be determined 
from which subset the LSC derives.  For example, accumulation of β-catenin in the nucleus 
of GMPs leads to increased self-renewal potential (Abrahamsson et al, 2009; Ysebaert et al, 
2006).  It seems pertinent, therefore, that the role for each evolutionary conserved self-
renewal pathway be determined, as this will aid understanding and the development of 
therapeutic strategies for BP CML. 
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1.3.5.2. Ph+ acute lymphoblastic leukaemia 
Ph+ acute lymphoid-phenotype leukaemias encompass both lymphoid BP CML (described 
above) and Ph+ ALL.  These two diseases are clinically distinct, but can often be 
mislabelled.  Ph+ ALL accounts for approximately 25-30% of ALL diagnosed in adults.  
Although 70-90% of cases will achieve a complete remission with conventional 
chemotherapy, long-term survival remains poor, reflecting high rates of relapse and failure 
of salvage regimens.  It encompasses three main phenotypes: 
 a lymphoid lineage restricted phenotype with either p190 or p210 BCR-ABL fusion 
variants 
 a stem cell phenotype with either p190 or p210 BCR-ABL fusion variant, or 
 misclassified lymphoid BP CML, which has a stem cell phenotype and expresses 
p210 BCR-ABL fusion variant. 
 
The differences between both lymphoid BP and Ph+ ALL lie in the BCR-ABL fusion 
variants and activation of other kinases, particularly SRC kinases, as well as potentially 
within the cell of origin (Hu et al, 2004).  The two BCR-ABL fusion variants, p190 and 
p210, are determined by the different amounts of BCR that they include, leading to different 
molecular weights (Soekarman et al, 1990).  The larger 210kD fusion protein (p210) is 
almost always found in CML, but is also present in approximately 10-15% of Ph+ ALL.  
Inversely, the 190kD fusion protein is found in the majority of paediatric Ph+ ALL, 25-30% 
of adult Ph+ ALL, and only rarely in CML (Advani & Pendergast, 2002).  In both, the 
signalling pathways involved in cell proliferation and survival are deregulated, leading to 
the phosphorylation of many proteins (Mullighan, 2012a; b; Radich et al, 2006).  Included 
in this is the activation and phosphorylation of STAT5, which has been demonstrated to be 
required for progression to lymphoid transformation (Hantschel et al, 2012). The JAK-STAT 
pathway is integral to disease progression, but it is also known to have many interactions 
with self-renewal pathways that have not yet been fully described.  Further to this, attempts 
to address the differences between lymphoid BP and Ph+ ALL have focussed on studies to 
address the cell of origin, with conflicting results.  As CML is known to be a stem cell 
disease, BCR-ABL should theoretically be identified in all cell types.  Similarly, with ALL 
being lineage-restricted, it would be anticipated that BCR-ABL would be restricted to the 
lymphoid lineage.  However, there is data to suggest that both produce a multi-lineage 
involvement.  Furthermore, it has been shown that Ph+ cells within a myeloid compartment 
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in ALL may correlate with a more favourable prognosis (Secker-Walker, 1984; Secker-
Walker et al, 1978), although this remains contentious (Cuneo et al, 1994b).   
 
1.3.5.3. De Novo Ph+ acute myeloid leukaemia 
De novo Ph+ AML accounts for 0.5-3% of all AML cases and by definition has no evidence 
of CML either before the onset of AML or after successful treatment (Keung et al, 2004; 
Soupir et al, 2007).  Its pathogenesis remains controversial with some reports suggesting that 
it represents a de novo myeloid BP of CML rather than signifying an isolated disease entity 
(Neuendorff et al, 2016).  Indeed, although p190 BCR-ABL transcripts have been described, 
most cases express the p210 BCR-ABL transcript (Neuendorff et al, 2016).  Further to this, 
it has been suggested that age-dependent clonal haemopoiesis may play a role, with previous 
data demonstrating that ‘healthy’ individuals harbour BCR-ABL.  Thus, the co-occurrence 
of BCR-ABL within age-dependent clonal haemopoiesis could lead to the development of 
disease.  Despite limited experimental and clinical data, the WHO classification has 
acknowledged de novo Ph+ AML in its most recent guidelines.    
 
In view that clinical descriptions of de novo Ph+ AML are so few, little is known about its 
characteristic features.  Clinical presentations, however, are similar to that of AML, with no 
difference in morphology and immunophenotypic analysis to differentiate it.  The criteria to 
differentiate it from BP-CML include an acute presentation, lack of previous history of CP-
CML and no splenomegaly.  In general, PB count will not demonstrate a basophilia and there 
will be a lower mature myeloid cell count. 
 
Cytogenetic and molecular features may differentiate between BP-CML and de novo Ph+ 
AML (Berger et al, 1993; Bacher et al, 2011).  For example, in CML, clonal evolution occurs 
in 60-80%, with a lower percentage in Ph+ AML.  Deletions in 7q have been described in 
Ph+ AML, but remain rare with BP-CML.  Molecular mutations such as NPM1 and FLT3, 
are more common in Ph+ AML.  Furthermore, deletions of IKZF and CDKN2A/B have been 
described in Ph+ AML, as well as the concomitant loss within immunoglobulins and T cell 
receptor gene complexes (Nacheva et al, 2013).   
 
Currently, no standardised treatment for de novo Ph+ AML exists, although given the small 
numbers, it would be difficult to conduct a randomised clinical trial to determine this.  From 
the limited data available, TKI-alone does not achieve a sustained response.  Although this 
is perhaps unsurprising as BCR-ABL is not thought to be the clinical driver of the disease, 
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but most likely provides a proliferative advantage.  The addition of TKI to standardised 
AML conventional chemotherapy seems a reasonable approach allowing treatment of an 
acute phenotype with the addition of a targeted TKI.  Prognosis, however, seems to be poor 
with induction failure and relapse common in cases of de novo Ph+ AML described (Keung 
et al, 2004; Soupir et al, 2007).  In keeping with this, the NCCN clinical guidelines in 
oncology recognise it as a poor-risk group, comparable with complex karyotype AML.   
 
1.3.5.4. The unanswered questions 
Ph+ acute leukaemias’ clearly represent a spectrum of disease entities, including myeloid 
and lymphoid BP-CML, Ph+ ALL, and de novo Ph+ AML.  All have a poor prognosis, but 
due to the paucity of patients and heterogeneity of disease, randomised controlled trials are 
difficult to initiate and evaluate.  Furthermore, the pathophysiology of each disease has not 
yet been fully elucidated.  
 
Within BP-CML, there is limited evidence on the factors that drive disease progression from 
a CP myeloid phenotype to an acute disease entity that can present in either lineage.  It has 
been hypothesised that LSCs are imperative as a causative mechanism, and that the initiating 
lesion remains at a stem cell level, rather than a more differentiated phenotype.  However, 
there is no real documented evidence to how lineage decision is driven within this subset.  
Furthermore, there is little to no evidence on the variation of self-renewal and survival 
signalling pathways between phenotypes, and if lymphoid BP should be managed as per a 
disease of lymphoid origin, rather than that of myeloid.  Without a randomised control trial, 
it is difficult to justify this treatment decision.  Perhaps understanding genomic regulation 
between myeloid and lymphoid BP disease and other acute Ph+ acute diseases will guide 
diagnostic strategies and potential therapeutic strategies.   
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1.4. Aims 
The following thesis is an investigation into the identification and eradication of the CML 
LSC in CP through evaluation of the self-renewal pathway, Notch, and the cell surface 
marker, CD93.  Further to this, it has enabled investigation into the genomic differences of 
self-renewal and survival pathways in both the progression of disease and between subsets 
of Ph+ acute leukaemia.  
 
Experiments were designed to address the following specific aims: 
 
1. To examination the role of the Notch signalling pathway in CP-CML and in the 
progression of disease to a myeloid BP phenotype 
As has been described through the introduction of this thesis, self-renewal pathways remain 
fundamental in the maintenance and propagation of the LSC in CML.  However, despite 
much experimental evidence into the role of Hh, Wnt/β-catenin and BMP signalling, there 
is limited and conflicting data on the role of Notch signalling within this disease model, or 
within disease progression.  Within this thesis I have extensively evaluated the role of Notch 
signalling within CP-CML and through disease progression to a myeloid BP phenotype.   
 
2. To examine the genomic variation in self-renewal signalling pathways in  
a. Disease progression to myeloid BP disease 
b. Between myeloid BP and lymphoid B 
c. Lymphoid BP and Ph+ ALL 
The role which self-renewal pathways play within disease progression and between Ph+ 
acute leukaemias has yet to be fully elucidated.  Within this thesis, I have analysed the 
genomic variation of self-renewal pathways through Fluidigm analysis in primary samples.  
This has allowed some understanding of the interconnectivity within and between diseases, 
and provides preliminary data to enable further targeted investigation.   
 
3. To evaluate the functional role of CD93 in CML LSC in vitro and in vivo 
Our group has recently identified upregulation of CD93 within a LSC phenotype in CP-
CML.  This data has been extended to include functional in vitro and in vivo experimentation, 
as well as single cell genomic analysis to validate this finding and examine the heterogeneity 
of the CP CML LSC.  
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2. Materials and Methods 
2.1. Materials 
The names and addresses of the suppliers are listed below. 
 
Company Address 
Applied Biosystems Lingley House, 120 Birchwood Boulevard, 
Warrington, WA3 7QH, UK 
BD Biosiences The Danby Building, Edmund Halley 
Road, Oxford, OX4 4DQ, UK 
BioRad Maxted Rd, Hemmel Hempstead, West 
Sussex, HP2 7DX, UK 
Bioscience Lifescience Ltd 10 Orchard Place, Nottingham Business 
Park, Nottingham, NG8 6PX, UK 
Cell Signalling Technology 2316 ZA Leiden, The Netherlands 
Cellagen Technology 5940 Pacific Mesa Court, San Diego, CA 
92121, USA 
eBioscience  3 Fountain Drive, Paisley, PA4 9RF, UK 
New England Biolabs 75-77 Knowl Piece, Wilbury Way, 
Hitchin, Herts SG4 0TY, UK 
Eppendorf UK Ltd Endurance House, Vision Park, Histon, 
Cambridge, CB24 9ZR 
Eurofins MWG Operon Westway Estate 28-32 Brunel Road, 
Acton, London, W3 7XR, UK 
Fisher Scientific UK Bishop Meadow Road, Loughborough, 
Leicestershire, LE1 5RG, UK 
Fluidigm UK Ltd 90 Fetter Lane, London, EC4A 1EQ, UK 
Fred Baker Scientific Ltd 3 Kancer Court, Cheshire, WA17 1PN, 
UK 
GraphPad Software, Inc. 7825 Fay Avenue, Suite 230 La Jolla, CA 
92037 USA 
Greiner Bio-One Ltd. Unit 5, Stroudwater Business Park, 
Gloucestershire, GL10 3SX, UK 
Invitrogen, Paisley, UK Ltd. Part of Life 
Technologies 
3 Foundation Drive, Paisley, UK 
Jackson ImmunoResearch, 
Laboratories, Inc. 
UK distributor; Stratech Scientific Limited 
Labtech International Ltd. Acorn House, The Broyle, Ringmer, East 
Sussex, BN8 5NN, UK 
Millipore (U.K.) Limited Suite 3 & 5, Croxley Green Buisiness 
Park, Watford, WD18 8YH, UK 
Miltenyi Biotec Ltd. Almac House, Church Lane, Bisley, 
Surrey, GU24 9DR, UK 
Novartis Pharmaceuticals UK Ltd Frimley, Camberley, Surrey, GU16 7SR, 
UK 
Peprotech EC Ltd. Peprotech House, 29 Margavine Road, 
London, W6 8LL, UK 
Promega UK Delta House, Southampton Science Park, 
Southampton, SO16 7NS, UK 
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Qiagen Fleming Way, Crawley, West Sussex, 
RH10 9NQ, UK 
R&D Systems 19 Barton Lane, Abingdon Science Park, 
Abingdon, OX14 3NB, UK 
Santa Cruz Biotechnology, Inc Heidelberg, 69115, Germany 
Scientific Lab Supplies Ltd 204 Main St, Coatbridge, ML5 3RB, UK 
Sigma-Aldrich The Old Brickyard, New Rd, Gillingham, 
Dorset, SP8 4XT, UK 
Stem Cell Technologies 40 Rues des Berges, Miniparc Polytec, 
Bâtiment Sirocco, 38000 Genoble, France  
Stratech Scientific Limited Oaks Drive, Newmarket, Suffolk, CB8 
7SY, UK 340 A Street #101 Ashland, 
OR97520, USA 
ThermoFisher Scientific  3 Fountain Drive, Paisley, PA4 9RF, UK 
 
2.1.1. Tissue culture 
2.1.1.1. Tissue culture materials 
Plastics Supplier 
Blunt ended needles Invitrogen, Paisley, UK 
Cryotubes Fisher Scientific, Loughborough, UK 
Eppendorf tubes (0.5 / 1.5ml) Invitrogen, Paisley, UK 
FACS tubes (sterile/unsterile) BD Biosciences, Oxford, UK 
Falcon tubes (15, 50ml)  Fred Baker Scientific, Cheshire, UK 
Flat bottomed culture plates 
(6, 12, 24, 48, 96 well) 
Greiner Bio-One, Gloucestershire, UK 
Flat bottomed culture plates coated with 
collagen type 1 (6 and 24 well) 
Scientific Lab supplies, Coatbridge, UK 
Haemocytometer Hawksey, UK 
Media filtration system Scientific Lab supplies, Coatbridge, UK 
Non-adherent tissue culture dishes 
(35mm / 100mm) 
Scientific Lab supplies, Coatbridge, UK 
Non-adherent tissue culture flasks 
(75cm3) 
Scientific Lab supplies, Coatbridge, UK 
Pipette tips  
(p10, p20, p100, p200, p1000) 
Greiner Bio-One, Gloucestershire, UK 
Sterile tissue culture pipettes  
(5, 10, 25, 50ml) 
Scientific Lab supplies, Coatbridge, UK 
Syringe filters (22 micron) Invitrogen, Paisley, UK 
Syringes (5, 10, 20, 50 ml) Invitrogen, Paisley, UK 
Tissue culture flasks (25, 75, 150 cm3 ) Greiner Bio-One, Gloucestershire, UK 
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2.1.1.2. Tissue culture reagents  
Reagent Supplier 
Alpha MEM medium Invitrogen, Paisley, UK 
BIT 9500 serum substitute (BIT) Stem Cell Technologies, British 
Columbia, Canada 
Bovine serum albumin (BSA) Sigma-Aldrich, Dorset, UK 
CliniMACS CD34+ beads Miltenyi Biotec, Auburn CA 
CliniMACS PBS/EDTA buffer Miltenyi Biotec, Auburn CA 
CliniMACS tubing set and columns Miltenyi Biotec, Auburn CA 
Demecolcine (Colcemid; N-Deacetyl – N – 
Methylcolchicine) 
Invitrogen, Paisley, UK 
Dimethylsulphoxide (DMSO) Sigma-Aldrich, Dorset, UK 
DNase I (Recombinant human DNAse) Stem Cell Technologies, British 
Columbia, Canada 
Dulbecco’s modified eagle medium 
(DMEM) 
Sigma-Aldrich, Dorset, UK 
Dulbecco’s phosphate buffered saline 
(PBS) 
Sigma-Aldrich, Dorset, UK 
Dulbecco’s phosphate buffered saline 
without Ca2+ and Mg2+ (DPBS) 
Invitrogen, Paisley, UK 
Ethanol 100%  Sigma-Aldrich, Dorset, UK 
Foetal bovine serum (FBS) Invitrogen, Paisley, UK 
Genetecin G418 (1013-027) Invitrogen, Paisley, UK 
Ham’s F12 / DMEM (F12/DMEM) Invitrogen, Paisley, UK 
Hanks balanced salt solution (Ca2+ Mg2+ 
free) (HBSS-CMF) 
Invitrogen, Paisley, UK 
Histopaque Miltenyi Biotec, Auburn CA 
Horse serum Invitrogen, Paisley, UK 
Human serum albumin 20% (HSA 20%) University of Glasgow 
Human serum albumin 4.5% (HSA 4.5%) University of Glasgow 
Hydrocortisone 21 – Hemisuccinate 
(Sodium salt) 
Stem Cell Technologies, British 
Columbia, Canada 
Hygromycin B Invitrogen, Paisley, UK 
Imatinib Novartis, Frimley, UK 
Iscove’s modified dulbecco’s medium 
(IMDM) 
Invitrogen, Paisley, UK 
L-glutamine 200mM (100x) Invitrogen, Paisley, UK 
Magnesium chloride (1.25M) Sigma-Aldrich, Dorset, UK 
Methocult H4034 Stem Cell Technologies, British 
Columbia, Canada 
Mitomycin C Invitrogen, Paisley, UK 
Myelocult 5100 Stem Cell Technologies, British 
Columbia, Canada 
N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-
(S)-phenylglycine t-butyl ester (DAPT) 
Cellagen Technology, USA 
Penicillin (5000u)/ streptomycin (5mg/ml) 
solution (Pen/Strep) 
Invitrogen, Paisley, UK 
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Recombinant human Flt-3 ligand (Flt3L) Peprotech EC Ltd, UK 
Recombinant human G-CSF (G-CSF) NHS pharmacy 
Recombinant human IL-3 (IL-3)  Peprotech EC Ltd, UK 
Recombinant human IL-6 (IL-6) Peprotech EC Ltd, UK 
Recombinant human SCF (SCF) Peprotech EC Ltd, UK 
Recombinant Jagged1 R&D systems, Abingdon, UK 
RPMI 1640 medium (RPMI) Invitrogen, Paisley, UK 
Sodium azide Sigma-Aldrich, Dorset, UK 
Sterile water (dH20) Invitrogen, Paisley, UK 
Tri-sodium citrate (0.155M) Sigma-Aldrich, Dorset, UK 
Trypan blue solution (8mM) Sigma-Aldrich, Dorset, UK 
Trypsin- EDTA (0.25%) Sigma-Aldrich, Dorset, UK 
β-mercaptoethanol (200mM) Invitrogen, Paisley, UK 
 
2.1.1.3. Tissue culture media components (not listed within text) 
2.1.1.3.1. Serum free media (SFM) 
 Volume 
IMDM 97.25ml 
BIT 25ml 
L-Glutamine 1.25ml 
Penicillin/streptomycin 1.25ml 
β-mercaptoethanol (200mM) 250ul (i.e. 400uM) 
Low density lipoprotein (10mg/ml) 250ul (40ug/ml) 
Filter sterilise through 0.22um filter before use 
 
2.1.1.3.2. SFM with high growth factor (SFM+5GF) 
 Volume Final Concentration 
SFM 10ml  
IL-3 (50ug/ml) 4ul 20ng/ml 
IL-6 (50ug/ml) 4ul 20ng/ml 
G-CSF (50ug/ml) 10ul 50ng/ml 
SCF (50ug/ml) 20ul 100ng/ml 
Flt3L (50ug/ml) 20ul 100ng/ml 
 
2.1.1.3.3. MSC media 
 Volume Final Concentration 
DMEM 400ml  
Hyclone FBS 100ml 20% 
 
2.1.1.3.4. Long-term myeloid culture medium (LTMCM) 
 Volume concentration Final Concentration 
Myelocult 500ml  
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Hydrocortisone 21 – 
Hemisuccinate (1x10-4M) 
1ml 0.2x10-6M 
 
2.1.1.4. Tissue culture solutions 
2.1.1.4.1. Thawing solution of primary samples (DAMP) 
 Volume concentration Final Concentration 
PBS 418.75ml  
Tri-sodium citrate (0.155M) 53ml 8.2mM 
HSA 20% 24ml 1% 
DNase I (~2500U/1ml) 2ml 10U/ml 
MgCl2 (1M) 1.25ml 2.5mM 
 
2.1.1.4.2. PBS/2% FBS washing solution 
 Volume 
PBS 490ml 
FBS 10ml 
 
2.1.1.4.3. PBS/20% FBS quenching solution 
 Volume 
PBS 400ml 
FBS 100ml 
 
2.1.1.4.4. Freezing solution for primary samples 
 Volume 
4.5% HSA 80ml 
DMSO 20ml 
 
2.1.1.4.5. Freezing solution for cell lines 
 Volume 
FBS 80ml 
DMSO 20ml 
 
2.1.1.4.6. LTC-IC harvest washing buffer 
 Volume 
IMDM 500ml 
FBS 2ml 
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2.1.2. Immunofluorescence 
2.1.2.1. Immunofluorescence reagents 
Reagent Supplier 
100% ethanol University of Glasgow 
100% methanol University of Glasgow 
Acetic acid  University of Glasgow 
4’,6-diamidino-2-phenyloindole (DAPI) Invitrogen, Paisley, UK 
Fix and Perm Reagents A/B Invitrogen, Paisley, UK 
Formamide Invitrogen, Paisley, UK 
KCL 0.75M University of Glasgow 
LS1 BCR-ABL Dual Colour FISH probe set Abbott Diagnostics, Maidenhead, UK 
Poly-L-Lysine Invitrogen, Paisley, UK 
Rubber cement Halfords, Braehead, UK 
SSC Invitrogen, Paisley, UK 
 
2.1.2.2. FISH solutions 
2.1.2.2.1. Hypotonic KCL solution 
 Volume 
KCl 0.75M 1ml 
dH2O 10ml 
 
2.1.2.2.2. Fixative 
 Volume 
Acetic acid 2ml 
Methanol 9ml 
 
2.1.2.2.3. Stock SSC buffer (x20 concentration) (20X SSC) 
 Volume 
SSC 132g 
dH2O 500ml 
Pure HCl Titrate to pH 5.3 
 
2.1.2.2.4. FISH wash buffer I (2xSSC 0.1% NP40) 
 Volume 
20X SSC 100ml 
dH2O 899ml 
NP40 1ml 
Pure HCl Titrate to pH7 
 
2.1.2.2.5. FISH wash buffer 2 (0.4xSSC 0.3% NP40) 
 Volume 
20X SSC 10ml 
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dH2O 493.5ml 
NP40 1.5ml 
Pure HCl Titrate to pH7 
 
2.1.2.2.6. FISH denaturation buffer 
 Volume 
Formamide 70% 49ml 
20X SSC 7ml 
dH2O 14ml 
Pure HCl Titrate to pH7 
 
 
2.1.3. Flow cytometry 
2.1.3.1. Flow cytometry reagents 
Reagent Supplier 
7  amino actinomycin D (7-AAD, Viaprobe 
solution) 
BD Biosciences, Oxford, UK 
AnnexinV – FITC or Annexin V - APC BD Biosciences, Oxford, UK 
Anti-goat FITC BD Biosciences, Oxford, UK 
Anti-mouse IgG2a FITC  BD Biosciences, Oxford, UK 
Anti-mouse IgG2a FITC BD Biosciences, Oxford, UK 
Anti-rabbit IgG FITC or PE  Sigma-Aldrich, Dorset, UK 
Anti-rabbit IgG PE  BD Biosciences, Oxford, UK 
Carboxyfluorescein diacetate succinimidyl 
diester (CFSE) 
Invitrogen, Paisley, UK 
FACS clean solution Becton Dickinson, Oxford, UK 
FACS flow solution Becton Dickinson, Oxford, UK 
Fix and Perm Kit  Invitrogen, Paisley, UK 
HBSS-CMF Invitrogen, Paisley, UK 
Propidium Iodide (PI) BD Biosciences, Oxford, UK 
 
2.1.3.2. Flow cytometry antibodies 
Reagent Supplier 
Mouse anti-human CD19-V450 (HIB19) BD Biosciences, Oxford, UK 
Mouse anti-human CD33-PerCP-Cy5.5 (P67.6) BD Biosciences, Oxford, UK 
Mouse anti-human CD34-APC (581) BD Biosciences, Oxford, UK 
Mouse anti-human CD34-PerCP (8G12) BD Biosciences, Oxford, UK 
Mouse anti-human CD36-APC (CB38) BD Biosciences, Oxford, UK 
Mouse anti-human CD38-V450 (HIT2) BD Biosciences, Oxford, UK 
Mouse anti-human CD45-FITC (H130) BD Biosciences, Oxford, UK 
Mouse anti-human CD45RA-APC H7 (HI100) BD Biosciences, Oxford, UK 
Mouse anti-human CD71-FITC (M-A712) BD Biosciences, Oxford, UK 
Mouse anti-human CD73-V450 (AD2) BD Biosciences, Oxford, UK 
Mouse anti-human CD90-PE Cy7 (5E10) BD Biosciences, Oxford, UK 
Mouse anti-human CD93-PE (R3) eBioscience, ThermoFisher 
Scientific, Paisley, UK 
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Mouse anti-human DLL1-PE (MHD1-314) BD Biosciences, Oxford, UK 
Mouse anti-human glycophorin A-PE (GA-R2) BD Biosciences, Oxford, UK 
Mouse anti-human Jagged1-PE (MHJ1-152) BD Biosciences, Oxford, UK 
Mouse anti-human Lineage cocktail-FITC (CD3 
(MϕP9), 14 (3G8), 16 (NCAM16.2), 19 
(SJ25C1), 20 (SK7), 56 (L27)) 
BD Biosciences, Oxford, UK 
Rat anti-mouse CD45-APC-Cy7 (30-F11) BD Biosciences, Oxford, UK 
Rat anti-mouse DLL1-PE (3OB11.1O) BD Biosciences, Oxford, UK 
 
2.1.4. Western blotting 
2.1.4.1. Western blotting reagents 
Reagent Supplier 
2-mercaptoethanol (50ul/ml) Sigma-Aldrich, Dorset, UK 
Ammonium persulphate (APS) Sigma-Aldrich, Dorset, UK 
Bromophenol blue Sigma-Aldrich, Dorset, UK 
BSA protein  BioRad, Hampstead, UK 
ECL BioRad, Hampstead, UK 
Glycerol Sigma-Aldrich, Dorset, UK 
horseradish-peroxidase (HRP)-labelled 
secondary antibodies 
Sigma-Aldrich, Dorset, UK 
Immune-blot polyvinyliden difluoride 
(PVDF) membrane 
BioRad, Hampstead, UK 
Milli Q ultrapure water Sigma-Aldrich, Dorset, UK 
NaCl Sigma-Aldrich, Dorset, UK 
NP40 Sigma-Aldrich, Dorset, UK 
Ovalbumin Sigma-Aldrich, Dorset, UK 
Phosphatase inhibitor cocktail Sigma-Aldrich, Dorset, UK 
Protease inhibitor cocktail Sigma-Aldrich, Dorset, UK 
Quickstart Bradford Dye Reagent BioRad, Hampstead, UK 
Sodium dodocyl sulphate (SDS) Sigma-Aldrich, Dorset, UK 
SRX-101A medical film processor Konica Minolta Medical Graphic, Inc., 
Banbury, UK 
Stripping solution Sigma-Aldrich, Dorset, UK 
TEMED Sigma-Aldrich, Dorset, UK 
Trisma base Sigma-Aldrich, Dorset, UK 
Tween 20 Sigma-Aldrich, Dorset, UK 
 
2.1.4.2. Western blotting antibodies  
Antibody Reactive 
Species 
Dilution Block Supplier 
ADAM10, C-
terminus 
Rabbit 1:1000 5% Milk Millipore 
Anti-mouse IgG 
(H+L)- HRP 
conjugated 
Horse 1:10000 5% BSA Cell Signalling 
Anti-rabbit IgG 
(H+L)- HRP 
conjugated 
Goat 1:10000 5% BSA Cell Signalling 
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Cleaved Notch1 
(Val1744) (D3B8) 
Rabbit 1:500 5% BSA  Cell Signalling 
GAPDH (D16H11) Rabbit 1:1000 5% Milk Cell Signalling 
Notch1 (A-8) Mouse 1:500 5% BSA Santa Cruz 
Notch2 (D67C8) Rabbit 1:1000 5% BSA Cell Signalling 
 
2.1.4.2.1. Western blotting solutions 
2.1.4.2.1.1. 1M Tris HCl 
 Volume 
Trisma base 60.6g 
dH2O 500ml 
HCl/NaCl To appropriate PH 
 
2.1.4.2.1.2. 10% SDS 
 Volume 
SDS 10g 
dH2O 91ml 
 
2.1.4.2.1.3. 10% APS 
 Volume 
APS 0.1g 
dH2O 1000ul 
 
2.1.4.2.1.4. 10X TBS 
 Volume 
NaCl 87.6g 
Tris 58.1g 
dH2O 1000ml 
 
2.1.4.2.1.5. 1X TBSN 
 Volume 
NP40 10% (25ml NP40/250ml H2O) 5ml 
1xTBS 1000ml 
 
2.1.4.2.1.6. Semi-dry transfer buffer (10X) 
 Volume 
Glycine 29.3g 
Tris 58.1g 
SDS 3.75g 
dH2O 1000ml 
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2.1.4.2.1.7. Semi-dry transfer buffer (1X) 
 Volume 
Methanol 200ml 
10X Transfer buffer stock 100ml 
dH2O 700ml 
 
2.1.4.2.1.8. Blocking solution (5X) 
 Volume 
BSA 25g 
Ovalbumin 5g 
1xTBS 500ml 
Sodium azide Sprinkle 
 
 
2.1.5. Molecular biology 
2.1.5.1. Molecular biology reagents 
Reagent Supplier 
20X taqman gene expression assay Applied Biosystems, Warrington, UK 
2X assay loading reagent Applied Biosystems, Warrington, UK 
2X taqman universal PCR mastermix Applied Biosystems, Warrington, UK 
Applied Bioscience micro RNA kit Applied Biosystems, Warrington, UK 
Arcturus picopure RNA isolation kit Applied Biosystems, Warrington, UK 
Boric acid Sigma-Aldrich, Dorset, UK 
DNAse1 Qiagen, Crawley, UK 
dNTP mix Applied Biosystems, Warrington, UK 
EDTA Sigma-Aldrich, Dorset, UK 
GE loading reagent Applied Biosystems, Warrington, UK 
Gene expression master mix Applied Biosystems, Warrington, UK 
Molecular biology grade 100% ethanol Qiagen, Crawley, UK, 
Molecular biology grade H2O Qiagen, Crawley, UK 
Random primers Applied Biosystems, Warrington, UK 
Reverse transcriptase Applied Biosystems, Warrington, UK 
RNA easy micro kit Qiagen, Crawley, UK 
RNA easy mini kit Qiagen, Crawley, UK 
RNase inhibitor Applied Biosystems, Warrington, UK 
RNeasy mini kit Qiagen, Crawley, UK 
Taqman gene expression assay Applied Biosystems, Warrington, UK 
TE buffer, pH 8 Applied Biosystems, Warrington, UK 
Tris base Sigma-Aldrich, Dorset, UK 
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2.1.5.2. Molecular biology solutions 
2.1.5.2.1. 10X TBE buffer 
 Volume 
Boric acid 55g 
EDTA (0.5M, pH 8.0) 40ml 
Tris base 108g 
dH2O 1000ml 
 
2.1.5.2.2. 2X reverse transcription mastermix 
 Volume 
10X RT Buffer 2ul 
25X dNTP mix 0.8ul 
10X RT Random primers 2ul 
Reverse transcriptase 50u/ul 1ul 
RNase inhibitor 1ul 
Nuclease free water 3.2ul 
 
2.1.5.2.3. Fluidigm assay mix 
 Volume 
2X assay loading reagent 2.5ul 
20X TaqMan Gene expression assay 2.5ul 
 
2.1.5.2.4. Fluidigm sample mix 
 Volume 
2X TaqMan universal PCR Mastermix 2.5ul 
20X GE sample loading reagent 0.25ul 
cDNA 2.25ul 
 
2.1.5.3. Primers 
 
Forward Reverse 
ABL-A3-B GTTTGGGCTTCACACCATTCC - 
ACVR2A ACCATGGCTAGAGGATTGGC GCCAACCCAAAGTCAGCAAT 
ACVR2B CTGCAACGAACGCTTCACTC CAGGACGATGAGGGAAAGGC 
ADAM 10 ATGGCAAAGATGATAAAGAATTATGC
C 
AATCGTTGCAAGGGGATCC 
ADAM 17 CTTCTACAGATACATGGGCAGAG CTCTATCTGTATTCCATAGCCTTTA
A 
ADAM19 GTTTACACAACAGACCAAGAAGC CTTGTGTTTGGTGGCGTCC 
AKT1 TGGACTACCTGCACTCGGAGAA GTGCCGCAAAAGGTCTTCATGG 
AKT2 CCAACACCTTTGTCATACGCTGC GCTTCAGACTGTTGGCGACCAT 
AKT3 GATGCCTCTACAACCCATCAT GTCCATGCAGTCCATACCATCCT 
ATM  CGGAGCTGATTGTAGCAACATACTA CAGATAGAGCCTGAAGTACACAGA
G 
ATR  CAGCTCTCTATGAAGGCCATTCAA GTTCTACTGTTTCACTGTCTGTTGC 
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B2M TTGTCTTTCAGCAAGGACTGG  ATCCGGCATCTTCAAACCTCC  
BCL2 ATCGCCCTGTGGATGACTGAGT GCCAGGAGAAATCAAACAGAGGC 
BCR-C5R BCR-C5R - 
BMI1 GCATCGAACAACGAGAATCA GCTGGTCTCCAGGTAACGAA 
BMI1 AACTGATGATGAGATAATAAGC CTTCTGAGAAACTTTCTTAAGTGC 
BMP10 ACCCACCAGAGTACATGTTGG GCCCATTAAAACTGACCGGC 
BMP7 CAGGCCTGTAAGAAGCACGA TGGTTGGTGGCGTTCATGTA 
C-JUN CTTGAAAGCTCAGAACTCGGAG CTGCGTTAGCATGAGTTGGC 
CCDN1 CAGAAGGAGATTGTGCCATCC GAAGCGGTCCAGGTAGTTCA 
CCNA1 CTCGTAGGAACAGCAGCTATGC GCTAGAACTTTCAGAAGCAAGTGTTC 
CCNA2 TGGCGGTACTGAAGTCCGG CAAGGAGGAACGGTGACATGC 
CCNB1 CAGCTCTTGGGGACATTGGTAAC ACTGGCACCAGCATAGGTACC 
CCNE1 CAACGTGCAAGCCTCGGA CAAAGTGCTGATCCCTTAAGTATGT
C 
CCNE2 CAAGTTGATGCTCTTAAAGATGCTCC GCAGCAGTCAGTATTCTGTACTGG 
CD79A GAACGAGAAGCTCGGGTTG TGCCCACATCCTGGTAGGT 
CD93 GGCAGACAGTTACTCCTGGGTT GGAGTTCAAAGCTCTGAGGATGG 
CDC25A GTCTAGATTCTCCTGGGCCATTG CAGAATGGCTCCTCTTCAGAGC 
CDC25B GGATTTGTGGACATCCTAGAGAGT ACTTGCTGTACATGACGAGGT 
CDC25C CACTCAGCTTACCACTTCTGCAG GGGCTACATTTCATTAGGTGCTGG 
CDK2 GCCTGATTACAAGCCAAGTTTCC TCCGCTTGTTAGGGTCGTAGT 
CDK4 GAAACTCTGAAGCCGACCAG AGGCAGAGATTCGCTTGTGT 
CDK4 CCCATCAGCACAGTTCGTGA AACACCAGGGTTACCTTGATCTC 
CDK6 CCTGCAGGGAAAGAAAAGTGC CCTCCTCTTCCCTCCTCGAA 
CDK6 CCGAAGTCTTGCTCCAGTCC GTTGATCAACATCTGAACTTCCACG 
CDKN1A GTGGACCTGGAGACTCTCAG CCTCTTGGAGAAGATCAGCCG 
CDKN1C CACGATGGAGCGTCTTGTC CCTGCTGGAAGTCGTAATCC 
CDKN2A CCGAATAGTTACGGTCGGAGG CACGGGTCGGGTGAGAGT 
CDKN2B GGTGGCTACGAATCTTCCG  CCTAAGTTGTGGGTTCACCA 
CDKN3A  GGTTTATGTGCTCTTCCAGGTTG  GTGCAGCTAATTTGTCCCGAAAC 
CHEK1 CCATCAGCAAGAATTACCATTCCAG CTGGGAGACTCTGACACACC 
CHEK2 ATGAGAACCTTATGTGGAACCCC GCTCAGAGAAAGGTGGATACCC 
CSF1R GGACATTCATCAACGGCTCT GCTCAGGACCTCAGGGTATG 
CSF2R GTTACCACACCCAGCATTCC TTGGCAGTCCCAGCTTAAAT 
CSF3R TGGGACCCAGGAATCTATCA ATGAGGCAGGAGAGGTTGTG 
CYC1 ACTGCGGGAAGGTCTCTACTT  GGGTGCCATCGTCAAACTCTA  
CYCLIN D3 TGGATGCTGGAGGTATGTGA TGCACAGTTTTTCGATGGTC 
CYCLIN E1 GTCCTGGCTGAATGTATACATGC CCCTATTTTGTTCAGACAACATGGC 
DAAM1 AGAAGTATGCCAGCGAAAGG TCTCCACTCCTGCACCTTGG 
DKK3 GCATCATCGACGAGGACTGT GTCTCCACAGCACTCACTGT 
DLL1 GCCTGGATGTGATGAGCAGC ACAGCCTGGATAGCGGATACAC 
DLL3 CACTCAACAACCTAAGGACGCAG GAGCGTAGATGGAAGGAGCAGA 
DLL4 TCGCTCATCATCGAAGCTTGG CAGTTCTGACCCACAGCTAGG 
DTX1 AATCCCGAGGATGTGGTTCG GTAGCCTGATGCTGTGACCA 
E2F1 GGACCTGGAAACTGACCATCAG CAGTGAGGTCTCATAGCGTGAC 
E2F2 CTCTCTGAGCTTCAAGCACCTG CTTGACGGCAATCACTGTCTGC 
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E2F3 AGCGGTCATCAGTACCTCTCAG TGGTGAGCAGACCAAGAGACGT 
EFNA1 GTCTGAGAAGTTCCAGCGCT CACTGACAGTCACCTTCAACC 
EFNA4 GAGGCTCCAGGTGTCTGTCT AATGCTCCATCTTGTCGGTCTG 
EGR1 TGACCGCAGAGTCTTTTCCT TGGGTTGGTCATGCTCACTA 
EGR2 CTGACACTCCAGGTAGCGAG GTTGATCATGCCATCTCCGGC 
ENOX2 GAGCTGGAGGGAACCTGATTT  CACTGGCACTACCAAACTGCA  
ETS1 GAGTCAACCCAGCCTATCCA ATGGGATGGAGCGTCTGATA 
FAT1 ATCTGTGGAGCCTCCTGGCATA CATCTGTAGCCTCGACTGTGAG 
FAT2 CACTGACAGTCATGGTCCGA GTGTCAGGAACACTTGCCTC 
FAT3 GACAGAGACACATCCGACGTT GCCTCTTCACATAGACCTTCCAC 
FAT4 CCCACATTTGCCAGTAAAGCG GTGAACTGAGAGTTTCCACCG 
FBXW7 CCTTCTCTGGAGAGAGAAATGC CTGTCTGATGTATGCACTTTTCC 
FOS AGGAGAATCCGAAGGGAAAGG TAGTTGGTCTGTCTCCGCTTG 
FOXM1 TCAAAACCGAACTCCCCCTG GCAGCACTGATAAACAAAGAAAGA 
FOXO1 CTACGAGTGGATGGTGAAGAGC CCAGTTCCTTCATTCTGCACTCG 
FOXO3 CCTACTTCAAGGATAAGGGCGAC GCCTTCATTCTGAACGCGCATG 
FURIN CCACATGACTACTCCGCAGAT TACGAGGGTGAACTTGGTCAG 
GATA3 CGAACTGTCAGACCACCACA GGTTTCTGGTCTGGATGCCTT 
GEMIN2 TTGTTACCTGAGGCTCATTCAC TCATCAGCTAAATCACGTTGGT 
GFI1 GCTCCCCAGGACCAGACTAT CTTCGGTCAGCTGCGATT 
GLI1 AGCCAAGCACCAGAATCGG TCTTGACATGTTTTCGCAGCG 
GLI3 CTCCTATGGTCACTTATCTGCAAGT TGAACCTAAGCTCTGTTGTCGG 
GNB2L1 TCCATACCTTGACCAGCTTG  GCAGATTGTCTCTGGATCTC  
GSK3B CGACTAACACCACTGGAAGCT GGATGGTAGCCAGAGGTGGAT 
HES1 GGAGAAAAATTCCTCGTCCC CGCGAGCTATCTTTCTTCAG 
HEY1 CCGTGGATCACCTGAAAATGC GGCATCTAGTCCTTCAATGATGC 
HEY2 GAAGATGCTCCAGGCTACAGG CCTTCCACTGAGCTTAGGTACC 
HHIP GCCATTCAGTAATGGTCCTTTGG CCACTGCTTTGTCACAGGAC 
HIF1A TACTCATCCATGTGACCATGAGG TAGTTCTTCCTCGGCTAGTTAGG 
HIPK1 GCCACTACAGATTCAGTCAGGAG GTGTGATGGTGGCTACTTGAGG 
HLF GCCCATGATCAAGAAAGCTC GGCGATCTGGTTCTCTTTCA 
HOXA4 ATGTCAGCGCCGTTAACCC TGTTGGGCAGTTTGTGGTCT 
HOXA5 AAGTCATGACAACATAGGCGGC GATACTCAGGGACGGAAGGC 
HOXA6 TGCGCGGGTGCTGTGTAT GCTGCGTGGAATTGATGAGC 
HOXB4 CTGGATGCGCAAAGTTCACGTG CGTGTCAGGTAGCGGTTGTAGT 
ICAT CATGCTGCGGAAGATGGGAT GGAAAACGCCATCACCACGT 
IHH GGACGCTATGAAGGCAAGATCG CAGCGAGTTCAGGCGGTCCTT 
IKZF1 AACGTCGCCAAACGTAAGAG AGTTGATGGCGTTGTTGATG 
INHB1 AAGTCGGGGAGAACGGGTAT GGTCACTGCCTTCCTTGGAA 
INK4A CTCGTGCTGATGCTACTGAGGA GGTCGGCGCAGTTGGGCTCC 
INK4C CGTCAATGCACAAAATGGATTTGG GAATGACAGCGAAACCAGTTCGG 
INK4D GTGCATCCCGACGCCCTCAAC TGGCACCTTGCTTCAGCAGCTC 
JAG1 TGGGATTCCAGTAATGACACCG GTAGTCATCACAGGTCACGC 
JAG2 CAAAAACCTGATTGGCGGCT CACACACTGGTACCCGTTCA 
LEF1 CACTGACAGTGACCTAATGC CAACGACATTCGCTCTCATT 
LEF1 CTACCCATCCTCACTGTCAGTC GATGTTCCTGTTTGACCTGAGG 
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LFNG GCCACAAGGAGATGACGTT GAGCAGTTTGTGATGACCACG 
MAML GCAACAGCAGTTCCTTCAGAGG GTGAACTGTCCAACCTGCTGTG 
MDM2 TGTTTGGCGTGCCAAGCTTCTC CACAGATGTACCTGAGTCCGATG 
MEIS1 AAGCAGTTGGCACAAGACACGG CTGCTCGGTTGGACTGGTCTAT 
MEIS1 AAGACACGGGACTCACCATC TGACCGTCCATTACGAAACC 
MFNG CTGGTACAGTTCTGGTTTGC ATGTGTCCATGAAACGGGAGC 
MPL ACTCAGCGAGTCCTCTTTGTGG CATAGCGGAGTTCGTACCTCAG 
MPO GCATCATCGGTACCCAGTTC GTGGTGATGCCTGTGTTGTC 
MTOR AGCATCGGATGCTTAGGAGTGG CAGCCAGTCATCTTTGGAGACC 
MYC GACTCTGAGGAGGAACAAGA TTGGCAGCAGGATAGTCCTT 
NFKB1 AGATGATCCATATTTGGGAAGGC TTGCTCTAATATTTGAAGGTATGGG
C 
NOTCH 1 TCCACTGTGAGAACAACACGC ACTCATTGACATCGTGCTGGC 
NOTCH 2 GCAAAGTGTATCGATCACCCGA TGCAGGTGTAGGAATCAATACCAT
C 
NOTCH 3 TACTGGTAGCCACTGTGAGCAG CAGTTATCACCATTGTAGCCAGG 
NOTCH 4 TTCCACTGTCCTCCTGCCAGAA TGGCACAGGCTGCCTTGGAATC 
NUMB CCAAACCAGTGACAGTGGTGGC CCCAAGGGTTGGTTTCACGC 
P190 BCR-
e1-A  
GACTGCAGCTCCAATGAGAAC - 
P210 BCR-
e1-A 
GAAGTGTTTCAGAAGGCTTCTCC - 
p38 GAGCGTTACCAGAACCTGTCTC AGTAACCGCAGTTCTCTGTAGGT 
PBX1 GGAGGATACAGTGATGGACTCG GGAGGTATCAGAGTGAACACTGC 
PML CCGTCATAGGAAGTGAGGTCTTC GTTTTCGGCATCTGAGTCTTCCG 
PREP1 ATTGCATCAGGAGTCGCACAGC GAGACTGAAGGCTGTCCACGTT 
PSEN1 GGTGGTTCTGTATAAATACAGGTGC AACAGTAATGTAGTCCACAGCAA 
PTCH1 ACATTTGTGTTACAAATCAGGAGAGC CTGTCCCAGACTGTAATTTCGC 
PTCH2 TGTGGTGGGAGGCTATCTG GCATGGTCACACAGGCATAG 
RFNG CTCTCACCTGGAGAACCTGCA TCTTGATGCAGGCTGAAGCCT 
RPS6kB1 TACTTCGGGTACTTGGTAA GATGAAGGGATGCTTTACT 
RUNX1 CACCTACCACAGAGCCATCAA CTCGGAAAAGGACAAGCTCC 
RUNX1T1 ATCACAACAGAGAGGGCCAA CTGCAGGTTTCACTCGCTTT 
RUNX2 AACAAGACCCTGCCCGTGG CATTCAGCAGAGGCATTCCGG 
SHH CGAGCGATTTAAGGAACTCACC GCGTTCAACTTGTCCTTACACC 
SMAD6 CTCCCTACTCTCGGCTGTCT AGAATTCACCCGGAGCAGTG 
SMAD7 CCATCACCTTAGCCGACTCT CCAGGGGCCAGATAATTCGT 
SMO CTGACCGCTTCCCTGAAGG CGTCCTCGTACCAGCTCTTGG 
SMURF1 ATGCAGTTCGTGGCCAGATA CAGGCCCGGAGTCTTCATAC 
SMURF2 GACAGGATCCTCTCGAGTGC AGCTTTCATAGGGTGGAATGTCT 
SPI1 GTGCCCTATGACACGGATCT AAGCTCTCGAACTCGCTGTG 
STAT3 CCTAGATCGGCTAGAAAACTGG GGGTCCCCTTTGTAGGAAAC 
STIL GACACAGTGCAAGCTGGAAGAC AGTCAGGCTCTTGATCCTCACC 
SUFU CTCCAGGTTACCGCTATCGTCA TGCTCAGGGATGTTGGCAGAAG 
TAZ CCGTGTCCAATCACCAGTCCT CTTGGTGAAGCAGATGTCTGC 
TCF3 TGACCTCCTGGACTTCAGC ACCTGAACCTCCGAACTGC 
TCF4 AATCAAAACAGCTCCTCCGATT CCATCTTGCCTCTTGGCCG 
TCF7 TCAACCAGATCCTGGGTCGC CCTTTCCTTGCGGGCCAG 
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TEAD1 CCTGGCTATCTATCCACCATGTG CTGGTCCTCGTCTTGCCTGT 
TEAD3 GCAGTAGATGTGCGCCAGAT TGGATGGTGCTGTTGAGGT 
TEAD4 GCTCTGGATGTTGGAGTTCTCG GGCTTGACTGGCTGATGTG 
TLE1 TGTCATATGGATTAAACATTGAAATG
C 
CACGTTCAACAGCCTGGG 
TLE2 TATGAGATGTCGTACGGGC CAGGAAGGGGATAATCTGAGC 
TLE3 GTCTTGTGACAGGATCAAAGACG CATTTCAATGTTCAAGCCATAGGA 
TLE4 GAAAACCACCAGGAGTTGACC GTCAGCTCTCCGTTCATTCC 
TP53 TTCTTGCATTCTGGGACAGCC GGGGGTGTGGAATCAACCC 
TP73 ACTTTGAGATCCTGATGAAGC GAGGACCGGCCCGTAGGA 
TYW1 ATTGTCATCAAGACGCAGGGC  GTTGCGAATCCCTTCGCTGTT  
UBE2D2 CCATGGCTCTGAAGAGAATCC  GATAGGGACTGTCATTTGGCC  
VEGF AGAAGGAGGAGGGCAGAATCA AGGGTACTCCTGGAAGATGTCC 
WWTR1 GAGGACTTCCTCAGCAATGTGG CGTTTGTTCCTGGAAGACAGTCA 
YAP1 GCAGTTGGGAGCTGTTTCTC GCCATGTTGTTGTCTGATCG 
ZEB2 CCGCCACGAGAAGAATGAAG TACCTGCTCCTTGGGTTAGC 
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2.2. Methods 
2.2.1. Drugs and reagents 
N-[N-(3,5-Difluorophenacetyl-L-alanyl)]-(S)-phenylglycine t-butyl ester (DAPT) was made into 
stock dilutions of 10mM in dimethylsulphoxide (DMSO) and stored at -20 degrees Celsius (°C). 
Imatinib was made into stock dilutions of 10mM in DMSO. Dilutions to working concentrations 
were made with media. DMSO was used as a negative control dependent on drug concentration.  
Growth factors were reconstituted as per manufacturer’s guidelines. 
 
2.2.2. General tissue culture 
A list of the materials used for tissue culture can be seen in section 2.1.1.1 and 2.1.1.2.  Media 
composition (not listed within table 2-4) and specific solutions can be seen in section 2.1.1.3 and 
2.1.1.4. 
 
2.2.2.1. Standard cell culture conditions 
All cell culture procedures were performed using sterile technique in a laminar airflow hood.  All 
cell culture was incubated in a humidified atmosphere at 37°C in 5% carbon dioxide (CO2). 
 
2.2.2.2. Culture of cell lines 
A variety of cell lines were used and are listed below (table 2-2).  All culture conditions were as 
described by either American Type Culture Collection (ATCC), Deutsche Sammlung von 
Mikroorganismen und Zellkulturen (DSMZ), or from the originating institution.  OP9-GFP and OP9-
DLL1 stromal cells were a kind gift from Professor Zúñiga-Pflücker (University of Toronto).  OP9-
JAG1 stromal cells were a kind gift from Dr Bianca Blom (University of Amsterdam).  The 
overexpression of DLL1 and JAG1 was initially confirmed using Western blotting or flow cytometry 
protein quantification.  
 
Cell Line Origin Culture conditions  
M210B4 Cell line derived from 
BM stromal cells from 
a (C57BL/6J X 
C3H/HeJ)F1 mouse;  
the cells express 
laminin and collagen 
IV, but do not express 
collagen I or Factor 
VIII.  These cells have 
90% RPMI 1640 + 10% FBS; 
maintain cells until 80% 
confluency; split cell 1:6 to 1:10 
every 2 to 3 days.  Every 2 weeks, 
160uL of genetecin and 25uL 
hygromycin B per 2ml media was 
added for cell selection. 
Stem Cell 
Technologies 
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been engineered to 
secrete human IL-3 
and human G-CSF. 
SL/SL Cell line derived from 
BM stromal cells from 
the SL/SL mouse; 
these cells have been 
engineered to produce 
IL-3 and human SCF. 
90% RPMI 1640 + 10% FBS; 
maintain cells until 80% 
confluency; split cell 1:6 to 1:10 
every 2 to 3 days. Every 2 weeks, 
320uL of genetecin and 50uL 
hygromycin B per 2ml media was 
added for cell selection. 
Stem Cell 
Technologies 
OP9GFP Murine embryonic 
stem cells from 
BM/stroma 
 Alpha Minimum Essential 
Medium without ribonucleosides 
and deoxyribonucleosides and 
with 2.2 g/L sodium bicarbonate. 
To make the complete growth 
medium, add the following 
components to the base medium: 
FBS to a final concentration of 
20% ; Maintain cultures at a cell 
concentration between 4x103 and 
1x104 cells/cm2. 
University of 
Toronto 
OP9DLL1 Murine embryonic 
stem cells from 
BM/stroma with 
retroviral stable 
expression of the 
notch ligand, DLL1.  
Alpha Minimum Essential 
Medium without ribonucleosides 
and deoxyribonucleosides and 
with 2.2 g/L sodium bicarbonate. 
To make the complete growth 
medium, add the following 
components to the base medium: 
FBS to a final concentration of 
20%; maintain cultures at a cell 
concentration between 4x103 and 
1x104 cells/cm2. 
University of 
Toronto 
OP9JAG1 Murine embryonic 
stem cells from 
BM/stroma with 
Alpha Minimum Essential 
Medium without ribonucleosides 
and deoxyribonucleosides and 
University of 
Amsterdam 
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retroviral stable 
expression of the 
notch ligand, JAG1. 
with 2.2 g/L sodium bicarbonate. 
To make the complete growth 
medium, add the following 
components to the base medium: 
FBS to a final concentration of 
20%; maintain cultures at a cell 
concentration between 4x103 and 
1x104 cells/cm2. 
Table 2- 1 Cell line origin and culture conditions 
 
2.2.2.3. Primary CML and normal CD34+ cell collection and enrichment 
Leukapheresis samples were obtained with written informed consent, in accordance with the 
declaration of Helsinki and with Greater Glasgow and Clyde NHS Trust Ethics Committee approval 
from patients with CML.   
 
In brief, on attainment of the sample, 6ml of histopaque solution was added to a 15ml falcon tube 
and allowed to warm to room temperature.  The whole blood sample was diluted 1 in 2 with PBS, 
and carefully layered drop-wise onto the histopaque solution.  Samples were centrifuged at 400xg 
for 30min at room temperature.  Following this, the opaque interface containing the mononuclear 
cells (MNC) was carefully aspirated with a 3ml sterile pastette and transferred to a sterile 15ml falcon 
tube.  These cells were then washed twice with sterile PBS at a centrifugation force of 300xg for 5 
min.   
 
Large volume samples from leukapheresis were CD34-purified directly through the CliniMACS 
system (Miltenyi Biotec, Bisley, UK) by Dr Alan Hair.  The CliniMACs system is an immune-
magnetic beads system that positively selects CD34+ cells using super-paramagnetic beads coupled 
with a suitable CD34+ monoclonal antibody.  Briefly, super-paramagnetic CD34+ beads (~50nM 
diameter) were added to the primary cell MNC sample and the resulting suspension passed through 
a high-gradient magnetic separation column, which resulted in the retention of the magnetic beads 
as the sample passed through.  Purity was assessed by flow cytometry, which confirmed all samples 
were >95% CD34+ post selection.  A representative example is shown in figure 2-1.  If the sample 
was not to be immediately used in vitro, samples were stored in cryotubes at -185°C until required 
for use.  Each sample was determined to be Ph+ by FISH following CD34+ enrichment.   
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Figure 2- 1 Representative flow cytometry plots pre and post CliniMACS system of a 
primary CML sample. 
CD34 expression is plotted against CD45 expression to assess the purity of the population.  
 
The CP-CML samples used within this thesis are listed in table 2-3, with AP and BP samples in table 
2-4, and Ph+ ALL samples in table 2-5.  Ph+ ALL samples were kindly gifted to us from the 
UKALL14 clinical trial by Professor Adele Fielding.   
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Identifier Chapter Experiment Age Gender Subtype Breakpoint WCC at 
diagnosis 
Pre 
Treatment 
CML110 6 Microarray validation 48 F CP p210 - none 
CML111 6 Microarray validation - - CP p210 - - 
CML112 4 Gene expression - - CP p210 - none 
CML113 3,4 Gene 
expression/functional 
data 
53 F CP p210 - - 
CML269 4 Gene expression 74 M CP p210 312 none 
CML273 4 Gene expression  60 F CP p210 307 none 
CML332 6 TKI effect 62 F CP p210 132 none 
CML339 6 NSG 34 F CP p210 - none 
CML340 6 NSG 55 M CP p210 - none 
CML342 6 Cell cycle 54 M CP p210 - none 
CML343 6 LT-CIC 46 M CP p210 4.8 none 
CML347 6 LT-CIC 34 F CP p210 385.8 Imatinib 
CML350 6 LT-CIC - - CP p210 - - 
CML351 6 NSG - - CP p210 - - 
CML366 4 Gene expression  41 F CP p210 - none 
CML368 4 Gene expression  51 M CP p210 - - 
CML373 6 NSG 48 M CP p210 - none 
CML385 6 NSG 51 M CP p210 - none 
CML388 6 TKI effect 61 F CP p210 227.6 none 
CML391 6 NSG 33 F CP p210 141 Interferon 
CML393 6 NSG 35 M CP p210 - none 
CML395 6 NSG 34 M CP p210 - none 
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CML399 6 TKI effect 51 M CP p210 214 none 
CML407 6 Cell cycle 50 M CP p210 - none 
CML436 3,4 Gene 
expression/functional 
data 
18 F CP p210 300 none 
CML441 3,4 Gene 
expression/functional 
data 
66 F CP p210 - none 
CML443 3,4 Gene 
expression/functional 
data 
63 M CP p210 - none 
CML444 3,4 Gene 
expression/functional 
data 
47 M CP p210 313.4 none 
CML446 3,4 Gene 
expression/functional 
data 
35 M CP p210 65.5 none 
CML452 3,4 Gene 
expression/functional 
data 
45 M CP p210 275 none 
CML456 3,4 Gene 
expression/functional 
data 
64 M CP p210 - none 
Table 2- 2  CP-CML samples used, including age, gender, breakpoint BCR-ABL mutation, WCC at diagnosis if known and pre-treatment. 
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Identifier Chapte
r 
Experiment Breakpoint Subtype Additional 
Chromosomal 
Abnormalities 
CML184 4 Gene expression p210 AP none 
CML402 4 Gene 
expression/functional 
data 
p210 AP none 
CML403 4 Gene 
expression/functional 
data 
p210 AP none 
CML404 4 Gene expression p210 AP none 
CML 
TN04 
4,5 Gene 
expression/functional 
data 
p210 mBP none 
CML371 4,5 Gene 
expression/functional 
data 
p210 mBP none 
CML384 4,5 Gene expression p210 mBP none 
CML405 4,5 Gene expression p210 mBP - 
CML406 4,5 Gene expression p210 mBP yes  
R6900 4,5 Gene expression p210 mBP - 
RB810 4,5 Gene 
expression/functional 
data 
p210 mBP - 
RB900 4,5 Gene expression p210 mBP - 
CML 
TN08 
5 Gene 
expression/functional 
data 
p210 lBP yes  
050-04 5 Gene expression p210 lBP none 
CML267 5 Gene expression p210 lBP none 
CML407 5 Gene 
expression/functional 
data 
p210 lBP none 
CML408 5 Gene 
expression/functional 
data 
- lBP - 
Table 2- 3 AP and BP samples used within this thesis 
 
Identifier Chapter Experiment UKALL14 
trial nos 
Breakpoint 
ALL1 5 Gene 
expression 
14-1-432 p190 
ALL2 5 Gene 
expression 
14-1-467 p190 
ALL3 5 Gene 
expression 
14-1-475 p190 
ALL4 5 Gene 
expression 
14-1-479 p190 
ALL5 5 Gene 
expression 
14-1-490 p210 
Table 2- 4 Ph+ ALL samples used within this thesis 
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2.2.2.4. Cryopreservation of cells 
Cryopreservation, in liquid nitrogen at -185°C, of both cell lines and fresh primary cells was 
used for long-term storage.  4x106 to 2x107 CD34+-selected cells or 1x108 unselected MNC were 
suspended in 1 to 2ml of an equal volume primary cell freezing solution (section 2.1.1.4.4; 20% 
DMSO in 4.5% HSA giving a final concentration of 10% DMSO) and aliquoted into cryotubes. 
 
Cell lines were cyropreserved as per guidelines from ATCC or DSMZ.  In brief, 5x106-1x107 
cells were suspended in cell line freezing solution (section 2.1.1.4.5; 90% FBS and 10% 
DMSO).  Cells were then transferred to a cryofreezer container (‘Mr Frosty’) and slowly cooled 
at a controlled rate to -80 °C before being transferred to -185 °C freezer for long-term storage.  
 
2.2.2.5. Cell recovery post cryopreservation 
CD34+ primary cells were removed from liquid nitrogen and immediately thawed at 37 °C in a 
water bath.  Following this, 10ml of thawing solution (DAMP; section 2.1.1.4.1) was gradually 
added to the cells over 10 min with constant gentle agitation to prevent clumping.  The cells 
were then centrifuged at 210xg for 10 min and washed a further twice in 10ml DAMP.  Finally, 
the cell pellet was re-suspended in SFM and 5 Growth Factor (SFM+5GF) (section 2.1.1.3.2); 
cell number and viability was assessed by trypan blue exclusion and the cells cultured overnight 
at 37°C with 5% CO2 in a non-adherent tissue culture flask at a maximum density of 1x106 
cells/ml.  Culture in SFM+5GF maximises cell recovery post thaw.  The following day these 
cells were washed twice in PBS with 2% FBS, re-suspended in fresh low growth factor SFM 
(SFM+LGF) (i.e. 1 in 100 dilution of SFM+5GF) and a viable cell count performed.  
 
2.2.2.6. FACS of Primary CD34+ cells 
Cell sorting was kindly performed by Miss Jennifer Cassels.  Fluorescence activated cell sorting 
(FACS) was utilised in a number of experiments to isolate CD34+38+ and CD34+38- fractions, 
as well as in the isolation of Lin-CD34+CD38-CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- 
cell populations.  In brief, fresh or recovered CD34+ cells were washed and resuspended in 
PBS/2%FBS.  Cells were counted and stained with appropriate antibodies (depending on the 
experiments) for 30 minutes (min) at room temperature in the dark.  2x104 cells were used for 
relevant single colour controls to define positive and negative staining for each marker and to 
set compensation.  Further to this, a fluorescence minus one (FMO) control was used to ensure 
the proper identification of appropriate gating strategy.  Stained cells were washed and filtered 
through a 0.22uM filter prior to sorting with a BD FACS Aria with Diva software.  Figure 2-2 
demonstrates a representative example for sorting of CD34+CD38-CD90+CD93-/+ populations.  
All CML samples were assessed for Ph+ status, confirmed by dual colour FISH.  
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Figure 2- 2  Representative flow cytometry analysis of cell sorting with a BD FACS 
Aria and DIVA software. 
Following antibody staining as described within the text, samples were analysed and sorted with a 
BD FACS Aria and DIVA software.  FMO controls were utilised for an accurate gating strategy.  Cell 
sorting was performed by Miss Jennifer Cassels. 
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2.2.2.7. Culture of primary cells 
CD34+ cells or sorted populations were maintained in suspension culture in SFM+LGF at 37  °C 
with 5% CO2 in tissue culture hydrophobic flasks prior to experimental set-up.  Prior to each 
experiment, cells were washed in PBS/2%FBS and resuspended in fresh medium at the desired 
density for each experimental arm.  Cells were harvested at different time points for RNA, 
protein and functional assays as dictated by the experimental design. 
 
2.2.2.8. Mesenchymal stem cells 
2.2.2.8.1. MSC Isolation 
Human MSCs were isolated from CP CML patient BM samples after written informed consent 
in accordance with the declaration of Helsinki and with Greater Glasgow and Clyde NHS Trust 
Ethics Committee approval.  Cells were placed into a T75 NunC flask in DMEM medium in the 
presence of 20% Hyclone FBS and incubated at 37°C with 5% CO2 for >7days until cell 
populations had adhered.  Suspension cells were subsequently removed and the adherent cells 
washed with PBS.  Cells were characterised in accordance with the International Society for 
Cellular Thearpy and cyropreserved at early passage number (i.e. passage 1 to 3) to maintain 
viability on thaw.  
 
2.2.2.8.2. MSC Characterisation 
MSC phenotype was confirmed according to the International Society for Cellular Therapy, 
with confirmation of CD45-CD34-Lin-CD90+CD73+CD105+ phenotype and positive Nestin 
immunofluorescence (Figure 2-3).  
2.2.2.9. Co-culture  
Figure 2- 3 Confirmation of MSC phenotype according to the International Society 
for Cellular Therapy 
(A) Flow cytometry of markers used in the identification of a confirmed MSC phenotype; pink 
represents the isotype control. (B) Immunofluorescence (IF) of MSCs from a CP-CML patient 
stained with Nestin. 
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Stromal cells were seeded onto sterile tissue culture flat bottom plastic (6 well/12 well plates).  
OP9 stromal cells were seeded at a 1 in 24 ratio with suspension cells (i.e. 1 stromal cell per 24 
suspension cells) 24 hours prior to co-culture.  All experiments were performed in at least 
experimental triplicate.  M210B4 and SL/SL were seeded at 75000 cells per 24 well plate as per 
the LTC-IC protocol.  When recombinant ligand was used, sterile tissue culture flat bottom 
plates were coated in differing concentrations of recombinant Jagged1 (R-Jag1) (10-50ng/ml), 
left at 37°C for 12 hours prior to removing the excess ligand, and then adding suspension cells.  
Binding the ligand to the plate ensures that they are competent to deliver a signal.  It has been 
previously demonstrated that soluble Notch ligands can act as dominant negative inhibitors, and 
therefore, assessment of activation was undertaken in all samples with IF of the cleaved form 
of the receptor.   
 
2.2.2.10. Cell counting and viability assessment 
All cell counts were performed using a haemocytometer.  Cell viability was assessed by trypan 
blue dye exclusion, utilising the finding that non-viable cells absorb trypan blue due to damaged 
membranes, whereas viable cells do not.  Trypan blue stock solution (8mM) was diluted 1:10 
with PBS to give a working solution of 0.8mM.  10ul of this solution was added to 10ul of cell 
suspension to give a 1:2 dilution of cells, prior to being added to a haemocytometer counting 
chamber. A minimum of 100 viable cells were counted, and where necessary, the cell 
suspension solution diluted if needed.  Cell count was performed on an inverted microscope.  
Given that the cover-slide is held 0.1mm above the counting surface, each 1mm2 has a volume 
of 0.1uL.  The absolute viable cell count per ml was the number of unstained cells per mm2 
multiplied by the trypan blue dilution factor and then by 104.  
 
2.2.2.11. Colony forming cell assay 
Colony forming cell (CFC) assays are clonal progenitor assays that measure the proliferation 
capacity and multipotency of haemopoietic progenitors.  Methylcellulose supplemented with 
growth factors (methocult H4034) was thawed at 4°C overnight, well mixed and divided into 
2.6ml tubes.  These aliquots could then be stored at -20°C until required.  Following recovery, 
CD34+ CML cells were cultured for 5 days with or without stromal support (OP9GFP, 
OP9JAG1, OP9DLL1, R-Jag1) in SFM+LGF.  The cells were then harvested, washed in PBS, 
re-suspended in fresh SFM and viable cell counts performed.  Each of the different cell 
suspensions was inoculated into a single tube of methocult to give a final concentration of 4x103 
cells/ml and the final volume of inoculums made up with SFM to equal 10% of the original 
volume of methocult.  These tubes were thoroughly mixed and 1.1ml of resultant single cell 
suspension plated in duplicate into 35mm culture dishes.  The duplicate assays were placed in 
a 100mm culture dish with a further 35mm dish containing 3ml sterile water to maximise 
humidity.  These were cultured under standard conditions for 14-18 days prior to colony 
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assessment using an inverted microscope and a counting grid.  Following culture, all progenitor 
cells with colony forming potential in that specific GF context will have proliferated and 
differentiated fully.  The resultant colonies can then be assessed for size (broadly reflective of 
original proliferative capacity) and constituent cell types from which can inferred the degree of 
lineage commitment and hence the maturity of the cell of origin.   
  
The capacity of an individual haemopoietic progenitor cell colony to replate in a CFC assay has 
been used as an indicator of the self-renewal potential of that progenitor.  CFC replating assays 
were performed to assess effects on self-renewal capacity.  In replating experiments, 50 single 
colonies from each experimental arm were harvested/’plucked’ from methocult between days 
10-12 of primary culture.  Each single colony was resuspended in 20uL of fresh SFM, before 
being plated in 100uL of methocult within each well of a 96-well plate.  The plates were 
incubated for 12-14 days at 37°C and 5% CO2 prior to counting the number of wells with viable 
colonies.  
 
2.2.2.12. Long-term culture-initiating cell assay 
The LTC-IC assay has been demonstrated to maintain human HSCs in vitro for at least 8-10 
weeks with extended culture of cells in the presence of a suitable supportive stromal 
environment.  It is an established technique that allows assessment of the maintained self-
renewal potential of cells in prolonged culture. 
 
The assay (figure 2-4) utilises an irradiated adherent feeder layer of M210B4 and SL/SL cells 
to support myelopoiesis (Hogge et al, 1996), with these stromal cells being genetically modified 
to stably express IL-3 and G-CSF, and IL-3 and SCF, respectively.  Stromal cell lines were 
maintained under selection with geneticin and hygromycin B.  Early passage was used within 
all experiments (i.e. <6 passage).  Stromal cells were initially irradiated under a cobalt γ-ray 
source for a total of 80Gy to prevent proliferation within the prolonged culture.  A viable cell 
count of both irradiated cells was performed and the concentration of each adjusted to 1.5x105 
per ml.  Cell suspensions were mixed in a 1 to 1 ratio before 1ml was plated to each central well 
of a 24-well type 1 collagen coated plate (i.e. 8 central wells).  This created a fully confluent 
layer. Humidity was maximised with the addition of 1ml sterile water to the remaining wells. 
Plates were maintained in an incubator for up to 1 week until required.  LTMCM was prepared 
by adding 1uM hydrocortisone to myelocult.  This media was made up fresh on each media 
change.   
 
In general, primary cells were cultured within their experimental condition for 5 days.  Viable 
cell counts were performed.  1x105 cells from each experimental condition were washed in 
PBS/2%FBS and resuspended in 2ml LTMCM.  The LTMCM was carefully aspirated from the 
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adherent cells, prior to 1ml of our primary cell suspension being added (i.e. 50,000 cells per 
well; each arm performed in at least duplicate).  The plates were cultured under standard 
conditions for 6 weeks.  Each week, 500uL media was removed carefully in an attempt not to 
disturb the adherent layer, and replaced with fresh LTMCM.  After 6 weeks in culture, the entire 
contents of each well was harvested.  The supernatant from each well was collected into a 15ml 
falcon tube.  The wells were washed twice with 1ml HBSS and added directly into the 15ml 
falcon tube.  500uL 0.25% trypsin/EDTA was added to each well and incubated at 37C.  
Following trypsinisation, 25uL of FBS was added to each well and the entire contents collected 
to the falcon tube.  The wells were washed with 1ml IMDM/2% FBS twice, with both washes 
transferred to the 15ml falcon tube.  The falcon tubes were centrifuged for 10 min at 210xg and 
the supernatant dispensed.  Cells were resuspended in 1ml IMDM/2% FBS and viable cell 
counts performed.  50,000 viable cells in 30uL of SFM were inoculated into 3ml methocult.  
These tubes were then thoroughly mixed, left to settle at room temperature and 1.1ml of the 
resultant single cell suspension was plated into duplicated 35mm culture dishes.  The assays 
were then placed in 100mm culture dishes with a 35mm dish containing 3ml sterile water to 
maximise humidity.  Assays were cultured under standard conditions for 12-14 days prior to 
colony assessment using an inverted microscope and counting grid.  Colony numbers were then 
counted and comparison between treatment arms was made.   
 
Figure 2- 4 The long-term culture initiating cell assay 
Schematic representation of the long-term culture initiating cell (LTC-IC) assay, where suspension 
cells (namely, sorted populations of CML cells) are cultured in the presence of an irradiated stromal 
layer that is necessary to maintain myelopoieiss.  Cells are cultured under specific conditions for 6 
weeks prior to assessment with colony forming cell assays.  
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2.2.3. Fluorescence in situ hybridisation 
FACS-sorted cells were incubated at 37C for 15 min in a hypotonic solution of 0.075M KCl. 
Cells were centrifuged at 1500rpm for 5 min and supernatant carefully removed. Cells were re-
suspended in fixative (3:1 methanol: acetic acid) added in a drop wise manner, with constant 
vortexing. Cells were then incubated for 5 min at room temperature, centrifuged at 12000rpm 
for 2 min and supernatant removed. Cells were washed twice in fixative before re-suspension 
in 1ml fixative. Fixed cells were centrifuged at 12000rpm for 2 min and re-suspended in fresh 
fixative.  3µl of fixed cell suspension was dropped onto a glass slide, air-dried and cell density 
checked using a phase contrast microscope.  Probe mixes were prepared according to 
manufacturer’s instructions and 2l added to cells on slide and coverslips placed and sealed 
with rubber solution. Slides were heated in a hybridisation chamber for 5 min at 72C and then 
37C overnight. Coverslips were removed and slides washed in a 0.4x SSC/3% NP40 wash 
buffer at 72 for 2 min and then washed in a 2x SSC/ 1% NP40 wash buffer at room temperature 
for 2 min. DAPI mounting medium (Vector Laboratories) was applied, a coverslip attached and 
the slide analysed using an AXIOvision AX10 fluorescent microscope and AXIOvision 
software. Chromosome t(9;22) BCR-ABL fusion was detected by a dual colour dual fusion 
probe (figure 2-5). 
 
 
 
 
 
 
 
 
 
Figure 2- 5 Representative example for FISH within CP-CML cells 
The identification of BCR-ABL is diagnostic of CML.  In order to effectively analyse the CML samples, 
FISH was utilised as per clinical protocol in the assessment of activated protein.   
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2.2.4. Flow cytometry 
2.2.4.1. Detection and quantification of protein expression 
Flow cytometry allows for the characterisation of both chemical and physical properties of a 
single cell through the use of fluorochrome-labelled antibodies.  In brief, a single cell suspension 
is presented to at least one laser leading to the excitation of the fluorochrome.  Light is emitted 
at different wavelengths allowing for simultaneous measurement of cellular properties.  For 
example, size and granularity of single cells can be measured by the forward-angle scatter 
(FSC), and side-angle scatter (SSC), respectively.  Typically, this can be used to identify cell 
types in PB for diagnostic purposes.  Furthermore, identification of specific cell surface and 
intracellular proteins can be utilised in sorting of cells phenotypically (described above), or into 
single cells, for diagnostic and experimental data. 
 
To detect and quantify levels of protein expression, cells were harvested and washed in 
PBS/2%FBS.  To allow for a precise gating strategy, a FMO control was used, whereby all 
antibodies bar one is used for each antibody in the series to allow for precise gating strategy 
(figure 2-2).  A single stain control was also used as an internal antibody control.  
 
Following washing, 5x104 cells were used within each unstained, single-stained and FMO 
control, where cells were re-suspended in 100ul PBS/2%FBS prior to the addition of antibody 
(concentration calculated in previous dilution experiments’).  The ‘bulk-stain’ sample was re-
suspended in 100-450ul PBS/2%FBS prior to the addition of antibody - this volume was 
dependent on cell number.  Samples were stained for 30 min at 4°C and then washed twice with 
PBS/2%FBS before being filtered through a 0.22uM filter.  Cells were resuspended in 100-
500uL of PBS/2%FBS and analysed immediately using a FACSCantoII flow cytometer (BD 
Biosciences), data was acquired using BD FACSDiva (BD Biosciences) software, and analysed 
using FlowJo (Tree Star Inc, Ashland, USA) software.  When an unconjugated primary antibody 
was used, the cells were washed and resuspended in 100µL of PBS/1%BSA with either 2µL of 
the secondary anti-rabbit IgG FITC conjugate (1:50 dilution), or 10µL of the secondary anti-
rabbit IgG PE conjugate (1:10 dilution), depending on the requirement for multi-parametric flow 
cytometry analysis, at 4°C in the dark for 30 min.  A range of antibodies used is detailed in 
section 2.1.2.2. 
 
Quantification of the protein of interest within each sample was calculated in relative terms, 
using the ratio between the geometric mean fluorescence intensity (MFI) of the antibody 
labelled live cells and the geometric MFI of the isotype labelled live cells. When measuring 
changes in levels of protein within each sample following treatment, the MFI ratio (calculated 
as explained above) for each treatment arm was expressed as a percentage. 
 
 
 89 
2.2.4.2. Apoptosis assays 
Apoptosis was measured by flow cytometry using annexinV and 7-amino actinomycin D 
(7AAD) staining.  AnnexinV is a phospholipid binding protein that has a high affinity for 
phosphatidylserine in the presence of physiological calcium concentration. As cells apoptose, 
there is a shift and translocation of phosphatidylserine to the external surface of the phospholipid 
layer that comprises the plasma membrane.  7AAD is only able to stain dead or late apoptotic 
cells, and therefore, when combined with annexinV allows for the detection of early and late 
apoptosis (figure 2-6).  Practically, following a wash in PBS/2%FBS 0.5-1x105 cells were 
resuspended in 100µL of annexinV buffer containing 5µL annexinV conjugated to relevant 
fluorochrome and 5µL 7AAD and incubated at room temperature for 15 min in the dark. 
Following incubation, 400µL of HBSS was added to the cell suspension and analysis was 
immediately performed by flow cytometry.  Unstained and single stained cells were used to set 
voltages and compensation. 
 
Figure 2- 6 Representative example of AnnexinV/7AAD staining in the context of 
apoptosis 
Representative example of annexinV/7AAD staining. Viable cell populations will be negative for both 
annexinV and 7AAD, cells in early apoptosis would be annexinV positive but 7AAD negative, and 
cells in late apoptosis would be positive for both annexinV and 7AAD.   
 
2.2.4.3. Cell cycle analysis 
Flow cytometry can be used in the assessment of the cell cycle status of cells within each sample 
and following treatment and varying culture conditions.  To do this, a DNA-binding fluorescent 
dye was used, termed propidium iodide (PI). 
 
Practically, cells were fixed with ice-cold 100% ethanol.  Ethanol allows cells to be fixed and 
permeabilised in a one-step process.  Samples were stored at -20°C for no more than 5 days 
before analysis.  When ready to be analysed, samples were washed twice in PBS/2%FBS. To 
 90 
ensure only DNA was stained, cells were treated with ribonuclease (100ug/ml), and then stained 
with PI (50ug/ml), before being immediately analysed using the FACSCantoII flow cytometer; 
data was acquired using BD FACSDiva software, and analysed using FlowJo software (figure 
2-7).   
 
 
 
 
 
 
 
 
 
 
Figure 2- 7 Representative example of PI staining and cell cycle analysis 
PI was used to assess cell cycle status within both primary and cell line samples.  Using FlowJo 
technology, samples were gated according to their PI content that can depict cells in G0-G1 and S-
G2-M.  Gates were fixed following first analysis (i.e. plastic or untreated control) to allow comparison 
with differing experimental conditions. 
 
2.2.4.4. CFSE 
Carboxyfluorescein diacetate succinimidyle ester (CFSE) is an intracellular dye used to track 
cell divisions of heterogeneous and asynchronous cell populations by flow cytometry.   It is a 
lipophilic molecule that upon entering the cell, intracellular esterases cleave the acetate groups 
to yield the fluorescent carboxyfluorescein molecule.  Further to this, the succinimidyl ester 
group reacts with primary amines on intracellular proteins, cross-linking the dye and fixing it 
within the cytoplasm of the cell.  It allows for stable cell staining, and upon division, the dye is 
equally divided between the two daughter cells determining a serial dilution of the dye with 
each division, and hence allowing a measure of the number of divisions a sample has undergone 
in culture (figure 2-8). 
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Practically, the cell sample was resuspended in 5ml PBS/2%FBS and stained with 10uL of a 
500uM solution of CFSE dye to give a final concentration of 1uM.  Cells were stained for 10 
min at 37C in a water bath, while a small aliquot of cells was kept unstained to allow for a 
control in analysis.  Following the 10 min incubation, CFSE was quenched by adding 10X 
volume of ice cold PBS/20%FBS and then washed once more in fresh PBS/2%FBS.  Cells were 
analysed every 24 hours to allow identification of cell divisions.  To identify the undivided cell 
population following treatment, a control well was set up to which 100ng/ml of colcemid was 
added which effectively blocks cells proliferation.  In some cases, cells were also stained with 
cell surface markers to allow for identification of differentiation with proliferation.  
 
2.2.5. Immunofluorescence 
Cells were plated on poly-lysine-coated slides at 60,000 cells/well at baseline and following 5 
days with or without treatment.  Preparations were fixed in 4% paraformaldehyde for 15 min 
then permeabilised with 0.2% TritonX100 (Sigma-Aldrich, Dorset) for 10 min.  Cells were 
blocked for 2 hours prior to primary antibodies being applied for 12 hours at 40C.  After washing 
fives times with PBS, cells were incubated in Alexa fluor linked secondary antibodies for 2 
hours.  After a final wash with PBS, the slides were mounted in 0.1ug/ml DAPI (4’,6-diamidino-
2-phenyloindole) mounting medium and viewed by fluorescence microscopy using a Zeiss 
imager M1 microscope.  To illustrate intensity of immunolabelling digital images were captured 
at identical exposure times.   
 
2.2.6. Western blotting 
Western blotting allows for a measure of a fractionated protein component.  Proteins are first 
separated according to their molecular weight, before being transferred onto a nitrocellulose or 
polyvinylidene fluoride (PVDF) membrane, which will contain all proteins in the sample being 
analysed.  The use of primary antibodies and the crosslinking with a secondary antibody that 
contains a detectable enzyme allows for the identification of specific proteins within each 
Figure 2- 8 Schematic representation of CFSE assay by flow cytometry 
When cells are stained with CFSE, it allows for stable intracellular staining, thereby on each cell 
division, the dye is equally shared between the two daughter cells. 
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sample.  Samples are quantified against a housekeeping gene that is stably expressed within the 
cells, such as GAPDH or SHP2. 
 
2.2.6.1. Preparation of protein lysates 
Protein lysates were prepared as follows; cells were harvested and washed twice in cold PBS 
(1200 rpm for 5 min).  They were then re-suspended in freshly made lysis buffer with protease 
inhibitors (approximately 50ul per 1x106 cells) and mixed thoroughly.  The lysate preparations 
were then incubated on ice for 30 min; then spun at 14000 rpm at 4oC for 10 min.  The 
supernatants were then decanted into 500uL eppendorf tubes and stored in aliquots at -80oC 
prior to use.  Samples were thawed and quantified prior to use to allow equal expression within 
the experimental design. 
 
2.2.6.2. Protein quantification 
Protein lysates were quantified using Quickstart Bradford Dye Reagent.  Following the 
manufacturers protocol, a standard curve was prepared using BSA protein standards, at 
concentrations ranging from 0 to 20ug/ml.  Absorbance was read at 595 nM on a Spectramax 
M5 plate reader and analysed with SoftMax Pro 5.2 software.   
 
2.2.6.3. Gel electrophoresis and immunolabelling 
Between 10-20ug of protein lysate was made up to a final volume of 12ul in solubilisation buffer 
and 3ul of sample buffer reducing agent.  Samples were heated to 95C for 5 min prior to 
Sodium Dodecyle Sulphate-polyacrylamide gel electrophoresis (SDS-PAGE).  7.5% 
acrylamide gels were used to separate proteins larger than 50kDa and 10% gels for proteins 
smaller that 50kDa.   Cell lysates were fractionated by SDS-PAGE in 1x running buffer at 80V 
for 30 min and 180V for 45 min.  Separated proteins were transferred onto PVDF membrane 
using a semi-dry transfer method.  PVDF was immersed in 100% methanol for 1 min before 
being saturated in 1x semi-dry transfer buffer. Four 1.0 mm Whatman paper strips were placed 
below the PVDF membrane, the gel was then added on top of the membrane followed by four 
more paper strips, the stack was then compressed to remove air bubbles.  Proteins were 
transferred onto the membranes at 40mA/gel for 60 min.  Blots were washed with 1xTBST, 
blocked in TBST containing either 5% BSA or 5% milk for 1 hour at room temperature.  
Following block, the blots were incubated with primary antibody overnight at 4C.  Blots were 
then washed four times with TBST and incubated with horseradish-peroxidase (HRP)-labelled 
secondary antibodies for 1 hour at room temperature.  Secondary antibody was washed four 
times with TBST, followed by two washes with TBS and then blots were developed using Bio-
Rad ECL and developed on a SRX0101A Medical Film Processor. 
 
2.2.6.4. Membrane re-probing 
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Membrane re-probing allows sequential incubation of a membrane with different antibodies by 
removing antibodies bound into the membrane without removing the actual protein. This was 
performed by incubating the PVDF membrane with the Re-Blot Plus Strong stripping solution 
diluted 1:10 with distilled water. Following two brief washes (5 min per wash) in TBST, the 
membrane was re-blocked for 1 hour and finally incubated with a different primary antibody. 
 
2.2.7. Gene expression analysis 
All reagents and primers used can be found in section 2.1.3. 
 
Gene expression is assessed through polymerase chain reaction (PCR) technology, a technique 
used to amplify short specific regions of DNA, provided at least part of the sequence is known.  
In general, two short oligonucleotide primers are designed to capture complimentary areas on 
each of the DNA strands of the double helix; these are at opposite ends of the sequence to be 
amplified.  In the presence of the primers and excess nucleotides, as well magnesium chloride, 
heating causes the double stranded DNA to separate.  Cooling allows the primers to anneal to 
their complimentary sequences.  The DNA sequence 3’ to the primer can be copied by 
polymerase (such as Taq) forming new complete double stranded DNA molecules extended 
from forward to reverse primary sequences.  Successive rounds of this process leads to 
amplification of the target gene. 
 
2.2.7.1. Primer design 
Primers were designed using NCBI software; all sequences can be seen in section 2.1.3.3.  
Primers were synthesised commercially using Eurofins MWG Operon and were reconstituted 
with the appropriate volume of nucleic acid free water to achieve a stock concentration of 
100uM.  Dilutions were made to achieve the appropriate working concentration of 25uM and 
aliquots prepared to ensure sterility and prevent numerous freeze-thaw events.  
 
2.2.7.2. RNA extraction 
Total RNA was isolated from pellets using either the Qiagen RNeasy Mini Kit or the Applied 
Biosystems Arcturus Picopure RNA isolation kit (depending on sample size) according to the 
manufacturer’s instructions. The quantity and purity of the extracted RNA was measured using 
a nanodrop spectrophotometer Nd-1000 (Labtech International, East Sussex, UK). An 
absorbance at 260nm quantified nucleic acid and the ratio of 260/280 determined purity (pure 
RNA ratio is 2.0). 
 
2.2.7.3. cDNA synthesis 
Reverse transcription of RNA into cDNA was carried out by using the High Capacity cDNA 
Reverse Transcription Kit. 10µL of the extracted RNA was mixed with 10µL of 2X Reverse 
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Transcription Mastermix (2.2.4.8) in a PCR tube and reaction carried out as per manufacturer’s 
protocol (i.e. 25°C for 10 min, 37°C for 120 min and 85°C for 5 seconds (secs)). cDNA was 
kept at -20°C for long-term storage. 
 
2.2.7.4. Target amplification 
Due to the low level of expression of target genes of interest and for consistency throughout 
experimental design, a preamplification step of the cDNA was carried out using Qiagen 
Multiplex PCR plus kit.  The manufacturers protocol was followed.  Pre-amplification cycling 
conditions involved an initial PCR activation step for 5 min at 95°C, then 14 cycles of: 30 secs 
at 95°C, 90 secs at 60°C, and 90 secs at 72°C; the reaction was then finished with an extension 
of 10 min at 68°C. 
 
2.2.7.5. Real time- PCR (RT-PCR) 
RT-PCR allows detection of messenger RNA expression following reverse transcription into 
cDNA.  Following a PCR reaction, the PCR products are run on an agarose gel by 
electrophoresis and separated according to their size and stained with ethidium bromide prior to 
their detection.  This is a qualitative analysis, and was used within this thesis to ensure primers 
were specific, and working prior to quantitative analysis.  
 
Practically, 50-100ng of cDNA was used and mixed with the RT-PCR mix in a PCR tube.  
Following cycling conditions, the PCR products were run in 2% agarose gel in order to visualise 
the individual DNA bands.  The gel was prepared with 1g agarose powder in 50ml of 1X TBE 
buffer.  The mixture was heated in a microwave until the agarose powder had completely 
dissolved.  2uL ethidium bromide (10mg/ml) was added and the mix poured into a casting tray.  
The gel was left to set for about 30 min.  Each well of the gel was loaded with 10uL of PCR 
product mixed with 2ul loading dye (6X); 2uL of 100bp DNA ladder was loaded in a separate 
lane and then run at 50V in a tank filled with 1x TBE buffer.  The PCR products were detected 
using an ultraviolet light source. 
 
2.2.7.6. Fluidigm gene expression 
Quantitative RT-PCR allows for the quantification of the cDNA products in a sample by 
detection of increasing level of fluorescence during the reaction, as the PCR products 
accumulate during amplification.  By plotting fluorescence against the number of cycles of the 
PCR reaction, it is possible to determine the cycle number at which the increase in fluorescence 
is exponential and exceeds the set background fluorescence threshold.  This is termed the Ct 
threshold.  During an exponential phase of the reaction, the reaction has not yet reached its 
saturation and the DNA target doubles every cycle so that the quantity of the PCR product is 
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directly proportional to the amount of template nucleic acid, with any differences in 
fluorescence signal secondary to different starting amounts of cDNA in the samples tested.   
 
The Fluidigm BioMark HD system integrates thermal cycling and fluorescence detection in a 
Fluidigm dynamic array integrated fluidic circuit (IFC) and provides a high-throughput qRT-
PCR using standard primers or TaqMan gene expression assays.  The system allows 
simultaneous PCR reactions in nanolitre volumes on a single microfluidic device.  Prior to 
Fluidigm analysis, all cDNA samples were preamplified as described above.  Unincorporated 
primers were removed using Exonuclease I, following the manufacturers protocol.  The thermal 
cycling conditions were 30 min at 37°C (digestion), then 15 min at 80°C (enzyme inactivation).   
 
Gene expression levels were determined by 48:48 or 96:96 Dynamic Biomark Array, following 
the manufacturer’s defined protocols for primer-based assays.  Sample mixes and assay mixes 
were loaded into the wells of a previously primed dynamic array integrated fluidic circuit.  The 
sample and assay mixes were combined through the IFC chip network of the microfluidic 
channels, chambers and valves automatically assembling individual PCR reactions.  Thereafter, 
cycling conditions involved 60 secs hot start at 95°C, and then 30 cycles of: 5 secs at 96°C and 
20 secs at 60°C, followed by a melting curve step for 3 secs at 60°C.   
 
Relative gene expressions were analysed by the delta delta (ΔΔ) Ct method using an average of 
five to six housekeeping genes (UBE2D2, B2M, ENOX2, GN2B1, TYW1, and CYC1) as a 
reference control and an assigned calibrator.  This allows analysis of the relative change in 
expression between samples by calculating the difference in delta Ct values between the cell 
types.  Fold change between samples can then be assessed as each cycle represents a doubling, 
assuming that the relative amplification efficiencies are similar between comparators. 
 
Primers were purchased from Eurofins MWG Operon shown in section 2.1.3.3.  Heat maps were 
produced using PermutMatrix software or heatmap.2 in R/Bioconductor; these used Pearson 
distance for dissimilarity and complete linkage for hierarchical clustering.   
 
 
 
 
 
 
 
 96 
2.2.7.7. Fluidigm C1 Single cell gene expression 
Advances in single cell analysis have allowed for a more complete investigation of the cellular 
heterogeneity that may exist within populations and enables a more detailed examination of the 
homogeneity or heterogeneity of a population than was previously possible. 
 
To assess single cell gene expression, Fluidigm C1 single cell gene expression was used to 
isolate single cells into individual reaction chambers using an IFC-based system.  Following 
capture, cells were examined by microscopy for viability and to ensure single cell capture.  Any 
concern over single cell status led to the well being withdrawn from examination.  The C1 single 
cell auto prep system allows a reliable approach to reproducibly process 96 cells in parallel with 
minimal user intervention that could lead to contamination.   
 
Practically, following sorting into appropriate populations, 4000 cells were loaded into a 10-17 
micron Fluidigm C1 single cell auto prep IFC, and cell capture performed according to the 
manufacturer’s instructions.  Capture efficiency was determined using microscopy to exclude 
samples from the analysis with no or more than one cell captures or samples where in addition 
to cell there was cellular debris.  Upon capture, reverse transcription and cDNA preamplifcaition 
were performed in the Fluidigm C1 single cell auto prep IFC, as per manufacturers instructions.    
Relative gene expressions were analysed by the ΔΔ Ct method as described above.  All statistical 
analysis was performed through R/Bioconductor.  The statistical analyses were performed using 
Limma modified t-test applying Benjamini-Hochberg adjustment for multiple hypothesis 
testing.  
 
2.2.8. In vivo experimentation 
2.2.8.1. Xenotransplantation model 
The NSG mouse model was used to assay human LSCs with in vivo engraftment capacity 
(SCID-repopulating cells or SRC).  CP-CML Lin-CD34+CD93+ or Lin-CD34+CD93- cells were 
isolated by FACS sorting (1x106 cells/ mouse), washed and transplanted via tail vein injection 
into sublethally irradiated (200 cGy) 8-12 week old NSG mice. Mice were euthanised after 16 
weeks and marrow contents of femurs were obtained. To assess human cell engraftment, cells 
were labeled with anti-human CD45, CD33 and CD19 antibodies prior to analysis by flow 
cytometry. Human CD45+CD33+ cells were isolated by FACS sorting and analysed by FISH for 
the BCR-ABL gene rearrangement. 
 
2.2.8.2. Notch2 overexpression model 
Rosa-Inl N2IC mouse – these mice were generated in the Aifantis lab (NYU) by the insertion 
of a loxP flanked splice acceptor NEO-ATG cassette with two polyA sites followed by ICN2 
into the ROSA26 locus, allowing the ROSA26 promoter to drive expression of the NEO-ATG 
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cassette.  Cre recombinase-mediated excision of NEO-ATG results in use of the splice acceptor 
in the ICN2 cassette and irreversible expression of the transgene  
 
2.2.9. Statistics 
All results shown are the mean +/- standard error of the mean (mean +/- SEM) unless otherwise 
stated.  All statistical analysis was performed with Graph Pad prism software using the two-
sided unpaired or paired student’s t-test when two groups were compared.  When multiple 
groups were compared, a one-way ANOVA with correction for multiple groups’ comparison 
was used.  Within single cell gene expression analysis, a Limma modified t-test applying 
Benjamini-Hochberg adjustment for multiple hypothesis testing was used.  A p value of <0.05 
was considered significant.  
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3. Results I 
3.1. Introduction 
The introductory chapter to this thesis has clearly demonstrated that despite TKI therapy 
being highly efficacious at eradicating BCR-ABL positive proliferative cells, they are 
unable to eradicate the most primitive quiescent LSCs in in vitro and in vivo assays 
(Bhatia et al, 2003b; Chomel et al, 2016; Chu et al, 2011; Graham, 2002).  These 
residual cells underpin the phenomenon of disease persistence.  This has been further 
highlighted in recent TKI discontinuation clinical trials, where more than half of patients 
developed an early molecular relapse upon discontinuation of therapy in the context of 
a deep molecular response (Clark et al, 2016; Imagawa et al, 2015; Mahon et al, 2010; 
Mahon et al, 2016; Rea et al, 2012; Ross et al, 2010; Ross et al, 2013; Ross, 2015; 
Takahashi et al, 2012).   This evidence concludes that CML LSCs are independent of 
BCR-ABL kinase activity for their survival, and imply that when BCR-ABL is inhibited 
through maximal pharmacological intervention with TKI therapy, other factors drive 
cell survival through genetic, epigenetic or alternative signalling pathways (Corbin et 
al, 2011b; Foley et al, 2013; Hamilton et al, 2012).  
 
As previously discussed, self-renewal is considered to be an integral property of the 
LSC, and its deregulation is known to affect the development, maintenance, and 
persistence of the CML LSCs within the context of disease persistence.  To date, a 
number of aberrant signalling pathways have been proposed to contribute to the LSC 
phenotype.  These pathways, including Hh, Wnt/β-catenin and BMP, are known 
regulators of cell survival, and are often differentially expressed following genetic 
events (Fukushima et al, 2013; Irvine et al, 2016; Laperrousaz et al, 2013; Liao et al, 
2012; Lu et al, 2013; Sengupta et al, 2007; Zhao et al, 2007).  A number of deregulated 
proteins within these pathways may represent a broadly applicable therapeutic strategy; 
however, it is well known that these pathways rarely work in isolation, and rely on an 
interconnecting web of activity leading to disease maintenance, persistence, and 
progression (Sengupta et al, 2007; Sinclair et al, 2013; Zon, 2008).  To understand the 
true potential of targeting an individual self-renewal pathway protein, one must 
ascertain the impact of manipulating an individual pathway in a given disease.  This will 
allow for better understanding of the acquired vulnerability in the mechanisms of the 
signalling pathway, which will, in turn, allow for a therapeutic window to eradicate the 
LSCs.  Although, our lab and others have documented the effects of many signalling 
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pathways in CML, including Hh, Wnt-β-catenin, and BMP, the role that the Notch 
signalling pathway plays in myeloid disease remains controversial.   
 
The Notch signalling pathway has been implicated in a number of malignancies with its 
role being cell- and tissue-dependent.  In cancer biology, Notch signalling has been 
demonstrated to play both an oncogenic and tumour suppressive role, depending on cell 
and cancer type (Al-Hajj et al, 2003; Leong & Karsan, 2006; Miele, 1999; Pancewicz 
& Nicot, 2011; Pasto et al, 2014; Prasetyanti et al, 2013; Suman et al, 2013).  In 
haemopoietic malignancies, accumulating evidence demonstrates its importance in 
growth, differentiation, and apoptosis (Chiang et al, 2013; Hannon et al, 2012b; Nwabo 
Kamdje et al, 2011; Pancewicz & Nicot, 2011; Seke Etet et al, 2012). 
 
Notch receptors 1-3 are expressed in both immature and mature blood cells (Chiba).  
Deregulation of Notch was first identified in T-cell ALL where mutation rates in 
NOTCH1 have been reported in 50-70% of cases (Ellisen et al, 1991; Hannon et al, 
2012b; Nwabo Kamdje et al, 2011; Roma et al, 2012).  Similarly, Notch receptor 
mutations have been identified in a range of mature B cell leukaemias and lymphomas 
(Crews & Jamieson, 2012). Improved understanding of the Notch signalling pathway in 
these malignancies suggests that the Notch pathway may be a prime drug target; 
however, the therapeutic role of Notch inhibition may be directly dictated by the effects 
of its inhibition on other cell lineages, including the myeloid lineage (Deangelo et al, 
2006; Tosello & Ferrando, 2013).  
 
Reports about the role which Notch plays in myeloid disease are conflicting, as Notch 
activation in myeloid precursors has been shown to promote self-renewal, induce or 
inhibit differentiation to monocytes, or induce apoptosis (Carlesso et al, 1999; Li et al, 
1998; Sarmento et al, 2005; Schroeder et al, 2003).  Early observations suggested that 
Notch signalling may play a role in myeloid progression (Schroeder et al, 2003; Tan-
Pertel et al, 2000).  For example, Tan-Pertel et al demonstrated that Notch enhanced 
cell survival of the 32D cell line and promoted entry into a myeloid cell fate.  32D cells 
proliferate as blasts in the presence of the cytokines GM-CSF and IL-3, but initiate 
differentiation and undergo granulopoeisis in the presence of G-CSF.  Interestingly, an 
earlier study contradicted this, observing that an activated form of Notch1 could inhibit 
G-CSF-induced granulocytic differentiation of 32D myeloid progenitors (Milner et al, 
1996).  It should be noted, however, that both studies used a truncated form of Notch 
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rather than inhibition of full-length Notch and inhibition of full-length Notch in this cell 
line has yet to be described.  
 
Importantly, in 2001, Todha et al showed that exposing AML cells to plate-bound Notch 
ligands led to a full range of responses from proliferation to growth arrest that varied 
with patient sample, suggesting a combinatorial role between self-renewal pathways 
and molecular disease (Tohda & Nara, 2001).  More recently, observations have 
supported a tumour suppressive role for Notch signalling in myeloid disease (Chen et 
al, 2008; Kannan et al, 2013; Klinakis et al, 2011; Lobry et al, 2013; Yin et al, 2009).  
A recent study identified a tumour suppressor role for the Notch pathway in another 
myeloproliferative disorder, chronic myelomonocytic leukaemia (CMML).  This offers 
evidence for the existence of inactivating Notch mutations in CMML, and is supportive 
of a loss-of-function mechanism in myeloid disease (Klinakis et al, 2011).  Furthermore, 
in AML cell lines and primary patient blasts, downregulation of Notch1 expression was 
associated with decrease in PU.1-mediated differentiation capacity, indicating a pivotal 
role in maintenance of an immature state (Chen et al, 2008).  Recently, it was observed 
that human AML samples, isolated into stem and progenitor populations, express Notch 
receptors, however activation of downstream Notch targets was low, suggesting that 
Notch is present but not active in the samples analysed (Kannan et al, 2013; Lobry et al, 
2013).  Subsequent activation of the Notch receptors or Notch targets led to AML 
growth arrest in vivo and conversely Notch inhibition via dnMAML enhanced 
proliferation (Kannan et al, 2013), again suggesting a role of Notch in myeloid 
neoplastic proliferation. 
 
Data is limited within CML.  Notch has been shown to inhibit growth of the CML cell 
line, K562, although the authors do not assess endogenous active Notch signalling, 
instead only analysing Notch receptors at an mRNA level (Yin et al, 2009).   
Furthermore, it has been demonstrated that, using an in vivo model of CP-CML and BP-
CML, that Numb, a Notch antagonist, was present at low levels in CP disease, but at 
high levels in BP, suggesting that there is a change in Notch signalling with progression 
of disease (Ito et al, 2010). 
 
Unpublished microarray studies by the Copland laboratory confirm that HES1, a Notch 
downstream target gene, expression is increased in very primitive lin-CD34+CD38-
CD90+ CML stem/progenitor cells compared to normal. Furthermore, there is a 
progressive increase in HES1 expression as CML progresses. Additional unpublished 
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microarray studies have shown that TKI treatment of CD34+ CML stem/progenitor cells 
regulates gene expression in pathways critical for self-renewal, including Notch.  In 
addition, HES1 was found to be highly expressed in CML blast crisis.  This has been 
further demonstrated in vivo, where retroviral co-expression of Hes1 with Bcr-Abl 
resulted in generation of an aggressive acute leukaemia.  However, the question 
remains, if HES1 is being regulated by the Notch pathway or, indeed, another signalling 
mechanism, as recent evidence suggests that despite relatively high levels of Notch1 
receptor in a panel of primary AML patients, HES1 was expressed at low levels 
(Chiaramonte et al, 2005).   
 
These differing observations could be explained by existence of multiple molecular 
interactions between Notch signalling and other self-renewal pathways, which are likely 
to correlate with the ability of Notch to function as an oncogene or a tumour suppressor. 
The role that Notch is playing within CP-CML in isolation or in combination with other 
self-renewal pathways, if any, remains unanswered. 
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3.2. Aims 
Based on the evidence provided above, the specific aims set out in this chapter are: 
1. To assess the expression of the Notch signalling pathway elements in CD34+ 
CP-CML patient samples; 
2. To assess the functional role, if any, of the Notch signalling pathway in CD34+ 
CP-CML patient samples; 
3. To assess differences in the functional role of the Notch signalling pathway 
between stem and progenitor cells in CP-CML. 
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3.3. Results 
3.3.1. The Notch signalling pathway is silenced in CD34+ CP-CML patient 
samples 
To address the possible involvement of the Notch signalling pathway in CML, Notch 
pathway gene expression was investigated in primary CML patient samples.  Using 
Fluidigm technology, mRNA expression of 24 CD34+ CP-CML patient samples was 
compared to normal BM CD34+ samples, purchased from Stem Cell Technologies.  
Relative gene expression levels were determined using the average normal CD34+ value 
as a calibrator, calculated using the delta delta (ΔΔ) CT method (Schmittgen & Livak, 
2008), using an average of six housekeeping genes as reference.  The CP-CML samples 
had no preceding treatment prior to analysis.  4 samples failed the analysis. 
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Figure 3 - 1 Notch pathway components are differentially expressed between CP-
CML CD34+ and normal CD34+ samples 
Gene expression profiling (GEP) for Notch pathway components was determined from normal CD34+ 
BM samples (n=6), and CML cells after CD34+-selection from peripheral blood (n=20).  Gene 
expression was determined by Fluidigm array analysis.  Relative gene expression levels were 
determined by the average normal CD34+ value as a calibrator calculated using the ΔΔCT method, 
with an average of six housekeeping genes as reference.  CP-CML CD34+ samples had no preceding 
treatment prior to analysis.  Heatmaps were produced using PermutMatrix software.  (A) Heatmap 
representation of fold change between CP-CML and normal CD34+ sample. (B) Heatmap 
representation of Notch pathway components between CP-CML and normal CD34+ samples with 
sample clustering. (C) Heatmap representation of Notch pathway components between CP-CML and 
normal CD34+ samples with gene clustering. (D) Heatmap representation of Notch pathway 
components between CP-CML and normal CD34+ samples with gene and sample clustering.  There 
was no prognostic significance between quantitative BCR-ABL level and Notch pathway components 
at 6, 12, and 18 months as determined by ELN guideline criteria (Baccarani et al. 2013).   
 
This demonstrated that the Notch signalling pathway components are highly 
deregulated at the mRNA level in CP-CML compared to normal (figure3-1A).  Gene 
clustering methods determined that patient samples (figure 3-1B) and Notch pathway 
components (figure 3-1C) could be clustered upon gene expression, however, on 
analysis of quantitative BCR-ABL expression at 6, 12, and 18 months, there was no 
prognostic relevance noted on clustering in isolation or together (figure 3-1D).  
 
Focussed gene analysis established that the Notch signalling pathway was inactive, as 
demonstrated through downregulation of the Notch target genes, HES1 (p<0.0001; 
figure 3-2A), and HIF1A (p=0.0029).  Decreased expression compared to normal was 
shown in other downstream targets, including HEY1, but this was not determined to be 
statistically significant (p=0.3019).  In parallel, the Notch negative regulators, MFNG 
(p=0.0108), and NUMB (p=0.0114) were upregulated (figure 3-2B).  Taken together, 
these data suggests that the pathway may be silenced in CP-CML. 
 
In these patient samples, the Notch receptor, NOTCH2, was significantly upregulated 
compared to normal CD34+ samples, p=0.0001 (figure 3-2C).  As Notch ligand 
expression was also downregulated at an mRNA level (figure 3-2D), this was highly 
suggestive that the downregulation of the pathway was not secondary to cis-inhibitory 
mechanisms (del Álamo et al, 2011).   
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Figure 3 - 2 Focussed gene analysis identifies that the Notch signalling pathway is 
silenced in CD34+ CP-CML 
Relative gene expression levels for 20 CD34+ CP-CML samples were determined against the 
average normal CD34+ values calculated using the ΔΔCT method with an average of six 
housekeeping genes as reference.  Fold change is relative to normal CD34+ samples (n=6). (A) Dot 
plot representing fold change expression values for Notch target genes. (B) Dot plot representing 
fold change expression values for negative regulators of the Notch pathway. (C) Dot plot representing 
fold change expression for Notch ligands.  (D) Dot plot representing fold change expression of Notch 
receptors. P values were determined by an unpaired t-test with Welch correction (* p<0.05, ** p<0.01, 
*** p<0.001, **** p<0.0001). 
 
Noted within this mRNA expression data were two distinct populations of low and high 
expression of the metalloprotease, ADAM17 (figure 3-3).  On further examination of 
these patient samples, it was noted that ADAM17 expression correlated with Notch 
receptor mRNA expression, as demonstrated through spearman rank correlation (R) (R 
= 0.7717 [p=0.0001], R= 0.8255 [p<0.0001] with NOTCH1 and NOTCH2, 
respectively).  However, this did not correlate to prognostic relevance in terms of 
quantitative BCR-ABL expression at 18 months.  Furthermore, there was no correlation 
with the downstream target gene, HES1.  Again, highlighting that the pathway is 
silenced within the samples analysed. 
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Figure 3 - 3 Focussed gene analysis identifies that the metalloprotease, ADAM17, 
statistically correlates with Notch receptor expression 
Relative gene expression levels for 20 CD34+ CP-CML samples were determined against the 
average normal CD34+ values calculated using the ΔΔCT method with an average of six 
housekeeping genes as reference.  Fold change is relative to normal CD34+ samples (n=6). P values 
were generated relative to normal CD34+ samples.  P values were determined by an unpaired t-test 
with Welch correction (* p<0.05, ** p<0.01, *** p<0.001).  The triangles represent samples with low 
ADAM17 expression, and the the circles represent samples with high ADAM17 expression. 
Pearson’s correlation coefficient between ADAM17 and NOTCH1 demonstrated an R-value of 
0.7717 (p=0.0001), and between ADAM17 and NOTCH2 0.8255 (p<0.0001). 
 
3.3.2. FBXW7 confers prognostic relevance at 12 and 18 months  
FBXW7 is an E3 ubiquitin ligase and is a substrate recognition component of the Cullin-
1/SCF complex that targets specific substrate proteins for poly-ubiquination and 
degradation of the 26S proteasome.  Fbxw7 has been shown in vivo to target many proto-
oncoproteins, growth promoters, and anti-apoptotic molecules, including Cyclin E, c-
Myc, Notch1, c-Jun, mTOR, and Mcl1 (King et al. 2013; Nakayama & Nakayam 2006; 
Matsuoka et al. 2008; Reavie et al. 2010).   Within the same dataset used in section 
3.3.1, we analysed the expression of FBXW7 in the 20 CML patient samples, where 
quantitative BCR-ABL expression was known at 6, 12, and 18 months.  Classifying these 
samples into good and intermediate/poor responders, in accordance with the ELN 
guidelines for management of CML (Baccarani et al. 2013), it was shown that FBXW7 
represents a prognostic indicator of BCR-ABL response at 12 and 18 months (figure 3-
4). FBXW7 has an indispensable role in the maintenance of quiescence, with deletions 
A D A M 1 0 A D A M 1 7 N O T C H 1 N O T C H 2 H E S 1 F B X W 7
0 . 0 1
0 . 1
1
1 0
1 0 0
C
M
L
 C
D
3
4
+
/
 C
D
3
4
+
 n
o
r
m
a
l
* * ** * * * * * * * *
 107 
in Fbxw7 leading to cell exhaustion.  This, perhaps, highlights the potential role of 
FBXW7 as a therapeutic modality within CP-CML in the eradication of the LSCs.  
 
Figure 3 - 4 FBXW7 represents a prognostic indicator at 12 and 18 months 
Relative gene expression levels for 20 CD34+ CP-CML samples were determined against the 
average normal CD34+ values calculated using the ΔΔCT method with an average of six 
housekeeping genes as reference.  Fold change is relative to normal CD34+ samples (n=6). 
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3.3.3. Upregulation of Notch receptors are present at protein level 
The upregulation of NOTCH1 and NOTCH2 genes was confirmed at protein level 
through IF.  Using an antibody for the full-length receptor, IF was performed on 4 
CD34+ CP-CML samples.  Within all samples, a punctate appearance was noted for both 
NOTCH1 and NOTCH2 full-length receptors within the cytoplasm of the cells, with 
varying expression levels noted across patient samples, consistent with the gene 
expression findings (figure 3-5).  In view that the pathway was inactive by gene 
expression, we confirmed this at protein level with the cleaved, activated form of the 
Notch receptor, val1744, which was absent on CD34+ CP-CML cells by either IF (n=4) 
or western blotting (n=2).  These results supported the gene expression data that the 
Notch receptors, NOTCH1 and NOTCH2, are present on the cell surface of CP-CML 
samples, but are not activated. 
 
 
Figure 3 – 5 Upregulation of Notch receptors was confirmed by IF 
To illustrate intensity of immunolabelling, digital images were captured at identical exposure times.  
The expression of full length (FL) Notch1, FL Notch2, and cleaved Notch 1/2 (val1744)  are depicted 
here for 4 CP-CML samples.  The punctate appearance of the FL receptor is visible in a cytoplasmic 
distribution in all samples.  There was no activation of cleaved Notch present.   
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3.3.4. Pharmacological inhibition of Notch does not alter cellular growth 
in CD34+ CP-CML in plastic culture conditions 
To ensure that Notch signalling was not active in CP-CML and gain further insight into 
the functional role of the Notch pathway in CP-CML, 5 CD34+ primary samples were 
cultured with and without the pharmacological Notch inhibitor, DAPT; a gamma 
secretase inhibitor (GSI) that prevents the dissociation and translocation of the 
intracellular aspect of the Notch receptor to the nucleus.  Cells (n=5) were thawed or 
used fresh from CD34+-selection and cultured in low growth factor SFM on non-stromal 
conditions (i.e. plastic culture without stromal support) with and without 10uM DAPT 
for 7 sequential days.  Trypan blue exclusion cell counts every 24 hours showed that 
there was no statistically significant difference between untreated and treated samples 
in terms of cell growth (figure 3-6). 
Figure 3 - 6 Pharmacological inhibition of Notch does not alter cellular growth in 
CD34+ CP-CML cells in plastic culture  
CD34+ CP-CML cells were used from isolation of fresh peripheral blood samples or thawed and 
cultured in low growth factor SFM with or without the presence of 10uM DAPT (n=5).  DMSO treated 
cells were used as an ‘untreated’ control.  Cells were counted using trypan blue exclusion cell counts 
every 24 hours.  No statistical difference was seen with the addition of DAPT over sequential days in 
culture as analysed using a paired student’s t-test at each time-point (n=5; p>0.05). 
 
Furthermore, analysis of cell cycle (figure 3-7) and apoptosis (figure 3-8) following up 
to 7 days of culture in these patient samples did not demonstrate any statistical change 
in cell cycle components or apoptotic ability with the addition of DAPT.   Together, 
these results, as expected, demonstrate that pharmacological inhibition of the Notch 
signalling pathway does not alter cellular growth function in CD34+ CP-CML samples 
in plastic culture conditions and validated our gene expression data.   
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Figure 3 - 7 Pharmacological inhibition of Notch does not alter the cell cycle in CD34+ 
CP-CML cells in plastic culture 
CD34+ CP-CML cells were used from isolation of fresh peripheral blood samples and cultured in low 
growth factor SFM with or without the presence of 10uM DAPT (n=5).  DMSO treated cells were used 
as ‘untreated’ control.  Following five days in culture, cells were washed with 2ml 2%FBS/PBS, and 
then fixed with ice-cold ethanol prior to freezing.  Within 48 hours of freezing, samples were 
centrifuged at 300g for 5 min prior to being washed with 2%FBS/PBS and PI stain added.  Samples 
were incubated for 15 min before being immediately analysed by flow cytometry.  (A) Representation 
of flow cytometry analysis of cell cycle. (B) There was no statistical difference seen in cell cycle status 
between populations as determined by a student’s t test (p=0.9, n=5).     
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Figure 3 - 8 Pharmacological inhibition of Notch does not affect apoptotic potential 
of CD34+ CP-CML cells in plastic culture conditions 
CD34+ CP-CML cells were used from thaw or isolation of CD34+-selected fresh peripheral blood 
samples and cultured in low growth factor SFM with or without the presence of 10uM DAPT (n=5).  
DMSO treated cells were used as ‘untreated’ control.  Following five days in culture, following a 2% 
FBS/PBS wash, 0.5-1x105 cells were re-suspended in 100µL of annexinV buffer containing 5µL 
annexin-V conjugated to relevant fluorochrome and 5µL 7AAD.  Samples were incubated at room 
temperature for 15 min in the dark. Following incubation, further 200µL of annexinV buffer was added 
to the cell suspension and analysis was immediately performed by flow cytometry.  Unstained and 
single stained cells were used to set voltages and compensation. (A) Representation of flow 
cytometry analysis of CML443; side panel demonstrates single stain controls.  (B) Combined data 
collection of annexinV/7AAD staining.  There was no statistical difference between populations 
(p>0.05, n=5).  
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3.3.5. Notch pathway silencing within CP-CML is not secondary to 
increased methylation of the receptor 
It was next sought to investigate if the Notch pathway was silenced by increased 
methylation of the Notch components.  To do this, H3K27me3 and H3K4me3 levels of 
the Notch components were interrogated within the E-MTAB-2581 microarray dataset.  
On global analysis, the Notch pathway was globally downregulated.  H3K27me3 was 
statistically significantly increased for LFNG only, with no increase in H3K4me3 
between normal (n=3) and CP (n=3) samples. This suggests that there were no aberrant 
methylation patterns to disrupt normal Notch signalling events and that, therefore, 
inferred that the Notch pathway could be exogenously activated in CP-CML samples. 
 
3.3.6. In vitro activation of the Notch pathway through ligand binding 
alters the growth potential of CP-CML CD34+ patient samples 
In view that the CP-CML CD34+ cells specifically and abundantly express the Notch 
receptor, NOTCH2, and that the pathway was confirmed to be functionally inactive at 
basal state (i.e. on plastic culture without stromal support), it was hypothesised that 
Notch signalling could be reactivated through exogenous activation in CP-CML CD34+ 
cells upon ligand binding to the Notch receptor.  As both the osteoblastic niche and 
MSCs express the Notch ligands, DLL1 and JAG1, it was decided to focus our 
experimental upregulation of the Notch pathway through these ligand interactions.  The 
OP9 co-culture system was utilised, to allow for the overexpression of the DLL1 or 
JAG1 proteins, using OP9-GFP cells as control stroma (figure 3-9). 
 
 
 
 
 
Figure 3 - 9 Schematic representation of co-culture experimentation 
CD34+ CP-CML samples were thawed or used fresh from CD34+-isolation, and cultured on plastic or 
on OP9 stromal conditions in low growth factor SFM for the duration of the experiment.  Functional 
analysis was then performed as described within each experimental model.  
 
 
 
The DLL1 protein was only expressed within the OP9DLL1 stroma; whereas, both 
OP9GFP and OP9JAG1 expressed the JAG1 protein, with a concentration effect seen 
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within the expression between the GFP and JAG1 cell line (i.e. increased expression 
within OP9JAG1).   
 
Compared to non-stromal conditions, culturing over 7 days on OP9-GFP led to a 
significant increase in growth as assessed by trypan blue exclusion cell counts (p=0.02, 
n=5).  The overexpression of JAG1 led a further increase compared to OP9-GFP 
(p=0.002), suggesting that the increase in growth potential was secondary to culturing 
in the presence of increasing concentrations of the JAG1 protein, and not due to 
‘stromal’ effects alone (figure 3-10).  
 
 
 
Figure 3 - 10 In vitro activation of the Notch pathway through ligand binding alters 
the growth potential of CP-CML CD34+ patient samples 
CD34+ CP-CML cells were used from isolation of fresh peripheral blood samples or thawed and 
cultured in low growth factor SFM with or without the presence of stroma.  Within each co-culture 
experiment, OP9 stromal cells only underwent a maximum of 8 passages before use.  OP9 stromal 
cells were seeded at a 1 in 24 ratio with suspension cells (i.e. 1 stromal cell per 24 suspension cells) 
24 hours prior to co-culture.  50,000 CD34+ cells were seeded onto plastic or stromal conditions in 
12 well plates and counted every 24 hours using trypan blue exclusion cell counts. Compared to non-
stromal conditions, culturing over 7 days on OP9GFP led to a statistically significant increase in 
growth (p=0.02, n=5).  The overexpression of JAG1 led to a further increase compared to OP9GFP 
(p=0.002, n=5), suggesting that the increase in growth potential was secondary to culturing in the 
presence of increasing concentrations of JAG1 protein.  
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In view of patient variability, the cell counts were normalised to their non-stromal 
control at day 5 (figure 3 – 11).  With this, it was clear, that there was a statistical 
significant increase in trypan blue exclusion cell count following 5 days of culture 
between the OP9GFP and OP9JAG1 experimental arms.  Subsequently, experiments 
following this were conducted for between five and seven days. 
 
 
 
 
 
 
 
 
 
Upregulation of the pathway was confirmed with increased expression of HES1, a 
downstream target of the Notch pathway, at the gene level (n=6 plastic conditions; n=4 
OP9JAG1 co-culture, p=0.001), and overexpression of the val1744 protein by IF (n=4) 
(figure 3-12).  Co-culturing with OP9GFP also led to an increase in expression 
compared to normal, consistent with the expression of JAG1 in the cell line.  There was 
no increase expression of HES1 in those CML cells co-cultured with OP9DLL1 cells. 
   
 
 
 
3 - 11 In vitro activation of the Notch pathway through ligand binding alters the 
growth potential at 5 days when samples are normalised to non-stromal conditions 
Cell counts taken from figure 3-10 were normalised to their plastic/non-stromal control.  This was to 
allow for sample variation.   Upon normalisation, on day 5 of culture, there was a statistically 
significant increase in trypan blue exclusion cell counts between the OP9GFP and OP9JAG1 
(p<0.05, n=5) by one way ANOVA.  Subsequently, experiments following this were conducted for 
between five and seven days.  
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Activation of the pathway through JAG1, and not DLL1, was further confirmed by 
utilising DAPT, where we observed a significant decrease in live cell counts within 
the OP9GFP (p=0.01) and OP9JAG1 (p=0.018) experimental arms (figure 3-13).  
There was no decrease in cell counts observed on non-stromal conditions (i.e. plastic), 
nor culturing on OP9DLL1 stroma, which was consistent with the HES1 gene 
expression data.    
 
 
 
 
 
 
Figure 3 - 12 Co-culturing on OP9JAG1 stroma is associated with increase activation 
of the Notch pathway at gene and protein level 
(A) Relative gene expression levels of HES1 for n=5 CD34+ CP-CML samples co-cultured against 
the average normal CD34+ values calculated using the ΔΔCT method with an average of six 
housekeeping genes as reference.  Fold change is relative to normal CD34+ samples (n=5).  1 
samples cultured on OP9JAG1, 2 samples cultured on OP9GFP, and 3 samples cultured on 
OP9DLL1 failed the analysis.  There was a statistically significant increase in HES1 in samples 
cultured on OP9JAG1 compared to non-stromal conditions. P values were determined by an unpaired 
t-test (* p<0.05, ** p<0.01, *** p<0.001). (B) Immunofluorescence of val1744 protein, the active form 
of the Notch receptor, suggested an increase in Notch activity in cells cultured with OP9GFP (not 
shown) and OP9JAG1. 
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3.3.7. In vitro activation of the Notch pathway through ligand binding 
does not alter cell cycle status in CP-CML CD34+ patient samples 
From this, it was questioned if activation of the Notch pathway through exogenous 
ligands pushed the CD34+ CP-CML cells into cycle (i.e. S-G2-M phase) leading to 
increased growth potential.  CP-CML CD34+ cells were cultured from thaw or used 
fresh from CD34+-isolation in low growth factor SFM, with or without stromal 
conditions and fixed prior to PI staining and flow cytometry analysis.  Culturing on 
stromal conditions with active Notch ligands did not influece the cell cycle distribution 
of CD34+ CP CML cells in short term in vitro culture (p >0.05, n=3) (figure 3-14). 
 
 
 
 
 
 
 
 
 
 
Figure 3 - 13 The Notch pathway can be activated in CD34+ CP-CML cells through 
the Jagged1 protein 
CD34+ CP-CML cells were used from isolation of fresh peripheral blood samples and cultured in low 
growth factor SFM with or without the presence of stroma.  Within each co-culture experiment, stroma 
only underwent a maximum of 8 passages before use.  OP9 stromal cells were seeded at a 1 in 24 
ratio with suspension cells (i.e. 1 stromal cell per 24 suspension cells) 24 hours prior to co-culture.  
Within each condition, 10uM DAPT, was added to one arm of the experiment.  Cells were 
subsequently counted at sequential days using trypan blue exclusion.  Results are shown at day 5.  
In view of patient variability, within each co-culture condition, counts were normalised to the untreated 
control.  There was a statistically significant decrease in cell number in the OP9GFP and OP9JAG1 
on addition of DAPT, suggesting that the activated pathway was being inhibited causing a reduction 
in cell number.  (n=5, p<0.05; p value determined by a students t-test). 
Figure 3 - 14 Notch activation through exogenous ligand binding does not 
influence cell cycle distribution of CD34+ CP-CML cells in short term culture 
CD34+ CP-CML cells were used from isolation of fresh peripheral blood samples or thawed and 
cultured in low growth factor SFM with or without the presence of stroma.  Within each co-culture 
experiment, stroma only underwent a maximum of 8 passages before use.  OP9 stromal cells were 
seeded at a 1 in 24 ratio with suspension cells (i.e. 1 stromal cell per 24 suspension cells) 24 hours 
prior to co-culture.  Cells were cultured between five and seven days before fixed with ethanol in 
preparation for PI staining (method 2.3.3.4).  On flow cytometry analysis, there was no statistical 
difference, as assessed by multiple comparison ANOVA, between different culture conditions 
(p>0.05, n=3). 
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3.3.8. In vitro activation of the Notch pathway through ligand binding 
leads to a decrease in CD34 positivity and early erythroid 
differentiation  
Next, it was questioned if the increased growth potential noted within the initial trypan 
blue exclusion cell counts could be explained by alteration in cell division kinetics.  This 
was in the knowledge that activation of the Notch pathway through Jagged1 ligand-
receptor interaction in other disease processes has been shown to alter symmetric and 
asymmetric division, which has accounted for proliferation states (Srinivasan et al. 
2016; Costa et al. 2016).    
 
In order to investigate the effect of exogenous Notch ligands on the cell division kinetics 
of CD34+ CP-CML cells, CFSE dye incorporation was used with flow cytometry 
analysis.  Briefly, CP-CML CD34+ cells were thawed or used fresh, stained with CFSE 
and cultured in the presence of non-stromal or stromal conditions.  Following 5 days in 
culture, cells were harvested for viable cell count and flow cytometry analysis.  CD34+ 
expression was assessed with a monoclonal CD34+ antibody conjugated to the 
fluorescent dye APC.  Only cells in the viable gate (set by FSC and SSC criteria) were 
included in the analysis.  Three samples were analysed. 
 
Although no statistical difference was noted between the three populations, there was a 
trend towards an increase in the percentage of viable cells in later divisions on stromal 
co-culture compared to non-stromal conditions, suggesting that cells are protected 
somewhat to enable increased divisions.  However, this was not dependent on activated 
Notch signalling with no statistical difference noted between OP9GFP and OP9JAG1 
co-cultures (figure 3-15).   
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Figure 3 – 15 Stromal co-culture with OP9 cells increases percentage of total viable 
cells in later cell divisions 
CD34+ CP-CML cells were stained with CFSE and cultured with or without stromal for five days before 
analysis using flow cytometry.  (A) Rainbow dot plot representing cells within each cell division for 
each of the co-culture conditions.  (B) Histogram representation of total divisions and colcemid control 
for each non-stromal and stromal condition.  From this visual representation, stromal co-culture can 
be seen to increase total cell divisions compared to culture on plastic only. (C) Percentage of total 
viable cells within each division for each condition.  The bars represent the mean value from 3 primary 
samples, while the error bars represent SEM.  There was no statistical difference between cell 
divisions and experimental conditions, but sample variability was extensive.  
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With a trend towards increased viable cells at day 5 on stromal co-culture with OP9 
cells, we hypothesised that this could be extended to a primitive population with the 
knowledge that if activation of the Notch signalling pathway was altering the balance 
between the number of self-renewal and commitment divisions that are occurring, there 
would be less primitive cells at each division gate due the resultant increased 
differentiation.  This was measured through reduced expression of primitive surface 
phenotypic markers, such as CD34 and, more primitively, CD38.   
 
Within the same samples used above (n=3, CD34+ CP-CML), there was an overall 
statistically significant decrease in overall expression of CD34 within the viable cell 
population (figure 3-16A) in cells cultured on OP9JAG1 stroma compared to plastic 
control.  However, due to sample variability, differences in CD34 expression for each 
cell division were not significant. (figure 3-16B).  
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Figure 3 – 16 Activation of Notch through Jagged1 leads to decreased expression 
of CD34 within a bulk viable cell population 
CD34+ CP-CML cells (n=3) were stained with CFSE and cultured with or without stroma for five days 
before analysis using flow cytometry. (A) Percentage of total viable cells within CD34 positive and 
negative gates.  Error bars represent SEM.  There was a statistically significant decrease in CD34 
positive cells between plastic and OP9JAG1 co-culture as determined by an unpaired student’s t-
test (p<0.05, n=3). (B) Percentage of total viable cells within each division for each condition.  The 
bars represent the mean value from 3 primary samples, while the error bars represent SEM.  There 
was no statistical difference between cell divisions and experimental conditions, but sample 
variability was extensive. 
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This led us to question if the decrease in CD34 positivity in the viable cell populations 
was secondary to cell differentiation or if there was an element of apoptosis within the 
samples to account for this loss. 
  
To investigate this, apoptosis was first analysed using annexinV and 7AAD staining in 
CD34+ samples following 5 days of co-culture with and without stromal conditions 
(n=3).  There was an increase in percentage of cells in late apoptosis in those cultured 
in the presence of OP9JAG1 compared to OP9GFP; this was evident in both raw and 
normalised values (figure 3-17); this was not statistically significant.    
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 3 – 17 Activation of Notch through Jagged1 potentially increases late 
apoptosis 
CD34+ CP-CML cells were used from thaw or isolation of CD34+-selected fresh peripheral blood 
samples and cultured in low growth factor SFM with or without the presence of stromal conditions 
(n=3). Following five days in culture, following a 2% FBS/PBS wash, 0.5-1x105 cells were re-
suspended in 100µL of annexinV buffer containing 5µL annexinV conjugated to relevant 
fluorochrome and 5µL 7AAD.  Samples were incubated at room temperature for 15 min in the dark. 
Following incubation, further 200µL of annexinV buffer was added to the cell suspension and analysis 
was immediately performed by flow cytometry.  Unstained and single stained cells were used to set 
voltages and compensation. (A) Combined data collection of annexinV/7AAD staining.  There was 
no statistical difference between populations as analysed by a multicomparison ANOVA (p>0.05, 
n=3). (B) OP9JAG1 percentages normalised to OP9GFP to allow for sample variability.  There was 
no statistical difference between populations (p>0.05, n=3) 
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To evaluate if this could be translated to co-culture within a ‘human’ co-culture model, 
human MSCs were isolated from CP-CML patient BM and authenticated with the 
CD45-CD34-Lin-CD90+CD73+CD105+ phenotype (figure 3-18A) and positive Nestin 
IF (chapter 2.3.2.8.2).  JAG1 expression was confirmed through IF (figure 3-18B), 
before CD34+ CP-CML samples (n=4) were cultured with and without the presence of 
MSCs, and with and without 5uM IM.  MSC co-culture protected from IM-induced 
apoptosis, as has previously been described (p<0.0001, n=4) (Zhang et al, 2013).  There 
was a modest increase in early apoptosis between untreated non-stromal and stromal co-
cultures, which may represent the release of cytokines from the stromal cells or 
activation through JAG1  (p.0.008, n=4) (figure 3-18C).  
 
 
 
 
 
Figure 3 – 18 Co-culture with CP-CML MSCs demonstrated expression of JAG1 and 
protection against IM. 
(A) Human MSCs were isolated from CP-CML patient bone marrow and authenticated with the CD45-
CD34-Lin-CD90+CD73+CD105+ phenotype. (B) Immunofluorescence demonstrated expression of 
Nestin and JAG1.  (C) AnnexinV and 7AAD analysis of apoptosis by flow cytometry demonstrated 
protection against IM-induced cell death (P<0.0001; viable cells), but an increase in early apoptosis 
on MSC was noted between untreated cultures (p.0.008, n=4) 
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In view that there was only a modest increase in apoptotic ability in activation of Notch 
through JAG1, cell surface expression was next determined for myeloid and erythroid 
differentiation markers; namely, CD33, CD36, Glycophorin A (GlyA), and CD71.   
Four CD34+ CP-CML samples were thawed or used fresh from CD34+-isolation and 
cultured with or without stroma for 5 days.  Suspension cells were washed with 
PBS/2%FBS solution and stained with the appropriate antibody and analysed with flow 
cytometry, as described within chapter 2.3.2.6.  Absolute percentage of positive cells is 
demonstrated in figure 3-19A.  In view of sample variability, values were normalised to 
the non-stromal control (i.e. plastic culture) (figure 3-19B).  This demonstrated that 
there was no significant change in CD33 or CD36 expression with the addition of co-
culture and exogenous activation of Notch through ligand binding with JAG1.  
However, there was an increase in expression of both CD71 and GlyA with the addition 
of stromal co-culture, specifically JAG1.  This was statistically significant for CD71 
(p<0.05, n=4), where a significant increase in expression was noted in association with 
activation of Notch through JAG1 interaction.  GlyA expression was not significantly 
increased, suggesting that although the samples had initiated erythroid differentiation, 
they were halted at an immature erythroid state.      
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If short-term culture, allowed for early myeloid/erythroid differentiation, it was 
hypothesised that long-term differentiation assays would yield an increase in erythroid 
colony formation with the exogenous activation of Notch signalling through co-culture.  
CFC assays are clonal progenitor assays that measure the proliferation capacity and 
multi-potency of haemopoietic progenitors.  CD34+ CP-CML cells (n=5) following co-
culture in non-stromal and stromal conditions were inoculated into a semi-solid culture 
medium containing a standard growth factor cocktail.  Following culture for 12 days, 
colonies were evaluated and counted.  Each condition was set up in duplicate and mean 
between plates calculated.  There was a huge variation between samples, but no 
statistical change was noted between OP9GFP and OP9JAG1 (p=0.7, n=5), and 
furthermore between the non-stromal and OP9JAG1 experimental arms (p=0.068, n=5).  
No difference noted in GM or GEMM colonies (data not shown). Colonies were BCR-
ABL positive in all conditions, as determined by FISH (figure 3-20). 
 
 
 
 
 
 
 
Figure 3 – 19 In vitro activation of Notch through JAG1 induces early differentiation 
of CD34+ CP-CML primary samples 
Four CD34+ CP-CML samples were thawed or used fresh from CD34+-isolation and cultured with 
or without stroma for 5 days.  Suspension cells were washed with 2%FBS/PBS solution and stained 
with the appropriate antibody and analysed with flow cytometry, as described within chapter 2.3.2.6.  
(A) Absolute percentage of positive cells within each experimental arm for each cell surface marker.  
No statistical difference was noted between samples. (B) values were normalised to the non-stromal 
control.  There was no significant change in CD33 expression with the addition of co-culture and 
exogenous activation of Notch through ligand binding with Jagged1.  However, there was an 
increase in expression of both CD71 and GlyA with the addition of stromal co-culture.  There was a 
statistically significant increase in CD71 expression (p<0.05, Tukey’s multicomparison ANOVA) with 
activation of Notch. 
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Figure 3 – 20 Notch activation within CD34+ CP-CML leads to a trend towards 
increased erythroid colony formation, although this was not statistically 
significant. 
CFC assays were performed with CD34+ CP-CML cells (n=5) following co-culture in non-
stromal and stromal conditions.  There was a huge variation between samples, but no statistical 
change was noted between OP9GFP and OP9JAG1 (p=0.7, n=5), and furthermore between 
the non-stromal and OP9JAG1 experimental arms (p=0.068, n=5).  Colonies were BCR-ABL 
positive in all conditions, as determined by FISH. 
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To corroborate the possible involvement of Notch activation through JAG1 interaction 
in early erythroid differentiation, gene expression was investigated in primary CD34+ 
CP-CML patient samples (n=5).  Using Fluidigm technology, mRNA expression of 
baseline/plastic culture, OP9GFP co-culture and OP9JAG1 co-culture after 5 days was 
compared to normal peripheral blood CD34+ samples.  Relative gene expression levels 
were determined using the average normal CD34+ value as a calibrator, calculated using 
the ΔΔ CT method, using an average of six housekeeping genes as reference.  The 
patients had had no TKI treatment prior to sample collection and analysis.    
 
 
 
 
 
 
 
 
 
 
 
Previous data available on gene transcription involved in differentiation through 
myeloid and erythroid phenotype was utilised to identify the major players in early 
erythroid differentiation (figure 3-21).  There was a statistically significant increase in 
expression of key genes involved in early erythroid differentiation, namely, p38 (p<0.05 
between baseline and OP9JAG1 culture) and PU.1 (p<0.05 between baseline and 
OP9JAG1 culture), which has known involvement in development of erythroblasts 
(figure 3-22).    Furthermore, there was little change in gene expression in regulators of 
the stem cell phenotype, namely GATA2, NFKB1, and PI3K.  Interestingly, there was a 
statistically significant increase in TP53 between culture on plastic alone and OP9JAG1 
Figure 3 – 21 Schematic representation of erythroid differentiation and associated 
gene changes. 
Schematic representation of erythroid differentiation according to cell surface expression.  
Regulatory genes are depicted dependent on activity within the differentiation path.  PU.1 is a key 
regulatory gene within erythroid function, with noted increased expression driving towards an 
erythroblast phase (Chen et al, 2008).  
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co-culture (p<0.05).  There was no statistical change between OP9GFP and OP9JAG1 
co-culture, but this may be explained by the amount of JAG1 that is present in OP9GFP 
compared to OP9JAG1 stromal cells (figure 3-22).   
 
In turn, these results, suggest the hypothesis that activation of Notch through Jagged1 
in CP-CML CD34+ cells may lead to halted early erythroid differentiation with a 
possible increase in apoptosis.  However, the difficulty in assessing Notch activation in 
CD34+ CP-CML cells is that the influence of the pathway is likely to change between a 
self-renewing population and a more mature population.  Therefore, it is  not surprising 
that experiments using bulk CD34+ cells produce large inter-patient variability, with a 
non-conclusive role of the pathway in short term in vitro culture.   
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3.3.9. In vitro activation of the Notch pathway has differing function in 
short and long-term culture, and in immature and mature populations 
To address if Notch signalling impacts stem and progenitor populations differently, CP-
CML patient samples (n=3) were sorted into immature and mature cell populations, 
namely Lin-CD34+CD38- and Lin-CD34+CD38+, using FACS.  In brief, fresh or 
recovered CD34+ cells were washed and resuspended in 2%FBS/PBS.  Cells were 
counted and stained with appropriate antibodies for 30 min at room temperature in the 
dark.  2x104 cells were used for relevant single colour controls to define positive and 
negative staining for each marker and to set compensation.  Stained cells were washed 
and filtered through a 0.22uM filter prior to sorting with a BD FACS Aria with Diva 
software.  Figure 3-23 demonstrates a representative example for the sorted populations.  
All CML samples were assessed for Ph+ status, confirmed by dual colour FISH. 
 
 
 
 
 
 
 
 
 
 
Figure 3 - 23 Representation of flow activated cell sorting to Lin-CD34+CD38- 
population 
Representative example of FACS sorting to Lin-CD34+CD38- cell populations. 
Figure 3 – 22 Gene expression of regulatory erythroid differentiation genes confirms 
functional data 
Using Fluidigm technology, mRNA expression of culture on plastic, OP9GFP co-culture and 
OP9JAG1 co-culture after 5 days was compared to normal peripheral blood CD34+ samples.  
Relative gene expression levels were determined using the average uncultured normal CD34+ value 
as a calibrator calculated using the ΔΔ Ct method, using an average of six housekeeping genes as 
reference.  There was a statistically significant increase in overexpression of key genes involved in 
early erythroid differentiation, namely, p38 (p<0.05 between baseline and OP9JAG1 culture) and 
PU.1 (p<0.05 between baseline and OP9JAG1 culture), which has known involvement in 
development of erythroblasts (figure 3-22).    Furthermore, there was little change in gene expression 
in regulators of the stem cell phenotype, namely GATA2, NFKB1, and PI3K.  Interestingly, there was 
a statistically significant increase in TP53 between baseline and OP9JAG1 co-culture (p<0.05).  
There was no statistical change between OP9GFP and OP9JAG1 co-culture. 
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Following cell sorting, cells were co-cultured on non-stromal or stromal conditions for 
5 days.  At day 5, there was a statistically significant increase in cell growth of the 
CD34+CD38+ population between the non-stromal (i.e. plastic) and OP9JAG1 stromal 
conditions (p<0.05, n=3).   There was a trend towards increased growth in the OP9JAG1 
experimental arm compared to OP9GFP, although this was not significant, likely in 
keeping with basal levels of JAG1 on the OP9GFP stroma.  This was, however, not 
statistically significant (figure 3-24).   Within the CD34+CD38- experimental arm, there 
was no statistical difference in trypan blue exclusion cell counts over the five days 
analysed, but there was a trend towards reduced cell counts in the OP9JAG1 arm 
compared to the OP9GFP arm (figure 2-24).  
 
 
 
 
 
 
 
 
 
In view of the decreased trend in growth potential in the CD34+CD38- population with 
OP9JAG1 co-culture, apoptotic ability was next analysed using annexinV and 7AAD 
staining between the stromal conditions in the mature and immature experimental arms.  
There was no statistical change within the CD34+CD38+ populations, but an increase 
trend in both early and late apoptosis with the CD34+C38- (p>0.05, n=3) (figure 3-25).  
This was important because it suggested that activation of the pathway within an 
immature LSC population was toxic to the cells in short-term in vitro culture.   In view 
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Figure 3 – 24 In vitro activation of Notch increases growth potential in mature CP-
CML populations, and not immature populations 
Following FACS sorting, CD34+ CP-CML cells were cultured with or without the presence of stroma.  
At day 5, there was a statistically significant increase in cell growth of the CD34+CD38+ population 
between the non-stromal (i.e. plastic) and OP9JAG1 stromal conditions (p<0.05, n=3).  Within the 
CD34+CD38- experimental arm, there was no statistical difference in trypan blue exclusion cell 
counts. 
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of this, it was hypothesised that Notch activation through OP9JAG1 may lead to 
decrease in self-renewal capacity in long-term assays. 
 
Self-renewal activity can be measured both in vitro and in vivo in assays that 
approximate stem cell activity in the original population by observing the behaviours of 
their progeny under various conditions.   As discussed within the methods section, the 
most robust demonstration and quantification of self-renewal activity is from limited 
dilution xenograft transplantation.  However, within our model of exogenous activation 
in an immature phenotype, this is impractical and infeasible.  In vitro assays offer a 
surrogate measure of self-renewal activity and allow for small cell numbers as well as 
co-culture conditions.  To question if exogenous activation would affect the long-term 
culture ability of an immature stem cell population, LTC-IC assays were used.  
Following extended culture over 6 weeks in a supportive stromal co-culture, cells with 
residual colony forming capacity can be assessed and their prevalence in the initial 
sample inferred.  
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Figure 3 – 25 In vitro activation of Notch increases apoptotic ability in immature CP-
CML populations 
CD34+ CP-CML cells were sorted into CD34+CD38+ and CD34+CD38- populations and cultured in 
low growth factor SFM with or without the presence of stroma (n=3).  Within each co-culture 
experiment, OP9 stromal cells only underwent a maximum of 8 passages before use.  OP9 stromal 
cells were seeded at a 1 in 24 ratio with suspension cells (i.e. 1 stromal cell per 24 suspension cells) 
24 hours prior to co-culture for 5 days.  Following five days in culture, following a 2% FBS/PBS wash, 
0.5-1x105 cells were re-suspended in 100µL of annexinV buffer containing 5µL annexin-V conjugated 
to relevant fluorochrome and 5µL 7AAD.  Samples were incubated at room temperature for 15 
minutes in the dark. Following incubation, further 200µL of annexinV buffer was added to the cell 
suspension and analysis was immediately performed by flow cytometry.  Unstained and single 
stained cells were used to set voltages and compensation.  There was no statistical change within 
the CD34+CD38+ populations, but an increase trend in both early and late apoptosis with the 
CD34+C38- when co-cultured with OP9JAG1 cells (p>0.05, n=3). 
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In brief (figure 3-26), CP-CML Lin-CD34+CD38+ and Lin-CD34+CD38- were co-
cultured for 7 days on non-stromal and stromal conditions as previously described.  To 
ensure no OP9-effect, cells were also cultured on plate-bound recombinant JAG1; this 
allowed for true representation of JAG1 exogenous activation without stromal 
influence.  Hygromycin and geneticin-selected M210B4 and SL-SL fibroblast stromal 
cells were irradiated at 80Gy 24 hours prior to use within the assay, before being plated 
on gelatin-coated plates at a confluence of each cell type adjusted to 1.5x105/ml.  50,000 
of the cultured CP-CML-selected cells were suspended in 1ml 
myelocult/hydrocortisone media in duplicate, and then seeded onto the M210B4/SL-SL 
irradiated stroma for 6 weeks.  Weekly, 500ul media was carefully changed with fresh 
myelocult/hydrocortisone media ensuring that the stromal and suspension cells were not 
disturbed.  Following 6 weeks in culture, cells were harvested and inoculated into 
methocult as per the CFC assay protocol, before colonies counted between 12-14 days 
following harvest.         
 
 
 
Figure 3 – 26 Schematic of long-term culture initiating cell assay experimental 
design 
Schematic representation of the LTC-IC assay, where suspension cells (namely, sorted populations 
of CML cells) are cultured in the presence of an irradiated stromal layer that is necessary to maintain 
myelopoieiss.  Cells are cultured under specific conditions for 6 weeks prior to assessment with 
colony forming cell assays.  
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Three CP-CML samples were analysed, with 4 replicates per experimental arm.  Colony 
numbers were counted following 12 -14 days in methocult.  Data was presented 
normalised to the plastic control.  Within the Lin-CD34+38+ population, there was no 
significant reduction in colony number in the samples cultured on OP9GFP or 
OP9JAG1 stroma.  On plate-bound recombinant JAG1 co-culture there was a decrease 
in colony number, although this was not statistically significant.  The addition of DAPT 
in the initial co-culture with OP9GFP and OP9JAG1, rescued the effect on colony 
formation in those that were co-cultured with OP9JAG1 stroma (figure 3-27).   
 
Within the Lin-CD34+38- experimental arm there was no change in colony formation 
between non-stromal conditions and co-culture with OP9GFP.  However, there was a 
statistically significant reduction in colony formation between both plastic and OP9GFP 
compared to OP9JAG1 or recombinant JAG1 co-culture (p<0.05 in both comparisons) 
(figure 3-27).  This suggested that short-term activation of Notch in in vitro culture led 
to a statistically significant reduction in self-renewal and the ability to form colonies, 
and therefore, suggests that short-term activation of Notch may represent a therapeutic 
modality towards the CML LSC.       
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Figure 3 – 27 In vitro activation of Notch through JAG1 significantly decreases 
colony formation in LTC-IC assays in an immature population, suggesting a possible 
therapeutic target towards the CP-CML LSC 
3 CP-CML samples were used in analysis, with 4 replicates per experimental arm.  Colony numbers 
were counted following 12 -14 days in methocult.  Data was presented normalised to the plastic 
control.  Within the Lin-CD34+38+ population, there was no significant reduction in colony number in 
the samples cultured on OP9GFP or OP9JAG1 stroma.  On plate-bound recombinant JAG1 co-
culture there was a decrease in colony number, although this was not statistically significant.  The 
addition of DAPT in the initial co-culture with OP9GFP and OP9JAG1, rescued the effect on colony 
formation in those that were co-cultured with OP9JAG1 stroma.  Within the Lin-CD34+38- 
experimental arm there was no change in colony formation between non-stromal conditions and co-
culture with OP9GFP.  However, there was a statistically significant reduction in colony formation on 
both plastic and OP9GFP compared to OP9JAG1 or recombinant JAG1 co-culture (p<0.05 in both 
experimental arms as per ANOVA).   
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3.4. Discussion 
For the first time, within this chapter, we present data that suggests a functional action 
of Notch signalling within CP-CML, and confirm previously suggested findings that 
there is, indeed, a role for Notch signalling within myeloid disease.  
 
Using CD34+ CP-CML primary samples, it was demonstrated that Notch receptors were 
present, but not active, within CP-CML at both mRNA and protein level.  This was 
shown through mRNA expression of the Notch receptors, NOTCH1 and NOTCH2, 
which were significantly overexpressed within a CP-CML population.  Protein 
expression of the extracellular receptor was validated using IF.  The pathway was 
inactive, as evidenced through the expression of the downstream targets, HES1 and 
HIF1A, and with absent expression, through IF and western blotting, of val1744, which 
represents the cleaved Notch receptor upon canonical pathway activation (Chiang et al, 
2013).  This was again shown on evaluation of microarray datasets, which showed the 
pathway was globally downregulated.  I next validated this gene and protein expression 
data through functional evaluation of the pathway on non-stromal culture conditions 
(i.e. plastic culture) with and without the addition of the pharmacological Notch 
inhibitor, DAPT.  Addition of DAPT on non-stromal in vitro culture conditions did not 
functionally alter cell growth, cell cycle, or apoptosis in CD34+ CP-CML samples, 
suggesting that Notch signalling is silenced in CD34+ CP-CML and excludes a 
“positive” role for Notch signalling in CML disease progression or treatment resistance.    
 
Overexpression of Notch receptors has previously been described in CP-CML (Aljedai 
et al, 2015).  However, within this paper, it was suggested that the pathway was active 
within the disease subset, through expression of HES1 transcripts compared to 
housekeeping genes in 4 samples (p<0.05).  This, however, was not consistent through 
samples, nor consistent within the subpopulations analysed.  Furthermore, the 
overexpression of HES1 was not described at a protein level and the protein expression 
of the receptor was identified using a monoclonal antibody that targets the extracellular 
aspect of the receptor, which does not confirm activation, merely the presence of an 
extracellular receptor.   Our results were more consistent with the data described in 
AML, where it has been shown that there is an upregulation of NOTCH2, but with no 
confirmed activation at basal cell level (Klinakis, 2011; Lobry et al, 2013; Oh et al, 
2013).  
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Analysis of global gene expression of Notch signalling components demonstrated no 
statistical correlation with BCR-ABL expression at 12 and 18 months.  However, 
FBXW7 was shown to be a prognostic indicator between good and poor responders in 
accordance to ELN guidelines (Baccarani et al, 2013).  FBXW7 is not unique to Notch 
signalling and has been shown in vivo to target many proto-oncogenes, growth 
promoters, and anti-apoptotic molecules.  Furthermore, FBXW7 has been shown to have 
an indispensable role in the maintenance of adult HSC quiescence (Matsuoka et al, 
2008; Thompson et al, 2008).  Deletions of Fbxw7 in HSCs and CML LSCs have been 
shown to lead to c-Myc accumulation, activation of the TP53 signalling pathway, 
aberrant cell cycle entry and eventual exhaustion (Reavie et al, 2013; Reavie, 2010).  
TP53 mutations can accompany disease progression in human CML and TP53 loss in 
some cases impedes the anti-leukaemic response to BCR-ABL inhibition (Kelman et al, 
1989; Wendel et al, 2006), suggesting that loss of TP53 in some tumours could 
constitute an adaptive response to the increase in the levels of c-Myc during CML 
progression.     
 
Figure 3 – 28 Schematic representation of c-MYC and p53 within CP-CML 
 
Recently, published work within the Holyoake group has highlighted the association 
between c-Myc and p53 within CML LSCs, functioning as central hubs within the 
regulatory process of disease maintenance (Abraham et al, 2016) (figure 3-28).  Using 
clinically tractable inhibitors, namely the HDM2 inhibitors, RG7112 (Roche), and BET 
inhibitors, CPI-203 and CPI-0610 (Constellation Pharmaceuticals), it was shown that 
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selectively targeting these transcription factors could lead to elimination of the CML 
LSC both in vitro and in vivo.  Our data, perhaps, highlights further the potential role 
now of FBXW7 as a therapeutic modality within CP-CML in the eradication of the 
LSCs, or at least in the identification of those who will inevitably be poor responders in 
accordance with BCR-ABL activity.  
 
In view that the CP-CML CD34+ cells specifically and abundantly express the Notch 
receptor, NOTCH2, and that the pathway was confirmed to be functionally inactive at 
basal state (i.e. on plastic culture without stromal support), it was then hypothesised that 
Notch signalling could be reactivated through exogenous activation in CP-CML CD34+ 
cells upon ligand binding to the Notch receptor.  As has been described in detail within 
the introductory chapter, multiple cell types within the BM microenvironment express 
Notch receptors and ligands.  This could be of particular importance in CML, where 
emerging evidence indicates that not only do the CML LSCs strongly rely on the BM 
niche for their self-renewal and proliferation, but they also modify the BM to their 
advantage (Bhatia et al, 1995; Krause et al, 2013b).  The BM contains an endosteal 
osteoblastic niche, which supports quiescence and self-renewal and a more 
vascular/peri-sinusoidal niche that promotes proliferation and differentiation; both 
associate with supporting MSCs.  Notch plays an important role in osteogenesis and 
angiogenesis, and can influence osteoblast differentiation positively or negatively 
(Ramasamy et al, 2014).  Despite the abundance of data on Notch and HSC function, 
controversy remains regarding the precise role of Notch signalling in normal physiology 
owing to the intricacies of some Notch-related phenotypes (Dahlberg et al, 2011; 
Delaney et al, 2005). For example, the effects of Notch ligand activation vary based on 
the relative density of Notch surface receptors (Delaney et al, 2005).  Also, there is 
precedence for differential effects by various Notch ligands, with distinct roles of 
JAG1/2 versus DLL in lymphoid development. For example, Delta1-induced signalling 
completely inhibits the differentiation of human haemopoietic progenitors into the B 
cell lineage and promotes the emergence of cells with a phenotype of T cell/natural 
killer (NK) precursors, while JAG1-induced signalling does not disturb B or T cell/NK 
development (Jaleco et al, 2001).   It was, therefore, decided to focus our experimental 
upregulation of the Notch pathway through JAG1 and DLL1 ligands utilising an OP9 
co-culture system and plate-bound recombinant ligand approach in an in vitro setting.  
This was of particular importance as manipulation of Notch ligands influences both 
haemopoietic and mesenchymal stromal cell fates and ultimately, alters the 
microarchitecture of the BM microenvironment, thereby altering the dynamics of the 
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same regulatory interactions under investigation.  We first needed to understand how 
upregulation through ligand binding could alter the myeloid CD34+ cells before trying 
to tackle a 3D in vitro or in vivo approach.   
 
Our data demonstrated that upon JAG1 activation of the Notch pathway, as 
demonstrated by differences between OP9GFP and OP9JAG1 experimental arms, there 
was increased growth potential of CD34+ cells, although this was not explained by 
CFSE assays to confirm proliferation rates, nor change in cell cycle distribution.  This 
can, in part, be explained by the basal concentration of JAG1 within the OP9GFP 
experimental arm.  Activation of the pathway was confirmed at gene level with 
increased expression of HES1 and the val1744 protein in both the OP9GFP and 
OP9JAG1 experimental arms.  To overcome the basal levels of JAG1 in the OP9GFP 
cell line, we adopted two approaches: the first was to assess all experiments against a 
non-stromal control, and then compare to plate-bound recombinant JAG1 in isolated 
experiments.  Recombinant JAG1 allowed for assessment of the influence of Notch 
activation negating the contributing factors from stromal cells, such as expression of 
other self-renewal pathways and cytokine release.      
 
CFSE assays showed a number of interesting findings.  Firstly, it demonstrated an 
increased trend towards percentage of viable cells in later division on stromal co-culture 
compared to non-stromal conditions, suggesting that in stromal conditions, cells are 
protected somewhat to enable increased divisions.  This was again confirmed within 
MSC experiments where co-culture on MSC led to protection of CD34+ against TKI-
induced apoptosis.  Within our experiments, this was not clearly dependent on activation 
of Notch through JAG1 expression.  This suggests that Notch activation is not solely 
responsible for protection of LSC within disease states.  Previously, it has been 
suggested that this protection of CML stem and progenitor cells from TKIs is through a 
close interplay between N-cadherin and the Wnt pathway (Zhang et al, 2013), amongst 
other pathways (Agarwal & Bhatia, 2015; Perrotti et al, 2016; Toofan et al, 2014; Zhou 
et al, 2016).  Secondly, this data demonstrated that globally, JAG1-induced Notch 
activation led to a decrease in the percentage of total viable CD34+ cells. This is perhaps, 
not surprising, in that Notch activation may be altering the balance between the number 
of self-renewal cells and commitment divisions that are occurring.  The normal function 
of Notch within HSCs has previously been discussed, but to recap, this is largely 
dependent on activating ligand strength that controls specifying haemopoietic fate 
(Gama-Norton et al, 2015).  It has been suggested that canonical Notch signalling is 
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dispensable for the maintenance of HSCs in the adult BM under physiologic conditions 
(Maillard et al, 2008), with further support found in the conditional deletion of Notch1 
or Notch1 plus Notch2 under the control of the interferon-dependent expression of Mx-
Cre that specifically and exclusively affected lymphoid differentiation, but not other 
haemopoietic lineages (Besseyrias et al, 2007; Radtke et al, 1999). 
 
This data led us to establish that upon JAG1 activation, cells undergo a degree of 
apoptosis, but more significantly, it causes a push towards early erythroid differentiation 
that is blocked in an immature state (i.e. proerythroblast phase).  This was determined 
through cell surface identification of erythroid markers.  There was an increase in 
expression of both CD71 and GlyA with the addition of stromal co-culture.  This was 
only statistically significant with CD71 surface expression.  As CD33 expression was 
maintained, it suggested that although the samples had initiated differentiation, they 
could not progress beyond an immature phenotype.  To corroborate the possible 
involvement of Notch activation through JAG1 interaction in early differentiation, gene 
expression was investigated in primary CD34+ CP-CML patient samples.  There was a 
statistically significant increase in overexpression of key genes involved in early 
erythroid differentiation, namely, p38 (p<0.05) and PU.1 (p<0.05), which have notable 
involvement in development of (pro)erythroblasts.    Furthermore, there was little 
change in gene expression in regulators of the stem cell phenotype, namely GATA2 and 
NFKB1.  This is the first time this has been proposed within a CML phenotype.  
 
Literature evidence remains conflicting regarding the role of Notch activation in normal 
differentiation models (Schroeder et al, 2003; Tan-Pertel et al, 2000; Zeuner et al, 2011).  
Initial in vitro studies suggested that Notch signalling accelerated myeloid 
differentiation (Schroeder et al, 2003; Tan-Pertel et al, 2000), with subsequent studies 
contesting this conclusion, with one study suggesting that Notch can suppress 
myelopoiesis in vitro (de Pooter et al, 2006) and further studies suggesting it can induce 
a megakaryocyte differentiation.  Within an AML subset, Notch activation through 
DLL4 led to leukaemia initiating cells differentiating into more mature cell types with 
morphology resembling macrophages or dendritic cells, and an increased proportion of 
cells undergoing apoptosis (Lobry et al, 2013).   Erythropoiesis involves the progressive 
differentiation of uncommitted progenitors to mature erythrocytes. However, not only 
differentiation but also apoptosis participates in the regulation of cell survival and 
mature red cell turnover. The amount of Epo mainly dependent on hypoxia, is one of 
the key factors in controlling the survival of erythroid cells. Other transcription factors 
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including GATA1 and, more recently, TP53 have been implicated in regulating 
apoptosis at different stages of erythroid maturation (Robert-Moreno et al, 2007); again 
consistent with the data presented within this chapter. 
 
The difficulty in assessing Notch activation in CD34+ CP-CML cells is that the 
influence of the pathway is likely to change between a self-renewing population and a 
more mature population.  Therefore, it is unsurprising that experiments using bulk 
CD34+ cells produce large inter-patient variability, with a non-conclusive role of the 
pathway in short term in vitro culture.   
 
Analysis of sorted immature and mature populations, suggested that the cellular 
function of Notch through Jagged1 interaction was variable dependent on cell maturity, 
with activation in mature progenitors leading to increased growth by trypan blue 
exclusion cell counts, and within an immature population, leading to apoptosis.  We 
next questioned if exogenous activation would affect the long-term culture ability of an 
immature stem cell population; LTC-IC assays were used.  Notably, there was a 
statistically significant reduction in colony formation between both plastic and OP9GFP 
compared to OP9JAG1 or recombinant JAG1 co-culture.  This suggested that short-
term activation of Notch in an in vitro co-culture system led to a statistically significant 
reduction in self-renewal and the ability to form colonies.  This has not previously been 
described, and although it provides a potential therapeutic role in the eradication of the 
LSC, I have failed to present the mechanism by which this occurs.  A hallmark feature 
of adult stem cells is their relative proliferative quiescence.  Although these cells are 
considered immortal, HSCs can exhaust and this is frequently hastened by proliferative 
stress.  For example, HSCs are capable of reconstituting the haemopoietic system 
following transplantation. However, after serial transplantation, HSCs gradually decline 
and are eventually exhausted.  I propose that activation of the Notch pathway through 
the JAG1 protein leads to increased cell growth, differentiation and apoptosis in CP-
CML cells, that ultimately leads to LSC exhaustion and a decrease in colony formation.   
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3.5. Future Work 
In order to evaluate the function of Notch activation as a therapeutic modality, we have 
firstly embarked on translating the in vitro findings to an in vivo setting.  This will allow 
for evaluation within a BM microenvironment.  With thanks to the Aifantis laboratory 
(NYU), we have utilised the ROSA26-ICN2 murine model, which were generated by 
insertion of a loxP flanked splice acceptor NEO-ATG cassette with two polyA sites 
followed by ICN2 into the ROSA26 locus, allowing the ROSA26 promoter to drive 
expression of the NEO-ATG cassette. Cre-recombinase–mediated excision of NEO-
ATG results in use of the splice acceptor in the ICN2 cassette and irreversible expression 
of the transgene (Lobry et al. 2013; Klinakis et al. 2011).  Following confirmed 
activation of Notch, animals will be sacrificed and BM cells retrovirally transduced with 
BCR-ABL as described (Mizuno et al. 2008; Li et al. 1999), and monitored for leukaemic 
progression.  
 
In order to prove that stem cell exhaustion is the mechanism by which Notch activation 
reduces LSC colony formation long-term, serial BM transplantation into lethally 
irradiated mice would be undertaken.  However, this is most likely going to be inhibited 
by cell numbers needed, as one would have to isolate the LSC population in view of the 
proposed dual functions of Notch.  A simpler approach in an in vitro setting is to use 
serial CFC assays following LTC-IC assays to mimic the in vivo approach.  This would 
provide evidence that the cells are becoming more exhausted within the Notch activated 
samples (i.e. colonies will not form in serial CFC assays in the Notch activated 
experimental arm). 
 
Further to this, we have recently set-up a 3D in vitro model to allow for evaluation of 
cell interactions between different niche components.  This will allow for a detailed 
evaluation of activating Notch on different cell types, as well as cell interactions.  Our 
quiescent 3D BM niche uses magnetic nanoparticles to form MSC spheroids via 
magnetic levitation (Lewis et al, 2017). On implantation into a type I collagen gel 
(stiffness akin to BM), the cells in the spheroids are viable, but quiescent, express high 
levels of STRO-1 and nestin, can be tracked/sorted (due to their fluorescent tag) and 
respond to stimulation. These are then co-cultured above a monolayer of osteoblasts or 
endothelial cells, recapitulating the endosteal and perivascular components of the BM 
niche, respectively. LSC are then introduced into the system and cultured on the 
collagen matrix, allowing homing and migration towards the MSC spheroid. By 
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fluorescently tagging MSC and LSC cell populations (using fluorescent magnetic 
nanoparticles (mNPs)), this system uniquely enables the migration/interaction with the 
various cell populations to be monitored over time by live imaging using Incucyte 
Zoom™ system. Following disaggregation using collagenase, self-renewal and 
differentiation of the cell populations can be monitored and enumeration using specific 
markers by multi-parameter flow cytometry performed.  The major advantages of this 
3D system are (1) all the cells used are human, derived from primary patient samples 
enabling the leukaemia cells to interact with osteoblasts, MSC and endothelial cells 
within an extracellular matrix, creating a physiological environment mimicking the 
human in vivo BM niche.  (2) By creating MSC spheroids using magnetic nanoparticles 
the MSC survive in an immature dormant quiescent state until stimulated by cell-to-cell 
interactions, tissue damage or extrinsic stimulation. The MSC then have the capacity to 
divide and differentiate appropriately akin to the natural BM microenvironment. (3) By 
fluorescently tagging MSC and HSC/LSC cell populations this system uniquely enables 
the migration, interaction and remodelling within the various cell populations to be 
monitored over time by live imaging. (4) Scale, sufficient cells can be co-culture using 
this system to enable the detailed biochemical and molecular assays to be performed-
thus advancing research into the pathophysiology of leukaemia initiation and 
progression. (5) Microinjection of growth factors/small molecule inhibitors using 
hydrogel systems will enable localised effects to be monitored. (6) This model provides 
an ideal platform for drug screening with the potential to be adopted for high throughput 
screening of small molecule inhibitors or siRNA libraries by pharmaceutical companies. 
(7) This system will provide a valid alternative to mouse models and allows for limited 
cell numbers.  Development of this project is currently underway in collaboration with 
Drs Helen Wheadon and Catherine Berry (both University of Glasgow). 
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4. Results II 
4.1. Introduction 
Despite a targeted therapeutic approach with TKIs in CML, a small number of patients 
will present in or progress to the acute phase of the disease, termed BC or BP.  The 
incidence of progression to BP under TKI treatment ranges between 0.7 and 4.5% 
(Cortes et al, 2013; Hehlmann et al, 2011; Hughes et al, 2014) and is defined, as 
described within the introduction, according to the World Health Organisation (Arber 
et al, 2016) by the presence of at least one of 
1. Blasts comprising approximately 20% of peripheral blood (PB) white cells or 
nucleated bone marrow cells,  
2. Extramedullary blast proliferation, or  
3. Large foci or clusters of blasts in the bone marrow.  
 
Responses to TKIs in BP are transitory, and median survival following diagnosis of BP 
remains at only 6.5 to 11 months in those treated with TKI alone (Hehlmann, 2012).  
Therefore, if progression is suspected, it needs to be acted on with immediate effect to 
optimise outcome.  As previous described within the introductory chapter, it can present 
as either myeloid, lymphoid, or biphenotypic in lineage, with approximately two-thirds 
of cases being found to be of a myeloid phenotype (Atallah et al, 2002; Kinstrie et al, 
2016; Rosenthal et al, 1977).  This suggests that within BP, LSCs may play an important 
role in view of the ability to differentiate to both lineages.  However, a high degree of 
heterogeneity has been recognised, with multiple immunophenotypically distinct 
populations identified (Kinstrie et al, 2016).  Furthermore, it has been shown that within 
BP disease, committed progenitors can acquire self-renewal properties (Jamieson et al, 
2004; Kinstrie et al, 2016).  As such, the LSC in BP-CML may reside in at least 3 
subsets, namely Lin–CD34+CD38–, Lin–CD34+ cells remaining from CP, and the 
disease-driving Lin–CD34+CD38+ GMPs and CMPs (Jamieson et al, 2004; Kinstrie et 
al, 2016). 
 
To date, it remains unclear the mechanisms responsible for progression to BP, nor those 
that determine lineage decision.  This has been discussed within the introductory section 
1.3.5.1.  It is clear, however, there may be a role for self-renewal pathways within this 
process, which remains unsurprising in view of the role that the LSC plays within 
disease development and persistence.  Most of the data available surrounds myeloid BP, 
which is more common.  In BP-CML, the LSC subsets has been shown to result in 
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multiple populations with the immunophenotype of normal progenitors, as well as stem 
cells (Kinstrie et al, 2016).  Various self-renewal pathways have been implicated in this, 
including Wnt/β-catenin, which is probably the most well established (Abrahamsson et 
al, 2009; Radich et al, 2006b; Sengupta et al, 2007; Zhao et al, 2007).  Other self-renewal 
pathways, including Hh and BMP, have been linked to this process, but their exact role 
has yet to be fully elucidated (Jamieson et al, 2004; Radich et al, 2006; Su et al, 2012).  
Certainly, it may be shown that the role for different self-renewal pathways will be 
determined dependent upon which subset the LSC derives from.  For example, 
accumulation of β-catenin in the nucleus of GMPs leads to increased self-renewal 
potential (Abrahamsson et al, 2009; Ysebaert et al, 2006).  It seems pertinent, therefore, 
that the role for each evolutionary conserved self-renewal pathway be determined, as 
this will aid understanding and the development of therapeutic strategies.  
 
In view of the finding that within a CP-CML model Notch activation, through JAG1, 
led to early differentiation and reduction in colony formation in short-term and long-
term in vitro culture, respectively, we questioned if this could be translated to a BP 
phenotype, and indeed lead to a therapeutic advantage.  There is a documented role for 
Notch pathway components in the progression of disease; however, the reports remain 
conflicting.  It has been documented that within the K562 cell line, Notch inhibition can 
induce erythroid maturation (Lam et al, 2000).  However, within the same cell line, 
activation of the pathway through a lentiviral model has led to a reduction in colony 
formation (Suresh & Irvine, 2015).  Furthermore, activated intracellular Notch has been 
shown to cooperate with Bcr-Abl contributing to CML blast crisis in an in vivo model 
(Mizuno et al, 2008).  Contrary to these observations, inactivation of Notch1 in mouse 
HSCs induced CMML and Notch1 here has been suggested to have a tumour suppressor 
role (Klinakis et al, 2011).  In this study, conditional knockdown of Notch1/2/3 genes 
in mouse models induced CMML-like disease and introduction of Notch1 or Notch2 
could rescue the disease phenotype.  This study also reported that intracellular Notch1 
expression in murine leukaemia-initiating cells upregulated Hes1 levels, which led to 
the repression of myeloid expansion. However, Hes1 has been previously reported to 
cause CML BP transformation in mice (Nakahara et al, 2010). 
  
The data presented within results I suggests a potential role for the eradication of the 
LSC in CP disease; therefore, it was sought to determine if this could be translated into 
a myeloid BP phenotype, where there is huge need for novel therapeutic agents.  
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4.2. Aims 
Based on the evidence provided above, the specific aims set out in this chapter are: 
1. To assess the expression of the Notch signalling pathway elements in myeloid 
BP-CML patient samples; 
2. To determine the functional role, if any, of the Notch signalling pathway in 
myeloid BP-CML patient samples; 
3. To assess the interconnectivity between self-renewal pathways through gene 
expression analysis between CP and myeloid BP. 
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4.3. Results 
4.3.1. The Notch signalling pathway is silenced in primary myeloid BP 
CML 
To evaluate the role of Notch signalling within a myeloid BP phenotype, Notch pathway 
gene expression was investigated in primary myeloid BP-CML samples.  Using 
Fluidigm technology, mRNA expression of 11 myeloid BP-CML patient samples was 
compared to normal PB CD34+ samples.  Relative gene expression levels were 
determined using the average normal CD34+ value as a calibrator calculated using the 
ΔΔCt method (Schmittgen & Livak, 2008), using an average of five housekeeping as 
reference.  All but one patient sample had been exposed to TKI prior to analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - 1 Focussed gene expression analysis demonstrates that the Notch 
pathway components are likely silenced within primary myeloid BP samples 
Relative gene expression levels for 11 CD34+ BP-CML samples were determined against the 
average normal CD34+ PB values calculated using the ΔΔCt method with an average of five 
housekeeping genes as reference. Fold change is relative to normal CD34+ PB samples (n=3).  
(A) Dot plot showing fold change expression values for Notch receptors. (B) Dot plot showing fold 
change expression values for Notch downstream targets and MAML. (C) Dot plot showing fold 
change expression of negative regulators of the pathway.  P values were determined by an 
unpaired t-test (* p<0.05, ** p<0.01).  
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Focussed gene analysis confirmed that the Notch receptor, NOTCH2, was statistically 
upregulated compared to normal CD34+ PB samples (p=0.0035; figure 4-1A).  
NOTCH1 was overexpressed, but this was not deemed statistically significant (p=0.21; 
figure 4-1A).  The downstream target, HES1, was statistically upregulated within the 
myeloid BP samples (p=0.0023; figure 4-1B); however, the pathway was deemed to be 
silenced with no statistical change shown in gene expression of other downstream 
targets, such as HIF1A (p=0.3632; figure 4-1B).  Furthermore, the intracellular complex 
of the pathway necessary for downstream activation, MAML was not significantly 
overexpressed within this population (p=0.96; figure 4-1B).  Negative regulators were 
overexpressed compared to normal samples, but this was not statistically significant 
(figure 4-1C).  
 
Although the gene expression analysis was suggestive that the majority of myeloid BP 
samples did not demonstrate active Notch signalling through gene expression analysis, 
it was not conclusive, as HES1, a major downstream target of the Notch pathway was 
significantly upregulated.  Furthermore, although HIF1A and MAML did not 
demonstrate a statistically significant upregulation, they had increased expression 
compared to the normal PB samples.  The cleaved aspect of the intracellular NOTCH2 
receptor, val1744, was absent through IF and western blotting.    
 
Therefore, to confirm that the pathway was not upregulated, the pharmacological Notch 
inhibitor, DAPT, was utilised.  Three myeloid BP-CML primary samples were thawed 
or used fresh, and sorted into CD34+ populations, as previously described.  Cells were 
cultured in low growth factor SFM on non-stromal conditions (i.e. plastic culture 
without stromal support) with and without 10uM DAPT for five sequential days.  
Trypan blue exclusion cell counts showed that there was no statistically significant 
difference between untreated and treated samples in terms of cell growth; however, 
there was notable heterogeneity between samples (figure 4-2).  Of note, there was a 
slight increase in growth potential amongst those samples treated with DAPT for 5 days 
in vitro.  
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To determine if the increase in growth potential was a ‘true’ finding, annexinV and 
7AAD were utilised to assess apoptosis and live cell populations.  There was no change 
in apoptotic ability, nor percentage of live cells, between experimental arms using flow 
cytometry measurement of annexinV and 7AAD, suggesting that Notch inhibition on 
plastic culture does not alter apoptotic ability, within a myeloid BP phenotype (figure 
4-3).   
 
 
Figure 4 - 3 Pharmacological inhibition of Notch does not affect apoptotic ability 
of myeloid BP samples in plastic culture conditions 
Myeloid BP cells were cultured in low growth factor SFM with or without the presence of 10uM 
DAPT for 5 days (n=3).  DMSO treated cells were used as ‘untreated’ control.  Samples were 
stained with annexinV and 7AAD as previously described. Unstained and single stained cells were 
used to set voltages and compensation.  There was no significant difference between populations 
as analysed using a paired student’s t-test at each time-point (n=3; p>0.05). 
Figure 4 - 2 Pharmacological inhibiton of Notch does not alter cellular growth in 
myeloid BP samples in plastic culture 
CD34+ myeloid BP cells were cultured in low growth factor SFM with or without the presence of 10uM 
DAPT (n=3).  DMSO treated cells were used as an ‘untreated’ control.  Cells were counted using 
trypan blue exclusion cell counts every 24 hours.  No significant difference was seen with the addition 
of DAPT over sequential days in culture as analysed using a paired student’s t-test at each time-
point (n=3; p>0.05). 
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4.3.2. In vitro activation of Notch through ligand binding does not alter 
cellular function in primary myeloid BP samples  
In view that myeloid BP CD34+ cells specifically and abundantly express the Notch 
receptor, NOTCH2, and that the pathway was deemed functionally inactive at basal state 
(i.e. on plastic culture without stromal support), it was hypothesised that Notch 
signalling could be reactivated exogenously by altering cellular function, as had been 
demonstrated within a CP phenotype.  As within the CP experimental model, an OP9 
co-culture system was used to allow for the overexpression of the DLL1 and JAG1 
proteins, using OP9-GFP cells as control stroma.  CP-CML samples had demonstrated 
changes between a mature and immature population, therefore myeloid BP-CML 
samples were sorted into these populations using CD34 and CD38 expression. Three 
samples were used.  
 
Following cell sorting, cells were cultured on non-stromal and stromal conditions for 
six sequential days in low growth factor SFM.  Trypan blue exclusion cell counts were 
conducted every 24 hours to assess cell growth between experimental arms.  There was 
no statistical change in cell growth between non-stromal and stromal conditions 
(p>0.05; figure 4-4).  
 
 
 
Figure 4 - 4 Co-culture with Notch ligand support does not alter the growth potential 
in mature and immature myeloid BP cells 
Myeloid BP progenitor cells were sorted by CD34 and CD38 expression before being cultured in low 
growth factor SFM with or without the presence of stroma.  Within each co-culture experiment, OP9 
stromal cells underwent a maximum of 8 passages before use.  OP9 stromal cells were seeded at a 
1 in 24 ratio with suspension cells (i.e. 1 stromal cell per 24 suspension cells) 24 hours prior to co-
culture.  50,000 myeloid cells were seeded onto plastic or stromal conditions in 12 well plates and 
counted every 24 hours using trypan blue exclusion cell counts.  There was no signficant change 
between co-culture conditions, nor between mature and immature populations as assessed by a 
multiple comparison ANOVA at each time-point (n=3; p>0.05).  
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To confirm this pattern, apoptosis assays were used to determine live population 
percentage and apoptotic ability within a co-culture system.  AnnexinV and 7AAD was 
assessed by flow cytometry as previously described.  Within both populations, culturing 
on stroma led to an apparent increase in live cells, however this was not significant, nor 
dependent on activation of the Notch signalling pathway (figure 4-5).  
 
CFC assays were used to assess the capacity for proliferation and differentiation within 
both population subsets.  This was in view of the differentiation potential seen within a 
CP phenotype.  CD34+ BP-CML cells following co-culture in non-stromal and stromal 
conditions were inoculated into a semi-solid culture medium containing a standard 
growth factor cocktail.  Following culture for 12 days, colonies were evaluated and 
counted.  Each condition was in duplicate and mean between plates calculated.  Over 
four BP-CML samples, there was no statistical change between colony formation upon 
co-culture (figure 4-6).   
 
Figure 4 - 5 Co-culture with Notch ligand support does not alter the apoptotic ability 
in mature and immature myeloid BP progenitor cells 
Myeloid BP cells were cultured in low growth factor SFM with or without the presence of stromal 
conditions for five days (n=3). Samples were stained with AnnexinV and 7AAD as previously 
described. Unstained and single stained cells were used to set voltages and compensation.  There 
was no statistical difference between populations, nor stromal conditions, as analysed using a 
multiple comparison ANOVA at each time-point (n=3; p>0.05). 
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This was suggestive that either the pathway was not being activated by the co-culture 
conditions or that activation had no effect on cellular function.  To determine this, RNA 
was extracted from the previously co-cultured samples and analysed for both the 
downstream Notch target, HES1, and the intracellular complex necessary for target 
activation, MAML.  This was to determine if there were changes at a gene level between 
co-culture conditions.  There was no statistical change between experimental arms 
(figure 4-7).  This was corroborated at protein level using IF of val1744, the intracellular 
component of the Notch receptor, which showed no activity.  This confirmed that the 
pathway was not being activated in any of the co-culture conditions, nor between 
immature and mature populations.  This was not comparable to the CP-CML data.    
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 - 6 Co-culture with Notch ligand support does not alter colony formation in 
mature and immature myeloid BP cells 
Myeloid BP cells were sorted by CD34 and CD38 expression. Following co-culture in non-stromal 
and stromal conditions for five days, cells were inoculated into a semi-solid culture medium containing 
a standard growth factor cocktail.  Following culture for 12 days, colonies were evaluated and 
counted.  Each condition was in duplicate and mean between plates calculated. There was no 
difference between co-culture conditions (p>0.05; n=3).  Colonies were BCR-ABL positive in all 
conditions, as determined by FISH. 
Figure 4 - 7 Gene expression of HES1 and MAML confirms that the Notch pathway is 
not actviated through exogenous ligand expression 
Using Fluidigm technology, mRNA expression of CD34+CD38+ and CD34+CD38- culture on plastic, 
OP9GFP co-culture, OP9DLL1 and OP9JAG1 co-culture after 5 days was compared to normal 
peripheral blood CD34+ samples.  Relative gene expression levels were determined using the 
average normal CD34+ value as a calibrator calculated using the ΔΔ Ct method, using an average of 
five housekeeping genes as reference.  There was no difference between populations, nor within co-
culture conditions, as determined by a multiple comparison ANOVA (p>0.05). 
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4.3.3. Gene expression analysis of evolutionary conserved self-renewal 
pathways between CP and myeloid BP disease 
The functional data generated above did not demonstrate a clear functional role for 
Notch signalling within myeloid BP primary samples.  In part, this could be due to the 
heterogeneity that is seen between BP samples (Kinstrie et al, 2016).  It can be 
concluded, however, that activation of the pathway does not have the same functional 
relevance as within CP (Results I).   It was hypothesised at this juncture that the Notch 
signalling pathway could not be activated in the same way as a CP phenotype due to 
aberrancies of other self-renewal pathways and/or upregulation of negative regulators.  
It is well documented that as CML progresses, self-renewal pathways are deregulated 
(Sengupta et al. 2007; Jamieson et al. 2004).  Self-renewal pathways are modulated by 
interconnecting signals within the microenvironment.  This, subsequently means, that 
upregulation of downstream targets, such as HES1, can be acquired via other pathways.  
Moreover, understanding the interconnectivity between pathways, may, in turn, help 
understand the reasons that CP disease can progress to either myeloid or lymphoid 
lineage BP.  
 
To try and delineate interconnections between self-renewal pathways, RNA was 
extracted from CP, AP, and myeloid BP before assessing gene expression of self-
renewal pathway components, including components of the Notch, Wnt/β-catenin, Hh, 
and BMP pathways, as well as the main apoptotic regulators, including TP53.  This was 
to determine gene expression changes between CP, AP, and myeloid BP disease. 
 
Using Fluidigm technology, quantitative PCR of 90 self-renewal and cell survival genes 
was performed with the primary sample RNA.  100ng was transcribed to cDNA across 
all samples to enable comparison between groups.  Samples were plated in duplicate, 
and as more than one Fluidigm plate was to be used, an internal sample control was used 
across plates to enable comparison.  On global gene expression analysis, CP could be 
segregated from AP and myeloid BP by differential gene expression through gene 
clustering of the fold change compared to the PB CD34+ population (figure 4-8).  AP 
and myeloid BP could not be distinguished through this method, suggesting that the 
differential gene expression in CML progression is a two-step phenomenon rather than 
three; this has been previously described (Radich et al. 2006).   
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Figure 4 - 8 Gene expression clustering suggests a two-stage disease process within 
CML 
Gene expression profiles (GEPs) were determined from CP, AP, and myeloid BP populations.  Gene 
expression levels were determined by Fluidigm array analysis. Relative gene expression levels were 
determined by ΔΔCt method using an average of five housekeeping genes as reference and the 
average CD34+ value as the calibrator for fold change.  Heat maps and gene clustering were 
produced by using heatmap.2 in R/Bioconductor. 
 
 
Focussed gene analysis of this dataset demonstrated that there was a notable 
deregulation of all self-renewal pathways between CP and myeloid BP disease.  The 
Notch pathway was no exception.  There was a statistically significant increase in the 
Notch receptors, NOTCH1 and NOTCH2, between CP and myeloid BP disease 
(p=0.007 and p=0.03, respectively; figure 4-9 A-B).  However, there was no statistical 
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change in the Notch ligands (figure 4-9 C-E).  Furthermore, there was a statistically 
significant increase in gene expression of the metalloproteases necessary for proteasome 
cleavage of the pathway on activation, namely ADAM10 (p=0.0004; figure 4-10A) and 
ADAM17 (p=0.0043; figure 4-10B).  
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Figure 4 - 9 Focussed gene expression of Notch receptors and ligands 
Using Fluidigm technology, mRNA expression was determined for CP, AP, and myeloid BP 
compared to normal PB CD34+ samples.  Relative gene expression levels were determined using 
the average normal CD34+ value as a calibrator calculated using the ΔΔCT method, using an 
average of five housekeeping genes as reference.  Statistical significance was generated by unpaired 
t test between populations to enable determination of significance gene changes within disease 
progression. (A) Dot plot showing gene expression of NOTCH1. (B) Dot plots showing gene 
expression of NOTCH2. (C) Dot plots showing gene expression of JAG1. (D) Dot plots showing gene 
expression of DLL1. (E) Dot plots showing gene expression of DLL3.  P values were determined by 
an unpaired t-test between populations (* p<0.05, ** p<0.01, *** p<0.001).  
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There was a statistically significant increase in MAML between CP and myeloid BP.  
However, compared to normal PB samples, these were not significant as stated above 
(figure 4-11).  This suggests that although there is a shift in Notch signalling through 
progression to myeloid BP disease, the pathway is not likely active as this critical co-
activator is not elevated compared to normal. 
 
 
  
 
 
 
 
 
 
 
 
 
 
Interestingly, the negative regulators, FBXW7 and MFNG, were increased in myeloid 
BP compared to CP (p=0.02, and p=0.007, respectively), and between CP and AP, 
Figure 4 - 11 Focussed gene expression of MAML 
Analysis of gene expression was determined using the ΔΔCt method as previously described. Dot 
plot represents gene expression of MAML compared to normal PB CD34+ samples in the three 
phases of disease.  P values were determined by an unpaired t-test between populations (** p<0.01).  
Figure 4 - 10 Focussed gene expression of the metalloproteases, ADAM10 and 
ADAM17, in CML progression to myeloid BP 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) Dot 
plot showing gene expression of ADAM10. (B) Dot plots showing gene expression of ADAM17.  P 
values were determined by an unpaired t-test between populations (* p<0.05, ** p<0.01, *** p<0.001).  
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suggesting that this could potentially be a mechanism to its silencing (figure 4-12A-B).  
Expression of the negative regulator, RFNG, was not altered in any phase of disease 
(figure 4-12C). 
 
 
As previously documented, the Notch downstream target, HES1, has a statistically 
significant increase in expression within myeloid BP compared to normal PB CD34+ 
samples.  Furthermore, the gene expression data demonstrated a statistically significant 
increase in expression of the Notch downstream targets, HES1 (p=0.0008) and HIF1A 
(p<0.0001), in progression from CP to myeloid BP (figure 4-12).  This cannot be 
explained by the gene expression of the Notch pathway components demonstrated 
above.    
Figure 4 - 9 Focussed gene expression of negative regulators of the Notch pathway 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) 
Dot plot showing gene expression of FBXW7 compared to normal PB CD34+ samples in the three 
phases of disease.  (B) Dot plot showing gene expression of MFNG compared to normal PB CD34+ 
samples in the three phases of disease. (C) Dot plot showing gene expression of RFNG compared 
to normal PB CD34+ samples in the three phases of disease.  P values were determined by an 
unpaired t-test between the experimental population and normal, with an ANOVA used to determine 
significance between phase of disease (* p<0.05, ** p<0.01).  
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Figure 4 - 13 Focussed gene expression of the Notch downstream targets, HES1 and 
HIF1A 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) 
Dot plot showing gene expression of HES1 compared to normal PB CD34+ samples in the three 
phases of disease.  (B) Dot plot showing gene expression of HIF1A compared to normal PB CD34+ 
samples in the three phases of disease. P values were determined by an unpaired t-test between 
the experimental population and normal, with an ANOVA used to determine significance between 
phase of disease (* p<0.05, *** p<0.001, **** p<0.0001).  
 
 
This led to the question also whether the upregulation of both HES1 and HIF1A was 
secondary to the activation of other self-renewal pathways.  Furthermore, it was 
hypothesised that the activation of other self-renewal pathways was preventing 
activation of Notch components.  For example, if considering HES1, the gene can be 
upregulated by numerous mechanisms (figure 4-14).  These include through the BMP, 
Wnt/β-catenin and Hh pathways, as well as directly through HIF1A.  Within each 
pathway, there is influence in the negative regulation of Notch. 
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Components of the canonical Wnt/β-catenin pathway were examined in view of 
previous literature evidence suggesting the pathway’s involvement in CML progression 
(Abrahamsson et al, 2009; Radich et al, 2006).  There was a statistically significant 
increase in expression of TCF4 (p=0.0002) and TCF7 (p=0.0005), the major endpoint 
mediators of Wnt/β-catenin signalling, between CP and myeloid BP (figure 4-15A-B).  
TCF7 was signifcantly increased between CP and AP (p=0.04; figure 4-15B).  
Lymphoid enhancer factor 1 (LEF1) was unchanged (figure 4-15C).  This indicated that 
the Wnt/β-catenin pathway was activated during disease progression.  GSK3β was 
statistically significantly increased between CP and both AP (p=0.02) and myeloid BP 
disease (p=0.02) (figure 4-15D).  It is, however, difficult to correlate gene expression 
of GSK3β, as it is the phosphorylated protein that accumulates during canonical Wnt/β-
catenin activation.  
Figure 4 - 14 The interconnectivity between self-renewal pathwyas and activation of 
HES1 
Notch activates HES1 through a canonical signalling approach that involves proteolytic cleavages as 
described within the introductory chapter.  The Wnt signalling pathway interconnects with Notch via 
activation of Notch target genes, including HES1 or from Notch signalling components, like Notch 
receptors and ligands. GSK3β potentiates Notch-dependent gene expression via phosphorylation of 
Notch1, but can also reduce the transcriptional activity of Notch2.  The Hh pathway induces HES1 
and Notch pathway components.  Hypoxia cross talks with the Notch pathway via induction of Notch 
receptors and ligands, and common downstream targets, such as HES1.   
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Figure 4 - 15 Focussed gene expression of components of Wnt/β-catenin canonical 
signalling 
Analysis of gene expression was determined using the ΔΔCt method as previously described. Dot 
plots showing gene expression of (A) TCF4 (B) TCF7 (C) LEF1 and (D) GSK3β compared to normal 
PB CD34+ samples in the three phases of disease P values were determined by an unpaired t-test 
between the experimental population and normal, with an ANOVA used to determine significance 
between phase of disease (* p<0.05, ** p<0.01, *** p<0.001).  
 
 
Furthermore, TLE3 and TLE4 had increased expression in myeloid disease progression, 
with a statistical increase in expression between CP and myeloid BP for both (p=0.0001 
and p=0.0003, respectively; figure 4-16A-B), and between AP and myeloid BP for TLE4 
(p=0.01) (figure 4-16A).  This data validates that canonical Wnt/β-catenin components 
are deregulated within a myeloid BP phenotype.   
 
 
Wnt/β-catenin activity influences Hh activity and vice versa.  It has been shown that 
Wnt/β-catenin signalling can influence the stability of GLI1 allowing for its cellular 
accumulation.  To investigate this, the Hh pathway was next analysed.  The Hh 
receptors, PTCH1 and PTCH2 were not statistically changed between CP, AP, and 
myeloid BP (figure 4-17A-B).  As expected, GLI1 was significantly overexpressed in 
myeloid BP compared to CP disease (p=0.01; figure 4-17C).  Interestingly, SUFU, a 
negative regulator of Hh was increased in myeloid BP compared to CP and AP (p=0.02 
and p=0.01, respectively; figure 4-17D).  This may suggest that GLI1 is being regulated 
through another self-renewal pathway, such as Wnt/β-catenin, or that SUFU has a dual 
role in the regulation of Hh.  
 
Figure 4 - 16 Focussed gene expression of components of Wnt-β-catenin canonical 
signalling 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) 
Dot plot showing gene expression of TLE3 compared to normal PB CD34+ samples in the three 
phases of disease.  (B) Dot plot showing gene expression of TLE4 compared to normal PB CD34+ 
samples in the three phases of disease. P values were determined by an unpaired t-test between the 
experimental population and normal, with an ANOVA used to determine significance between phase 
of disease ( ** p<0.01, *** p<0.001).  
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There is known cooperation between BMP4 and both Hh and Wnt/β-catenin signalling.  
BMP4 expression associates with Hh signalling in determining HSC fate, both in 
embryonic and adult haemopoiesis.  There was no statistical change in BMP4 expression 
in progression of disease (figure 4-18). 
 
 
 
 
 
 
 
 
 
 
Figure 4 - 18 Focussed gene expression of BMP4 
Analysis of gene expression was determined using the ΔΔCt method as previously described. Dot 
plot represents gene expression of BMP4 compared to normal PB CD34+ samples in the three phases 
of disease  (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  
Figure 4 - 17 Focussed gene expression of components of Hh signalling 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) 
Dot plot representing gene expression of PTCH1 compared to normal PB CD34+ samples in the three 
phases of disease.  (B) Dot plot showing gene expression of PTCH2 compared to normal PB CD34+ 
samples in the three phases of disease. (C) Dot plot showing gene expression of GLI1 compared to 
normal PB CD34+ samples in the three phases of disease. (D) Dot plot showing gene expression of 
SUFU compared to normal PB CD34+ samples in the three phases of disease. P values were 
determined by an unpaired t-test between the experimental population and normal, with an ANOVA 
used to determine significance between phase of disease (* p<0.05, ** p<0.01).  
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Within the canonical BMP pathway, SMADs are the major signal transducers.  Upon 
phosphorylation of type I receptors, SMAD1, 5, and 7 become phosphorylated and form 
a complex with SMAD4.  Within our data, there was no increase in SMAD5 between 
CP and AP/myeloid BP (figure 4-19D).  SMAD1 and 7 were not analysed.  SMAD4 had 
increased expression in myeloid BP (p=0.005) compared to CP (figure 4-19C), and this 
may suggest that a complex between SMAD1/5/7 and SMAD4 was not formed.  
Interestingly SMAD6 was statistically significantly upregulated in advanced phases 
compared to CP (p=0.04 between CP and AP; p=0.01 between CP and myeloid BP) 
(figure 4-19E).  The BMP pathway is inhibited by SMAD6, which inhibits 
phosphorylation of SMAD1/5/7.  Therefore, this gene expression data may suggest that 
the pathway is downregulated in all stages of CML.  
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It is clear from the gene expression data presented above, that varying components of 
self-renewal pathways’ are deregulated between CP and advanced CML.  It is this 
deregulation that makes deciphering a therapeutic target within a self-renewal pathway 
challenging.  We next analysed the downstream targets of these pathways that have a 
function in cell cycle, differentiation, and apoptosis, in an attempt to determine the cause 
of deregulation within CML progression.  
 
CCND1, CCND2, and CYCLIN E1 were picked to assess G0-G1 phase of the cell cycle; 
STIL was chosen to assess cell cycle regulation through mitosis; and p21 was used to 
determine cell cycle inhibition (although varying reports suggest that within CML, this 
is increased in proliferative capacity, as considered within the discussion).  The cell 
cycle genes, including CCND1¸ CCND2, p21, CYCLIN E1, and STIL were statistically 
and significantly upregulated during disease progression, in keeping with the increased 
proliferative rate seen within an acute phase phenotype.   CCND1 and CCND2 were 
upregulated between myeloid BP and CP (p<0.0001 and p=0.03, respectively; figure 4-
20A-B), with a statistically significant increase in expression of CCND1 between CP 
and AP (p=0.04; figure 4-20A).  CYCLIN E1 was also significantly upregulated between 
CP and AP (p=0.01), as well as CP and myeloid BP disease (p=0.002; figure 4-20E).  
These findings are in keeping with increased cell cycle transition and proliferative 
capacity seen with disease progression.  p21 is known to confer resistance to TKI in 
disease progression (Ferrandiz et al, 2010).  Within our dataset, it was shown to have 
an increased expression compared to normal PB and between CP and myeloid BP 
disease (p=0.0001; figure 4-20C)).  FOXO1 was not statistically increased in disease 
progression (figure 4-20D).  
 
 
Figure 4 - 19 Focussed gene expression of components of BMP signalling 
Analysis of gene expression was determined using the ΔΔCt method as previously described.  Dot 
plots showing gene expression of (A) SMAD2, (B) SMAD3, (C) SMAD4, (D) SMAD5, and (E) SMAD6, 
compared to normal PB CD34+ samples in the three phases of disease. P values were determined 
by an unpaired t-test between the experimental population and normal, with an ANOVA used to 
determine significance between phase of disease (* p<0.05, ** p<0.01, *** p<0.001).  
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Figure 4 - 20 Focussed gene expression of cell cycle components 
Analysis of gene expression was determined using the ΔΔCt method as previously described.  Dot 
plot showing gene expression of (A) CCND1, (B) CCND2, (C) p21, (D) FOXO1, (E) CYCLIN E1, and 
(F) STIL, compared to normal PB CD34+ samples in the three phases of disease.  P values were 
determined by an unpaired t-test between the experimental population and normal, with an ANOVA 
used to determine significance between phase of disease (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001).  
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It is known that as CML progresses abnormalities develop within DNA replication and 
subsequent formation of DNA double stranded breaks, leading to cellular instability.  In 
keeping with this, MCM7 and MCM9 were analysed.  MCM7 has been demonstrated to 
encode the protein essential for the initiation of genomic replication, with MCM9 
required as a pre-replication complex.  Both were increased between CP and myeloid 
BP (p=0.002 and p=0.005, respectively; figure 4-21). 
 
 
 
 
 
 
 
 
 
 
RUNX1, a downstream target of BMP, was evaluated as it has been previously shown 
that abnormalities with RUNX1 expression may promote CML disease progression, with 
mutations demonstrated within progressive phenotypes.  In keeping with this, RUNX1 
was statistically increased between CP and myeloid BP (p=0.008) and between AP and 
myeloid BP (p=0.0093; figure 4-22A).    We next analysed markers of a proliferative 
phenotype, namely the GATA gene family, where GATA2 has been shown previously to 
be involved in evolution to myeloid BP, and cJUN, which has been demonstrated to 
regulate cell cycle.  There was no change in expression of cJUN or GATA1 (figure 4-
22B-C).  GATA2 has been shown to correlate with prognosis within CML progression 
(Giotopoulos et al, 2015).  Within our dataset, there was increased expression between 
CP and AP (p=0.01), as well as CP and myeloid BP, as expected (p<0.0001; figure 4-
22D).  GATA3 was also increased between CP and both AP and myeloid BP, but the 
overall expression was lower compared to normal PB CD34+ cells (figure 4-22E).  
Figure 4 - 21 Focussed gene expression of MCM7 and MCM9 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) 
Dot plot representing gene expression of MCM7 compared to normal PB CD34+ samples in the three 
phases of disease.  (B) Dot plot representing gene expression of MCM9 compared to normal PB 
CD34+ samples in the three phases of disease. P values were determined by an unpaired t-test 
between the experimental population and normal, with an ANOVA used to determine significance 
between phase of disease (** p<0.01) 
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MPO expression was comparable between disease stages, in keeping with the myeloid 
phenotype of the samples (figure 4-23A); there was no significant change in expression 
between phases.  Both MEIS1 and SPI1 have been implicated in the balance of 
differentiation and disease progression.  Within our data, there was an increase in 
expression of MEIS1 through disease progression, although there was no significant 
change compared to normal PB (figure 4-23B).  SPI1 demonstrated an increase between 
Figure 4 - 22 Focussed gene expression of differentiation components 
Analysis of gene expression was determined using the ΔΔCt method as previously described. Dot 
plots showing (A) RUNX1, (B) cJUN, (D) GATA1, (E) GATA2, and (F) GATA 3, compared to normal 
PB CD34+ samples in the three phases of disease.  P values were determined by an unpaired t-test 
between the experimental population and normal, with an ANOVA used to determine significance 
between phase of disease (* p<0.05, ** p<0.01, **** p<0.0001).  
 163 
myeloid BP and normal PB, as well as between CP and myeloid BP disease (p=0.01; 
figure 4-23C).  
 
Figure 4 - 23 Focussed gene expression of differentiation components 
Analysis of gene expression was determined using the ΔΔCt method as previously described. (A) 
Dot plot representing gene expression of MPO compared to normal PB CD34+ samples in the three 
phases of disease.  (B) Dot plot representing gene expression of MEIS compared to normal PB 
CD34+ samples in the three phases of disease. (C) Dot plot representing gene expression of SPI1 
compared to normal PB CD34+ samples in the three phases of disease. P values were determined 
by an unpaired t-test between the experimental population and normal, with an ANOVA used to 
determine significance between phase of disease (* p<0.05, *** p<0.001, **** p<0.0001).  
 
Transcription factors necessary for apoptosis were significantly increased between CP 
and myeloid BP disease.  HIPK1, which is downstream of Hh, has been shown to 
activate Wnt/β-catenin.  It was statistically increased between CP and myeloid BP 
disease (p<0.0001; figure 4-24A).  NFKβ activity has been shown to be present within 
a blast phenotype; in keeping with this, there was a statistically significant increase in 
expression between CP and myeloid BP (p=0.0002; figure 4-24B).   TP53 and MYC 
have been demonstrated within our group to be key ‘hubs’ within LSC persistence and 
targeting these has been shown to lead to LSC eradication (Abraham et al, 2016).  
Within our data, there was increased expression of TP53 between CP and AP, as well 
as myeloid BP disease (figure 4-24C).  However, there was also increased expression 
of MDM2 with disease progression (figure 4-24D); this was not significant in 
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comparison to normal PB.  MYC showed increased expression between CP and myeloid 
BP (p=0.01 (figure 4-24E); again, this was not significant compared to normal PB 
controls, as was also the case for TGF-β which showed a statistically significant increase 
between CP and both AP (p=0.006) and myeloid BP (p=0.001; figure 4-24F).    
 
 
 
 
 
 
 
 
 
 
Figure 4 - 24 Focussed gene expression of components involved in 
apoptosis 
Analysis of gene expression was determined using the ΔΔCt method as previously described.  Dot 
plots showing (A) HIPK1, (B) NFKβ, (C) TP53, (D) MDM2, (E) MYC, and (F) TGF-β compared to 
normal PB CD34+ samples in the three phases of disease. P values were determined by an unpaired 
t-test between the experimental population and normal, with an ANOVA used to determine 
significance between phase of disease (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  
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EZH2 has been demonstrated to result in myeloprolifeative neoplasm and has been 
shown to mediate activity of methyltransferase activity.  Our data showed statistically 
significant increase in expression in all phases of disease, compared to normal. (CP, 
p=0.0066, AP, p=0.012, mBC, p= 0.0005), although this was not significant between 
stage of disease.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4 – 25 Focussed gene expression of EZH2 in CML disease progression 
Analysis of gene expression was determined using the ΔΔCt method as previously described. Dot 
plot representing gene expression of EZH2 compared to normal PB CD34+ samples in the three 
phases of disease. P values were determined by an unpaired t-test between the experimental 
population and normal, with an ANOVA used to determine significance between phase of disease 
(* p<0.05, ** p<0.01, *** p<0.001). 
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4.4. Discussion 
Within this chapter, data is presented that suggests the Notch pathway has a differing 
functional role in myeloid BP-CML compared to CP-CML.  This is the first time that 
primary myeloid BP cells have been used to understand this pathway in this phase of 
the disease.  Previous literature evidence relies on cell line data or in vivo retroviral 
models and provides conflicting outcomes.  
 
Firstly, our data suggests that within primary myeloid cells, the Notch pathway is 
inactive at a basal state (i.e. on plastic non-stromal culture).  This was based on gene 
expression data, where, despite a statistically significant increase in the Notch 
downstream target, HES1, there was no objective evidence of the pathway being 
activated, with no statistical change in other downstream targets, such as HIF1A, and 
no increase in expression of MAML, the intracellular complex necessary for downstream 
activation.  This was confirmed through functional analysis, which suggested that 
despite inhibition of the pathway using the gamma-secretase inhibitor, DAPT, there was 
no statistically significant change in trypan blue cell counts or apoptotic ability over six 
days in in vitro culture.  
 
As there was an abundance of the Notch receptor, NOTCH2, on the myeloid BP cells, 
we next questioned if the pathway could be upregulated through exogenous expression 
of the Notch ligands, DLL1 and JAG1, as had been demonstrated within CP-CML.  An 
OP9 co-culture system was used as previously described within chapter 3, and samples 
were sorted into immature and mature progenitor phenotypes using CD34 and CD38 
expression.  In cell proliferation, apoptosis, and differentiation assays, there was no 
change in cellular function within any co-culture model.  The pathway was not deemed 
to be upregulated through exogenous activation with Notch ligands, by both gene 
expression of HES1 and MAML, as well as IF of the val1744 protein.  
 
This was, somewhat, surprising, in view of the mounting evidence that Notch signalling 
plays a role in acute myeloid disease, namely AML, with increasing and convincing 
evidence suggesting that Notch activation in myeloid precursors promotes self-renewal, 
induces and inhibits differentiation to monocytes, or can induce apoptosis (Carlesso et 
al, 1999; Li et al, 1998; Sarmento et al, 2005; Schroeder et al, 2003).  Furthermore, early 
observations have shown that Notch signalling may play a role in myeloid progression 
(Schroeder et al, 2003; Tan-Pertel et al, 2000).  More recently, observations have 
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supported a tumour suppressive role for Notch signalling in AML (Chen et al, 2008; 
Kannan et al, 2013; Klinakis et al, 2011; Lobry et al, 2013; Yin et al, 2009).  It was 
observed that human AML samples expressed Notch receptors, however activation of 
downstream Notch targets was low, suggesting that Notch was present but not active in 
the samples analysed (Kannan et al, 2013; Lobry et al, 2013).  Subsequent activation of 
the Notch receptors or Notch targets led to AML growth arrest in vivo and conversely 
Notch inhibition via dnMAML enhanced proliferation (Kannan et al, 2013), again 
suggesting a role of Notch in myeloid neoplastic proliferation.  Within CML itself, there 
is a clear role for Hes1 within an acute phenotype, with in vivo data using a retroviral 
model resulting in an aggressive acute Bcr-Abl positive leukaemia, and as our data has 
suggested, myeloid BP disease is associated with an increasing activation of HES1.  It 
is likely, as our data suggests, that this is not being mediated by Notch signalling and 
the question remains, what is driving its expression.  
 
To evaluate this, it was next questioned if other signalling pathways were driving the 
increasing expression of HES1.  This was in the knowledge that aberrancies within 
signal transduction pathways are the key in self-renewal, proliferative, and anti-
apoptotic potential within CML progression and the CML LSC (Crews & Jamieson, 
2012; Radich et al, 2006; Steelman et al, 2004; Zon, 2008).  These pathways include 
the evolutionary conserved self-renewal pathways, Hh, Wnt/β-Catenin, TGF-β, 
BMP, and Notch, as well as survival pathways, such as MAPK and JAK-STAT 
signalling, leading to the upregulation of oncogenic transcription factors, such as 
c-MYC.  It is known that these pathways and transcription factors do not act in 
isolation, relying on interconnective networks between them (Sinclair et al, 2013).   
RNA was extracted from CP, AP, and myeloid BP samples before being transcribed 
into cDNA at equal concentrations to allow for comparison between samples.  Gene 
clustering of the data generated suggested that CML progression is a two-step 
phenomenon from CP to advanced/acute phase disease.  This has previously been 
documented within the GSE1470 microarray dataset (Radich et al, 2006) and 
suggested that our dataset would be comparable in determining changes in gene 
expression through focussed gene analysis.  Gene expression demonstrated 
notable deregulation of all evolutionary conserved self-renewal pathways 
between CP and AP/myeloid BP.  Within the Notch pathway, there was a 
statistically significant increase in NOTCH1, NOTCH2, ADAM10, and ADAM17, which 
suggested that these cells had the machinery to allow for upregulation of the 
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pathway.  In conjunction with this, there was a statistically significant increase in 
expression of the negative regulators, MFNG and FBXW7. 
 
In addition to the core components of the Notch pathway, additional proteins 
modulate its activity; these include the Fringe family of glucosyltransferases 
(Haltiwanger & Stanley, 2002; Thomas & van Meyel, 2007).  Fringe molecules, 
including MFNG, glycosylate Notch, thereby modifying the receptor’s response to 
its ligands.  In general, glycosylation increases the response of Notch to Delta-like, 
but decreases Jagged-induced Notch signalling.  In mammals, this decrease in 
Jagged-induced Notch cleavage occurs with no reduction in Jagged-Notch binding 
(Hicks et al, 2000; Yang et al, 2005).  This perhaps offers an explanation for the 
inability of the Notch receptors to activate through JAG1, as would have been 
expected following the CP data generated in the previous chapter.   
 
As has been discussed within earlier chapters, FBXW7 is not unique to Notch signalling 
and has been shown in vivo to target many proto-oncogenes, growth promoters, and 
anti-apoptotic molecules.  Furthermore, FBXW7 has been shown to have an 
indispensable role in the maintenance of adult HSC quiescence (Matsuoka et al, 2008; 
Thompson et al, 2008).  Deletions of Fbxw7 in HSCs and CML LSCs have been shown 
to lead to c-Myc accumulation, activation of the TP53 signalling pathway, aberrant cell 
cycle entry and eventual exhaustion (Reavie et al, 2013; Reavie, 2010).  Within our 
dataset, there was a small but statistically significant increase in MYC expression 
between CP and myeloid BP.  c-MYC is activated through direct BCR-ABL-mediated 
phosphorylation and the MAPK and JAK-STAT pathways to induce growth-factor 
independent proliferation and has been shown to be a key mediator of leukaemogenesis 
in CML (Afar et al, 1994; Askew et al, 1991; Notari et al, 2006; Xie et al, 2002).  In 
keeping with this, p38 was statistically and significantly increased between CP and 
myeloid BP.  c-MYC has been also implicated in driving disease progression, as 
elevated expression confers an increased risk of progression to BP (Calabretta, 2004; 
Lucas et al, 2015; Radich, 2007). Additionally, inhibition of c-MYC is able to target 
TKI-resistant CML cells (Abraham et al, 2016; Winter et al, 2012), indicating that 
inhibition of c-MYC may have further therapeutic applications in advanced stage or 
TKI resistant disease.  Activation of c-MYC has been shown to increase TP53 and, 
indeed, this is apparent within our own dataset.  TP53 mutations can accompany disease 
progression in human CML and TP53 loss in some cases impedes the anti-leukaemic 
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response to BCR-ABL inhibition (Kelman et al, 1989; Wendel et al, 2006), suggesting 
that loss of p53 in some tumours could constitute an adaptive response to the increase 
in the levels of c-Myc during CML progression.  Within our own dataset, although there 
is a statistically significant increase in TP53, we cannot correlate this as being clinically 
relevant without the TP53 mutational status of each of the samples used and evaluation 
at a protein level.  
 
The gene expression data demonstrated a statistically significant increase in expression 
of the Notch downstream targets, HES1 and HIF1A, in progression from CP to myeloid 
BP.  Both may be modulated through other self-renewal pathways.  Their importance, 
however, in CML proliferation and progression is well documented, as described for 
HES1 earlier in this chapter (Jamieson, 2010; Nakahara et al, 2010).  HIF1A has been 
shown to promote chronic CML cell proliferation by upregulating p21 expression 
(Zhang et al, 2012).  p21, a cell cycle inhibitor has been shown to be upregulated with 
high levels of Bcr-Abl and that retaining p21 in a cytosolic location can allow Bcr-Abl 
to evade the cell cycle arrest normally induced by nuclear p21 (Keeshan et al, 2003). To 
understand the potential mechanisms for upregulation of HES1 and HIF1A, we next 
assessed self-renewal components of other pathways in view that the interconnectivity 
between self-renewal pathway components has been shown to alter expression of these 
genes.  
 
We demonstrated that Wnt/β-catenin expression was increased between CP and myeloid 
BP disease.  This was through the statistically increased expression of TCF4 and TCF7.  
There was no statistically significant change in LEF expression.  The Wnt/β-catenin 
pathway plays an essential role in the maintenance and differentiation of LSCs and the 
propagation of malignancies (Clevers, 2006).  Its activation has been shown to be 
critical within the previously mentioned GSE1470 dataset (Radich et al, 2006).  The 
importance of deregulation of Wnt/β-catenin has been described in both disease 
initiation and disease progression within CML (Zhao et al, 2007).  It has been previously 
reported that TLE3  expression can be directly induced by Wnt/β-catenin signalling, as 
part of a negative feedback loop within the canonical pathway (Kokabu et al, 2014).  It 
is, therefore, unsurprising that both TLE3 and TLE4 have increased expression within 
our dataset.  Furthermore, in unpublished data, with our collaborator, Dr Helen 
Wheadon, TLE3 has been shown to be of prognostic relevance in the determination of 
poor responders to TKIs.  In the absence of Wnt/β-catenin signalling, cytoplasmic β-
catenin is ultimately phosphorylated by GSK3β and targeted for degradation by an 
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actin-mediated multimeric complex.  GSK3β can, therefore be increased within the 
context of Wnt/β-catenin activation.  GSK3β is an interesting area of leukaemia 
research because of its role in preserving a quiescent HSC despite having negative 
effects on self-renewal (through inhibitory phosphorylation of Hh, Notch and Wnt/β-
catenin signalling) (Foltz et al, 2002; Grimes & Jope, 2001; Jia et al, 2002).  
Retrospectively, it is difficult to ascertain any functional relevance from gene 
expression data of GSK3β because its function is from a phosphorylated protein.  This 
is despite data suggesting that the ability of self-renewal in Ph+ precursors being linked 
to Wnt/β-catenin activation through GSK3β missplicing, or via impairment in 
binding through a BCR-ABL-mediated phosphorylation (Abrahamsson et al, 2009; 
Jamieson et al, 2004; Reddiconto et al, 2012).  NFKβ was shown to be upregulated 
within our data between CP and myeloid BP.  Increased GSK3β has been shown to 
upregulate NFKβ leading to increased proliferation and aggressiveness of solid 
tumours, such as Gliomas (Hoesel & Schmid, 2013).  Furthermore, GSK3β has been 
shown to bind and phosphorylate the intracellular Notch component, and 
attenuation of GSK3β activity reduces phosphorylation of intracellular Notch in 
vivo, suggesting a dual functional role in Notch inhibition and activation (Foltz et 
al, 2002; McCubrey et al, 2013). 
 
Wnt/β-catenin signalling can influence the stability of GLI1 allowing for its 
intracellular accumulation (Noubissi et al, 2009).  Furthermore, downstream Hh targets 
have been shown to modulate Wnt/β-catenin signalling.  Within our gene expression 
data, GLI1 was statistically overexpressed when CP was compared to myeloid BP.  
However, SUFU, a negative regulator of Hh, was significantly increased within a 
myeloid phenotype and between CP and myeloid BP.  This could suggest that 
Wnt/β-catenin signalling, in part, is driving the expression of GLI1 within our subset.  
However, HIP1K, a downstream target of Hh was also upregulated between CP and 
myeloid BP.  HIP1K has been shown to both promote and antagonise Wnt/β-catenin 
signalling, as well as its autophosphorylation being shown to drive TP53 
expression.   Mutations within SUFU have been demonstrated to drive 
hyperactivation of the pathway in basal cell carcinomas and medulloblastomas, 
which may offer an explanation (Taylor et al, 2002).  Regardless, there is a clinical 
role for inhibition of Hh signalling within a myeloid BP phenotype as discussed 
within the introductory chapter (Cortes et al, 2016a; Fukushima et al, 2013; 
Fukushima et al, 2016b; Jamieson et al, 2011).    
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The BMPs belong to the TGF-β superfamily and have been shown to be involved in 
a huge array of diverse cellular functions, including cell proliferation, 
differentiation, apoptosis, and stem cell self-renewal, in both embryonic and adult 
phenotypes (Herpin & Cunningham, 2007; Miyazono et al, 2005). Dysregulation 
within the BMP-TGF-β pathway has been shown to be critical in LSC survival 
(Laperrousaz et al, 2013; Miyazono, 2012; Naka et al, 2010).  The BMP pathway 
functions through receptor-mediated intracellular signalling (Toofan et al, 2014).  
It has been shown that type 1 receptors are present on LSCs in primary CML 
samples, with an associated downregulation of BMP ligands (Laperrousaz et al, 
2013).  Within the same study, CML aspirate and trephine BM samples had 
significantly higher levels of BMP2 and BMP4 compared to normal donors.  Our 
data suggested that BMP4 was upregulated compared to normal PB, but that there 
was no change between CP and AP/advanced disease.  SMADs are the major signal 
transducers in the canonical BMP pathway.  Upon phosphorylation of type I receptors, 
SMAD1/5/7 become phosphorylated and form a complex with SMAD4.  Within our 
data set, there was no increase in SMAD5.  SMAD4 had increased expression in myeloid 
BP, but this may suggest that the SMAD-complex was not formed.  Interestingly 
SMAD6 was statistically significantly upregulated in all phases compared to CP.  The 
BMP pathway is inhibited by SMAD6 and SMAD7 which inhibits phosphorylation of 
SMAD1/5/8.  Therefore this suggests, as previous functional data has, that within 
isolated CML cells, the pathway is not activated, but has the ability to be activated 
through receptor-ligand binding, and this may represent a therapeutic modality.   
 
Cell cycle gene expression favoured a positive regulation of cell cycle progression 
(i.e. progression through all phases of the cell cycle, mitosis, and proliferation), 
with statistically significant increased expression of CCND1  ¸CCND2, CYCLIN E1, 
and STIL.  This is in keeping with an increased proliferative rate seen within an acute 
disease setting.  For example, CCND2 has been shown to be increased in BCR-ABL 
expressing lymphoblasts and required for their proliferation (Deininger et al, 2001).  The 
regulation of quiescence remains important despite the increased proliferation seen 
within BP disease.  Interestingly, p21, a cell cycle inhibitor, is increased in myeloid BP 
compared to CP as the disease balances acute proliferation with stem cell quiescence.   
Furthermore, the location of p21 seems to be integral in its function, as described above, 
with cytosolic p21 allowing Bcr-Abl to evade the cell cycle arrest normally induced by 
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nuclear p21 (Keeshan et al, 2003).  Furthermore, p21 is known to confer resistance to 
TKI in disease progression.  In keeping with this idea, TGF-β was increasingly 
upregulated between CP and myeloid BP.  TGF-β has a key role in maintenance of 
quiescence and has been hugely implicated in LSC survival (Miyazono, 2012; Naka et 
al, 2010).  
 
The transition of CML from CP to BP is characterised by the accumulation of molecular 
and chromosomal abnormalities, but the molecular mechanisms underlying this genetic 
instability are poorly understood.  There is some evidence as to the relationship between 
BCR-ABL expression and activity of proteins involved in DNA repair (Radich, 2007; 
Shet et al, 2002).  To this avail, our data demonstrated an increased expression in the 
DNA replication genes, MCM7 and MCM9, between CP and myeloid BP disease.  There 
is accumulating evidence that suggests that BCR-ABL causes this directly through 
induction of ROS inducing DNA breaks requiring repair and by interacting directly with 
the repair machinery to inhibit performance (Skorski, 2008). It has also been shown that 
BCR-ABL directly drives expression of certain members of the DNA repair pathways 
resulting in increased DNA instability (Skorski, 2008).  The uncontrolled activity of 
MCM7 and MCM9 may represent an interesting therapeutic target in myeloid BP disease 
in the control of genomic instability.  
 
Interestingly, our data revealed that EZH2 was significantly and consistently 
upregulated through all phases of CML.  Within our centre, and others, recently 
published data has described the use of global and transcriptomic analysis to determine 
the functional dependency of LSCs on EZH2 and its use as a therapeutic modality.  Our 
group showed that combining an EZH2 inhibitor with TKI was highly effective at 
eradicating the LSC population (Scott et al, 2016).  Our data, therefore, may suggest the 
possibility of expanding this therapeutic modality to a myeloid BP phenotype.  
 
Our gene expression data highlights the difficulty in understanding the interconnectivity 
between signalling pathways.  This is an area of research that needs further investigation 
and understanding to enable the development of therapeutic agents to eradicate myeloid 
BP.  Our data has shown that Notch signalling has no relevance within this model.  This 
may, in part be due to the increase of MFNG and FBXW7, but will be largely due to 
modification of other self-renewal pathways’, such as Wnt/β-catenin and Hh.  
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4.5. Future work 
The data presented above raises interesting possibilities for further research into the 
regulation of self-renewal pathways within myeloid BP.  The mechanism by which 
Notch is inhibited within myeloid BP disease has not been fully elucidated.  The role 
which the Fringe process plays in this offers exciting potential as glycosylation is an 
elegant means for regulating self-renewal pathways, particularly Notch.  Although the 
functional relevance of this within myeloid BP is unlikely to offer a practical therapeutic 
advantage as, not only would a two-step approach need to be utilised to inhibit the fringe 
affect, followed by Notch activation.  As we demonstrate no functional relevance to 
either inhibition or activation of the pathway, it is difficult to predict if this will yield 
therapeutic potential.  
 
More relevant to therapeutic intervention is the continued understanding of gene 
regulation within disease progression.  The regulation of DNA repair genes, including 
MCM7 and MDM9, may prove an interesting area of therapeutic advantage and 
experimental models analysing their inhibition are currently under investigation within 
our group. 
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5. Results III 
5.1. Introduction 
As has previously been discussed within this thesis, the transformation of CP CML to 
BP, or the presentation of CML in BP, is associated with a high mortality despite 
therapeutic intervention with TKIs (Radich, 2007; Saußele & Silver, 2015).  Progression 
to BP may present as either myeloid, lymphoid, or an undifferentiated phenotype.  This 
variation can be, somewhat, anticipated in view of the importance of the LSC in CML 
pathogenesis (Crews & Jamieson, 2012; Graham et al, 2008; Holyoake et al, 1999; 
Jamieson et al, 2004).  The pathophysiology of what drives disease progression, 
however, remains poorly understood.  Furthermore, the literature available determining 
factors that induce lineage potential within the disease phenotype is limited (Wang et 
al, 2015). 
 
It is thought that BCR-ABL provides a favourable environment for the development and 
maintenance of secondary DNA modifications (Bacher et al, 2005a; Radich, 2007).  
Although this, in itself, does not explain why some of these mutations are lineage-
specific.  Numerous genetic mutations have been identified in BP disease.  Some are 
common to both lineages, and it has been hypothesised that these merely act as a 
surrogate for genomic instability rather than the genes pivotal for progression.  Others 
are implicated more commonly in either myeloid or lymphoid disease, such as TP53 
and RUNX1, respectively (Calabretta, 2004; Roche-Lestienne et al, 2008).  Within 
myeloid BP, deregulation of self-renewal and cell survival pathways can be correlated 
with progression, as described in Results II.  However, the exact mechanisms by which 
they act have not been fully elucidated.  Within lymphoid BP, less information is 
available and, therefore, it is difficult to hypothesise cause and effect of genetic 
mutations or indeed alteration of signalling pathways.  
 
Further to this, studies to identify the LSC population in BP disease are more limited 
when compared to the information available for CP.  Jamieson et al found that the HSC 
population (lin-CD34+CD38-CD90+CD45RA-) was not expanded in myeloid BP-CML 
and identified the GMP population as a potential source of LSCs in myeloid BP 
(Jamieson et al, 2004). However, this study did not assess the multipotent progenitor 
(MPP; lin-CD34+CD38-CD90-CD45RA-)/LMPP-like subpopulations, nor did it assess 
in vivo LSC activity.  Further studies by the Jamieson group identified activation of β-
catenin as the likely mechanism of enhanced self-renewal capacity in the myeloid BP 
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GMP cells (Jamieson et al, 2004; Minami et al, 2008).  Less information is available 
regarding the LSC populations in lymphoid BP CML.  A case report of a patient with 
imatinib-resistant lymphoid BP-CML indicated that the imatinib-resistant sub-clone 
(E255K kinase domain mutation) likely originated in the B-cell committed progenitor 
compartment, but no functional stem cell assays were performed (Kobayashi et al, 
2011).  In order to increase understanding of the lineage-specificity within CML 
progression, one must understand not only the differences in cell survival and self-
renewal pathway components that may occur between a myeloid and lymphoid 
phenotype, but also the heterogeneity that is seen within Ph+ acute leukaemias, 
especially if the cell of origin is not the LSC, as would be expected.  This will allow 
understanding for alternative therapeutic strategies between the conditions.  
 
Ph+ acute lymphoid-phenotype leukaemias encompass both lymphoid BP CML and 
Ph+ ALL.  These two diseases are clinically distinct, but can often be mislabelled.  Ph+ 
ALL accounts for approximately 25-30% of ALL diagnosed in adults.  Although 70-
90% of cases will achieve a complete remission with conventional chemotherapy, long-
term survival remains poor reflecting high rates of relapse and failure of salvage 
regimens.  It encompasses three main phenotypes: 
 A lymphoid lineage restricted phenotype with either p190 or p210 BCR-ABL 
fusion variant; 
 A stem cell phenotype with either p190 or p210 BCR-ABL fusion variant, or 
 Misclassified lymphoid BP CML, which has a stem cell phenotype and 
expresses p210 BCR-ABL fusion variant. 
 
The differences between both lymphoid BP and Ph+ ALL lie in the BCR-ABL fusion 
variants, as described within the introduction to this thesis, as well as potentially within 
the cell of origin.  The two BCR-ABL fusion variants, p190 and p210, are determined 
by the different amounts of BCR that they include, leading to different molecular 
weights (Soekarman et al. 1990).  The larger 210kD fusion protein (p210) is almost 
always found in CML, but is also present in approximately 30% of Ph+ ALL.  Inversely, 
the 190kD fusion protein is found in the majority of paediatric Ph+ ALL, 25-30% of 
adult Ph+ ALL, and only rarely in CML (Advani & Pendergast, 2002).  In both, the 
signalling pathways involved in cell proliferation and survival are deregulated, leading 
to the phosphorylation of many proteins (Mullighan, 2012a; Radich et al, 2006).  
Included in this is the activation and phosphorylation of STAT5, which has been 
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demonstrated to be required for progression to lymphoid transformation (Hantschel et 
al, 2012). The JAK-STAT pathway is integral part to disease progression, but it is also 
known to have many interactions with self-renewal pathways that have not yet been 
fully described.  Further to this, attempts to address the differences between lymphoid 
BP and Ph+ ALL have focussed on studies to address the cell of origin, with conflicting 
results (Hovorkova et al, 2017; Hunger, 2017; Thomas, 2012).  As CML is known to be 
a stem cell disease, BCR-ABL should theoretically be identified in all cell types.  
Similarly, with ALL being lineage restricted, it would be anticipated that the BCR-ABL 
would be restricted to the lymphoid lineage.  However, there is evidence to suggest that 
both produce a multi-lineage involvement (Anastasi et al, 1996; Cuneo et al, 1994a; 
Pajor et al, 2000; Schenk et al, 1998).   
 
Based on this information, we firstly hypothesised that there would be changes between 
gene expression patterns of cell survival and self-renewal pathways between myeloid 
and lymphoid BP disease.  Furthermore, we hypothesised that the gene expression 
patterns would be different between Ph+ ALL and lymphoid BP, in keeping with the 
idea that these are distinct disease subtypes.    
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5.2. Aims 
Based on the evidence provided above, the specific aims set out in this chapter are: 
1. To evaluate the heterogeneity of lymphoid progenitor sub-populations within 
lymphoid BP disease;  
2. To evaluate the gene expression changes of self-renewal and cell survival 
signalling pathways between myeloid and lymphoid BP; 
3. To evaluate the gene expression changes of self-renewal and cell survival 
signalling pathways between lymphoid BP and Ph+ ALL. 
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5.3. Results 
5.3.1. Lymphoid BP is an immunophenotypically heterogeneous disease 
To identify if lymphoid BP samples were heterogeneous at an immunophenotypic level, 
samples were thawed and cultured in high growth factor SFM overnight.  This was to 
ensure the samples had been under the same conditions to allow gene expression 
comparison with myeloid BP samples in later experiments.  Samples were sorted by 
FACS into HSC, MPP, CMP, CLP (lin-CD34+CD38+CD45RA+CD10+CD19-CD33-), 
and pro B (lin-CD34+CD38+CD45RA+CD10+CD19+CD33-) cell populations (figure 5-
1).   
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Samples were analysed using FlowJo software to determine heterogeneity.  Four 
samples were analysed in detail; however, two of these samples had a recovery rate of 
only 10% and only Lin-CD34+CD38+ and Lin-CD34+CD38- populations identified and, 
therefore, are not included in the detailed immunophenotypic analysis.  Of the two 
remaining samples, recovery rate was low, as has been previously demonstrated with 
BP samples (figure 5-2A).   Furthermore, there was a variation in percentage of lineage 
negative cells within the live population (range between 43% and 85%) (figure 5-2B).   
 
 
Figure 5 - 2 Following thaw, lymphoid BP samples have a low recovery rate with a 
variation in percentage of a lineage negative population 
Cells were thawed and sorter as per figure 5-3.  Immediately after FACS sorting, cells were analysed using 
FlowJo v7 software. (A) Percentage of live cells in each sample. (B) Percentage of lineage negative cells 
isolated and FACS sorted into sub-populations.  
 
Next, the percentage of CD34+ and CD34+CD38- populations was assessed in 
comparison to the lineage negative population (figure 5-3).  There was again a variation 
between the two samples, with CD34 and CD34+CD38- expression of lineage negative 
cells.  There appeared to be a lower immature component (i.e. CD34+CD38-) compared 
to previous experiments within myeloid BP CML, with  the population ranging between 
0.03 and 1%. 
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Figure 5 - 1 FACS strategy for lymphoid BP samples 
Cells were washed in PBS/2%FBS and counted following thawing.  5x104 cells were used within 
each unstained and single-stained control, where cells were re-suspended in 100ul PBS/2%FBS 
prior to the addition of antibody. The ‘multi-stain’ sample was re-suspended in 450ul PBS/2%FBS 
prior to the addition of antibody.  Samples were stained for 30 min at 4°C and then washed twice 
with PBS/2%FBS before being filtered through a 0.22uM filter.  Cells were sorted with a BD FACS 
Aria with Diva software.    
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Between the samples, there were differences in the proportion of immature and mature 
populations (figure 5-4).  For example, sample 1 had an increased percentage of 
immature cells, with an increased percentage of HSCs and MPPs, whereas sample 2 had 
a greater number of differentiated cells (i.e. CMP).  The CLP populations were 
comparable between samples. Neither sample had a pro-B population.  Despite this, the 
majority of cells within both samples were akin to a CMP population, namely 20-83% 
of cells when compared to the lin-CD34+CD38+ population. Samples were collected and 
immediately isolated into RNA samples due to small cell numbers following sorting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - 3 Lymphoid BP samples have a varying percentage of CD34+ and 
CD34+CD38- cells 
Cells were thawed and sorted as per figure 5-1.  Immediately after FACS sorting, cells were analysed 
using FlowJo v7 software.  The percentage of CD34+ and CD34+CD38- populations were calculated 
against the lineage negative population.  There was variation in both with CD34+ cells ranging between 
22 and 83%, and CD34+CD38- cells ranging between 0.03 and 1%.  
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Figure 5 - 4 The CMP population is the largest of the lymphoid BP sub-populations 
Cells were thawed and FACS sorted as per figure 5-3.  Immediately after FACS sorting, cells were 
analysed using FlowJo v7 software.  The percentages of sub populations were gated in the lineage 
negative population according to the sorting strategy.   
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5.3.2. Self-renewal gene expression is equivalent between myeloid and 
lymphoid BP 
 
As described, myeloid (n=11), lymphoid BP (n=4) and normal PB (n=3) samples were 
thawed, cultured, and sorted into stem and progenitor populations as previously 
described and RNA extracted.  Using Fluidigm technology, quantitative PCR of 90 self-
renewal and cell survival signalling genes was performed.  100ng of RNA was 
transcribed to cDNA across all samples to enable comparison between groups.  Samples 
were plated in duplicate or triplicate, and as more than one Fluidigm plate was to be 
used, an internal sample control was used across plates to enable comparison.  Myeloid 
and lymphoid BP sub-populations were pooled for analysis to ascertain a global 
expression pattern between disease phenotypes, rather than between sub-populations.  
The sub-population data will be presented within publication.  On global gene 
expression analysis, myeloid and lymphoid BP could not be distinguished by gene 
clustering methods (figure 5-5).  Each duplicate or triplicate was represented 
independently within all analysis.  This is perhaps, unsurprising, in view that the cell of 
origin will be the same for both populations and in view that on immunophenotypic 
analysis, the majority of cells were within a CMP population.  
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Figure 5 - 5 Gene clustering could not segregate myeloid and lymphoid BP disease 
Gene expression profiles (GEPs) were determined from myeloid BP and lymphoid BP populations.  
GEP levels were determined by Fluidigm array analysis. Relative gene expression levels were 
determined by ΔΔCt method using an average of five housekeeping genes as reference and the 
average Normal PB value as the calibrator for fold change.  Heat maps and gene clustering were 
produced by using heatmap.2 in R/Bioconductor. 
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For the purpose of this chapter, focussed gene expression results will be presented 
as fold change against normal to represent the change associated with a malignant 
phenotype.  Black asterisks above the gene of interest represent statistically 
significant change between leukaemic samples and normal CD34+ PB.  These were 
determined using an unpaired student’s t-test between experimental arms on the 
delta CT values.  Black asterisks with a contector represent statistically significant 
change between myeloid and lymphoid BP.  This was again done using an unpaired 
student’s t-test between myeloid and lymphoid BP samples on the delta CT value.  
Although, there were many genes that were statistically significantly changed 
between leukaemic and normal, the main question in this chapter was surrounding 
gene expression changes between myeloid and lymphoid BP disease.  
 
In keeping with the global gene expression analysis, there was little difference in 
gene expression of the key self-renewal and cell survival signalling pathway 
components between myeloid and lymphoid BP disease.  For example, within the 
Notch pathway, there was little statistically significant difference in Notch 
components between myeloid and lymphoid BP (figure 5-6).  This was, despite, 
statistically significant changes in the pathway’s components between leukaemic 
samples and normal PB samples.  Interestingly, MAML was statistically 
significantly upregulated compared to normal PB in the lymphoid BP subset, but 
not within myeloid BP.  This, perhaps, suggests that there is activated expression 
of the pathway in lymphoid BP disease and may represent an interesting 
therapeutic target.    
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Figure 5 - 6 Focused gene expression of Notch pathway components suggests active 
Notch in a lymphoid phenotype 
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP compared to 
normal PB CD34+ samples.  Relative gene expression levels were determined using the average normal 
PB value as a calibrator calculated using the ΔΔCt method, using an average of five housekeeping genes 
as reference.  (A-B) Dot plots showing gene expression of NOTCH1 and NOTCH2. (C-F) Dot plots showing 
gene expression of Notch components, ADAM10, ADAM17, MAML and MFNG.  P values were determined 
by an unpaired t-test (* p<0.05, ** p<0.01).  
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HES1 was statistically significantly upregulated in both myeloid and lymphoid disease 
compared to normal PB.  There was no statistically significant increase in HES1 
expression in lymphoid compared to myeloid BP (figure 5-7).  This is, perhaps, 
surprising in view of its known influence in lineage commitment inducing normal HSCs 
to move into a lymphoid path.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Similarly, the Notch downstream target, HIF1A, was upregulated in both lymphoid 
and myeloid BP; however, there was no change in expression between disease 
phenotypes (figure 5-8).  Together, this suggests that the downstream targets of 
Notch and the pathway components do not necessarily influence lineage specificity 
between myeloid and lymphoid BP disease.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - 7 Focussed gene expression of HES1 between myeloid BP and lymphoid 
BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP compared 
to normal PB CD34+ samples.  Relative gene expression levels were determined using the average 
normal PB value as a calibrator calculated using the ΔΔCt method, using an average of five 
housekeeping genes as reference. P values were determined by an unpaired t-test (** p<0.01, **** 
p<0.0001).  
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Again, in keeping with the global gene expression analysis, there was only 
significant statistical change in a small number of genes from components of self-
renewal pathways’ between disease phenotypes.  This is not in keeping with our 
initial hypothesis and, perhaps suggests a limited dependence on self-renewal 
pathways in myeloid and lymphoid BP.  Furthermore, it suggests that self-renewal 
pathways do not seem to be important in terms of lineage specificity in driving the 
disease phenotype.  
 
Of the genes assessed, the only significant change in the self-renewal pathways was 
within the Wnt/β-catenin pathway, with increased expression of LEF1 (p=0.02) 
and TLE4 (p=0.04) within the lymphoid BP samples (figure 5-9).  There was a 
statistically significant increased expression of TLE4 in both disease phenotypes 
compared to normal PB.  There is a noted role of LEF1 is B-cell lineage commitment 
through the activation of Pax5, and loss of TLE4 enables stem cell self-renewal 
(Laing et al, 2015; Nutt et al, 1999).  
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Figure 5 – 9 Focussed gene expression of Wnt/β-catenin pathway components 
between myeloid BP and lymphoid BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of five 
housekeeping genes as reference.  (A) Focussed gene expression of LEF1. (B) Focussed gene 
expression of TLE4.  P values were determined by an unpaired t-test (p<0.05, **** p<0.0001).  
 
Figure 5 - 8 Focussed gene expression of HIF1A between myeloid BP and lymphoid 
BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of five 
housekeeping genes as reference.  Statistical significance was generated by unpaired t-test to 
enable determination of significant gene changes between disease phenotypes (* p<0.05). 
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Although, there was only minimal statistically significant change in a small number 
of self-renewal pathway components, a number of the downstream targets were 
statistically changed between myeloid and lymphoid lineage.  These included STIL, 
which was statistically significantly decreased in lymphoid disease (figure 5-10).  
This is in keeping with its role in the regulation of lineage commitment, with 
increased expression favouring myeloid differentiation.   
 
 
 
 
 
 
 
 
 
Further to this, a statistically significant decrease in expression was noted in TGF-
β and p38 within in lymphoid BP samples compared to myeloid BP (p=0.02 and 
p=0.04, respectively; figure 5-11).  Both genes were increased in expression 
compared to normal PB, but this was not statistically significant.   
Figure 5 - 10 Focussed gene expression of STIL between myeloid BP and lymphoid 
BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of five 
housekeeping genes as reference.  P values were determined by an unpaired t-test (** p<0.01, *** 
p<0.001, **** p<0.0001).  
m B P l B P
0 . 1
1
1 0
1 0 0
1 0 0 0
S T I L
F
o
ld
 C
h
a
n
g
e
 r
e
la
t
iv
e
 t
o
 P
B
**
* * ** * * *
 188 
m B P l B P
0 . 1
1
1 0
1 0 0
1 0 0 0
T G F B
F
o
ld
 C
h
a
n
g
e
 r
e
la
t
iv
e
 t
o
 P
B *
m B P l B P
0 . 1
1
1 0
1 0 0
1 0 0 0
P 3 8
F
o
ld
 C
h
a
n
g
e
 r
e
la
t
iv
e
 t
o
 P
B *
A B
The cell cycle regulators, CCND1 and CCND2, were significantly decreased in 
lymphoid compared to myeloid BP samples (p=0.05 and p=0.0001, respectively; 
figure 5-12A and B).  CCND1 was statistically significantly increased in both disease 
phenotypes compared to normal PB, with CCND2 statistically significantly 
increased compared to normal in the lymphoid BP samples alone.  Moreover, 
RUNX1 and CYCLIN E1 were significantly decreased in the lymphoid BP compared 
to myeloid (p=0.002 and p=0.002, respectively; figure 5-12C and D).  CJUN and 
FOXO1 were significantly increased in lymphoid BP compared to myeloid (p=0.003 
and p=0.05, respectively; figure 5-12E and F), although there was no statistically 
significant change compared to normal PB.  The difficulty in ascertaining 
information from cell cycle regulators is the large degree of variation that is seen 
between samples.  This is highlighted when analysing samples at a ΔCt level.  For 
examples, within CCND2 and FOXO1 (figure 5-13), the ΔCt levels are presented for 
all populations within the analysis.  ΔCt was used to acquire statistical change as 
described above.   
Figure 5 - 11 Focussed gene expression of TGFB and p38 between myeloid BP 
and lymphoid BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of 
five housekeeping genes as reference. (A) Focussed gene expression of TGF-B. (B) Focussed 
gene expression of p38.  P values were determined by an unpaired t-test (* p<0.05).  
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Figure 5 - 12 Focussed gene expression of cell cycle regulators between myeloid 
BP and lymphoid BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCT method, using an average of five 
housekeeping genes as reference.  (A) Focussed gene expression of CCND1. (B) Focussed gene 
expression of CCND2. (C) Focussed gene expression of RUNX1. (D) Focussed gene expression of 
CYCLINE1. (E) Focussed gene expression of CJUN. (F) Focussed gene expression of FOXO1.  P 
values were determined by an unpaired t-test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  
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The changes in the downstream target genes listed above are unlikely to represent 
a change in cell lineage specificity, but merely describe the differences in cell cycle 
pattern between the two BP phenotypes.   
 
Within our dataset, the most striking finding was that there was no change 
between BP phenotypes for genes known to be involved in lineage commitment.  
Most notably, the GATA genes (GATA1, GATA2, and GATA3), and MYC, which have a 
known effect on myeloid commitment, were not statistically changed between 
myeloid and lymphoid BP (figure 5-14).  Together these data suggest that 
lymphoid BP disease has a similar gene expression pattern to myeloid BP.  This is, 
perhaps, in keeping with its stem cell origin.   
   
 
 
 
 
 
 
 
 
 
 
Figure 5 – 13 ΔCT values for all populations within gene expression analysis 
ΔCT values for all populations within gene expression analysis demonstrate the variability between 
samples 
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Figure 5 – 14 Focussed gene expression of lineage commitment regulators 
between myeloid BP and lymphoid BP  
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCT method, using an average of five 
housekeeping genes as reference. (A) Focussed gene expression of GATA1. (B) Focussed gene 
expression of GATA2. (C) Focussed gene expression of GATA3. (D) Focussed gene expression of 
MYC. P values were determined by an unpaired t-test (* p<0.05, ** p<0.01, *** p<0.001, **** 
p<0.0001).  
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5.3.3. Lymphoid BP and Ph+ ALL have distinct gene expression 
alterations of self-renewal and cell survival signalling pathway 
components 
Because of the similarities in self-renewal and cell survival gene expression 
between myeloid and lymphoid BP, we next questioned if there was a significant 
change between Ph+ ALL samples and lymphoid BP disease.  This was with the 
view that the cell of origin differs between lymphoid BP and Ph+ ALL and it may 
guide potential future therapeutic targets, as well as increasing the understanding 
of the gene expression differences between them. 
 
Ph+ ALL sample RNA (n=5) was kindly gifted to us from the UKALL14 clinical trial 
by Professor Adele Fielding.  All samples were of B cell origin and treatment naive.  
Again, 100ng of RNA was used in keeping with previous experiments.  Lymphoid 
BP sample RNA (n=5) were used in duplicate or triplicate and generated as 
previously.  Again, Fluidigm technology was used to determine the quantitative 
gene expression of 90 self-renewal and cell survival signalling genes.  Relative gene 
expression levels were determined using the average normal PB samples as a 
calibrator calculated using the ΔΔCt method, using an average of five housekeeping 
genes as reference.    
 
Global gene analysis demonstrated that Ph+ ALL and lymphoid BP could be 
segregated by gene clustering methods (figure 5-15).  This suggests that these are 
distinct disease entities as described by self-renewal and cell survival signalling 
pathways.  
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Figure 5 – 15 Gene clustering of self-renewal and cell survival components can 
segregate lymphoid BP and Ph+ ALL 
Gene expression profiles (GEPs) were determined from lymphoid BP and Ph+ ALL samples.  GEP 
levels were determined by Fluidigm array analysis. Relative gene expression levels were determined 
by ΔΔCt method using an average of five housekeeping genes as reference and the average normal 
PB value as the calibrator for fold change.  Heat maps and gene clustering were produced using 
heatmap.2 in R/Bioconductor. 
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Focussed gene expression analysis of the Ph+ ALL and lymphoid BP samples 
demonstrated that there was little change in self-renewal pathway components 
between the two diseases.  For example, within the Notch pathway (figure 5-16), a 
pathway with a noted role within T-cell ALL, the only gene to be significantly 
altered was the Notch receptor, NOTCH2, which was significantly lower in the Ph+ 
ALL arm (p=0.02; figure 5-16B).  However, compared to normal PB samples, 
NOTCH2, ADAM10, and ADAM17 were significantly overexpressed in both 
lymphoid BP and Ph+ ALL.  Compared to normal PB, MAML was significantly 
increased in lymphoid BP, but not within Ph+ ALL.   
 
Figure 5 – 16 Focussed gene expression of lineage commitment regulators 
between myeloid BP and lymphoid BP  
Using Fluidigm technology, mRNA expression was determined for lymphoid BP and Ph+ ALL 
samples compared to normal PB samples.  Relative gene expression levels were determined using 
the average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of 
five housekeeping genes as reference.  Statistical significance was generated by unpaired t-test to 
enable determination of significant gene changes between disease phenotypes (* p<0.05, ** p<0.01, 
*** p<0.001).  
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Expression of JAG1 was significantly lower in Ph+ ALL compared to lymphoid BP 
(p=0.017; figure 5-17A), although neither disease phenotype had altered expression in 
comparison to normal PB.   No change was noted for DLL1 or DLL3 between lymphoid 
BP and Ph+ ALL; however, a statistically significant increase in DLL1 was noted 
compared to normal for both (figure 5-17B and C).  This may have implications in cis-
inhibitory mechanisms within the cells, especially if translated to protein level.  
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To investigate this further, the downstream targets of the Notch signalling pathway were 
evaluated.  Interestingly, compared to normal PB, there was no statistical change in 
HES1 expression in Ph+ ALL, suggesting that the Notch pathway was not activated 
within this disease phenotype (figure 5-18A).  There was, however, a statistically 
significant increase in expression of HIF1A in both diseases (p=0.03 for lymphoid BP 
and p=0.001 for Ph+ ALL), and of HES1 in the lymphoid BP population (p=0.01), 
Figure 5 - 17 Focussed gene expression of Notch ligands between lymphoid BP 
and Ph+ ALL  
Using Fluidigm technology, mRNA expression was determined for lymphoid BP and Ph+ ALL 
samples compared to normal PB samples.  Relative gene expression levels were determined using 
the average normal PB value as a calibrator calculated using the ΔΔCt method, using an average 
of five housekeeping genes as reference. (A) Focussed gene expression of JAG1. (B) Focussed 
gene expression of DLL1. (C) Focussed gene expression of DLL3.  P values were determined by 
an unpaired t-test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  
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compared to normal PB (figure 5-18).  This is perhaps suggestive that there are not the 
same interactions between self-renewal pathways’ in different Ph+ acute leukaemias; 
furthermore, as discussed within the introduction to this thesis, the BM niche has been 
shown to be remodelled differently in disease and perhaps this varies between the Ph+ 
acute leukaemias.  There was a statistically significant increase in expression of HIF1A 
in Ph+ ALL compared to lymphoid BP which may suggest an interesting therapeutic 
target in Ph+ ALL pending further functional experiments’ (p=0.01; figure 5-18B).  
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There was a statistically significant increase in FBXW7 compared to normal PB within 
the Ph+ ALL (p=0.002; figure 5-19A), but there was no change in expression between 
lymphoid BP and Ph+ ALL of the Notch negative regulators, FBXW7, MFNG, and 
RFNG (figure 5-19).  
 
Figure 5 – 18 Focussed gene expression of HES1 and HIF1A between lymphoid BP 
and Ph+ ALL  
Using Fluidigm technology, mRNA expression was determined for lymphoid BP and Ph+ ALL 
samples compared to normal PB samples.  Relative gene expression levels were determined using 
the average normal PB value as a calibrator calculated using the ΔΔCT method, using an average 
of five housekeeping genes as reference.  Statistical significance was generated by unpaired t-test 
to enable determination of significant gene changes between disease phenotypes. (A) Focussed 
gene expression of HES1. (B) Focussed gene expression of HIF1A.  P values were determined by 
an unpaired t-test (* p<0.05, ** p<0.01).  
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As per previous results, self-renewal pathway components and downstream targets were 
next analysed to determine interaction and potential therapeutic targets within both 
diseases.  Within the Wnt/β-catenin pathway, there was no statistical difference 
between lymphoid BP and Ph+ ALL; however, in keeping with other results, 
statistically significant change was noted for both conditions compared to normal PB.  
This is in keeping with the leukaemic phenotype.  Notably, TCF4 (p=0.012; figure 5-
20A), TCF7 (p=0.0055; figure 5-20B), LEF1 (p=0.04; figure 5-20C), TLE3 (p=0.008; 
figure 5-20E), and TLE4 (p=0.0002; figure 5-20F) were statistically significantly 
upregulated within Ph+ ALL compared to normal PB, suggesting a dependence on the 
Wnt pathway in the leukaemic phenotype.   TLE3 (p=0.04; figure 5-20E) and TLE4 
(p<0.0001; figure 5-20F) were overexpressed in lymphoid BP compared to normal.   
 
 
Figure 5 – 19 Focussed gene expression of Notch negative regulators between 
lymphoid BP and Ph+ ALL  
Using Fluidigm technology, mRNA expression was determined for lymphoid BP and Ph+ ALL 
samples compared to normal PB samples.  Relative gene expression levels were determined using 
the average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of 
five housekeeping genes as reference.  (A) Focussed gene expression of FBXW7. (B) Focussed 
gene expression of MFNG. (C) Focussed gene expression of RFNG.  P values were determined by 
an unpaired t-test (** p<0.01).  
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Similarly, within the components of the Hh pathway, there was no change in expression 
between lymphoid BP and Ph+ ALL (figure 5-21).  There was, however, an increased 
expression of SUFU (p<0.0001 in lymphoid BP, p=0.0032 in Ph+ ALL; figure 5-21A) 
in both experimental arms compared to normal PB, with no statistically significant 
increase in the expression of the downstream target, HIPK1.   
 
Figure 5 - 20 Focussed gene expression of Wnt/β-catenin pathway components 
between lymphoid BP and Ph+ ALL  
Using Fluidigm technology, mRNA expression was determined for lymphoid BP and Ph+ ALL 
samples compared to normal PB samples.  Relative gene expression levels were determined using 
the average normal PB value as a calibrator calculated using the ΔΔCT method, using an average 
of five housekeeping genes as reference.  (A) Focussed gene expression of TCF4. (B) Focussed 
gene expression of TCF7. (C) Focussed gene expression of LEF1. (D) Focussed gene expression 
of GSK3β. (E) Focussed gene expression of TLE3. (F) Focussed gene expression of TLE4. P values 
were determined by an unpaired t-test (* p<0.05, ** p<0.01, *** p<0.001, **** p<0.0001).  
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As previously described, there is known cooperation between BMP4 and both Hh and 
Wnt/β-catenin signalling.  There was no statistical change between lymphoid BP and 
Ph+ ALL in BMP4 expression, or between the Ph+ leukaemias and normal PB (figure 
5-22).  Furthermore, there were no significant difference in the SMADs analysed 
between lymphoid BP and Ph+ ALL, or compared to normal PB (data not shown).  This 
suggests that there is a limited role for BMP within lymphoid BP and Ph+ ALL.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – 21 Focussed gene expression of Hh pathway components between 
lymphoid BP and Ph+ ALL  
Using Fluidigm technology, mRNA expression was determined for lymphoid BP and Ph+ ALL 
samples compared to normal PB samples.  Relative gene expression levels were determined using 
the average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of 
five housekeeping genes as reference. (A) Focussed gene expression of GLI1. (B) Focussed gene 
expression of SUFU. (C) Focussed gene expression of HIPK1. P values were determined by an 
unpaired t-test (** p<0.01, **** p<0.0001).  
Figure 5 - 22 Expression of BMP4 in lymphoid BP and Ph+ ALL  
Relative gene expression levels were determined using the average normal PB value as a 
calibrator calculated using the ΔΔC method, using an average of five housekeeping genes as 
reference.  Statistical significance was generated by unpaired t-test to enable determination of 
significant gene changes between disease phenotypes. There was no statistical change between 
experimental arms, nor compared to normal PB.   
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As expected, there was significant difference in stem cell survival regulators, namely 
GATA1 (p=0.004) and GATA2 (p<0.0001), which had a statistically significant lower 
expression in Ph+ ALL compared to lymphoid BP disease (figure 5-23).  This is perhaps 
representative of the stem cell origin of lymphoid BP disease, compared to Ph+ ALL.  
Compared to normal, there was no statistical change between normal and lymphoid BP 
for GATA1 expression, likely owing to the degree of variation noted within samples.  
There was, however, a statistically significant increase in expression of GATA1 (p<0.05) 
and a decrease in GATA2 (p<0.05), when comparing Ph+ ALL to normal.  There was 
no change in GATA3 expression between lymphoid BP and Ph+, nor compared to 
normal. GATA3 has a known role within the T-lymphocyte lineage, but its role within 
self-renewal and the HSC population remains unclear.  
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Figure 5 – 23 Focussed gene expression of stem cell survival components 
between lymphoid BP and Ph+ ALL 
Using Fluidigm technology, mRNA expression was determined for myeloid and lymphoid BP 
compared to normal PB samples.  Relative gene expression levels were determined using the 
average normal PB value as a calibrator calculated using the ΔΔCt method, using an average of 
five housekeeping genes as reference. (A) Focussed gene expression of GATA1. (B) Focussed 
gene expression of GATA2. (C) Focussed gene expression of GATA3. P values were determined 
by an unpaired t-test (* p<0.05, *** p<0.001, **** p<0.0001). 
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Contrary to data in AML, which suggests a clinical significance in increased expression 
of GATA1, GATA2 and SCL expression (Shimamoto et al, 1994), there was no 
statistically significant change in expression of SCL compared to normal or between 
disease phenotypes (figure 5-24).  
 
 
 
 
 
 
 
 
 
 
 
 
 
No significant change was noted between other cell cycle regulators in the two Ph+ 
leukaemias, including CCND1, CCND2, p21, FOXO1, STIL and CYCLINE1 (figure 5-
25).  There was a statistically significant increase expression in p21 (p=0.01 for 
lymphoid BP and p=0.001 for Ph+ ALL) and STIL (p=0.0002 for lymphoid BP and 
p<0.0001 for Ph+ ALL) in both populations, with statistically significant increase 
expression in FOXO1 (p<0.05) within Ph+ ALL. 
Figure 5 – 24 Focussed gene expression of SCL between lymphoid BP and Ph+ 
ALL  
Relative gene expression levels were determined using the average normal PB value as a 
calibrator calculated using the ΔΔCT method, using an average of five housekeeping genes as 
reference.  Statistical significance was generated by unpaired t test between populations to enable 
determination of significance gene changes within disease phenotype. There was no statistical 
change between experimental arms, or compared to normal PB. 
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Figure 5 – 25 Focussed gene expression of cell cycle regulators between lymphoid 
BP and Ph+ ALL  
Relative gene expression levels were determined using the average normal PB value as a calibrator 
calculated using the ΔΔCT method, using an average of five housekeeping genes as reference. (A) 
Focussed gene expression of CCND1. (B) Focussed gene expression of CCND2. (C) Focussed gene 
expression of p21. (D) Focussed gene expression of FOXO1. (E) Focussed gene expression of STIL. 
(F) Focussed gene expression of CYCLIN E1. P values were determined by an unpaired t-test (* 
p<0.05, ** p<0.01, *** p<0.001).  
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5.4. Discussion 
The data presented above raises the possibility that lymphoid BP and myeloid BP 
samples are similar in gene expression of self-renewal and cell survival pathway 
components. This suggests that the two disease processes are, perhaps, more similar 
than previously anticipated.  Furthermore, it provides evidence to suggest that perhaps 
the treatment of lymphoid BP should be based on chemotherapeutic agents used within 
acute myeloid disease, rather than acute lymphoblastic disease.  In keeping with this, 
the current UK BP clinical trial, MATCHPOINT (Management of Transformed Chronic 
myeloid leukaemia: Ponatinib and Intensive chemotherapy: a dose finding study), 
utilises a chemotherapy regimen commonly used for high risk and relapsed/refractory 
AML (FLAG-Ida) in both disease subtypes (Bergua et al, 2016; Burnett et al, 2013).  
  
Furthermore, both myeloid and lymphoid BP are heterogeneous diseases encompassing 
immature and mature phenotypes within the same population (Kinstrie et al, 2016).  The 
heterogeneity described within lymphoid BP in this chapter is only based on two 
samples, and clearly this needs to be expanded to encompass other samples to 
understand the true heterogeneity that is present.  There are some difficulties in this, 
however, as lymphoid BP disease is a rare entity and, therefore, this will be a 
longstanding endeavour.  Although our group has recently published with regards to 
heterogeneity in myeloid BP disease (Kinstrie et al, 2016), within lymphoid BP this data 
is limited to case-based analysis and immunophenotypic change (Bettelheim et al, 1985; 
Cervantes et al, 1998; Ilaria, 2005).  Within the Cervantes study, 17 out of 19 patients 
were of B-lineage phenotype, with the other 2 being T-lineage.  Similar to our own data, 
all the samples had one or more myeloid markers expressed (Cervantes et al, 1998).  
This report also suggested that lymphoid BP was seldom associated with an AP, which 
clearly has an implication in management.  Subsequently, being able to identify a gene 
expression profile within lymphoid BP may help in the earlier diagnosis of the disease 
and quick initiation of treatment.    
 
To determine this, we assessed the gene expression of 90 self-renewal and cell survival 
components between myeloid and lymphoid BP disease.  This was with the initial 
hypothesis that there would be aberrancies between the two disease phenotypes that may 
guide earlier diagnosis and novel therapeutic approaches.  Self-renewal pathways were 
utilised because of the known association of acquisition of self-renewal properties, 
specifically of Wnt/β-catenin pathway, within BP disease (Jamieson et al, 2004).  
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Although there is some data to describe this within myeloid BP, there is inadequate data 
within lymphoid BP, with even less known about the genes responsible for determining 
lineage-selectivity.  As described within the introductory paragraph to this discussion, 
the gene expression data, firstly, demonstrated that the 90 self-renewal and cell survival 
components could not segregate myeloid and lymphoid BP phenotypes on global gene 
analysis through gene clustering methods.  This is in keeping with recent single cell 
transcriptomic data within a BCR-ABL+ population, where lymphoid (n=2) and myeloid 
(n=1) BP samples were clustered together (Giustacchini et al, 2017).  Furthermore, our 
data suggests that the cells have limited alteration in self-renewal components, likely 
owing to the LSC in the disease pathogenesis. It is known that the LSC in BP-CML may 
result in at least 3 subsets, namely Lin–CD34+CD38–, Lin–CD34+ cells remaining from 
CP, and the disease-driving Lin–CD34+CD38+ GMPs (Jamieson et al, 2004).  Our data, 
in some respects, reflects this, as there were no statistical differences between both 
myeloid and lymphoid BP disease.  Furthermore, as the data was pooled, it suggests that 
there are similar degrees of immature and mature populations in both disease 
phenotypes.  
 
All key self-renewal pathway components of Notch, Wnt/β-catenin, Hh, and BMP, were 
analysed, although not all were reported within this results section due to statistical 
significance not being achieved.  The Notch signalling pathway has a known role within 
lineage decision making of the normal HSC population, particularly towards a lymphoid 
bias (Delaney et al, 2010; Jaleco et al, 2001; Ohishi et al, 2003a; Ohishi et al, 2002).  
The main components of the pathway were not statistically changed between myeloid 
and lymphoid BP disease.  However, as there was a statistically significant increased 
expression of NOTCH2, ADAM10, and ADAM17 compared to normal PB, it suggested 
that within BP disease these may be the components to upregulate the pathway.  
Interestingly, MAML, the intracellular component of Notch required for canonical 
activation of its downstream targets, was signficantly increased in lymphoid BP 
compared to normal, but not within myeloid BP.  This perhaps suggests that the Notch 
pathway is, indeed, upregulated within lymphoid BP disease, however, further 
functional analysis is required to fully determine this and we are currently in the process 
of extending this experimental work.  Despite this, there was no statistically significant 
increase in the downstream targets of Notch, HES1 and HIF1A, between myeloid and 
lymphoid disease.  Within the previous chapter, the complex activation of these 
downstream targets was explored and therefore, although HES1 was statistically 
significantly increased in both myeloid and lymphoid BP compared to normal, this 
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could be driven through a number of different mechanisms within each phenotype; for 
example, through the activation of other self-renewal pathways.   
 
Assessing a role for the Notch signalling pathway using gene expression data is difficult 
due to differing ligand-receptor interactions leading to varying functional roles.  For 
example, although within previous chapters, we have demonstrated the potential for 
LSC eradication with NOTCH2-JAG1 interaction in CP disease, it is known that Notch-
Delta1 interactions can promote T-cell lineage commitment and maturation (Besseyrias 
et al, 2007).  Further functional analysis needs to be evaluated within Lymphoid BP as 
to the effect of differing ligand-receptor binding.  
 
In keeping with the global gene expression analysis through clustering methods between 
myeloid and lymphoid BP, there were limited changes between self-renewal pathway 
components in other pathways analysed.  Only within the Wnt/β-catenin pathway were 
there significant changes between myeloid and lymphoid BP disease.  Within lymphoid 
BP, there was a statistically significant increase in LEF1 and TLE4.  Furthermore, TLE4 
was shown to be statistically significantly increased within both myeloid and lymphoid 
BP compared to normal PB.  The importance of deregulation in Wnt/β-catenin has been 
described in disease initiation and progression of CML (Abrahamsson et al, 2009; 
Radich et al, 2006; Zhao et al, 2007).  Furthermore, LEF1 has been shown to regulate 
accumulation of β-catenin intracellularly and be important in leukaemogenesis.  In 
murine experiments, increased LEF1 led to abnormalities of haemopoietic 
differentiation and developed B-ALL and AML, with the LSC exhibiting lymphoid 
characteristics (Petropoulos et al, 2008).  Furthermore, there has shown to be 
inactivation of LEF1 in T-cell ALL (Gutierrez et al, 2010a; Gutierrez et al, 2010b), with 
overexpression perhaps highlighting the B-cell phenotype of our Ph+ ALL samples.  
TLE4 has been previously demonstrated to enable stem cell differentiation. 
 
Within our dataset, STIL was significantly unregulated in both myeloid and lymphoid 
BP compared to normal PB.  STIL has a noted role in the regulation of lineage 
commitment, with increased expression favouring myeloid differentiation.  In keeping 
with this, expression in lymphoid BP was significantly lower compared to the myeloid 
BP samples.  The increase in expression in comparison to normal may be explained by 
the mixed population seen within lymphoid BP samples, with the identification of a 
CMP populton in the samples extensively immunophenotyped.  TGF-β was noted to be 
significantly decreased in lymphoid BP compared to myeloid BP.  TGFβ has been 
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shown to maintain leukaemic initiating cell potential within CML CP (Miyazono, 2012; 
Naka et al, 2010) and the decreased expression in lymphoid BP may be in keeping with 
a more differentiated phenotype.  Within our dataset, the most striking area was that 
there was no change between populations of genes known to be involved in lineage 
commitment.  Most notably, the GATA genes (GATA1, GATA2, and GATA3), and MYC, 
which have a known effect on myeloid commitment, did not significantly change 
between myeloid and lymphoid BP.  Together this data suggests that lymphoid BP 
disease has a similar gene expression pattern to myeloid BP.  This is, perhaps, in 
keeping with its stem cell and myeloid origin.   
 
These data presented emphasise the similarities between myeloid BP and 
lymphoid BP disease, with only minimal changes suggestive of novel therapeutic 
targets.   In view of this, we next sought to question if there were differing gene 
expression profiles of self-renewal and cell survival pathways within the Ph+ acute 
leukaemias’.  This was in view of the known differences in cell of origin between 
them, with lymphoid BP representing a distinctly stem cell disease, and Ph+ ALL a 
more differentiated phenotype.  Indeed, on global gene expression of the 90 self-
renewal and cell survival components, the two diseases could be segregated with 
gene clustering methods.  
 
On focussed gene analysis, there were similar expression patterns of the self-
renewal pathway components between lymphoid BP and Ph+ ALL.  Although there 
was a statistically significant decrease in NOTCH2 expression in Ph+ ALL compared 
to lymphoid BP. NOTCH2, ADAM10, and ADAM17 were significantly upregulated 
compared to normal PB samples in both Ph+ leukaemias.  This suggests that, as 
with lymphoid BP, Ph+ ALL has the components necessary for Notch activation.  
However, despite this, only lymphoid BP had a statistically significant increase in 
expression of MAML compared to normal.  In keeping with this, HES1 was not 
statistically significantly increased in Ph+ ALL samples, suggesting that the 
pathway was not active at a gene level.   FBXW7, a negative regulator of Notch, was 
statistically significantly increased in Ph+ ALL compared to normal.  As there was 
no statistical change in TP53 and MYC, this suggests that FBXW7 is acting 
independently of these survival mechanisms, and may offer a therapeutic target 
within the disease.  
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HIF1A is important within leukaemogenesis, particularly in CML (Zhang et al, 
2012; Zhou et al, 2016).  Within our dataset, HIF1A was statistically significantly 
increased in Ph+ ALL compared to both lymphoid BP and normal PB.  Although 
further investigation is required to ascertain its importance in Ph+ ALL, it seems 
an exciting area of development.  It has been shown that within ALL, blockade of 
HIF1A-mediated signalling may play an important role in chemo-sensitisation of 
ALL cells under hypoxic conditions of the BM (Frolova et al, 2012).  Furthermore, 
within childhood B-ALL, high expression of HIF1A is associated with a good 
prognosis (Silveira et al, 2014), as well as being required for active Wnt signalling 
in T-ALL (Giambra et al, 2015).  Although our focussed gene analysis demonstrated 
no significant difference between lymphoid BP and Ph+ ALL within Wnt/β-catenin 
pathway components, there appeared to be an increased dependency on the 
Wnt/β-catenin pathway within Ph+ ALL, with a statistically significant increase in 
key Wnt components, namely TCF4, TCF7, and LEF1, compared to normal PB.   
There is clearly an identified role for the Wnt pathway in the propagation of 
malignancy (Clevers, 2006; van Rhenen et al, 2007), but there is only limited data 
of its role within Ph+ ALL (Gregory et al, 2010).  There is increasing evidence of its 
reliance, however, in normal B-cell development and, therefore, it represents a 
potential area of interesting further development in its role as a novel therapeutic 
intervention.   
 
As expected, there was significant change in the cell survival regulators, namely 
GATA1 and GATA2, which had a statistically significant decrease in expression in 
Ph+ ALL compared to lymphoid BP disease.  This is likely in keeping with the 
myeloid and stem cell component noted within lymphoid BP.  For example, GATA1 
is known to play an essential role in the commitment to, and subsequent 
differentiation within, myeloid lineages, particularly, erythroid, megakaryocyte 
and eosinophilic (Drissen et al, 2016; Ferreira et al, 2005).  Contrary to AML data, 
which suggests a clinical significance of GATA1, GATA2 and SCL expression 
(Shimamoto et al, 1994), there was no statistical difference in SCL expression compared 
to normal or between lymphoid BP and Ph+ ALL.   Furthermore, there was no 
significant change between other cell cycle regulators in the Ph+ acute lymphoid 
leukaemias, including CCND1, CCND2, FOXO1, STIL and CYCLINE1.  This is in 
keeping with the leukaemic phenotype of the diseases.   
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Together, this data confirms that lymphoid BP and Ph+ ALL are distinct disease entities 
and offers potentially interesting targets for further evaluation.   This chapter has offered 
novel insight into the similarities between myeloid and lymphoid BP disease, which has 
not been previously described.  Further to this, it has allowed discussion into the 
differences between self-renewal pathways between the Ph+ acute lymphoid 
leukaemias, which may guide potential therapeutic targets in the future, including 
FBXW7 and components of the Wnt/β-catenin pathway within Ph+ ALL.  
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6. Results IV 
6.1. Introduction 
The concept of disease persistence through quiescent LSCs has been highlighted in 
recent years by trials exploring the discontinuation of TKIs in CP-CML patients with 
sustained deep molecular response (i.e. those that achieve a 4 log or greater reduction 
of quantitative BCR-ABL expression from standardised baseline over a prolonged 
period) (Etienne et al, 2017; Mahon et al, 2014; Mahon, 2015; Mahon et al, 2010; 
Mahon et al, 2016; Rea et al, 2012; Ross et al, 2010; Ross et al, 2013; Takahashi et al, 
2012).  These trials have demonstrated that discontinuation of therapy can be selectively 
achieved, with STIM trial data stating the cumulative incidence of molecular relapse at 
60 months was 61% (CI 52-67%), with few cases of late relapse being observed (Mahon 
et al, 2014).  This suggests that if molecular relapse is to occur, it happens early.  
Comparable results have been reported worldwide (Mahon et al, 2014; Mahon et al, 
2010; Rea et al, 2012; Ross et al, 2010; Ross et al, 2013; Takahashi et al, 2012).  The 
EURO-SKI trial is the largest study to date, with recruitment of over 800 patients.  Most 
recent analysis demonstrated a molecular-recurrence free survival of 62% at 6 months, 
56% at 12 months, and 52% at 24 months (Mahon et al, 2016).  The DADI study 
analysed molecular-relapse free survival after stopping dasatinib as second-line therapy 
or beyond.  The probability of molecular-recurrence free survival was 49% at 6 months, 
and 48% at 12 months, with all molecular relapses occurring within 7 months of 
stopping therapy.  All patients with molecular relapse regained deep molecular response 
within 6 months  (Imagawa et al, 2015).  The UK equivalent trial currently in progress 
(DESTINY) is analysing the role of dose reduction before complete suspension of TKI 
treatment.  Interim data has suggested that decreasing TKI treatment to half the standard 
dose was associated with improvement in TKI adverse events, in patients with stable 
MR3 or more.  This suggested that many patients are being overtreated and that there is 
scope for TKI dose reduction prior to discontinuation to assess response (Clark et al, 
2016).   
 
Although these results indicate the possibility for TKI discontinuation in a small subset 
of CML patients, they highlight an uncertainty surrounding the ‘trigger’ event(s) in 
molecular relapse, and question if sustained BCR-ABL expression, LSC persistence, 
microenvironmental factors, or, indeed, multiple factors are contributory factors.  It is 
known that in up to 30% of normal individuals, low levels of BCR-ABL expression can 
be identified (Biernaux et al, 1995; Bose et al, 1998), perhaps suggesting that BCR-ABL 
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transcript level alone is not sufficient in CML maintenance.  It is unknown, however, 
what cell types these transcripts are originating from and if this is significant long-term.  
Interestingly, a single copy of BCR-ABL expressed from the endogenous BCR locus in 
a knock-in murine model is not sufficient to induce leukaemia (Foley et al, 2013; Huntly 
& Gilliland, 2005; Huntly et al, 2004) .  Therefore, although it is clear that a certain level 
of BCR-ABL needs to be expressed at the stem cell level to cause CML, it is unclear if 
further molecular changes or aberrant signalling is needed to drive disease persistence, 
molecular relapse and disease progression.  Furthermore, it is unknown if BCR-ABL is 
the initiating insult, or if host factors, such as epigenetic and genetic changes influence 
disease outcome.  Regardless, it is clear that eradication of BCR-ABL is not a 
prerequisite for long-term disease free survival, and this suggests that other factors, 
including CML LSCs, are responsible for molecular relapse.  
 
It has been well documented that CML LSCs are not eradicated by TKIs in vitro, with 
initial studies by the Holyoake group demonstrating that a population of Lin-CD34+ 
CML progenitors have the ability to remain quiescent, are insensitive to the TKI, 
imatinib, and can engraft into NOD SCID gamma (NSG) mice (Graham, 2002; 
Hamilton et al, 2012; Verstegen et al, 1999).  Furthermore, Bhatia et al translated this 
into the clinical setting by showing that cells of a similar phenotype could be identified 
in the bone marrow of imatinib-treated CML patients in CCyR (Bhatia et al, 2003b).  
These studies, amongst others, verify that CML LSCs are not absolutely dependent on 
BCR-ABL activity for their survival and may determine disease persistence (Chomel et 
al, 2011; Corbin et al, 2011b; Deininger, 2012). 
 
It seems pertinent therefore, that a biomarker of the CML LSC is discovered to enable 
detection of those individuals that can come off therapy and those that need to remain 
on therapy, as this will have both financial and psychological implications for the 
healthcare system and the patient group, respectively.  Although many labs have 
performed extensive analysis to identify markers of a primitive cell population in the 
preclinical setting, including CD26 (Culen et al, 2016; Herrmann et al, 2015; Warfvinge 
et al, 2017) and IL1-RAP (Järås et al, 2010; Landberg et al, 2016; Warfvinge et al, 2017; 
Ågerstam et al, 2016), none have been shown, as yet, to be robust enough for clinical 
translation.  CD26, however, is showing increasing promise in this regard with recent 
data suggesting a correlation between CD26 expression and treatment response, as well 
as Lin-CD34+CD38-/lowCD45RA-cKIT-CD26+ population being identified as a potential 
therapeutic target at a single cell level (Culen et al, 2016; Warfvinge et al, 2017). 
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Although identification of the CML LSC appears to be within reach, little is known 
about the biology of the LSC in those patients that are in deep molecular response, with 
much of our understanding and the previous data coming from a drug-naïve population.  
Clinically, the therapeutic need will be in those that are on TKI therapy.  In keeping 
with this, (Giustacchini et al, 2017) recently described a novel approach in determining 
single-cell gene expression within a LSC phenotype between BCR-ABL+ and BCR-
ABL negative cells of the same patients, as well as those on TKI treatment.  This will 
advance our understanding of LSC biology within CML and other stem cell diseases.   
 
Within the Copland group, we have sought to understand the biology of CML LSCs 
compared to normal, in an effort to aid the identification of this subset of cells.  Previous 
unpublished work has demonstrated that the GEP of CML LSCs is more akin to normal 
stem and progenitor cells, and not normal HSCs, as represented through Principal 
Component Analyses (PCA) where, when plotted together, LSCs from patients with CP 
CML (n=6) have a global gene expression signature that appears more mature than 
normal HSCs (n=3), and is positioned overlapping the progenitor subpopulations’ 
(GSE47927) (figure 6-1).   
 
Within this dataset (GSE47927), 1217 genes were deregulated between CP-CML LSCs 
and normal HSCs (figure 6-2).  We initially utilised this gene expression data to evaluate 
the expression of cell surface markers.   Using z scores to normalise the gene expression 
for each sample, we plotted heat maps using R/Bioconductor.   This demonstrated the 
variable expression of cell surface markers between CP-CML LSCs and normal HSCs 
(figure 6-3).  
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Figure 6 - 1 PCA of normal HSC, CP-CML LSC, and progenitor populations 
Data analysed by DI as part of (Irvine, 2013).  Each axis represents a principal component of the 
variability in the normal and CP samples.  An individual point within the axes represents each 
microarray and each subpopulation grouping by a different colour (green for HSC, orange for MPP); 
an ellipse is positioned at 2 standard deviations around the normal HSC (red), normal MPP (Orange) 
and CP-CML LSC (black).  The other progenitor populations are shown without ellipses.   
Figure 6 - 2 Gene expression is deregulated between normal and CP-CML LSCs 
A volcano plot showing deregulation of genes in a comparison of Lin-CD34+CD38-CD90+ cells from 
6 CP-CML samples against the same population derived from 3 normal samples (GSE47927).  Areas 
of significance are indicated by a dark green (equivalent to q<=0.01) or light green (equivalent to 
q<=0.05) background.  Genes reaching significance are coloured red (q<=0.01) or orange (q<=0.05); 
non-significant genes are grey.  Data analysed by GH and LH. 
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Figure 6 - 3 Cell surface markers are deregulated between normal and CP-CML LSCs 
Mean expression levels between normal HSCs (n=3) and CP-CML LSCs (n=6) from GSE47297 were 
normalised across each gene (z score) and represented using heatmap.2 in R/Bioconductor.  Yellow 
represents increased expression and blue represents decreased expression within the data set. 
Samples could be clustered into disease process, i.e. normal and CP-CML.  Data analysed by GH 
and HM. 
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Although there was variable expression noted across the cell surface markers analysed, 
some cell surface markers were expressed at significant and differential levels between 
the CML LSC and normal HSC populations (Table 6-1).  Of note, CD93 demonstrated 
a six-fold increased expression in CP-CML compared to normal HSC and represented 
an interesting target for further analysis.   
 P-value Fold change 
CP-CML vs. 
normal 
CD93 2.5x10-6 6 
CD47 9.25x10-8 -1.88 
CD96 0.0017 -3.08 
CD59 0.0013 -1.63 
CD53 0.0011 -1.62 
CD62L 0.085 -2.72 
 
Table 6 - 1 Cell surface marker fold change between CP-CML LSC versus normal 
Analysis of the microarray, GSE47927, demonstrated significant fold change between CP-CML vs. 
normal in a number of cell surface markers.  The table represents the most statistically significant 
genes identified.  Data analysed by HM and GH.  
 
This was confirmed at the gene level within CD34+-selected PB and BM CML 
samples compared to normal BM samples, purchased from Stem Cell Technologies 
(figure 6-4A).  A statistically significant increase in CD93+ cells was noted within 
the LSC population of PB CP-CML samples at the protein level (n=20) compared 
to normal (figure 6-4B). 
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Figure 6 - 4 CD93 is upregulated within CP-CML at gene and protein level 
(A) RNA from 30 BM and PB CP-CML samples was utilised to validate the gene expression of 
CD93.  All samples were isolated from CD34+-selected cells, and compared to normal BM (n=5).  
Compared to normal, there was a statistically significant increase in CD93 gene expression in 
BM and PB, as determined by an unpaired student’s t test (p<0.001). (B) CD93 protein 
expression was assessed by flow cytometry in CD34+CD38-CD90+ populations between CML 
(n=22) and normal (n=7).  A statistically significant increase in percentage of CD93+ cells was 
determined using an unpaired student’s t test (p<0.0001).   
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CD93 is a glycoprotein, which comprises a C-type lectin-like domain, five EGF-like 
domains, a transmembrane domain and a short cytoplasmic tail (Christian et al, 2001; 
Nepomuceno et al, 1997).  It can appear in two forms: a cell-associated full-length and 
a truncated soluble form (Greenlee-Wacker et al, 2011), which confer functional 
variability.  Although CD93 was previously identified as a receptor for complement 
component 1, subcomponent q phagocytosis (C1qRp), which was initially shown to be 
involved in the C1q-mediated enhancement of phagocytosis, several studies have 
reported the contrary and the functional roles for CD93 are extensive.  A variety of 
functions have been described, including high expression promoting dissemination of 
malignancy through angiogenesis (Bao et al, 2016; Langenkamp et al, 2015; Orlandini 
et al, 2014), apoptosis (Norsworthy et al, 2004), and monocyte inflammation (Greenlee-
Wacker et al, 2011; Jeon et al, 2010), as well as being implicated in leukocyte migration 
and cell adhesion (Galvagni et al, 2016).  Knockout CD93 murine models remain viable 
and show no severe developmental abnormalities, although phagocytosis is decreased 
in vivo in these animals (Norsworthy et al, 2004).  Furthermore, membrane CD93 
protein and mRNA expression has been described in cells of myeloid origin, stem cells, 
endothelial cells and platelets (Ikewaki et al, 2010; Nepomuceno & Tenner, 1998).   
 
The role of CD93 as an immature cell marker, or biomarker, has been explored in a 
variety of malignancies (Lee et al, 2009; Olsen et al, 2015), including within multiple 
myeloma, where a recent study showed that higher gene expression of CD93 was 
associated with higher survival rates amongst patients with multiple myeloma (MM) 
treated with bortezomib, indicating that high levels of CD93 may be a possible marker 
for better outcome in these patients (Stessman et al, 2013).   
 
Within myeloid disease, CD93 has been shown to offer potential as a biomarker for an 
AML LSC population, where it has been identified as a part of the AML LSC gene 
signature, and expression confirmed at protein level (Saito et al, 2010).  Furthermore, it 
has been shown, more recently, that CD93 expression can identify a predominantly 
cycling, non-quiescent leukaemia-initiating cell population in MLL-rearranged AML, 
providing opportunities for selective targeting and eradication of the AML LSC 
(Iwasaki et al, 2015b).  The functional role of CD93 expressing cells within CML has 
yet to be identified.  
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6.2. Aims 
In view of the above, the specific aims set out in this chapter were 
1. to assess the self-renewal capability of CD93 within the LSC compartment, 
and  
2. to assess the gene expression differences between Lin-CD34+CD38-
CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- cells at bulk and single cell 
level. 
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6.3. Results 
6.3.1. CD93+, but not CD93- CML cells have LIC and self-renewal capacity in vitro 
and in vivo 
Because CD93 was upregulated within an LSC phenotype at gene and protein level, it 
was hypothesised that CD93+ cells would correlate with the self-renewal properties of 
CML LSCs.  To address this, primary CP-CML samples were sorted into Lin-
CD34+CD38-CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- populations (figure 6-
5).   
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We first sought to identify differential potential of the cells with CFC assays.  Two 
thousand FACS-sorted cells from the Lin-CD34+CD38-CD90+CD93+ and Lin-
CD34+CD38-CD90+CD93- populations were plated in duplicate in Methocult.  Plates 
were incubated at 37°C for 10-12 days before colonies were counted.  Colonies were 
BCR-ABL positive as determined by FISH.  An increase in number of colonies was 
noted within the Lin-CD34+CD38-CD90+CD93+ population compared to Lin-
CD34+CD38-CD90+CD93- (n=4 CP-CML samples) (figure 6-6A); however, this was 
not statistically significant as determined by a paired student’s t test, and perhaps reflects 
the fact that primary colony formation in progenitor assays is largely driven by 
committed progenitors and not stem cell self-renewal.  Up to 50 primary colonies per 
sample were next individually picked and re-suspended in 200ul fresh Methocult in 96 
well plates.  Plates were incubated at 37°C for 12 days before positive wells were 
counted.  This demonstrated no statistical change in replatiting capability between Lin-
CD34+CD38-CD90+CD93+ population compared to Lin-CD34+CD38-CD90+CD93-  
(figure 6-6B); there was, however, a trend towards increased replating potential in the 
CD93+-selected cells.  
Figure 6 - 5 Sorting strategy for Lin-CD34+CD38-CD90+CD93+/- populations 
Cells were thawed and cultured overnight in SFM+5GF.  Cells were then washed in PBS/2%FBS 
and counted.  5x104 cells were used within each unstained, single-stained and FMO control, where 
cells were re-suspended in 100ul PBS/2%FBS prior to the addition of antibody (concentration 
calculated in previous dilution experiments’). The ‘5-stain’ sample was re-suspended in 450ul 
PBS/2%FBS prior to the addition of antibody.  Samples were stained for 30 minutes at 4°C and then 
washed twice with PBS/2%FBS before being filtered through a 0.22uM filter.  Cells were sorted with 
a BD FACS Aria with Diva software.    
Figure 6 - 6 Lin-CD34+CD38-CD90+CD93+ do not differ in CFC and replating 
potential 
(A) CP-CML samples (n=4) were sorted according to figure 5-3 and plated in duplicate into methocult 
for 12-14 days prior to colony counts.  The graph indicates the mean number of colonies for each CP-
CML, with mean and standard deviation for each population.  There was no statistical significance 
between the populations (p>0.05; n=4 CP-CML samples). (B) The graph indicates the percentage of 
positive wells per population from replating assays (p>0.05; n=4 CP-CML samples), with mean and 
standard deviation.  There was no statistical difference between populations, as determined by a paired 
student’s t test; however, there was an apparent trend towards an increase in percentage of positive 
wells in the Lin-CD34+38-90+93+ population.  
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To interrogate this further, LTC-IC assays were utilised. LTC-IC assays represent the 
most stringent in vitro surrogate measure of the functional activity of HSCs.  Samples 
were sorted into Lin-CD34+93+ and Lin-CD34+93- populations.  50,000 cells from each 
sorted population (n=3, CP-CML samples) were cultured in six duplicates on a stromal 
feeder layer (a 1:1 mix of irradiated (80Gy) SL/SL and M210B4 murine fibroblasts) in 
long-term myeloid culture medium (MyeloCult supplemented with hydrocortisone).  
Cultures were maintained for 6 weeks with 50% media changes performed weekly 
before being harvested into Methocult for 12 days prior to colonies being counted.  
Results demonstrated a statistically significant increase in colonies within the Lin-
CD34+93+ arm of the experiment with no, or few, colonies within the Lin-CD34+93- 
experimental arm (Figure 6-7A and 6-7B).  This suggested that CD93+-selected cells 
have increased self-renewal capacity in vitro compared to CD93--selected cell 
population.  
 
 
Figure 6 - 7 Lin-CD34+CD93+ have greater self-renewal capacity that Lin-CD34+CD93- 
in vitro 
3 CP-CML samples were sorted in Lin-CD34+93+ and Lin-CD34+93- populations.  50,000 cells from 
each sorted population were cultured in six duplicates on a stromal feeder layer of irradiated SL/SL 
and M210B4 in long-term myeloid culture medium.  Cultures were maintained for 6 weeks with 50% 
media changes performed weekly.  (A) The graph indicates the number of colonies from each 
experimental arm (n=3 CPCML samples), with mean and standard deviation.  There was a 
statistical significant difference between Lin-CD34+93+ and Lin-CD34+93- populations as 
demonstrated using a paired students t-test (****, p<0.0001). 
 
 
We next sought to identify if this increased self-renewal capacity could be translated in 
vivo and utilised a NSG engraftment model to evaluate this (figure 6-8).  The NSG 
mouse model was used to assay human LSCs with in vivo engraftment capacity (SCID-
repopulating cells).   
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Figure 6 - 8 Schematic of NSG experiment 
CP-CML Lin-CD34+CD93+ or Lin-CD34+CD93- cells were isolated by FACS sorting (1x106 
cells/mouse), washed and transplanted via tail vein injection into sub-lethally irradiated (2 Gy) 
8-12 week old NSG mice. Peripheral blood was sampled at 8 weeks to assess for CD45+33+ 
expression. All mice were euthanised after 16 weeks and marrow contents of femurs were 
obtained.  To assess human cell engraftment, cells were labeled with anti-human CD45, 
CD33 and CD19 antibodies prior to analysis by flow cytometry.  This allowed for analysis of 
lineages within the engrafted samples. Performed and analysed by GH and RK.   
 
 
Prior to sorting, CP-CML samples (n=5) were assessed for BCR-ABL expression within 
a Lin-CD34+ population by FISH (figure 6-9).  CP-CML Lin-CD34+CD93+ or Lin-
CD34+CD93- cells were then isolated by FACS sorting (1x106 cells/mouse) (figure 6-
5), washed and transplanted via tail vein injection into sub-lethally irradiated (2 Gy) 8-
12 week old NSG mice.  Samples were not selected for CD38 or CD90, as cell numbers 
were deemed too small to proceed with transplantation.  
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Figure 6 - 9 BCR-ABL analysis by FISH prior to NSG engraftment model 
FISH was performed as per 2.3.2.13 prior to being analysed using an AXIOvision AX10 fluorescent 
microscope and AXIOvision software.  Chromosome t(9;22) BCR-ABL fusion was detected by a dual 
colour dual fusion probe (Abbott Molecular).  Upon thawing, all samples were BCR-ABL positive, with 
only one sample (CML395) being less than 100%.   
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PB was removed at 8 weeks from the mice utilised for three of the CML samples, and 
analysed for engraftment using CD45 and CD33 expression by flow cytometry.  There 
was no significant difference in CD45+33+ expression between the Lin-CD34+93+ and 
Lin-CD34+93- populations at this time point, suggesting that engraftment had not yet 
occurred or was not detectable and, therefore, peripheral blood engraftment was not 
analysed in the further 2 samples (figure 6-10).   
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All mice were euthanised after 16 weeks and marrow contents of femurs were obtained.  
To assess human cell engraftment, cells were labeled with anti-human CD45, CD33 and 
CD19 antibodies prior to analysis by flow cytometry.  This allowed for analysis of 
lineages within the engrafted samples.  Within CML395, there was no statistical change 
in engraftment potential between the Lin-CD34+CD93+ and Lin-CD34+CD93- 
experimental arms (figure 6-11A). However, on closer analysis of the flow cytometry 
data, it is clear that the engraftment potential in the CD93- population is mixed lineage, 
suggesting that this is secondary to BCR-ABL negative cells, which engraft better than 
BCR-ABL positive cells and engraft with both myeloid and lymphoid lineage cells.  This 
was, indeed, validated in the pre-FISH analysis, which demonstrated a small, but 
biologically significant, percentage of BCR-ABL negative cells within the sample.  
Furthermore, on analysis of the post engraftment sort, the CD34+ populations were 
Figure 6 - 10 Significant engraftment was not identified at 8 weeks in CD93+ or 
CD93- populations 
Following transplantation via tail vein injection into sublethally (2 Gy) irradiated NSG mice, blood 
sampling was performed at 8 weeks. To assess human cell engraftment, cells were labelled with 
anti-human CD45, CD33 and CD19 antibodies prior to analysis by flow cytometry.  CD45+CD33+ 
cells were determined as a percentage of total cells.  There was no statistically signficant 
difference between the experimental arms at 8 weeks, suggesting that engraftment had not yet 
occurred.  n=3 CP-CML samples, p value calculated from paired student’s t test between arms of 
the experimental for each CP-CML sample.  Performed and analysed by GH and RK.   
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BCR-ABL negative within the CD93--selected populations (figure 6-11B).  
Consequently, within this sample, it is clear that the engraftment potential in the CD93-
-selected population is driven by ‘normal’ stem cells, which have good engraftment 
potential and engraft both lymphoid and myeloid lineages (figure 6-11C).   
 
Figure 6-11 Non-BCR-ABL engraftment leads to multi-lineage cell potential 
Mice were euthanised after 16 weeks and marrow contents of femurs were obtained. (A) To 
assess human cell engraftment, cells were labeled with anti-human CD45, CD33 and CD19 
antibodies prior to analysis by flow cytometry.  Human cell engraftment was characterised 
by percentage of CD45+. (B) Human CD45+ cells were isolated by FACS sorting and 
analysed by FISH for the BCR-ABL gene rearrangement.  Percentage of BCR-ABL positive 
cells, as determined from analysis of 100 cells, was assessed for each murine experiment.  
All mice within the CD93- experimental arm were predominantly BCR-ABL negative, with a 
mixed BCR-ABL population evident within the CD93+ arm.  (C) Example of FACS analysis 
isolating both myeloid and lymphoid lineages within the CD45+ sample. 
 
 
There was a statistically significant increase in engraftment with CD93+-selected cells, 
as determined by student’s t test, in the further 4 independent CP-CML samples (figure 
6-12A), where prior to engraftment there was 100% BCR-ABL positive expression with 
FISH in CD93+- and CD93--selected ssamples.  Human CD45+CD33+ cells were 
isolated by FACS sorting at 16 weeks and again analysed by FISH for the BCR-ABL 
gene rearrangement. These samples were BCR-ABL positive (figure 6-12B) 
demonstrating again that the CD93+-selected population has an increased leukaemia-
CD45+ cells 
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initiating and self-renewal capacity and, ultimately, may represent an immature 
phenotype within the hierarchy that can be used as a biomarker for the CML LSC.  
 
 
Figure 6 - 12 Lin-CD34+CD93+ cells confer higher rates of engraftment 
compared to Lin-CD34+93- cells 
Mice were euthanised after 16 weeks and marrow contents of femurs were obtained. (A) 
Human cell engraftment was characterised by percentage of CD45+CD33+ cells. There was 
a statistically significantly increased engraftment in the CD93+ experimental arm as 
determined by the student’s t test (*, p<0.05; **, p<0.01; ***, p<0.001). (B) Human CD45+ 
cells were isolated by FACS sorting and analysed by FISH for the BCR-ABL gene 
rearrangement.  Percentage of BCR-ABL positive cells, as determined from analysis of 100 
cells, was assessed for each murine experiment.  Performed and analysed by GH and RK.   
 
6.3.2.  Gene expression profiling of CD93+-selected CP-CML stem cells 
confirms their quiescent character and biomarker potential 
These results have demonstrated that CD93+Ph+-selected populations have functional 
properties of the CML LSC, with evidence of increased self-renewal and engraftment 
potential.  It was subsequently hypothesised that lin-CD34+CD38-CD90+CD93- CML 
cells would have a more mature and less lineage restricted gene expression profile 
compared to lin-CD34+CD38-CD90+CD93+ cells.  We next sought to characterise the 
differences in the lineage gene expression profile between CD93+ and CD93--selected 
CML LSC populations and determine gene expression for each population at the single 
cell level.   
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To interrogate this, CP-CML subpopulations with the greatest functional capability 
compared to normal were identified from previous data generated within our lab 
(Copland, 2007).  In brief, normal and CP-CML samples were FACS-sorted into 
HSC/LSC, CMP, GMP, and MEP subpopulations.  Results suggested a significant 
change in functional status between normal and CP-CML subpopulations within the 
HSC/LSC compartment (lin-CD34+CD38-CD45RA-CD90+), where the CML LSC 
population demonstrated significantly increased proliferation (14 fold expansion; 
P<0.001) compared to normal HSCs (no expansion) after 5 days in vitro culture in 
physiological growth factors.  In addition, equivalent numbers of CML LSCs produced 
approximately 4-fold more colonies in CFC assays than normal HSCs (329±56 versus 
86±17 per 2,000 cells, respectively (p<0.05)).  The LSC compartment was, therefore, 
utilised in subsequent experiments to accurately characterise the expression between the 
93+ and 93- populations.  
 
CP-CML cells were sorted into (1) lin-CD34+, (2) lin-CD34+CD38-CD90+CD93- and (3) 
lin-CD34+CD38-CD90+CD93+ populations (figure 5-5).  RNA was harvested at baseline 
from ‘bulk’ populations (1) to (3) and cDNA generated.  cDNA was generated from 
single cells using the Fluidigm C1 autoprep system.  Using Fluidigm technology, 
quantitative PCR of 90 lineage-specific and cell survival genes was performed within 
all populations of cells (1) to (3) in ‘bulk’ samples (n=3), and at single cell level (n=150 
lin-CD34+CD38-CD90+CD93+, n=150 lin-CD34+CD38-CD90+CD93- single cells; n=3 
samples in total).  Multiplex PCR was used to determine if BCR-ABL was present at a 
single cell level following pre-amplification with the Fluidigm C1 autoprep system 
(figure 6-13) 
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The inherent biological heterogeneity between patient samples can result in a greater 
variability of gene expression when compared with cell line-based experiments.  This 
can lead to minimal statistically significant difference between populations.  
Furthermore, any significant changes that were noted between lineage gene expression 
between CD93+ and CD93--selected populations were within an already immature LSC 
population, making them biologically significant. ΔCT was determined as an average 
of 4 housekeeping genes, namely ATP, β-actin, B2M, and UBE2D2.  Statistical 
significance was determined through an unpaired student’s t-test from ΔCT values; 
results are presented as fold change compared to the CD34+ population. 
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Figure 6 - 13 Schematic experimental design for gene expression profiles between 
Lin-CD34+CD38-CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- populations 
CP-CML samples were thawed and cultured in SFM+5GF overnight prior to FACS-sorting into (1) 
Lin-CD34+, (2) Lin-CD34+CD38-CD90+CD93+, and (3) Lin-CD34+CD38-CD90+CD93-.  RNA was 
generated from the ‘bulk’ populations (1) to (3), and 100ng was used to generate cDNA, prior to 
Fluidigm gene expression analysis.  5000 cells from the ‘bulk’ samples were run through the C1 
Autoprep to generated pre-amped single cell cDNA.  1ul of this sample was used in a multiplex 
BCR-ABL PCR to identify BCR-ABL positive cells, and the rest of the sample was used in the 
Fluidigm gene expression analysis. 
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Gene expression of CD93 was shown to be upregulated within our Lin-CD34+38-90+93+ 
population compared to CD34+ control and Lin-CD34+38-90+93- population (p=0.0068) 
(figure 6-14).   
 
 
 
 
 
On global gene expression analysis, the two populations could be segregated by 
differential gene expression through gene clustering of the fold change compared to the 
CD34+ population, although this was sample-dependent (figure 6-15).  Within this 
expression cluster, the Lin-CD34+CD38-CD90+CD93- population was associated with 
overexpression of genes involved in lineage restriction.  Included in these were GATA1 
(p=0.0007), and CBX8 (p=0.0002).  Furthermore, there was an overexpression in the 
cell cycle gene, CYCLIND2, and lower expression of MCM4, suggesting that these cells 
have a more active cell cycle pattern (figure 6-16).  The lin-CD34+CD38-CD90+CD93+ 
population displayed a less lineage-restricted profile with increased expression of CDK6 
(p=0.05), HOXA6 (ns), CDKN1C (ns) and C-KIT (p=0.0014), compared to the Lin-
CD34+CD38-CD90+CD93- population (figure 6-17).  Taken together, this suggests that 
gene expression profiles of bulk lin-CD34+CD38-CD90+CD93+ population correlates 
with the primitive functional status of the population, and confirms previous findings 
that a CD93+-selected population may represent a potential biomarker of the CML LSC. 
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Figure 6 - 14 CD93 gene expression is higher within the Lin-CD34+CD38-CD90+CD93+ 
population 
Gene expression was determined from CD34+ selected CP CML samples (n=3 samples, Lin-
CD34+CD38-CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- CP-CML samples.  Gene expression 
levels were determined by Fluidigm array analysis using the delta delta Ct method with an average 
of four housekeeping genes as reference.  Fold change is relative to CD34+.  Increase gene 
expression of CD93 was determined in the Lin-CD34+CD38-CD90+CD93+ population compared to 
CD34+.  P values were determined by an unpaired t-test (*, p<0.05; **, p<0.01; ***, p<0.001).  
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Figure 6 - 15 Gene expression profiling can segregate Lin-CD34+CD38-CD90+CD93+ 
and Lin-CD34+CD38-CD90+CD93- populations 
Gene expression profiles (GEPs) were determined from CD34+, Lin-CD34+CD38-CD90+CD93+, and 
Lin-CD34+CD38-CD90+CD93- populations after thawing in SFM+5GF for 24hours.  GEP levels were 
determined by Fluidigm array analysis. Relative gene expression levels were determined by delta 
delta Ct method using an average of four housekeeping genes as reference and the average CD34+ 
value as the calibrator for fold change.  Heat maps were produced by using heatmap.2 in 
R/Bioconductor. 
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Figure 6-16 Gene expression of Lin-CD93- suggests lineage restriction 
Gene expression was determined from CD34+ selected CP CML samples (n=3), Lin-CD34+CD38-
CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- CP-CML samples.  Gene expression levels were 
determined by Fluidigm array analysis using the delta delta Ct method with an average of four 
housekeeping genes as reference.  Fold change is relative to CD34+.  The Lin-CD34+CD38-
CD90+CD93- population was associated with decreased expression of genes involved in lineage 
restriction.  Included in these were GATA1 (p=0.0007), and CBX8 (p=0.0002).  Furthermore, there 
was an overexpression in the cell cycle gene, CYCLIND2, and lower expression of MCM4, 
suggesting that these cells have a more active cell cycle.  P values were determined by an unpaired 
t-test (*, p<0.05; **, p<0.01; ***, p<0.001) 
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Figure 6 - 17 Gene expression of Lin-CD93+ confers a stem cell signature 
Gene expression was determined from CD34+ selected CP CML samples (n=3), Lin-CD34+CD38-
CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- CP-CML samples.  Gene expression levels were 
determined by Fluidigm array analysis using the delta delta Ct method with an average of four 
housekeeping genes as reference.  Fold change is relative to CD34+.  The lin-CD34+CD38-
CD90+CD93+ population displayed a less lineage-restricted profile with increased expression of 
CDK6 (p=0.05), HOXA6 (ns), CDKN1C (ns) and CKIT (p=0.0014), compared to the Lin-CD34+CD38-
CD90+CD93- population.  P values were determined by an unpaired t-test (*, p<0.05; **, p<0.01; ***, 
p<0.001). 
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Advances in single cell analysis have allowed for a more complete investigation of the 
cellular heterogeneity that may exist within populations and enables a more detailed 
examination of the homogeneity or heterogeneity of a population than was previously 
possible.  Cells were isolated using fluorescence-activated cell sorting.  We then 
performed targeted expression profiling of 90 genes in 150 single human lin-
CD34+CD38-CD90+CD93- and lin-CD34+CD38-CD90+CD93+ cells isolated using 
Fluidigm C1 technology.  Single cells were pooled into each population across 3 
individual CP-CML samples.  Data was analysed using R/Bioconductor.  As only 2 
housekeeping genes were consistent across all Fluidigm chips within the single cell 
experiments, namely B2M and UBE2D2, these were used to determine ΔΔ Ct levels.  
False discovery rate was determined at a significance level of 0.05 and all single cell 
analyses were adjusted for this.  
The frequency of expression (i.e. the number of cells with expression for the gene above 
five events per population per chip) for each gene was first determined.  Of the genes 
eligible for analysis, 20 genes had a higher frequency within the CD93+-selected 
population, and 53 genes had a higher frequency within the CD93--selected single cell 
population (figure 6-18).    
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Figure 6 - 18 Frequency of gene expression identifies gene differences 
between CD93+ and CD93- single CML cells 
Cells were isolated using FACS.  Targeted expression profiling of 90 genes in 150 single 
human lin-CD34+CD38-CD90+CD93- and lin-CD34+CD38-CD90+CD93+ cells isolated using 
Fluidigm C1 technology.  Single cells were pooled into each population across 3 individual 
CP-AML samples.  Data was analysed using R/Bioconductor.  False discovery rate of 0.05 
was used within the analysis.  Of the genes eligible for analysis, 20 genes had a higher 
frequency within the CD93+-selected population, and 53 genes had a higher frequency within 
the CD93--selected single cell population.  An unpaired student’s t-test was used to 
determine significance (*, p<0.05; **, p<0.01; ***, p<0.001).   
 
Gene expression analysis was performed by the ΔΔCt method using B2M and UBE2D2 
as a normalisation control.  Hierarchical clustering was performed using 
R/Bioconductor.  For the purpose of clustering, only genes that were expressed in all 
three samples were included in analysis.   Hierarchical gene clustering could not clearly 
discriminate between CD93+ and CD93- populations at a single cell level, and therefore 
highlighted the heterogeneity seen within a single cell analysis (figure 6-19).  However, 
on analysis of correlation using Spearman’s coefficient between the single cells versus 
bulk for each individual gene, there was correlation identified, with R2=0.65 and 0.56 
for CD93+ and CD93-, respectively, against bulk samples (figure 6-20).  This suggests 
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that any statistically significant gene changes are true for the selected populations, and 
not secondary to technical variation between experimental design.  
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Figure 6 - 19 Gene clustering cannot clearly discriminate between CD93+ and 
CD93- populations 
Gene expression profiles were determined from CD34+, Lin-CD34+CD38-CD90+CD93+, and 
Lin-CD34+CD38-CD90+CD93- populations after thawing in SFM+5GF for 24 hours.  GEPs 
were determined by Fluidigm array analysis. Relative gene expression levels were 
determined by ΔΔCt method using an average of two housekeeping genes as reference and 
the average CD34+ value as the calibrator for fold change.  Heat maps were produced by 
using heatmap.2 in R/Bioconductor. 
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Figure 6 – 20 Correlation is identified between CD93+ and CD93- samples vs 
bulk using Spearman’s Coefficient 
Cells were isolated using FACS.  Targeted expression profiling of 90 genes in 150 single 
human lin-CD34+CD38-CD90+CD93- and lin-CD34+CD38-CD90+CD93+ cells isolated using 
Fluidigm C1 technology.  Single cells were pooled into each population across 3 individual 
CP-CML samples.  Data was analysed using R/Bioconductor.  False discovery rate of 0.05 
was used within the analysis.  Of the genes eligible for analysis, a Spearman’s Correlation 
Coefficient was identified.  R2 was 0.65 and 0.56 for CD93+ and CD93- single cells, 
respectively.   
 
 
Next, analysis of individual genes between pooled CD93+ and CD93--selected single 
cell populations’ were conducted.  Using a limma modified t-test and correcting for false 
discovery rate with 0.05, 16 genes were noted to demonstrate statistically significant 
changes in expression between CD93+ and CD93--selected populations.  Of note, CD93+ 
genes had lower expression of genes involved in differentiation, namely SPI1 and 
GATA1, and higher expression of self-renewal genes, SCA1, MAFB, LMO2, HOXA5, 
SPI1, FLT3, RUNX1, CSF1R, MCM7, HOXA6, and BMI1 (table 6-2).  Multiplex PCR 
was used to determine BCR-ABL expression in single cells following pre-amplification.  
There was no statistical significant change in BCR-ABL expression between the CD93+ 
and CD93--selected populations, but a trend towards higher BCR-ABL expression in the 
CD93+ population (p=0.13) (figure 6-21).   
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logFC P.Value adj.P.Val 
SCA1 -2.09578 2.27E-07 9.75E-06 
MAFB -1.54523 2.18E-05 0.000313 
LMO2 -1.19493 1.89E-05 0.000313 
SPI1 0.802386 3.05E-05 0.000328 
ORC2 -1.00764 4.74E-05 0.000407 
HOXA5 -1.27036 7.31E-05 0.000449 
CITED2 -0.978 7.28E-05 0.000449 
FLT3 -0.94912 0.000349 0.001876 
GATA1 1.914533 0.000529 0.002529 
RUNX1 -0.62017 0.000767 0.003298 
CSF1R -1.1231 0.005552 0.019894 
FLT1 -1.25481 0.007225 0.020712 
MCM7 -0.72342 0.006025 0.019927 
HOXA6 -0.78185 0.006518 0.020019 
BMI1 -0.52627 0.012059 0.032407 
 
 
Table 6 - 2 Single cell GEP identifies that CD93+-selected single cells have a 
stem cell signature 
Gene expression profiles were determined from CD34+, Lin-CD34+CD38-CD90+CD93+, and 
Lin-CD34+CD38-CD90+CD93- populations after thawing in SFM+5GF for 24 hours.  GEP 
levels were determined by Fluidigm array analysis. Relative gene expression levels were 
determined by ΔΔCt method using an average of two housekeeping genes as reference.  
Analysis of individual genes between pooled CD93+ and CD93- single cell populations’ were 
analysed.  Using a limma modified t-test and correcting for false discovery rate with 0.05, 16 
genes were noted to demonstrate statistically significant changes in expression between 
CD93- and + populations. 
 
 
 
 
 
 
 CD93+ CD93-
0
20
40
60
80
%
 B
C
R
-A
B
L
+
Figure 6 – 21 No significant change of BCR-ABL expression was identified 
between CD93+ and CD93--selected single cells as determined by multiplex PCR 
Following single cell harvest with the Fluidigm C1 autoprep system, 1ul of the 
preamplified sample was used within a multiplex PCR.  Single cell data was pooled 
across 3 CP-CML samples. Positive expression of BCR-ABL as determined through gel 
electrophoresis allowed identification of BCR-ABL expression for each single cell 
analysed.  There was no statistically significant change in expression, as determined by 
an unpaired student’s t-test (p=0.13). 
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Single cell gene expression demonstrates that, even at a single cell level, there is 
evidence that CD93+ selection confers cell immaturity and self-renewal capability, 
although overall gene expression profiling cannot distinguish amongst the populations.  
In future experiments, it would be prudent to isolate the gene expression for BCR-ABL+ 
and BCR-ABL negativie cells within the CD93+- and CD93--selected populations.  
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6.4. Discussion 
Within this chapter, we have presented both functional and gene expression data to 
support our groups preliminary data that the glycoprotein, CD93, may represent a 
biomarker for the CML LSC.  This was supported using both Lin-CD34+CD38-CD90+ 
and Lin-CD34+ populations.  Initial in vitro analysis of clonal progenitor assays 
demonstrated no change in colony forming capacity between Lin-CD34+CD38-
CD90+CD93+ and Lin-CD34+CD38-CD90+CD93- populations.  This perhaps is not 
surprising since the ability to form a multi-lineage colony focuses on the populations’ 
ability to differentiate, with only limited involvement from properties of self-renewal.  
Colony re-plating represents a self-renewal model with re-plating capacity greater in 
primitive multi-lineage or mixed colonies.  This capacity has been shown to decline 
with cell maturity.  Within our model, there was an increased trend towards re-plating 
efficiency from CFC assays, but this was not statistically significant.  This may be, in 
part, due to inter-patient variability, with previous evidence suggesting that re-plating 
within CML is variable between different patients and can relate to patient 
characteristics, such as prognostic index (Gordon et al, 2003).  To address this, LTC-IC 
were utilised to quantitatively assess HSC function.  The LTC-IC assay represents the 
most stringent in vitro surrogate measure of the functional activity of HSCs, and relies 
on more extensive self-renewal capacity that the shorter-duration CFC assay with 
replates.  Our results demonstrated a statistically significant increase in colonies within 
the Lin-CD34+CD93+ arm of the experiment (p=0.0001).  These results suggest that 
CD93+-selected cells have increased in vitro self-renewal capacity.  
 
Because the in vitro measurements of self-renewal do not reflect the complex multi-
directional interactions seen within the HSC niche, we utilised an in vivo NSG 
engraftment model to determine if the CD93+-selected population could be truly 
representative of an increased self-renewal and leukaemia-initiating population.  The 
experiments performed demonstrated that engraftment could only really be evaluated if 
the BCR-ABL status was known for each population.  Furthermore, engraftment data 
could only be generated at 16 weeks through analysis of BM cells, with no PB 
engraftment evident at 8 weeks, or 16 weeks.  Within four independent CP-CML 
samples, there was a statistically significant increase in engraftment in the CD93+ 
compared to the CD93--selected population.  This verified our previous findings that the 
CD93+-selected population has functional properties of LSCs, with evidence of 
increased self-renewal and engraftment potential.  Our xenograft model allowed for 
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analysis of the capability of the transplanted cells to initiate CML disease in recipient 
mice.  However, it does not evaluate the long-term potential of the engraftment to lead 
to a myeloproliferative neoplasm.  To determine this serial transplantation experiments’ 
would be needed.  However, within the CML xenograft murine model lies an inherent 
problem in that there is generally low engraftment as demonstrated within our model 
and others (Eisterer et al, 2005; Lewis et al, 1998). 
 
To support our previous findings, we next sought to characterise the differences in the 
gene expression profiles between CD93+ and CD93--selected CML populations and 
determine heterogeneity of each population at bulk and single cell level.  To interrogate 
this, we initially identified the CP-CML LSC population as having the greatest 
functional capability compared to normal, and all gene expression experiments were 
subsequently confined to this population. 
 
We hypothesised that lin-CD34+CD38-CD90+CD93- CML cells would have a more 
mature GEP compared to lin-CD34+CD38-CD90+CD93+ cells. CP-CML cells were 
sorted into (1) lin-CD34+, (2) lin-CD34+CD38-CD90+CD93- and (3) lin-CD34+CD38-
CD90+CD93+ populations. RNA was harvested at baseline from bulk populations (1) to 
(3) and cDNA was generated from single cells using the Fluidigm C1 autoprep 
system. Using Fluidigm technology, quantitative PCR of 90 lineage-specific and cell 
survival genes was performed within all populations of cells (1) to (3) in ‘bulk’ samples 
(n=3), and at single cell level (n=123 CD93+, n=120 CD93-single cells; n=3 samples in 
total). 
 
Bulk sample analysis demonstrated a significant increase in expression of lineage 
commitment genes within the lin-CD34+CD38-CD90+CD93- population, as shown by 
increased expression of GATA1 (p=0.0007), and CBX8 (p=0.0002). The lin-
CD34+CD38-CD90+CD93+ population displayed a less lineage-restricted profile with 
increased expression of CDK6 (p=0.05), HOXA6 (ns), CDKN1C (ns) and CKIT 
(p=0.0014), compared to the lin-CD34+CD38-CD90+CD93- population. Furthermore, 
the two populations could be segregated by differential gene expression through gene 
clustering. 
 
At a single cell level, differences were noted in the frequency of expression between lin-
CD34+CD38-CD90+CD93- and lin-CD34+CD38-CD90+CD93+ populations, particularly 
in GATA1, TPOR, and VWF. Although a statistically significant change was 
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demonstrated in gene expression between the lin-CD34+CD38-CD90+CD93- and lin-
CD34+CD38-CD90+CD93+ populations in a number of genes, we were not able to 
segregate the populations by differential expression using gene clustering. This 
highlights the heterogeneous nature of the cell populations and the inability to distinctly 
characterise between the two populations at a single cell level by GEP.  However, there 
was positive correlation noted between the bulk and single cell data, suggesting that the 
gene expression changes determined between CD93+ and CD93--selected populations 
are not purely confounding variation caused by patient heterogeneity, or technical 
variation between bulk and single cell experimental design, but are inherent to the 
CD93-selectivity.     
 
This heightens the argument that CD93+-selectivity represents an immature LSC 
phenotype at both gene and functional level.   
 
There is no previous data to suggest that CD93 is a potential marker of a LSC within 
CML.  Although, our group is the first to report a functional role for CD93 within CP-
CML, previous reports have demonstrated it to be upregulated within human LSCs in 
AML (Iwasaki et al, 2015b; Saito et al, 2010). Most recently (Iwasaki et al, 2015b), 
within AMLs with genomic rearrangements of the MLL gene, it was demonstrated that 
LSC expression of CD93 is essential for MLL-mediated leukaemogenesis, but, in 
contrast to our findings, the CD93+ LSCs were cycling, non-quiescent leukaemia-
initiating cells, whereby CD93-regulated self-renewal was secondary to silencing of 
CDKN2B, a major tumour suppressor in AML. Within the primary CP-CML samples 
analysed, CDKN2B was upregulated compared to CD34+ bulk within the CD93+ 
population. These differences may be purely an inherent feature within the disease 
process. 
 
Based on the above, our results validate CD93 as a potential functional marker of the 
primitive CP-CML LSC population and highlight key lineage and cell survival 
pathways that are altered in CML LSC. The results demonstrate the heterogeneity seen 
within gene expression at the single cell level, which may allow for further insight into 
the CML LSC compartment with further analyses.  An inherent flaw within our data is 
that both BCR-ABL+ and BCR-ABL- samples are present within the CD93+- and 
CD93-- selected populations.   Recently, (Giustacchini et al, 2017) described a novel 
technique that combines BCR-ABL detection with whole-transcriptome analysis of the 
same single cell.  They demonstrated that significantly higher number of genes were 
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detected within the BCR-ABL+ stem cells, which correlated with increased 
proliferation gene expression and reduced quiescence-associated gene expression, 
compared to normal HSCs and BCR-ABL negative stem cells.  This correlates with the 
activation of BCR-ABL-driven proliferation.  This important work has allowed for 
analysis of samples from patients established already on TKI.  Within these samples, a 
distinct subpopulation of highly quiescent BCR-ABL+ stem cells were identified, which 
demonstrated deregulation of specific pathways, including TGF-β, NFKβ, TNF-α, JAK-
STAT, and Wnt/β-catenin.  Cell cycle quiescence and a capacity for self-renewal are 
key features that underlie leukaemic initiation, progression, and relapse within CML.  
Identification, and subsequent, targeting this subset of cells is necessary for complete 
eradication of the disease.   
 
Recent evidence has suggested that CD26 may represent an interesting target for the 
CML-LSC; indeed single cell gene analysis confers this notion (Warfvinge et al, 2017).  
Although, CD93 was analysed within (Warfvinge et al, 2017), analysis of its expression 
was within an MNC population.  Our data similarly demonstrated that within an MNC 
population there is limited expression of CD93.  Our experimental model utilised a more 
primitive population to include CD34+CD38-CD90+ cells. Further work is necessary to 
establish if there is co-expression between CD93 and CD26 population and if this alters 
the functionality of the cells.  Furthermore, further work is necessary to establish if, as 
well as identifying the LSC population, CD93 can be targeted to eradicate it.   
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7. Thesis summary and future directions 
Within this thesis, we have presented data for the identification of the cell surface 
marker, CD93, as a potential marker for the CP-CML LSC.  Further to this, we present 
data for the role of the self-renewal pathway, Notch, in CP-CML LSC eradication.  In 
view of the complexity of the Notch pathway within CP and myeloid BP, we 
characterised self-renewal pathway deregulation through transcriptional analysis of 
CML progression to myeloid and lymphoid BP, and offer a comparison between 
lymphoid BP and Ph+ ALL.   
 
The identification and eradication of LSCs within CML remains an important area 
clinically.  This has been highlighted in recent trials exploring the discontinuation of 
TKIs in CP patients with sustained deep molecular remission (Mahon et al., 2010, 
Mahon et al., 2014, Mahon, 2015, Mahon et al., 2016, Rea et al., 2012, Etienne et al., 
2017, Ross et al., 2010, Ross et al., 2013, Takahashi et al., 2012).  These trials have 
demonstrated that discontinuation of therapy can be selectively achieved.  
 
Although these results indicate the possibility for TKI discontinuation in a small subset 
of CML patients, they highlight an uncertainty surrounding the ‘trigger’ event(s) in 
molecular relapse, and question if sustained BCR-ABL expression, LSC persistence, 
microenvironmental factors or, indeed, multiple factors are contributing.  A single copy 
of Bcr-Abl expressed from the endogenous BCR locus in a knock-in murine model is 
not sufficient to induce leukaemia (Foley et al., 2013).  Therefore, although it is clear 
that a certain level of BCR-ABL needs to be expressed at the stem cell level to cause 
CML, it is unclear if further molecular changes or aberrant signalling is needed to drive 
molecular relapse and disease progression.  Furthermore, it is unknown if BCR-ABL is 
the initiating insult, or if host factors, such as epigenetic and genetic changes influence 
disease outcome and precede the acquisition of BCR-ABL.  Regardless, it is apparent, 
that further insight into why LSCs survive TKIs is vital in the quest for cure.  
Furthermore, understanding of the LSC within CML, may offer insight in other CSC 
driven diseases.  This is in view of the fact that CML is an extrememly well understood 
disease, with numerous well validated experimental in vitro and in vivo models that can 
be manipulated , when compared to the heterogeneity seen within AML, for example.   
 
As has been extensively described in previous chapters, identification of the CML LSC 
population in a clinical setting would enable therapeutic decisions in identifying those 
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at risk of molecular relapse, and those where TKIs can be stopped.  Additionally, it 
would aid further evaluation of the LSC population at a biological level, that would, in 
turn, allow for a greater understanding in potential therapeutic targets to help in their 
eradication.  Although many labs have performed extensive analysis to identify markers 
of a primitive cell population in the preclinical setting, including CD26 (Herrmann et 
al., 2015, Culen et al., 2016, Warfvinge et al., 2017) and IL1-RAP (Ågerstam et al., 
2016, Landberg et al., 2016, Warfvinge et al., 2017, Järås et al., 2010), none have been 
shown, as yet, to be robust enough at clinical translation.  CD26, however, is showing 
increasing promise in this area with recent data suggesting a correlation between CD26 
expression and treatment response, as well as a potential therapeutic target at a single 
cell level (Warfvinge et al., 2017, Culen et al., 2016).   
 
To determine further markers to identify the CP-CML LSC population, we utilised data 
from a microarray study where Lin-CD34+CD38-CD45RA-CD90+ normal HSC (n=3) 
and CP-CML LSC (n=6 patients at diagnosis) populations were isolated using a 
FACSAria and applied to Affymetrix HuGene 1.0ST arrays.  The raw data (.CEL files) 
was imported into Partek Genomics Suite and Ingenuity Pathway Analysis software and 
PCA and gene ontology ANOVA performed.  A total of 1217 genes were significantly 
deregulated between normal HSC and CP-CML LSCs.  The most significantly 
deregulated genes and pathways were involved with the molecular and cellular 
functions of cell cycle, cell assembly and organisation, cellular movement, cell death 
and DNA replication, recombination and repair.  These results suggested that CML 
LSCs were less quiescent than normal HSCs.  Within this dataset, we further sought to 
assess if there were differences in expression of cell surface molecules that may be 
amenable to therapeutic manipulation.  Of particular interest, our microarray studies 
demonstrated that CD93 was highly upregulated in CP-CML LSCs (6 fold, p=2.5x10-
6).  Increased CD93 expression was validated by Fluidigm digital PCR (6 fold increase, 
p=0.02; n=6).  Furthermore, using flow cytometry, we demonstrated significant 
upregulation of CD93 protein expression on lin-CD34+CD38-CD45RA-CD90+ CML 
LSCs from PB and BM of CP-CML patients (n= 17; mean = 63.8% CD93+) compared 
to normal HSC from healthy PB stem cell donors (n=7; mean = 0.8% CD93+) and BM 
donors (n=4; mean = 0.2% CD93+; p < 0.0001). FISH confirmed that 100% of lin-
CD34+CD38-CD90+CD93+ CML cells were BCR-ABL positive in all samples assessed.  
CD93 (also known as C1qRp) is a C-type lectin-like domain (CTLD)-containing 
glycoprotein which regulates phagocytosis, with roles in cell adhesion and leukocyte 
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migration.  It is normally expressed on endothelial cells, haemopoietic precursors and 
mature cells including neutrophils, monocytes and platelets.  
 
Within this thesis, we sought to assess the functional capability of the CD93-selected 
population and ascertain if these cells had ‘true’ stem cell capability.  LTC-IC assays 
were utilised to quantitatively assess stem cell function.  The LTC-IC assay represents 
the most stringent in vitro surrogate measure of the functional activity of HSCs, and 
relies on more extensive self-renewal capacity than the shorter-duration CFC assay with 
replates.  Our results demonstrated a statistically significant increase in colonies within 
the Lin-CD34+CD93+ arm of the experiment (p=0.0001).  These results suggest that 
CD93+-selected cells have increased in vitro self-renewal capacity.  Furthermore, in 
xenograft transplantation experiments (n = 5), after 16 weeks, CD34+CD93+ CML LSC 
engrafted lethally irradiated NSG mice with BCR-ABL positive cells, whereas 
CD34+CD93- cells from the same patient samples failed to engraft to significant levels 
(3.5-30-fold increase in engraftment with CD34+CD93+ cells; p<0.03).  FISH confirmed 
that engrafted human cells were BCR-ABL positive. 
 
We subsequently hypothesised that CD93+-selected cells would represent a more 
immature functional phenotype compared to CD93--selected cells. The aim of this 
aspect of this thesis was to characterise differences in the gene expression profiles 
between CD93+ and CD93- CML LSC populations and determine heterogeneity of each 
population at a single cell level. 
 
To interrogate this, we initially identified CP-CML subpopulations with the greatest 
functional capability compared to normal from existing data within our lab. Normal and 
CP-CML samples were FACS-sorted into HSC/LSC, CMP, GMP, and MEP sub-
populations.  Results suggest a significant change in functional status between normal 
and CP-CML subpopulations within the HSC/LSC compartment (lin-CD34+CD38- 
CD45RA-CD90+), where CML LSC demonstrated significantly increased proliferation 
(14 fold expansion; P<0.001) compared to normal HSC (no expansion) after 5 days in 
vitro culture in physiological growth factors. In addition, equivalent numbers of CML 
LSC produce ~4-fold more colonies in CFC assays than normal HSC (329±56 versus 
86±17 per 2,000 cells, respectively (p<0.05)).  Furthermore, FISH demonstrated that 
>90% of lin-CD34+CD38-CD45RA-CD90+ CML LSC from all patient samples were 
BCR-ABL positive. Subsequent experiments were confined to the LSC population. 
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We hypothesised that lin-CD34+CD38-CD45RA-CD90+CD93- CML cells would have a 
more mature gene expression profile compared to lin-CD34+CD38-CD45RA-
CD90+CD93+ cells. CP-CML cells were sorted into (1) lin-CD34+, (2) lin-CD34+CD38-
CD90+CD93- and (3) lin-CD34+CD38-CD90+CD93+ populations.  Using Fluidigm 
technology, quantitative PCR of 90 lineage-specific and cell survival genes was 
performed within all populations of cells (1) to (3) in ‘bulk’ samples (n=3), and at single 
cell level (n=123 CD93+, n=120 CD93- single cells; n=3 samples in total). 
 
Bulk sample analysis demonstrated a significant increase in expression of lineage 
commitment genes within the lin-CD34+CD38-CD90+CD93- population, as shown by 
increased expression of GATA1 (p=0.0007), and CBX8 (p=0.0002).  The lin-
CD34+CD38-CD90+CD93+ population displayed a less lineage-restricted profile with 
increased expression of CDK6 (p=0.05), HOXA6 (ns), CDKN1C (ns) and C-KIT 
(p=0.0014), compared to the lin-CD34+CD38-CD90+CD93- population.  Furthermore, 
the two populations could be segregated by differential gene expression through gene 
clustering.  At a single cell level, differences were noted in the frequency of expression 
between lin-CD34+CD38-CD90+CD93- and lin-CD34+CD38-CD90+CD93+ populations, 
particularly in GATA1.  Although a statistically significant change was demonstrated in 
gene expression between the lin-CD34+CD38-CD90+CD93- and lin-CD34+CD38-
CD90+CD93+ populations in a number of genes, we were not able to segregate the 
populations by differential expression using gene clustering. This highlights the 
heterogeneous nature of the cell populations and the inability to distinctly characterise 
between the two populations at a single cell level.  However, on analysis of correlation 
using Spearman’s coefficient between the single cells versus bulk for each individual 
gene, there was correlation identified, with R2=0.65 and 0.56 for CD93+ and CD93-, 
respectively, against bulk samples.  This suggested that any statistically significant gene 
changes are true for the selected populations, and not secondary to technical variation 
between experimental design.  Our data on CD93 heightens the argument of the use of 
CD93 in the isolation and identification of the CML LSC.  Further work needs to 
ascertain if, as well as its identification, CD93 can be utilised within CML LSCs 
eradication.  This work is currently ongoing, where we have utilised a lentiviral 
approach to knock-down CD93 within primary CP-CML samples.  This will need to be 
extended to a normal HSC population to ensure no detrimental effect, prior to 
discussions regarding in vivo translation into patients. 
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Further to the identification of CD93 as a marker for a primitive cell population within 
CP-CML, we explored the role self-renewal signalling within CML maintenance and 
progression.  In particular, the role of the Notch pathway was evaluated extensively.  
Firstly, we identified, at gene and protein level, the expression of Notch pathway 
components within CP-CML primary samples.  This identified variable expression 
between samples, but that the Notch pathway was deemed inactive through utilisation 
of the gamma secretase inhibitor, DAPT, which upon culture with primary samples, led 
to no change in cellular functions of proliferation or apoptosis.  As CD34+ CP-CML 
cells abundantly express the Notch receptor, NOTCH2, we investigated whether the 
pathway could be reactivated through exogenous stimulation upon ligand binding.  An 
OP9 co-culture system was utilised to allow for overexpression of Notch ligands, DLL1 
or JAG1, using OP9GFP as control stroma. Compared to non-stromal conditions, 
culturing over 7 days on OP9GFP led to a significant increase in growth (p=0.02, n=5). 
The overexpression of JAG1 led to a further increase compared to OP9GFP (p=0.002). 
We confirmed that activation of the pathway was through JAG1, and not DLL1, by 
utilising DAPT, where we observed a significant decrease in live cell counts within the 
OP9GFP (p=0.01) and OP9JAG1 (p=0.018) experimental arms. Upregulation of the 
pathway was confirmed with increased expression of HES1 at the gene level (n=4, 
p=0.001), and val1744 protein by IF (n=5).  CP-CML samples (n=3) were FACS-sorted 
into Lin-CD34+38+ and Lin-CD34+38- populations to assess for functional variation in 
stem and progenitor populations.  Following 7 days in culture, live cell counts showed 
a significant increase in Lin-CD34+38+ cells on OP9JAG1 co-culture (p=0.04). There 
was a decrease in cell growth of Lin-CD34+38- cells in the same experimental conditions 
(p=0.02), with an associated increased trend in late apoptotic cells (ns). We 
hypothesised that Notch activation would have a toxic influence on an immature CML 
LSC population. LTC-IC assays showed a significant decrease in colonies for Lin-
CD34+38- cells co-cultured with OP9JAG1 for 7 days (p<0.05).  Futher to this, CFSE 
assays demonstrated an increased trend towards percentage of viable cells in later 
division on stromal co-culture compared to non-stromal conditions, suggesting that in 
stromal conditions, cells are protected somewhat to enable increased divisions.  This 
was again confirmed within MSC experiments where co-culture on MSC led to 
protection of CD34+ against TKI-induced apoptosis.  Within our experiments, this was 
not clearly dependent on activation of Notch through JAG1 expression.  This suggested 
that Notch activation is not solely responsible for protection of LSC within disease 
states.  This data led us to establish that upon JAG1 activation, cells undergo a degree 
of apoptosis, but more significantly, it causes a push towards early erythroid 
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differentiation that is blocked in an immature state (i.e. proerythroblast phase).  This 
was determined through cell surface identification of erythroid markers.  There was an 
increase in expression of both CD71 and GlyA with the addition of stromal co-culture.  
This was only statistically significant with CD71 surface expression.  As CD33 
expression was maintained, it suggested that although the samples had initiated 
differentiation, they could not progress beyond an immature phenotype.  To corroborate 
the possible involvement of Notch activation through JAG1 interaction in early 
differentiation, gene expression was investigated in primary CD34+ CP-CML patient 
samples.  There was a statistically significant increase in overexpression of key genes 
involved in early erythroid differentiation, namely, p38 (p<0.05) and PU.1 (p<0.05), 
which have notable involvement in development of (pro)erythroblasts.    Furthermore, 
there was little change in gene expression in regulators of the stem cell phenotype, 
namely GATA2 and NFKB1.  This is the first time this has been proposed within a CML 
phenotype.  This data together allows us to propose that activation of the Notch pathway 
through JAG1 protein leads to increased differentiation and apoptosis in CP-CML cells, 
that ultimately leads to LSC exhaustion and a decrease in colony formation.   
 
In order to evaluate the function of Notch activation as a therapeutic modality, we have 
embarked on translating the in vitro findings to an in vivo setting.  This will allow for 
evaluation within a BM microenvironment.  With thanks to the Aifantis laboratory 
(NYU), we are in the process of utilising the ROSA26-ICN2 murine model, which was 
generated by insertion of a loxP flanked splice acceptor NEO-ATG cassette with two 
polyA sites followed by ICN2 into the ROSA26 locus, allowing the ROSA26 promoter 
to drive expression of the NEO-ATG cassette. Cre-recombinase–mediated excision of 
NEO-ATG results in use of the splice acceptor in the ICN2 cassette and irreversible 
expression of the transgene (Lobry et al. 2013; Klinakis et al. 2011).  Following 
confirmed activation of Notch, animals will be sacrificed and BM cells retrovirally 
transduced with BCR-ABL as described (Mizuno et al. 2008; Li et al. 1999), and 
monitored for leukaemic development.  
 
In myeloid BP (n=4), in similar experiments, sorted Lin-CD34+CD38+ and Lin-
CD34+38- populations did not demonstrate this functional profile of Notch activation, 
despite an overexpression in the NOTCH2 receptor compared to normal (p=0.0035).  To 
investigate this further, we sought to investigate the changes in gene expression of 90 
self-renewal and cell survival components in all stages of CML, including CP (n=13), 
myeloid BP (n=12), and lymphoid BP (n=4).  Samples were sorted in stem and 
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progenitor populations.   The self-renewal pathway components were highly 
deregulated between CP and myeloid BP disease.  Of interest, there was a statistically 
significant upregulation in Wnt components in myeloid BP compared to CP, particularly 
TCF7 (p=0.0011). We hypothesise that Wnt upregulation is preventing Notch activation 
in myeloid BP-CML.  Furthermore, there was a statistically significant increase in the 
DNA replication genes, MCM7 and MCM9, between CP and myeloid BP.  The 
transition of CML from CP to BP is characterised by the accumulation of molecular and 
chromosomal abnormalities, although the molecular mechanisms are poorly 
understood.  There is accumulating evidence that suggests that BCR-ABL causes this 
directly through induction of ROS, inducing DNA breaks requiring repair and by 
interacting directly with the repair machinery to inhibit performance (Skorski, 2008). It 
has also been shown that BCR-ABL directly drives expression of certain members of 
the DNA repair pathways resulting in increased DNA instability (Skorski, 2008).  The 
uncontrolled activity of MCM7 and MCM9 may represent an interesting therapeutic 
target in myeloid BP disease in the control of genomic instability and remains an 
interesting area of future work. 
 
Further to this, we explored the transcriptional changes within the Ph+ acute 
leukaemias.  This led to some interesting observations.  Firstly, the differential gene 
expression of self-renewal and cell survival pathways was comparable between 
lymphoid BP and myeloid BP, with an inability to segregate the samples by gene 
clustering.  This is perhaps, unsurprising, in view that the disease phenotypes arise from 
the same cell origin, i.e. the BCR-ABL positive HSC.  The Notch signalling pathway has 
a known role within lineage decision, particularly towards a lymphoid bias (Delaney et 
al., 2010, Ohishi et al., 2002, Ohishi et al., 2003, Jaleco et al., 2001).  However, the 
main comonents of the pathway were not statistically changed between myeloid and 
lymphoid BP disease.  The data of self-renewal gene expression, together, suggests that 
these pathways are not involved in the lineage decision in myeloid or lymphoid BP 
development.  
 
Ph+ acute lymphoid-phenotype leukaemias encompass both lymphoid BP CML and 
Ph+ ALL.  These two diseases are clinically distinct, but can often be mislabelled, as 
suggested within  (Hovorkova et al, 2017).  In view of this, we next sought  to question 
if there was differing gene expression profiles of self-renewal and cell survival pathways 
within the Ph+ acute leukaemias’.  This was in view of the known differences in cell of 
origin between them, with lymphoid BP representing a distinctly stem cell disease, and 
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Ph+ ALL a more differentiated phenotype.  Indeed, on global gene expression of the 90 
self-renewal and cell survival components, the two diseases could be segregated with 
gene clustering methods and confirmed that the diseases are distinct entities.  Of 
particular interest, within our dataset, HIF1A was statistically significantly increased in 
Ph+ ALL compared to both lymphoid BP and normal PB.  Although further 
investigation is required to ascertain its importance in Ph+ ALL, it seems an exciting 
area of development.  It has been shown that within ALL, blockade of HIF1A-mediated 
signalling may play an important role in chemo-sensitisation of ALL cells under 
hypoxic conditions of the BM (Frolova et al., 2012).  Furthermore, within childhood B-
ALL, high expression of HIF1A is associated with a good prognosis (Silveira et al., 
2014), as well as being required for active Wnt signalling in T-ALL (Giambra et al., 
2015).  Although our focussed gene analysis demonstrated no statistical change between 
lymphoid BP and Ph+ ALL within Wnt pathway components, there appeared to be an 
increased dependency on the Wnt pathway within Ph+ ALL, with a statistically 
significant increase in key Wnt components, namely TCF4, TCF7, and LEF1, compared 
to normal PB.     Furthermore, FBXW7, a negative regulator of Notch, was statistically 
significantly increased in Ph+ ALL compared to normal.  FBXW7 is not unique to Notch 
signalling and has been shown in vivo to target many proto-oncogenes, growth 
promoters, and anti-apoptotic molecules.  Furthermore, FBXW7 has been shown to have 
an indispensable role in the maintenance of adult HSC quiescence (Matsuoka et al, 
2008; Thompson et al, 2008).  Deletions of Fbxw7 in HSCs and CML LSCs have been 
shown to lead to c-Myc accumulation, activation of the TP53 signalling pathway, 
aberrant cell cycle entry and eventual exhaustion (Reavie et al, 2013; Reavie, 2010).  
TP53 mutations can accompany disease progression in human CML and TP53 loss in 
some cases impedes the anti-leukaemic response to BCR-ABL inhibition (Kelman et al, 
1989; Wendel et al, 2006), suggesting that loss of p53 in some tumours could constitute 
an adaptive response to the increase in the levels of c-Myc during CML progression.  
As there was no statistical change in TP53 and MYC, this suggests that FBXW7 is acting 
independently of these survival mechanisms, and may offer a therapeutic target within 
the disease. 
 
This transciptional data provides some understanding of the differences in self-renewal 
and cell survival signalling pathway components that may offer interesting areas of 
future development.  Furthermore, it may lead to further work in the identification of a 
gene expression signature that would allow for a greater diagnositc capability and, 
subsequently, improvement in patient care.  
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Overall the work presented in this thesis has furthered our understanding of the role of 
self-renewal within CML maintenance and progression, as well as further implicating 
the use of the cell surface marker, CD93, in the identification of the CML-LSC.  This 
data will help guide novel therapeutic approaches towards the CML LSC in future 
experimental work, as well as guide further development in the transcriptional 
differences and potential targets in the Ph+ acute leukaemias.  
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